Sentence,class,file
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.09Molecular Testing of Lymphoproliferative Disease   •     239 Blood 2016; 127: 2375-90.,Non-OADS,/arxiv_data1/oa_pdf/5a/eb/jptm-2017-04-09.PMC5445208.pdf
https://doi.org/10.1001/ja-maoncol.2016.5763.,Non-OADS,/arxiv_data1/oa_pdf/5a/eb/jptm-2017-04-09.PMC5445208.pdf
"http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.09240     •  Jeon YK, et al.",OADS,/arxiv_data1/oa_pdf/5a/eb/jptm-2017-04-09.PMC5445208.pdf
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.09Molecular Testing of Lymphoproliferative Disease   •     241 define a unique subgroup of patients with angioimmunoblastic T- cell lymphoma.,Non-OADS,/arxiv_data1/oa_pdf/5a/eb/jptm-2017-04-09.PMC5445208.pdf
"242pISSN 2383-7837 eISSN 2383-7845 © 2017 The Korean Society of Pathologists/The Korean Society for Cytopathology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/   by-nc/ 4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Testing of Lung Cancers Hyo Sup Shim · Yoon-La Choi1  Lucia Kim2 · Sunhee Chang3  Wan-Seop Kim4 · Mee Sook Roh5  Tae-Jung Kim6 · Seung Yeon Ha7  Jin-Haeng Chung8 · Se Jin Jang9  Geon Kook Lee10 · The Korean  Cardiopulmonary Pathology Study  Group · The Korean Molecular   Pathology Study Group Department of Pathology, Yonsei University  College of Medicine, Seoul; 1Department of  Pathology and Translational Genomics, Samsung  Medical Center, Sungkyunkwan University School  of Medicine, Seoul; 2Department of Pathology,  Inha University School of Medicine, Incheon;  3Department of Pathology, Inje University Ilsan  Paik Hospital, Inje University, Goyang;   4Department of Pathology, Konkuk University  School of Medicine, Seoul; 5Department of   Pathology, Dong-A University College of Medicine,  Busan; 6Department of Pathology, College of  Medicine, The Catholic University of Korea,  Seoul; 7Department of Pathology, Gachon   University Gil Medical Center, Incheon;   8Department of Pathology, Seoul National   University Bundang Hospital, Seongnam;  9Department of Pathology, Asan Medical Center,  University of Ulsan College of Medicine, Seoul;  10Department of Pathology, National Cancer  Center, Goyang, KoreaTargeted therapies guided by molecular diagnostics have become a standard treatment of lung  cancer.",Non-OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
"Key Words:  Lung neoplasms; Molecular testing; Guideline; Precision medicineReceived:  April 3, 2017 Accepted:  April 9, 2017 Corresponding Author Geon Kook Lee, MD Department of Pathology, National Cancer Center,  323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea  Tel: +82-31-920-1746 Fax: +82-31-920-1369 E-mail: gklee@ncc.re.krJournal of Pathology and Translational Medicine 2017; 51: 242-254 https://doi.org/10.4132/jptm.2017.04.10▒ REVIEW ▒ Molecular diagnostics-guided targeted therapies have become  a standard treatment for patients with lung cancer.1 Driver  genetic alterations such as epidermal growth factor receptor  (EGFR ) mutations and anaplastic lymphoma kinase ( ALK)  rearrangements are currently used as predictive biomarkers for EGFR tyrosine kinase inhibitors (TKIs) and ALK inhibitors,  respectively.1 Since Korean guideline recommendations for  EGFR  and ALK molecular testing were published,2,3 the list of  druggable genetic alterations has been growing as tremendous  amounts of information on the cancer genome are becoming",Non-OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10Molecular Testing of Lung Cancers   •     243 available (Table 1).4-6 Molecular analyses of various biomarkers  in tumor tissue or cytology specimens have become standard  laboratory tests for the clinical management of lung cancers.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
"http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10244     •  Shim HS, et al.",OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10Molecular Testing of Lung Cancers   •     245 clamping method and allele-specific PCR method have been  approved in Korea.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
"http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10246     •  Shim HS, et al.",OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10Molecular Testing of Lung Cancers   •     247 gene rearrangements regardless of fusion partners.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
"http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10248     •  Shim HS, et al.",OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10Molecular Testing of Lung Cancers   •     249 and a chromosome-specific centromere (CEP) probe is a standard  method for the detection of gene amplifications.,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
"http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10250     •  Shim HS, et al.",OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10Molecular Testing of Lung Cancers   •     251 Acknowledgments This research was supported by The Korean Society of Patholo - gists Grant (2016).,Non-OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
"http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10252     •  Shim HS, et al.",OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
"http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10Molecular Testing of Lung Cancers   •     253 and EGFR status of non-small cell lung carcinoma in biopsy and  cytologic material, using a panel of mucin staining, TTF-1, cytoker - atin 5/6, and P63, and EGFR mutation analysis.",Non-OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
"http://jpatholtm.org/ https://doi.org/10.4132/jptm.2017.04.10254     •  Shim HS, et al.",OADS,/arxiv_data1/oa_pdf/ed/c2/jptm-2017-04-10.PMC5445209.pdf
Svenska Akademiens Ordbok [Dictionnary of the Swedish Academy] http://g3.spraakdata.gu.se/saob/ .,Non-OADS,/arxiv_data1/oa_pdf/37/1c/520_2017_Article_3634.PMC5445221.pdf
"Taverna, 8KNIME,9Kepler,10 Activiti (http://activiti.org), Navigator (Mango Solutions,Chippenham, UK), Improve (scinteco, Vienna, Austria), and Pipeline Pilot (BIOVIA, San Diego, CA) are some examples.",Non-OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
We use the PROV-O ontology (http://www.w3.org/TR/ prov-o/) as the basis of our approach to defining and captur-ing provenance information.,Non-OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
"Using tagging and appropriate queries, a Thoughtflow tool could also facilitate the rapid generation of complete reports (through LaTeX (https://www.latex-project.org) and support tools such as knitr 11) and summary outputs, such as run logs, model development summaries that includeFigure 2 Entities, activities, agents, and relationships in PROV-O at a high level.",OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
"Reports are typically authored using literate programming tools, such as Rmarkdown (http://rmarkdown.rstudio.com) and LaTeX/knitr, or Microsoft Word (Microsoft, Redmond, WA).",OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
"The prototype uses ApacheJena (https://jena.apache.org), a free and open sourceJava framework for building semantic web and linked dataapplications to support the interface with the triplestore.",OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
"A request from the client is then implemented using SPARQL (a semantic query language for databases: SPARQL Protocol and RDF Query Lan-guage, https://www.w3.org/TR/rdf-sparql-query).",OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
"This function is per-formed in the prototype by Git (https://git-scm.com), a free, open source, and ubiquitous distributed version control sys- tem designed to handle everything from small to very largeprojects with speed and efficiency.",Non-OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart 51>.,OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
<http://arxiv.org/abs/1411.1607 >(2014).,Non-OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.psp-journal.com)Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition Wilkins et al.,OADS,/arxiv_data1/oa_pdf/cc/85/PSP4-6-285.PMC5445227.pdf
<https://www.r-project.org > 26.,Non-OADS,/arxiv_data1/oa_pdf/2c/76/PSP4-6-331.PMC5445229.pdf
Abstracts of the Annual Meeting of the Population Approach Group in Europe .<http://www.page- meeting.org/?abstract 51434>(2008).,Non-OADS,/arxiv_data1/oa_pdf/2c/76/PSP4-6-331.PMC5445229.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)Population PK of Morphine in NASH and Healthy Subjects Pierre et al.,OADS,/arxiv_data1/oa_pdf/2c/76/PSP4-6-331.PMC5445229.pdf
"<http://www.fda.gov/downloads/AdvisoryCommittees/Committees- MeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM420461.pdf >, Last updated 20 Oct 2014; Accessed 21 Nov 2016.",Non-OADS,/arxiv_data1/oa_pdf/fc/13/PSP4-6-322.PMC5445230.pdf
<http://www.fda.gov/ohrms/dock- ets/ac/08/briefing/2008-4361b1-01-FDA%20.pdf >.,Non-OADS,/arxiv_data1/oa_pdf/fc/13/PSP4-6-322.PMC5445230.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)Dose Optimality for Tofacitinib in Plaque Psoriasis Hutmacher et al.,Non-OADS,/arxiv_data1/oa_pdf/fc/13/PSP4-6-322.PMC5445230.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.psp-journal.com)Population Pharmacokinetics of Selumetinib Patel et al .,OADS,/arxiv_data1/oa_pdf/55/fc/PSP4-6-305.PMC5445231.pdf
Postprocessing of NONMEM output to generategoodness-of-fit plots and predictive checks and logistic regression analyses were performed using R software (v. 2.15.2; http://www.r-project.org).,OADS,/arxiv_data1/oa_pdf/8e/ad/PSP4-6-340.PMC5445237.pdf
"Visual predictive checksand simulations were conducted using Perl-Speaks- NONMEM (PsN v. 3.5.4, http://psn.sourceforge.net/), and Xpose (v. 4.4, http://xpose.sourceforge.net/) was utilized forplotting of simulation results.",OADS,/arxiv_data1/oa_pdf/8e/ad/PSP4-6-340.PMC5445237.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)Subjects Treated for Venous Thromboembolism Byon et al.,Non-OADS,/arxiv_data1/oa_pdf/8e/ad/PSP4-6-340.PMC5445237.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/02/f3/awx090.PMC5445252.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/06/a1/awx074.PMC5445255.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0010; May 2017 DOI: 10.1530/EDM-17-0010Limbic encephalitis in APECED A Kopczak,   A-M Schumacher and others GAD antibody-associated limbic encephalitis  in a young woman with APECED Anna Kopczak1,2,*, Adrian-Minh Schumacher3,*, Sandra Nischwitz1, Tania Kümpfel3,  Günter K Stalla1 and Matthias K Auer1 1Max Planck Institute of Psychiatry, Clinical Neuroendocrinology Group, Munich, Germany, 2Institute for  Stroke and Dementia Research and 3Institute of Clinical Neuroimmunology, Klinikum der Universität  München, Ludwig-Maximilians Universität LMU, Munich, Germany *(A Kopczak and A-M Schumacher contributed equally to this work) Summary The autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) syndrome is a genetic disorder caused  by a mutation in the autoimmune regulator (AIRE) gene.",Non-OADS,/arxiv_data1/oa_pdf/a5/b0/edmcr-2017-170010.PMC5445423.pdf
"A Kopczak,   A-M Schumacher and othersLimbic encephalitis in APECEDID: 17-0010; May 2017 DOI: 10.1530/EDM-17-0010 http://www.edmcasereports.com  2it is also known as autoimmune polyendocrinopathy– candidiasis–ectodermal dystrophy (APECED) syndrome.",Non-OADS,/arxiv_data1/oa_pdf/a5/b0/edmcr-2017-170010.PMC5445423.pdf
"A Kopczak,   A-M Schumacher and othersID: 17-0010; May 2017 DOI: 10.1530/EDM-17-0010 Limbic encephalitis in APECED http://www.edmcasereports.com  3temporary increase of HC dosage.",Non-OADS,/arxiv_data1/oa_pdf/a5/b0/edmcr-2017-170010.PMC5445423.pdf
"A Kopczak,   A-M Schumacher and othersLimbic encephalitis in APECEDID: 17-0010; May 2017 DOI: 10.1530/EDM-17-0010 http://www.edmcasereports.com  4It is known that GAD antibodies in the CNS may cause  stiff person syndrome, cerebellar syndrome and LE.",Non-OADS,/arxiv_data1/oa_pdf/a5/b0/edmcr-2017-170010.PMC5445423.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0032; May 2017 DOI: 10.1530/EDM-17-0032Primary cutaneous B-cell  lymphoma and T2DMA Mantovani and others Primary cutaneous B-cell lymphoma and  chronic leg ulcers in a patient with type 2 diabetes Alessandro Mantovani1, Fabrizia Perrone1, Vincenzo Stoico1, Isabella Pichiri1,  Laura Salvotelli1, Ilaria Teobaldi1, Massimiliano Bruti2, Michela Conti3, Luca Cima4,  Albino Eccher4 and Enzo Bonora1 1Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, 2Division of Plastic  Surgery, Department of Surgery, 3Division of Infectious Disease, Department of Medicine and 4Division  of Pathology Unit, Department of Diagnostics and Public Health, University and Azienda Ospedaliera  Universitaria Integrata of Verona, Verona, Italy Summary The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide.",Non-OADS,/arxiv_data1/oa_pdf/88/21/edmcr-2017-170032.PMC5445424.pdf
"PROOF ONLY A Mantovani and others Primary cutaneous B-cell  lymphoma and T2DMID: 17-0032; May 2017 DOI: 10.1530/EDM-17-0032 http://www.edmcasereports.com  2In addition to the excess risk of vascular and infectious  disease, recent data strongly suggest that patients with T2DM had a two-fold increased risk of dying from cancer, including lymphomas, compared to those without diabetes ( 2 ,  3 ).",Non-OADS,/arxiv_data1/oa_pdf/88/21/edmcr-2017-170032.PMC5445424.pdf
PROOF ONLY A Mantovani and othersID: 17-0032; May 2017 DOI: 10.1530/EDM-17-0032 Primary cutaneous B-cell  lymphoma and T2DM http://www.edmcasereports.com  3to the reduction of inflammatory markers (CRP 5  mg/L)  and the improvement of the inflammatory component  of the ulcers.,Non-OADS,/arxiv_data1/oa_pdf/88/21/edmcr-2017-170032.PMC5445424.pdf
"PROOF ONLY A Mantovani and others Primary cutaneous B-cell  lymphoma and T2DMID: 17-0032; May 2017 DOI: 10.1530/EDM-17-0032 http://www.edmcasereports.com  4To date, the physiopathology of PCDLBCL is not  completely understood.",Non-OADS,/arxiv_data1/oa_pdf/88/21/edmcr-2017-170032.PMC5445424.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0110; May 2017 DOI: 10.1530/EDM-16-0110ACTH secreting medullary  thyroid cancerA A Wijewardene   and others ACTH-secreting medullary thyroid cancer:   a case series Ayanthi A Wijewardene1, Sarah J Glastras2,3,4, Diana L Learoyd2,4, Bruce G Robinson2,4  and Venessa H M Tsang2,4 Departments of 1Medicine, 2Endocrinology, Diabetes & Metabolism, Royal North Shore Hospital, Sydney, Australia,  3Kolling Institute of Medical Research, and 4Sydney Medical School, University of Sydney, Sydney, Australia Summary Medullary thyroid cancer (MTC) is a rare neuroendocrine tumour that originates from the parafollicular cells of the  thyroid gland.",Non-OADS,/arxiv_data1/oa_pdf/5c/cf/edmcr-2017-160110.PMC5445425.pdf
"A A Wijewardene   and othersACTH secreting medullary  thyroid cancerID: 16-0110; May 2017 DOI: 10.1530/EDM-16-0110 http://www.edmcasereports.com  2Case 2 A 53-year-old male presented in 2002 with increasing back  pain associated with Cushingoid features of weight gain,  facial plethora, abdominal striae and proximal myopathy.",Non-OADS,/arxiv_data1/oa_pdf/5c/cf/edmcr-2017-160110.PMC5445425.pdf
"A A Wijewardene   and othersID: 16-0110; May 2017 DOI: 10.1530/EDM-16-0110 ACTH secreting medullary  thyroid cancer http://www.edmcasereports.com  3elevated 24-h urinary cortisol at 15 708 nmol (NR <300),  early morning cortisol of 2045 nmol (NR: 25–695) and an  inappropriately normal ACTH level of 8.7 pmol/L (NR:  0–12).",Non-OADS,/arxiv_data1/oa_pdf/5c/cf/edmcr-2017-160110.PMC5445425.pdf
"A A Wijewardene   and othersACTH secreting medullary  thyroid cancerID: 16-0110; May 2017 DOI: 10.1530/EDM-16-0110 http://www.edmcasereports.com  4Ketoconazole was recommenced and titrated to   200 mg twice daily, though there was poor drug compliance  due to gastrointestinal side effects.",Non-OADS,/arxiv_data1/oa_pdf/5c/cf/edmcr-2017-160110.PMC5445425.pdf
A A Wijewardene   and othersID: 16-0110; May 2017 DOI: 10.1530/EDM-16-0110 ACTH secreting medullary  thyroid cancer http://www.edmcasereports.com  5endocrine syndromes associated with RET proto-oncogene  mutation ( 2).,Non-OADS,/arxiv_data1/oa_pdf/5c/cf/edmcr-2017-160110.PMC5445425.pdf
A A Wijewardene   and othersACTH secreting medullary  thyroid cancerID: 16-0110; May 2017 DOI: 10.1530/EDM-16-0110 http://www.edmcasereports.com  6Declaration of interest The authors declare that there is no conflict of interest that could be  perceived as prejudicing the impartiality of the research reported.,Non-OADS,/arxiv_data1/oa_pdf/5c/cf/edmcr-2017-160110.PMC5445425.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0029; May 2017 DOI: 10.1530/EDM-17-0029Pachydermoperiostosis N R A Abdullah and others Pachydermoperiostosis: a rare mimicker  of acromegaly Noor Rafhati Adyani Abdullah1, Wong Lok Chin Jason2 and Azraai Bahari Nasruddin1 1Endocrinology Unit, Department of Medicine, Putrajaya Hospital, Putrajaya, Malaysia and 2Department  of Medicine, National University of Malaysia Medical Centre, Kuala Lumpur, Malaysia Summary Pachydermoperiostosis is a very rare osteoarthrodermopathic disorder whose clinical and radiographic presentations may  mimic those of acromegaly.",Non-OADS,/arxiv_data1/oa_pdf/b3/c3/edmcr-2017-170029.PMC5445428.pdf
p N R A Abdullah and others PachydermoperiostosisID: 17-0029; May 2017 DOI: 10.1530/EDM-17-0029 http://www.edmcasereports.com  2Case presentation A 17-year-old male was referred to the endocrinology  clinic with complaints of bilateral enlargement of his hand and feet for the past 2 years.,Non-OADS,/arxiv_data1/oa_pdf/b3/c3/edmcr-2017-170029.PMC5445428.pdf
p N R A Abdullah and othersID: 17-0029; May 2017 DOI: 10.1530/EDM-17-0029 Pachydermoperiostosis http://www.edmcasereports.com  3Stage was 3.,Non-OADS,/arxiv_data1/oa_pdf/b3/c3/edmcr-2017-170029.PMC5445428.pdf
p N R A Abdullah and others PachydermoperiostosisID: 17-0029; May 2017 DOI: 10.1530/EDM-17-0029 http://www.edmcasereports.com  4prominent soft tissue thickening of both knees and hands  and posterior cortical thickening with subperiosteal new bone formation of bilateral fibula ( Figs.,Non-OADS,/arxiv_data1/oa_pdf/b3/c3/edmcr-2017-170029.PMC5445428.pdf
"p N R A Abdullah and othersID: 17-0029; May 2017 DOI: 10.1530/EDM-17-0029 Pachydermoperiostosis http://www.edmcasereports.com  5Discussion Pachydermoperiostosis is a rare hereditary disorder,  which mainly appears as an autosomal dominant pattern with variable penetrance ( 1 ,  2 ).",Non-OADS,/arxiv_data1/oa_pdf/b3/c3/edmcr-2017-170029.PMC5445428.pdf
p N R A Abdullah and others PachydermoperiostosisID: 17-0029; May 2017 DOI: 10.1530/EDM-17-0029 http://www.edmcasereports.com  6and enlargement of the distal phalanx of the digits  along with hypertrophy of the bones and soft tissue are described in patients with acromegaly.,Non-OADS,/arxiv_data1/oa_pdf/b3/c3/edmcr-2017-170029.PMC5445428.pdf
"p N R A Abdullah and othersID: 17-0029; May 2017 DOI: 10.1530/EDM-17-0029 Pachydermoperiostosis http://www.edmcasereports.com  7 10 Lee S, Park SY, Kwon HJ, Lee C-H, Kim O-H & Rhee Y 2016  Identification of the Mutations in the Prostaglandin Transporter Gene, SLCO2A1 and Clinical Characterization in Korean Patients with  Pachydermoperiostosis.",Non-OADS,/arxiv_data1/oa_pdf/b3/c3/edmcr-2017-170029.PMC5445428.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0019; May 2017 DOI: 10.1530/EDM-17-0019Euthyroid athyroxinemia N Woodhouse and others Euthyroid athyroxinemia – a novel endocrine  syndrome Nicholas Woodhouse, Fatima Bahowairath  and Omayma Elshafie Department of Medicine, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman Summary A 55-year-old female was referred with abnormal thyroid function tests (TFTs); the free thyroxine level (FT4) was  undetectable <3.3 pmol/L (normal: 7.9–14.4), while her FT3, TSH and urinary iodine levels were normal.",Non-OADS,/arxiv_data1/oa_pdf/6c/7c/edmcr-2017-170019.PMC5445432.pdf
N Woodhouse and others Euthyroid athyroxinemiaID: 17-0019; May 2017 DOI: 10.1530/EDM-17-0019 http://www.edmcasereports.com  2during the scan).,Non-OADS,/arxiv_data1/oa_pdf/6c/7c/edmcr-2017-170019.PMC5445432.pdf
"N Woodhouse and othersID: 17-0019; May 2017 DOI: 10.1530/EDM-17-0019 Euthyroid athyroxinemia http://www.edmcasereports.com  3Funding This research did not receive any specific grant from any funding agency in  the public, commercial or not-for-profit sector.",Non-OADS,/arxiv_data1/oa_pdf/6c/7c/edmcr-2017-170019.PMC5445432.pdf
"p This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0004; May 2017 DOI: 10.1530/EDM-17-0004Tumor produced Pro-IGF2  and hypoglycaemiaS A A van den Berg and  C G Krol Pro-IGF2-induced hypoglycaemia associated  with hepatocellular carcinoma S A A van den Berg1,† and C G Krol2 Departments of 1Clinical Chemistry and Hematology and 2Internal Medicine, Amphia Hospital, Breda,  The Netherlands †(S A A van den Berg is now at Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam,  The Netherlands) Summary We present a patient (87 years, female) who was admitted to the emergency department because of loss of consciousness.",Non-OADS,/arxiv_data1/oa_pdf/5c/67/edmcr-2017-170004.PMC5445433.pdf
p S A A van den Berg and  C G KrolTumor produced Pro-IGF2  and hypoglycaemiaID: 17-0004; May 2017 DOI: 10.1530/EDM-17-0004 http://www.edmcasereports.com  2head and neck cancer ( 2).,Non-OADS,/arxiv_data1/oa_pdf/5c/67/edmcr-2017-170004.PMC5445433.pdf
p S A A van den Berg and  C G KrolID: 17-0004; May 2017 DOI: 10.1530/EDM-17-0004 Tumor produced Pro-IGF2  and hypoglycaemia http://www.edmcasereports.com  3Treatment is aimed at achieving and maintaining  euglycaemia.,Non-OADS,/arxiv_data1/oa_pdf/5c/67/edmcr-2017-170004.PMC5445433.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0026; May 2017 DOI: 10.1530/EDM-17-0026Pheochromocytomatosis and  TMEM127 mutationR Yu and others Pheochromocytomatosis associated with a  novel TMEM127  mutation Run Yu1, Danielle Sharaga2, Christopher Donner3, M Fernando Palma Diaz4,  Masha J Livhits5 and Michael W Yeh5 1Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, Los Angeles,  USA, 2Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, USA, 3Sansum Clinic,   Santa Barbara, California, USA, 4Department of Pathology and 5Section of Endocrine Surgery, UCLA David  Geffen School of Medicine, Los Angeles, USA Summary Pheochromocytomatosis, a very rare form of pheochromocytoma recurrence, refers to new, multiple, and often small  pheochromocytomas growing in and around the surgical resection bed of a previous adrenalectomy for a solitary  pheochromocytoma.",Non-OADS,/arxiv_data1/oa_pdf/a0/fa/edmcr-2017-170026.PMC5445434.pdf
R Yu and others Pheochromocytomatosis and  TMEM127 mutationID: 17-0026; May 2017 DOI: 10.1530/EDM-17-0026 http://www.edmcasereports.com  2the life-time risk ~20–25% ( 1).,Non-OADS,/arxiv_data1/oa_pdf/a0/fa/edmcr-2017-170026.PMC5445434.pdf
"R Yu and othersID: 17-0026; May 2017 DOI: 10.1530/EDM-17-0026 Pheochromocytomatosis and  TMEM127 mutation http://www.edmcasereports.com  3inferior vena cava was also found, which was removed  separately.",Non-OADS,/arxiv_data1/oa_pdf/a0/fa/edmcr-2017-170026.PMC5445434.pdf
R Yu and others Pheochromocytomatosis and  TMEM127 mutationID: 17-0026; May 2017 DOI: 10.1530/EDM-17-0026 http://www.edmcasereports.com  4pheochromocytoma and further revealed a 0.1-cm  pheochromocytoma and a few even smaller ones ( Fig.,OADS,/arxiv_data1/oa_pdf/a0/fa/edmcr-2017-170026.PMC5445434.pdf
R Yu and othersID: 17-0026; May 2017 DOI: 10.1530/EDM-17-0026 Pheochromocytomatosis and  TMEM127 mutation http://www.edmcasereports.com  5The patient’s children were recommended to undergo  genetic testing for the same mutation.,Non-OADS,/arxiv_data1/oa_pdf/a0/fa/edmcr-2017-170026.PMC5445434.pdf
"R Yu and others Pheochromocytomatosis and  TMEM127 mutationID: 17-0026; May 2017 DOI: 10.1530/EDM-17-0026 http://www.edmcasereports.com  6ruptured, she should have been followed more closely  for recurrence.",Non-OADS,/arxiv_data1/oa_pdf/a0/fa/edmcr-2017-170026.PMC5445434.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0044; May 2017 DOI: 10.1530/EDM-17-0044Pituitary apoplexy and hiccups G Simsek Bagir and others Stubborn hiccups as a sign of massive  apoplexy in a naive acromegaly patient with  pituitary macroadenoma Gulay Simsek Bagir1, Soner Civi2, Ozgur Kardes2, Fazilet Kayaselcuk3 and  Melek Eda Ertorer1 Departments of 1Endocrinology, 2Neurosurgery, and 3Pathology, Baskent University Faculty of Medicine,  Adana, Turkey Summary Pituitary apoplexy (PA) may very rarely present with hiccups.",Non-OADS,/arxiv_data1/oa_pdf/e6/18/edmcr-2017-170044.PMC5445435.pdf
G Simsek Bagir and others Pituitary apoplexy and hiccupsID: 17-0044; May 2017 DOI: 10.1530/EDM-17-0044 http://www.edmcasereports.com  2stubborn hiccups that began five days before.,Non-OADS,/arxiv_data1/oa_pdf/e6/18/edmcr-2017-170044.PMC5445435.pdf
"G Simsek Bagir and othersID: 17-0044; May 2017 DOI: 10.1530/EDM-17-0044 Pituitary apoplexy and hiccups http://www.edmcasereports.com  3On the third day of his admission, growth hormone  suppression test with 75 g oral glucose was performed.",Non-OADS,/arxiv_data1/oa_pdf/e6/18/edmcr-2017-170044.PMC5445435.pdf
"G Simsek Bagir and others Pituitary apoplexy and hiccupsID: 17-0044; May 2017 DOI: 10.1530/EDM-17-0044 http://www.edmcasereports.com  4very rarely present with hiccups, which is probably due to  midbrain involvement.",Non-OADS,/arxiv_data1/oa_pdf/e6/18/edmcr-2017-170044.PMC5445435.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0002; May 2017 DOI: 10.1530/EDM-17-0002Thyrotoxicosis reveals  adrenal lymphomaC Roque and others Thyrotoxicosis leading to adrenal crises  reveals primary bilateral adrenal lymphoma Catarina Roque1, Ricardo Fonseca1, Carlos Tavares Bello1, Carlos Vasconcelos1,  António Galzerano2 and Sância Ramos2 1Endocrinology Diabetes and Metabolism Clinic and 2Anatomopathology Department, Hospital de Egas  Moniz C.H.L.O.-E.P.E, Lisbon, Portugal Summary Primary adrenal lymphoma is a rare malignancy.",Non-OADS,/arxiv_data1/oa_pdf/78/b1/edmcr-2017-170002.PMC5445442.pdf
"p C Roque and others Thyrotoxicosis reveals  adrenal lymphomaID: 17-0002; May 2017 DOI: 10.1530/EDM-17-0002 http://www.edmcasereports.com  2of primary adrenal lymphoma, revealed in the context of  amiodarone-induced thyrotoxicosis.",Non-OADS,/arxiv_data1/oa_pdf/78/b1/edmcr-2017-170002.PMC5445442.pdf
p C Roque and othersID: 17-0002; May 2017 DOI: 10.1530/EDM-17-0002 Thyrotoxicosis reveals  adrenal lymphoma http://www.edmcasereports.com  3atelectasis of the inferior lobe.,Non-OADS,/arxiv_data1/oa_pdf/78/b1/edmcr-2017-170002.PMC5445442.pdf
"p C Roque and others Thyrotoxicosis reveals  adrenal lymphomaID: 17-0002; May 2017 DOI: 10.1530/EDM-17-0002 http://www.edmcasereports.com  4<1.1 (1–16)  pg/mL, ACTH <5 (<46)  pg/mL, CEA 13.5 (<5),  CA125 425 (<35); CA19.9, CA15.3 and NSE were normal.",Non-OADS,/arxiv_data1/oa_pdf/78/b1/edmcr-2017-170002.PMC5445442.pdf
"p C Roque and othersID: 17-0002; May 2017 DOI: 10.1530/EDM-17-0002 Thyrotoxicosis reveals  adrenal lymphoma http://www.edmcasereports.com  5 3 Kung AW, Pun KK, Lam K, Wang C & Leung CY 1990  Addisonian crisis as presenting feature in malignancies.",Non-OADS,/arxiv_data1/oa_pdf/78/b1/edmcr-2017-170002.PMC5445442.pdf
"PROOF ONLY This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0003; May 2017 DOI: 10.1530/EDM-17-0003Gordon C2305 crossover  case studyM B Gordon and K L Spiller Pasireotide in an insulin-requiring diabetic  acromegalic patient without worsening of  hyperglycemia Murray B Gordon  and Kellie L Spiller Allegheny Neuroendocrinology Center, Departments of Medicine and Neurosurgery, Allegheny General Hospital,  Pittsburgh, Pennsylvania, USA Summary Long-acting pasireotide is an effective treatment option for acromegaly, but it is associated with hyperglycemia, which  could impact its use in patients with diabetes.",Non-OADS,/arxiv_data1/oa_pdf/cb/3a/edmcr-2017-170003.PMC5445444.pdf
"PROOF ONLY M B Gordon and K L Spiller Gordon C2305 crossover  case studyID: 17-0003; May 2017 DOI: 10.1530/EDM-17-0003 http://www.edmcasereports.com  2features, increased perspiration, headaches, paresthesia,  sexual dysfunction, skeletal growth and soft-tissue  swelling.",Non-OADS,/arxiv_data1/oa_pdf/cb/3a/edmcr-2017-170003.PMC5445444.pdf
"PROOF ONLY M B Gordon and K L SpillerID: 17-0003; May 2017 DOI: 10.1530/EDM-17-0003 Gordon C2305 crossover  case study http://www.edmcasereports.com  3After 3  months, IGF-1 (344.1  ng/mL) and GH (1.6  ng/ mL) levels remained elevated ( Fig.",OADS,/arxiv_data1/oa_pdf/cb/3a/edmcr-2017-170003.PMC5445444.pdf
"PROOF ONLY M B Gordon and K L Spiller Gordon C2305 crossover  case studyID: 17-0003; May 2017 DOI: 10.1530/EDM-17-0003 http://www.edmcasereports.com  4IGF-1 levels normalized reaching 193.0  ng/mL, and  GH levels further decreased to 0.2  ng/mL.",Non-OADS,/arxiv_data1/oa_pdf/cb/3a/edmcr-2017-170003.PMC5445444.pdf
"PROOF ONLY M B Gordon and K L SpillerID: 17-0003; May 2017 DOI: 10.1530/EDM-17-0003 Gordon C2305 crossover  case study http://www.edmcasereports.com  5continued to take metformin 1000  mg b.i.d., while dosing  of insulin varied due to changes in diet and exercise  (Table  1 ).",Non-OADS,/arxiv_data1/oa_pdf/cb/3a/edmcr-2017-170003.PMC5445444.pdf
"PROOF ONLY M B Gordon and K L Spiller Gordon C2305 crossover  case studyID: 17-0003; May 2017 DOI: 10.1530/EDM-17-0003 http://www.edmcasereports.com  6insulin-requiring type 2 diabetes, the patient presented  here did not experience a long-term increase in HbA1c  levels after initiating pasireotide, likely because a long- term stable reduction in GH levels resulted in an increase  in insulin sensitivity.",Non-OADS,/arxiv_data1/oa_pdf/cb/3a/edmcr-2017-170003.PMC5445444.pdf
"PROOF ONLY M B Gordon and K L SpillerID: 17-0003; May 2017 DOI: 10.1530/EDM-17-0003 Gordon C2305 crossover  case study http://www.edmcasereports.com  7Pasireotide LAR maintains inhibition of GH and IGF-1 in patients  with acromegaly for up to 25 months: results from the blinded  extension phase of a randomized, double-blind, multicenter, phase III  study.",Non-OADS,/arxiv_data1/oa_pdf/cb/3a/edmcr-2017-170003.PMC5445444.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0155; May 2017 DOI: 10.1530/EDM-16-0155Insulinoma in a 10 year   old boyN Ahmad and others Recurrent insulinoma in a 10-year-old boy with  Down’s syndrome Noman Ahmad, Abdulmonem Mohammed Almutawa, Mohamed Ziyad Abubacker,  Hossam Ahmed Elzeftawy and Osama Abdullah Bawazir King Faisal Specialist Hospital and Research Centre, Pediatrics, Jeddah, SA, Saudi Arabia Summary An insulinoma is a rare tumour with an incidence of four cases per million per year in adults.",Non-OADS,/arxiv_data1/oa_pdf/f0/f1/edmcr-2017-160155.PMC5445445.pdf
"PROOF ONLY N Ahmad and others Insulinoma in a 10 year   old boyID: 16-0155; May 2017 DOI: 10.1530/EDM-16-0155 http://www.edmcasereports.com  R2presenting with non-ketotic hypoglycaemia should  be evaluated for hyperinsulinism, pituitary hormone deficiencies and fatty acid oxidation defects ( 1 ).",Non-OADS,/arxiv_data1/oa_pdf/f0/f1/edmcr-2017-160155.PMC5445445.pdf
PROOF ONLY N Ahmad and othersID: 16-0155; May 2017 DOI: 10.1530/EDM-16-0155 Insulinoma in a 10 year   old boy http://www.edmcasereports.com  R3Investigations He was admitted to our unit for diagnostic workup.,Non-OADS,/arxiv_data1/oa_pdf/f0/f1/edmcr-2017-160155.PMC5445445.pdf
"PROOF ONLY N Ahmad and others Insulinoma in a 10 year   old boyID: 16-0155; May 2017 DOI: 10.1530/EDM-16-0155 http://www.edmcasereports.com  R4revealed a well-differentiated neuroendocrine tumour  grade 1, with a size of 2   cm, mitotic rate of <2/10 hpf  and Ki-67 proliferative index of <2% ( Fig.",Non-OADS,/arxiv_data1/oa_pdf/f0/f1/edmcr-2017-160155.PMC5445445.pdf
PROOF ONLY N Ahmad and othersID: 16-0155; May 2017 DOI: 10.1530/EDM-16-0155 Insulinoma in a 10 year   old boy http://www.edmcasereports.com  R5at the age of 35 years ( 11 ); no cases have been reported in  the paediatric population Down’s syndrome has a well-known association with  neoplasms.,Non-OADS,/arxiv_data1/oa_pdf/f0/f1/edmcr-2017-160155.PMC5445445.pdf
PROOF ONLY N Ahmad and others Insulinoma in a 10 year   old boyID: 16-0155; May 2017 DOI: 10.1530/EDM-16-0155 http://www.edmcasereports.com  R6localisation of the insulinoma can provide an opportunity  for laparoscopic resection.,Non-OADS,/arxiv_data1/oa_pdf/f0/f1/edmcr-2017-160155.PMC5445445.pdf
"The region includes the entire Carpathian Mountains and large part of the Danube catchment, which have been recently receiv-ing increased attention in EU coordinated actions, suchas the Carpathian EcoRegion Initiative (http://www.carpates.org) and the Danube Strategy (http://www.danube-region.eu).",Non-OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
"To support the adjustment of E-OBS by CRUTS 1.2, we performed additional evaluation of theaccuracy of both E-OBS and CRU TS datasets, usingthe CarpatClim dataset (http://www.carpatclim-eu.org/;Szalai et al.",OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
"Results –structure and dissemination of the FORESEE FORESEE data are primarily available in NetCDF for- mat, which was designated to contain both data andmetadata in an easily accessible format (http://www.unidata.ucar.edu/).",OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
"Once a request has been sent out through the FORESEE website (http://nim-bus.elte.hu/FORESEE), the requested ﬁles (one ﬁle per model per variable) are made available for downloadfrom the site.",OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
The dataset is also available via Zenodo(http://zenodo.org/record/9614?ln=en; doi: 10.5281/zenodo.9614).,OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
"The REST style web service (Fielding and Taylor, 2002) of FORESEE database is provided by the ‘ecos ’ server of the Centre for Ecological Research of theHungarian Academy of Sciences, catalogued in ‘Biodi- versityCatalogue ’–The Biodiversity Sciences Web Ser- vices Registry for discovering, registering, annotating,and monitoring biodiversity web services (http://www.biodiversitycatalogue.org) powered by BioCata-logue (Bhagat et al.",OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
This service provides tai- lored access to the database at http://nimbus.elte.hu/ FORESEE/map_query/index.html.,OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
"The base URL of the service is ‘http://ecos.ok- ologia.mta.hu:5000/foresee ’, the REST endpoint is ‘/ ﬁnd’(GET method).",OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
The development ofweb services and the creation of work ﬂows is a major task within the frame of the BioVeL project (http://www.biovel.eu).,Non-OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
"Acknowledgements We acknowledge the E-OBS dataset of the EU FP6project ENSEMBLES (http://ensembleseu.metof-ﬁce.com), and the data providers in the ECA&D project (http://eca.knmi.nl).",Non-OADS,/arxiv_data1/oa_pdf/95/04/GDJ3-2-1.PMC5445562.pdf
9) were converted from genome assembly mm9 to mm10 using the LiftOver utility inUCSC ( http://genome.ucsc.edu ).,OADS,/arxiv_data1/oa_pdf/2c/02/41514_2017_Article_7.PMC5445584.pdf
http://www.nature.com/nm/journal/v11/n6/suppinfo/nm1242_S1.html .,OADS,/arxiv_data1/oa_pdf/2c/02/41514_2017_Article_7.PMC5445584.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ .",Non-OADS,/arxiv_data1/oa_pdf/2c/02/41514_2017_Article_7.PMC5445584.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a1/98/kew498.PMC5445601.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1b/0c/kew477.PMC5445602.pdf
"Monochromatic Clique Decompositions of Graphs Henry Liu,1Oleg Pikhurko,2and T eresa Sousa3 1CENTRO DE MATEM ´ATICA E APLICAC ¸˜OES F A C U L D A D ED EC I ˆENCIAS E TECNOLOGIA UNIVERSIDADE NOVA DE LISBOA CAMPUS DE CAPARICA, 2829-516 CAPARICA, PORTUGAL E-mail: h.liu@fct.unl.pt 2MATHEMATICS INSTITUTE AND DIMAP UNIVERSITY OF WARWICK COVENTRY CV4 7AL, UNITED KINGDOM http://homepages.warwick.ac.uk/staff/O.Pikhurko 3DEPARTAMENTO DE MATEM ´ATICA AND CENTRO DE MATEM ´ATICA E APLICAC ¸˜OES F A C U L D A D ED EC I ˆENCIAS E TECNOLOGIA UNIVERSIDADE NOVA DE LISBOA CAMPUS DE CAPARICA, 2829-516 CAPARICA, PORTUGAL E-mail: tmjs@fct.unl.pt Received January 23, 2014; Revised November 11, 2014 Published online 12 January 2015 in Wiley Online Library (wileyonlinelibrary.com).",Non-OADS,/arxiv_data1/oa_pdf/15/4c/JGT-80-287.PMC5445619.pdf
31(http://lgsun.grc.nia.nih.gov/ANOVA/ ) and Genome Network Platform Viewer from the National Institute of Geneticsin Japan ( http://genomenetwork.nig.ac.jp/ ).,OADS,/arxiv_data1/oa_pdf/8a/3a/41514_2016_Article_1.PMC5445629.pdf
"Gene expression pro ﬁles used in this study were deposited in NCBI’s Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/ , accession number GSE71867).",OADS,/arxiv_data1/oa_pdf/8a/3a/41514_2016_Article_1.PMC5445629.pdf
"© 2017 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comSNI: NeurovascularOriginal Article Safe time duration for temporary middle cerebral artery occlusion  in aneurysm surgery based on motor‑evoked potential monitoring Jun Tanabe, Tatsuya Ishikawa, Junta Moroi Department of Surgical Neurology, Research Institute for Brain and Blood Vessels‑AKITA, Akita, Japan E‑mail: *Jun Tanabe ‑ j.tanabe@akita‑noken.jp; Tatsuya Ishikawa ‑ teddyish@akita‑noken.jp; Junta Moroi ‑ moroi@akita‑noken.jp   *Corresponding author Received: 19 October 16  Accepted: 20 March 17  Published: 10 May 17 Abstract Background: Temporary vessel occlusion of the parent artery is an essential  technique for aneurysm surgery.",Non-OADS,/arxiv_data1/oa_pdf/2a/66/SNI-8-79.PMC5445649.pdf
"Surg Neurol Int 2017;8:79. http://surgicalneurologyint.com/Safe-time-duration-for-temporary-middle- cerebral-artery-occlusion-in-aneurysm-surgery-based-on-motor -evoked-potential- monitoring/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/2a/66/SNI-8-79.PMC5445649.pdf
"Surgical Neurology International 2017, 8:79  http://www.surgicalneurologyint.com/content/8/1/79on electrical recordings in experimental studies, and the  efficacy of using somatosensory‑evoked potentials (SEP)  during aneurysm surgery to confirm sufficient cerebral  circulation was subsequently reported.",Non-OADS,/arxiv_data1/oa_pdf/2a/66/SNI-8-79.PMC5445649.pdf
"Surgical Neurology International 2017, 8:79  http://www.surgicalneurologyint.com/content/8/1/79was applied at M1.",Non-OADS,/arxiv_data1/oa_pdf/2a/66/SNI-8-79.PMC5445649.pdf
"Surgical Neurology International 2017, 8:79  http://www.surgicalneurologyint.com/content/8/1/79this LSA, particularly in the presence of subarachnoid  hemorrhage.",Non-OADS,/arxiv_data1/oa_pdf/2a/66/SNI-8-79.PMC5445649.pdf
"OPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com SNI: InfectionEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USA © 2017 Surgical Neurology International | Published by Wolters Kluwer - MedknowCase Report Pseudotumoral neuroparacoccidioidomycosis of the posterior  fossa: A  case report and review of the literature Luiz Antonio Jorge Jr, Seizo Yamashita, André Petean Trindade, Luiz Antonio Lima Resende1,  Marco Antonio Zanini1, José Cândido Caldeira Xavier Jr2, Marcelo Padovani de Toledo Moraes2 Departments of Tropical Diseases and Imaging Diagnosis, 1Neurology and Neurosurgery, 2Pathology, School of Medicine, University of São Paulo State, São Paulo, Brazil E‑mail:  Luiz Antonio Jorge Jr ‑ lajjunior@gmail.com; *Seizo Yamashita ‑ seizo_eid@uol.com.br; André Petean Trindade ‑ andreptrindade@hotmail.com;   Luiz Antonio Lima Resende ‑ ladlr@gmail.com; Marco Antonio Zanini ‑ mzanini@fmb.unesp.br; José Cândido Caldeira Xavier Jr ‑ josecandidojr@yahoo.com.br;  Marcelo Padovani de T oledo Moraes ‑ mmoraes@fmb.unesp.br   *Corresponding author Received: 01 June 16  Accepted: 01 December 16  Published: 10 May 17 Abstract Background:  Paracoccidioidomycosis is a systemic mycosis of significant  importance in some Latin American countries.",Non-OADS,/arxiv_data1/oa_pdf/5a/aa/SNI-8-76.PMC5445650.pdf
"Surg Neurol Int  2017;8:76. http://surgicalneurologyint.com/Pseudotumoral-neuroparacoccidioidomycosis-of- the-posterior-fossa:-A case-report-and-review-of-the-literature/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/5a/aa/SNI-8-76.PMC5445650.pdf
"Surgical Neurology International 2017, 8:76  http://www.surgicalneurologyint.com/content/8/1/76Males are the most affected, especially rural workers  aged 30–50 years.",Non-OADS,/arxiv_data1/oa_pdf/5a/aa/SNI-8-76.PMC5445650.pdf
"Surgical Neurology International 2017, 8:76  http://www.surgicalneurologyint.com/content/8/1/76DISCUSSION A review of national and international literature  regarding evaluation of NPCM by neuroimaging  methods shows the most common occurrence of  NPCM, usually as with multiple granulomas, is the  pseudotumoral form.",Non-OADS,/arxiv_data1/oa_pdf/5a/aa/SNI-8-76.PMC5445650.pdf
"Surgical Neurology International 2017, 8:76  http://www.surgicalneurologyint.com/content/8/1/76increased choline peak.",Non-OADS,/arxiv_data1/oa_pdf/5a/aa/SNI-8-76.PMC5445650.pdf
"© 2017 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: Nancy E. Epstein, MD Winthrop University Hospital, Mineola, NY, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comSNI: SpineOriginal Article Preventive effect of tamsulosin on postoperative urinary retention  in neurosurgical patients Azam Basheer, Mohammed Alsaidi, Lonni Schultz1, Mokbel Chedid, Muwaffak Abdulhak,  Donald Seyfried Departments of Neurosurgery and 1Public Health Sciences, Henry Ford Hospital, Detroit, Michigan, USA E‑mail: *Azam Basheer ‑ abashee1@hfhs.org; Mohammed Alsaidi ‑ mhka80@gmail.com; Lonni Schultz ‑ lschult1@hfhs.org;   Mokbel Chedid ‑ mchedid1@hfhs.org; Muwaffak Abdulhak ‑ mabdulh1@hfhs.org; Donald Seyfried ‑ dseyfri1@hfhs.org   *Corresponding author Received: 04 January 17  Accepted: 02 March 17  Published: 10 May 17 Abstract Background: Postoperative urinary retention (POUR) is common in neurosurgical  patients.",Non-OADS,/arxiv_data1/oa_pdf/21/09/SNI-8-75.PMC5445651.pdf
"Surg Neurol Int 2017;8:75. http://surgicalneurologyint.com/Preventive-effect-of-tamsulosin-on-postoperative-urinary-retention-in-neurosurgical-patients/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and  build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/21/09/SNI-8-75.PMC5445651.pdf
"Surgical Neurology International 2017, 8:75  http://www.surgicalneurologyint.com/content/8/1/75INTRODUCTION Postoperative urinary retention (POUR) has been  defined as the inability to void despite a full  bladder.",Non-OADS,/arxiv_data1/oa_pdf/21/09/SNI-8-75.PMC5445651.pdf
"Surgical Neurology International 2017, 8:75  http://www.surgicalneurologyint.com/content/8/1/75and discharge disposition (P = 0.394).",Non-OADS,/arxiv_data1/oa_pdf/21/09/SNI-8-75.PMC5445651.pdf
"Surgical Neurology International 2017, 8:75  http://www.surgicalneurologyint.com/content/8/1/75Tamsulosin was first developed in Japan and marketed in  1996 under the trade name Flomax®.",Non-OADS,/arxiv_data1/oa_pdf/21/09/SNI-8-75.PMC5445651.pdf
"Surgical Neurology International 2017, 8:75  http://www.surgicalneurologyint.com/content/8/1/75et al .",Non-OADS,/arxiv_data1/oa_pdf/21/09/SNI-8-75.PMC5445651.pdf
"Surgical Neurology International 2017, 8:75  http://www.surgicalneurologyint.com/content/8/1/75however, the type of surgery had little to no bearing on  the development of POUR in the tamsulosin and placebo  groups.",Non-OADS,/arxiv_data1/oa_pdf/21/09/SNI-8-75.PMC5445651.pdf
"© 2017 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comOriginal Article Musculoskeletal neck pain in children and adolescents: Risk  factors and complications Jawad Fares1,2, Mohamad Y. Fares3, Y oussef Fares1 1Department of Neurosurgery, Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, 2Faculty of Medicine, American University of  Beirut, 3Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon E‑mail:  *Jawad Fares ‑ jyf04@mail.aub.edu; Mohamad Y .",Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
"Surg Neurol Int  2017;8:72. http://surgicalneurologyint.com/Musculoskeletal-neck-pain-in-children-and- adolescents:-Risk-factors-and-complications/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
"Surgical Neurology International 2017, 8:72  http://www.surgicalneurologyint.com/content/8/1/72Prevalence data have shown that, in a general population,  the 1‑year incidence of neck pain can be as high as  40%.",Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
"Surgical Neurology International 2017, 8:72  http://www.surgicalneurologyint.com/content/8/1/72all participants (100%) showed strong flexion of the  neck  (≥45  degrees)  when engaged  in the activity.",Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
"Surgical Neurology International 2017, 8:72  http://www.surgicalneurologyint.com/content/8/1/72The weight put on the spine dramatically increases when  flexing the head forward at varying degrees [ Figure  1].",Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
"Surgical Neurology International 2017, 8:72  http://www.surgicalneurologyint.com/content/8/1/72Financial support and sponsorship Nil.",Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
Healthessentials 2015. https://health.clevelandclinic.org/2015/03/ text-neck- is-smartphone- use-causing- your- neck- pain/.,Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
"“The Effects of Texting on Your Eye Health,”  CORRECTVISION 2015. http://www.correctvision.com/eye-health/ effects-of-texting/.",Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
The Telegraph 2014. http://www.telegraph.co.uk/technology/ mobile -phones/10721014/Texting -for-long -periods-could -lower-life- expectancy.html.,Non-OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
HealthData.org 2015.  http://vizhub.healthdata.org/gbd-compare/.,OADS,/arxiv_data1/oa_pdf/b9/ff/SNI-8-72.PMC5445652.pdf
"© 2017 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comSNI: NeurovascularOriginal Article Transradial approach to treating endovascular cerebral  aneurysms: Case series and technical note Javier Goland1,2, Gustavo Fabián Doroszuk1, Silvia Lina Garbugino2, María Paula Ypa2 1Hospital El Cruce Néstor Kirchner, Florencio Varela, Buenos Aires, 2Hospital de Clínicas José de San Martín, CABA, Argentina E‑mail: *Javier Goland ‑ javiergoland@gmail.com; Gustavo Fabián Doroszuk ‑ gusdoro@yahoo.com.ar; Silvia Lina Garbugino ‑ silviagarbu@gmail.com;   María Paula Ypa ‑ paulaypa@gmail.com   *Corresponding author Received: 08 October 16  Accepted: 09 February 17  Published: 10 May 17 Abstract Background:  Several benefits have been described over the years of the transradial  versus femoral endovascular approach to cardiac interventions.",Non-OADS,/arxiv_data1/oa_pdf/ef/15/SNI-8-73.PMC5445653.pdf
"Surg Neurol Int 2017;8:73. http://surgicalneurologyint.com/Transradial-approach-to-treating-endovascular- cerebral-aneurysms:-Case-series-and-technical-note/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/ef/15/SNI-8-73.PMC5445653.pdf
"Surgical Neurology International 2017, 8:73  http://www.surgicalneurologyint.com/content/8/1/73the puncture site (0.1%), and arterial dissections (0.3%).",Non-OADS,/arxiv_data1/oa_pdf/ef/15/SNI-8-73.PMC5445653.pdf
"Surgical Neurology International 2017, 8:73  http://www.surgicalneurologyint.com/content/8/1/73proximal to the wrist, using a 21‑gauge micropuncture  needle [Figure  1].",Non-OADS,/arxiv_data1/oa_pdf/ef/15/SNI-8-73.PMC5445653.pdf
"Surgical Neurology International 2017, 8:73  http://www.surgicalneurologyint.com/content/8/1/73more superficial than femoral and liable location of it  and its adjacent structures has no risk of injury.",Non-OADS,/arxiv_data1/oa_pdf/ef/15/SNI-8-73.PMC5445653.pdf
"Surgical Neurology International 2017, 8:73  http://www.surgicalneurologyint.com/content/8/1/73equity interest, or expert testimony or patent‑licensing  arrangements), and no financial interest (such as personal  or professional relationships, affiliations, knowledge or  beliefs) in subject matter or materials discussed in this  manuscript.",Non-OADS,/arxiv_data1/oa_pdf/ef/15/SNI-8-73.PMC5445653.pdf
"© 2017 Surgical Neurology International | Published by Wolters Kluwer - MedknowOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com SNI: General NeurosurgeryEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USACase Report Abdominal pseudocyst as a complication of ventriculoperitoneal  shunt placement: Review of the literature and a proposed  algorithm for treatment using 4 illustrative cases Samir Kashyap, Hammad Ghanchi, Tanya Minasian, Fanglong Dong1, Dan Miulli Department of Neurosurgery, Riverside University Health System ‑ Medical Center, Cactus Avenue, Moreno Valley, CA, 1Department of Biomedical Science,   Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, California, USA E‑mail: *Samir Kashyap ‑ skashyap41@gmail.com; Hammad Ghanchi ‑ hammadghanchi@gmail.com; Tanya Minasian ‑ tminasian@gmail.com;   Fanglong Dong ‑ fdong@westernu.edu; Dan Miulli ‑ miullid@armc.sbcounty.gov   *Corresponding author Received: 28 August 16  Accepted: 27 October 16  Published: 10 May 17 Abstract Background:  Ventriculoperitoneal (VP) shunt placement is one of the most  commonly performed procedures in neurosurgery.",Non-OADS,/arxiv_data1/oa_pdf/28/2f/SNI-8-78.PMC5445654.pdf
"Surg Neurol Int 2017;8:78. http://surgicalneurologyint.com/Abdominal-pseudocyst-as-a-complication-of-ventriculoperitoneal-shunt-placement:-Review-of-the-literature-and-a-proposed-algorithm-for- treatment-using-4-illustrative-cases/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and  build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/28/2f/SNI-8-78.PMC5445654.pdf
"Surgical Neurology International 2017, 8:78  http://www.surgicalneurologyint.com/content/8/1/78INTRODUCTION Ventriculoperitoneal (VP) shunts are a staple procedure  in the neurosurgical field.",Non-OADS,/arxiv_data1/oa_pdf/28/2f/SNI-8-78.PMC5445654.pdf
"Surgical Neurology International 2017, 8:78  http://www.surgicalneurologyint.com/content/8/1/78revisions in the past, which were performed at an outside  hospital.",Non-OADS,/arxiv_data1/oa_pdf/28/2f/SNI-8-78.PMC5445654.pdf
"Surgical Neurology International 2017, 8:78  http://www.surgicalneurologyint.com/content/8/1/78Six years later, she was admitted to the hospital with  sepsis, which was likely secondary to cellulitis as well  as poorly controlled diabetes mellitus (A1C = 13.4%).",Non-OADS,/arxiv_data1/oa_pdf/28/2f/SNI-8-78.PMC5445654.pdf
"Surgical Neurology International 2017, 8:78  http://www.surgicalneurologyint.com/content/8/1/78was attempted in an effort to eliminate the possibility of  future hardware infections.",Non-OADS,/arxiv_data1/oa_pdf/28/2f/SNI-8-78.PMC5445654.pdf
"Surgical Neurology International 2017, 8:78  http://www.surgicalneurologyint.com/content/8/1/78for a conservative approach in asymptomatic patients.",Non-OADS,/arxiv_data1/oa_pdf/28/2f/SNI-8-78.PMC5445654.pdf
"© 2017 Surgical Neurology International | Published by Wolters Kluwer - MedknowOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comSNI: Unique Case ObservationsEditor: S. A. Enam,  MD  Aga Khan University; Karachi,  Sindh, PakistanCase Report Multidisciplinary surgical treatment of presacral meningocele and  teratoma in an adult with Currarino triad Daniel Chakhalian, Arunprasad Gunasekaran, Gautam Gandhi, Lucas Bradley, Jason Mizell1,   Noojan Kazemi Departments of Neurosurgery and 1Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA E‑mail:  Daniel Chakhalian ‑ dchakhalian@uams.edu; Arunprasad Gunasekaran ‑ AGunasekaran@uams.edu; Gautam Gandhi ‑ GhandiGautamK@uams.edu; Lucas  Bradley ‑ LHBradley@uams.edu; Jason Mizell ‑ JSMizell@uams.edu; *Noojan Kazemi ‑ NJKazemi@uams.edu   *Corresponding author Received: 11 November 16  Accepted: 13 January 17  Published: 10 May 17 Access this article online Website: www.surgicalneurologyint.com DOI:   10.4103/sni.sni_439_16 Quick Response Code: Abstract Background: Currarino syndrome (CS) is a rare genetic condition that presents  with the defining triad of anorectal malformations, sacral bone deformations, and  presacral masses, which may include teratoma.",Non-OADS,/arxiv_data1/oa_pdf/f6/cd/SNI-8-77.PMC5445655.pdf
"Surg Neurol Int 2017;8:77. http://surgicalneurologyint.com/Multidisciplinary-surgical-treatment-of-presacral- meningocele-and-teratoma-in-an-adult-with-Currarino-triad/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/f6/cd/SNI-8-77.PMC5445655.pdf
"Surgical Neurology International 2017, 8:77  http://www.surgicalneurologyint.com/content/8/1/77CASE REPORT A 36‑year‑old female presented with intermittent  constipation and bilateral lower extremity radiculopathy  in the L4 distribution on the right and L5 distribution on  the left.",Non-OADS,/arxiv_data1/oa_pdf/f6/cd/SNI-8-77.PMC5445655.pdf
"Surgical Neurology International 2017, 8:77  http://www.surgicalneurologyint.com/content/8/1/77located on chromosome 7q36, and which encodes the  HB9 nuclear protein.",Non-OADS,/arxiv_data1/oa_pdf/f6/cd/SNI-8-77.PMC5445655.pdf
"© 2017 Surgical Neurology International | Published by Wolters Kluwer - MedknowSNI: NeurovascularEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com Case Report Microvascular decompression for hypoglossal nerve palsy  secondary to vertebral artery compression: A  case report and  review of the literature Yasuhiro Kuroi, Shigeru Tani, Hidenori Ohbuchi, Hidetoshi Kasuya Department of Neurosurgery, T okyo Women’s Medical University Medical Center East, T okyo, Japan E‑mail: *Yasuhiro Kuroi ‑ kuroi.yasuhiro@twmu.ac.jp; Shigeru Tani ‑ stani@twmu.ac.jp; Hidenori Ohbuchi ‑ hide.ohbuchi@gmail.com;   Hidetoshi Kasuya ‑ hkasuya@twmu.ac.jp   *Corresponding author Received: 26 January 2017  Accepted: 01 February 17  Published: 10 May 17 Access this article online Website: www.surgicalneurologyint.com DOI:   10.4103/sni.sni_42_17 Quick Response Code: Abstract Background:  Neurovascular‑compression syndrome (NCS) is described as a  prominent pathological contact between cranial nerves and vessels.",Non-OADS,/arxiv_data1/oa_pdf/ec/11/SNI-8-74.PMC5445656.pdf
"Surg Neurol Int 2017;8:74. http://surgicalneurologyint.com/Microvascular-decompression-for-hypoglossal- nerve-palsy-secondary-to-vertebral-artery-compression:-A case-report-and-review- of-the-literature/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/ec/11/SNI-8-74.PMC5445656.pdf
"Surgical Neurology International 2017, 8:74  http://www.surgicalneurologyint.com/content/8/1/74by NCS, but we encountered a case of hypoglossal  nerve palsy (HNP) secondary to vertebral artery (VA)  compression.",Non-OADS,/arxiv_data1/oa_pdf/ec/11/SNI-8-74.PMC5445656.pdf
"Surgical Neurology International 2017, 8:74  http://www.surgicalneurologyint.com/content/8/1/74Graham et al .",Non-OADS,/arxiv_data1/oa_pdf/ec/11/SNI-8-74.PMC5445656.pdf
"Surgical Neurology International 2017, 8:74  http://www.surgicalneurologyint.com/content/8/1/74hypoglossal nerve was performed using Teflon®.",Non-OADS,/arxiv_data1/oa_pdf/ec/11/SNI-8-74.PMC5445656.pdf
"Published by Oxford University Press on behalf of the European Public Health Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provi ded the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/54/a6/ckx001.PMC5445720.pdf
Available at: http://www.mipex.,Non-OADS,/arxiv_data1/oa_pdf/54/a6/ckx001.PMC5445720.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e0/f5/ckx054.PMC5445721.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any  medium, provided the original work is not altered or transformed in any way, and that the work  is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/98/54/ofx066.PMC5445722.pdf
Available at: https://www.gsksource.com/pharma/content/ dam/GlaxoSmithKline/US/en/Prescribing_Information/Rotarix/pdf/ROTARIX- PI-PIL.PDF .,Non-OADS,/arxiv_data1/oa_pdf/98/54/ofx066.PMC5445722.pdf
Available at: https://www.merck.com/product/ usa/pi_circulars/r/rotateq/rotateq_pi.pdf .,OADS,/arxiv_data1/oa_pdf/98/54/ofx066.PMC5445722.pdf
Available at: http://apps.who.int/immunization_mon- itoring/globalsummary/schedules.,Non-OADS,/arxiv_data1/oa_pdf/98/54/ofx066.PMC5445722.pdf
"MeSH Keywords:  Postoperative Care • Receptors, Adrenergic, beta-1 • Thoracic Surgery  Full-text PDF:  http://www.basic.medscimonit.com/abstract/index/idArt/902820Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Cardiac Surgery, Heart Center Leipzig University of Leipzig, Leipzig,  Germany 2 Department of Cardiac Surgery, European University Oldenburg-Groningen,  Oldenburg, Germany 3 Department of Cardiothoracic Surgery, Faculty of Health Science, University of  the Free State, Bloemfontein, South Africa  2807   7   5   33eISSN 2325-4416 © Med Sci Monit Basic Res, 2017; 23: 223-233  DOI: 10.12659/MSMBR.902820 223 HUMAN STUDY Indexed in: [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]   [Chemical Abstracts/CAS] [Index Copernicus]This work is licensed under Creative Common Attribution- NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/1a/3a/medscimonitbasicres-23-223.PMC5445899.pdf
"MeSH Keywords:  Brain Injuries • Magnetic Resonance Imaging • Magnetic Resonance Spectroscopy  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/904788Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, P.R.",Non-OADS,/arxiv_data1/oa_pdf/4c/c6/medscimonit-23-2365.PMC5445900.pdf
"MeSH Keywords:  Oxidative Stress • Pulmonary Fibrosis • Transforming Growth Factor beta1  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/900452Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 School of Kinesiology, Shanghai University of Sports, Shanghai, P.R.",Non-OADS,/arxiv_data1/oa_pdf/34/d0/medscimonit-23-2357.PMC5445901.pdf
"MeSH Keywords:  Critical Pathways • Drugs, Chinese Herbal • Morpholines • Transplantation, Autologous  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/900098Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Prosthodontics, Stomatology Hospital of Hebei Medical University,  Shijiazhuang, Hebei, P.R.",Non-OADS,/arxiv_data1/oa_pdf/a0/50/medscimonit-23-2373.PMC5445908.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/17/83/djx088.PMC5445946.pdf
https://cran.r-project.org/package=coda.,Non-OADS,/arxiv_data1/oa_pdf/c7/2f/67_16027.PMC5445959.pdf
https://www.r-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/c7/2f/67_16027.PMC5445959.pdf
"Ravelle, W. (2014) psych: Procedures for Psychological, Psychomet- ric, and Personality Research, Northwestern University, Evanston,  Illinois, USA, http://CRAN.R-project.org/package=psych.Ritchie, D.F.",Non-OADS,/arxiv_data1/oa_pdf/c7/2f/67_16027.PMC5445959.pdf
"Version 2.9.0. https://github.com/stan-dev/stan/releases/download/v2.9.0/stan-reference-2.9.0.pdf Viruel, M.A., D. Madur, E. Dirlewanger, T. Pascal and J. Kervella  (1998) Mapping quantitative trait loci controlling peach leaf curl resistance.",OADS,/arxiv_data1/oa_pdf/c7/2f/67_16027.PMC5445959.pdf
"Fur - thermore, many countries in Europe produce durum in com-mercially significant quantities (https://en.wikipedia.org/wiki/Durum#CITEREFMatz1992).",Non-OADS,/arxiv_data1/oa_pdf/57/bd/67_16074.PMC5445962.pdf
"1998) and 54 CSSLs  (http://www.rgrc.dna.affrc.go.jp/ineNKCSSL54.html) devel-oped from a cross between japonica  Nipponbare and  indica Kasalath, backcrossed to Nipponbare, provided by the Rice Genome Resource Center (www.rgrc.dna.affrc.go.jp/stock.html).",OADS,/arxiv_data1/oa_pdf/81/65/67_16096.PMC5445965.pdf
"To map QTLs, we used R/qtl soft-ware (http://www.rqtl.org/).",OADS,/arxiv_data1/oa_pdf/81/65/67_16096.PMC5445965.pdf
PCR duplication was removed by Picard Tools 1.94 software (http://picard.sourceforge.net).,OADS,/arxiv_data1/oa_pdf/81/65/67_16096.PMC5445965.pdf
2012) using Rice  Annotation Project annotation data downloaded from the RAP-DB (http://rapdb.dna.affrc.go.jp/download/archive/irgsp1/IRGSP-1.0_representative_2015-03-31.tar.gz) (Sakai et al.,OADS,/arxiv_data1/oa_pdf/81/65/67_16096.PMC5445965.pdf
b Location of pseudomolecule IRGSP-1.0 (RAP-DB:http://rapdb.dna.affrc.go.jp/).,OADS,/arxiv_data1/oa_pdf/81/65/67_16096.PMC5445965.pdf
"FAOSTAT: http://faostat3.fao.org.Kawahara, Y ., M. de la Bastide, J. Hamilton, H. Kanamori, W.   McCombie, S. Ouyang, D. Schwartz, T. Tanaka, J. Wu, S. Zhou et  al.",OADS,/arxiv_data1/oa_pdf/81/65/67_16096.PMC5445965.pdf
http://statgen.ncsu.edu/qtlcart/WQTLCart.htm.,OADS,/arxiv_data1/oa_pdf/f7/b8/67_16099.PMC5445966.pdf
European Brewery Convention (1987) Analytica-EBC Gleadell (2015) NULL-LOX (web page) URL: http://www.gleadell.,Non-OADS,/arxiv_data1/oa_pdf/06/f9/67_16104.PMC5445967.pdf
"The nucleotide­binding site leucien­rich repeat type resistance genes for virus have been mapped on chr 2, 8, 9 & 18 in the Phytozome database (https://phytozome.jgi.doe.gov/pz/portal.html).",OADS,/arxiv_data1/oa_pdf/ee/e4/67_16115.PMC5445968.pdf
"(http://www.ncipm.org.in) Singh, B.B.",Non-OADS,/arxiv_data1/oa_pdf/ee/e4/67_16115.PMC5445968.pdf
Twenty genomic SSR primers specific for chromosome  5BL were selected from the GrainGenes website (http://wheat.pw.usda.gov/cgi-bin/GG3/browse.cgi.),Non-OADS,/arxiv_data1/oa_pdf/6e/ea/67_16148.PMC5445969.pdf
http://www.shigen.nig.ac.jp/wheat/komugi/ge-nes/symbol Class List.,OADS,/arxiv_data1/oa_pdf/6e/ea/67_16148.PMC5445969.pdf
Detailed information of the SSR markers are avail-able from [https://www.gene.affrc.go.jp/databases-marker_information_en.php].,OADS,/arxiv_data1/oa_pdf/46/b0/67_16184.PMC5445970.pdf
"To develop more markers, we first BLASTed the marker se quences of CEDG156 and CEDG271 in soybase v1.1  (http://soybase.org/) (Grant et al.",OADS,/arxiv_data1/oa_pdf/46/b0/67_16184.PMC5445970.pdf
The sequence of the assembled BAC clone was deposited as LC101731 in DNA Data Bank of Japan (http://www.ddbj.nig.ac.jp/).,OADS,/arxiv_data1/oa_pdf/46/b0/67_16184.PMC5445970.pdf
"MeSH Keywords:  Biopsy, Fine-Needle • Bronchoscopes • Mediastinal Neoplasms • Solitary Fibrous Tumors •  Ultrasonography  Full-text PDF: http://www.amjcaserep.com/abstract/index/idArt/903680Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Division of Critical Care Medicine, Mayo Clinic, Rochester, MN, U.S.A. 2 Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN,  U.S.A.ISSN 1941-5923 © Am J Case Rep, 2017; 18: 549-552 DOI: 10.12659/AJCR.903680 549 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/3b/92/amjcaserep-18-549.PMC5445977.pdf
"MeSH Keywords:  Hodgkin Disease • Lymphoma, AIDS-Related • Lymphoma, B-Cell • Psoriasis  Full-text PDF: http://www.amjcaserep.com/abstract/index/idArt/903118Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Internal Medicine, Abington Jefferson Health, Abington, PA, U.S.A. 2 Department of Internal Medicine, Abington Jefferson Health, Abington, PA, U.S.A.ISSN 1941-5923 © Am J Case Rep, 2017; 18: 553-557 DOI: 10.12659/AJCR.903118 553 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/65/5a/amjcaserep-18-553.PMC5445978.pdf
"However, patients with prior diverticulitis areunlikely to be overrepresented in patients treated with TCZsince ﬁrst clinical trials of TCZ reported a higher risk of LIP and the German Society for Rheumatology recommended notusing TCZ in patients with a history of diverticulitis (http://dgrh.de/rheumatocilizumab.html).",Non-OADS,/arxiv_data1/oa_pdf/58/28/annrheumdis-2016-209773.PMC5445993.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Hart AR, Kennedy HJ, Stebbings WS, et al.",Non-OADS,/arxiv_data1/oa_pdf/58/28/annrheumdis-2016-209773.PMC5445993.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Humira®(adalimumab).,Non-OADS,/arxiv_data1/oa_pdf/06/09/annrheumdis-2015-208914.PMC5445997.pdf
"Rockville, MD, 2015. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/ Guidances/UCM291128.pdf 7 US Food and Drug Administration.",Non-OADS,/arxiv_data1/oa_pdf/06/09/annrheumdis-2015-208914.PMC5445997.pdf
"Rockville, MD, 2015. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf 8 US Food and Drug Administration.",Non-OADS,/arxiv_data1/oa_pdf/06/09/annrheumdis-2015-208914.PMC5445997.pdf
"London, UK, 2006. http://www.ema.europa.",Non-OADS,/arxiv_data1/oa_pdf/06/09/annrheumdis-2015-208914.PMC5445997.pdf
"Rockville, MD, 2003. http://www.fda.gov/ohrms/dockets/ac/03/brie ﬁng/3995B1_07_GFI-BioAvail- BioEquiv.pdf 18 European Medicines Agency.",Non-OADS,/arxiv_data1/oa_pdf/06/09/annrheumdis-2015-208914.PMC5445997.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/REFERENCES 1 Gordon C, Isenberg D, Lerstrøm K, et al.",Non-OADS,/arxiv_data1/oa_pdf/d1/7b/annrheumdis-2016-209668.PMC5446001.pdf
See: http://creativecommons.org/ licenses/by-nc/4.0/ REFERENCES 1 Østensen M. New insights into sexual functioning and fertility in rheumatic diseases.,Non-OADS,/arxiv_data1/oa_pdf/e1/4b/annrheumdis-2016-209770.PMC5446003.pdf
"Geneva:World Health Organization, 2010. http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf 62 Pisoni CN, Cuadrado MJ, Khamashta MA, et al .",Non-OADS,/arxiv_data1/oa_pdf/e1/4b/annrheumdis-2016-209770.PMC5446003.pdf
"http://dx.doi.org/10.7326/0003-4819-142-12_Part_ 1-200506210-00004 135 Sánchez-Guerrero J, Gonzalez-Perez M, Durand-Carbajal M, et al .",OADS,/arxiv_data1/oa_pdf/e1/4b/annrheumdis-2016-209770.PMC5446003.pdf
"London: NationalInstitute for Health and Care Excellence (UK) Copyright (c) 2015 NationalCollaborating Centre for Women ’s and Children ’s Health, 2015. https://www.nice.",Non-OADS,/arxiv_data1/oa_pdf/e1/4b/annrheumdis-2016-209770.PMC5446003.pdf
April 2015. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed 11 Feb 2016).,OADS,/arxiv_data1/oa_pdf/68/06/annrheumdis-2016-209540.PMC5446025.pdf
"5, 991 –994 http://dx.doi.org/10.1080/15548627.2017.1291480",Non-OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Biochim Biophys Acta 2016; 1863(5):922-33; PMID:26611709; http://dx.doi.org/10.1016/j.bbamcr.2015.11.015 [2] Waterham HR, Ebberink MS. Genetics and molecular basis of human peroxisome biogenesis disorders.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Biochim Biophys Acta 2012; 1822(9):1430-41; PMID:22871920; http://dx.doi.org/10.1016/j.bbadis.2012.04.006 [3] Fujiki Y, Nashiro C, Miyata N, Tamura S, Okumoto K. New insights into dynamic and functional assembly of the AAA peroxins, Pex1p and Pex6p, and their membrane receptor Pex26p in shuttling ofPTS1-receptor Pex5p during peroxisome biogenesis.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Biochim Bio- phys Acta 2012; 1823(1):145-9; PMID:22079764; http://dx.doi.org/ 10.1016/j.bbamcr.2011.10.012 [4] Grimm I, Saf ﬁan D, Platta HW, Erdmann R. The AAA-type ATPases Pex1p and Pex6p and their role in peroxisomal matrix protein import in Saccharomyces cerevisiae.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Biochim Biophys Acta 2012; 1823(1):150- 8; PMID:21963882; http://dx.doi.org/10.1016/j.bbamcr.2011.09.005 [5] Titorenko VI, Chan H, Rachubinski RA.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"J Cell Biol2000; 148(1):29-44; PMID:10629216; http://dx.doi.org/10.1083/ jcb.148.1.29 [6] Titorenko VI, Rachubinski RA.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"J Cell Biol 2000; 150(4):881- 6; PMID:10953011; http://dx.doi.org/10.1083/jcb.150.4.881 [7] van der Zand A, Gent J, Braakman I, Tabak HF.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
Cell 2012; 149(2):397-409; PMID:22500805; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"J Cell Biol 2015; 211(5):955-62; PMID:26644511; http://dx.doi.org/10.1083/jcb.201506059 [9] Motley AM, Galvin PC, Ekal L, Nuttall JM, Hettema EH.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"FEBS J 2016; 283(6):986-92; PMID:26476099; http://dx.doi.org/10.1111/ febs.13569 [11] Nuttall JM, Motley AM, Hettema EH.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Autophagy 2014; 10(5):835-45;PMID:24657987; http://dx.doi.org/10.4161/auto.28259 [12] Nazarko TY, Farr /C19e JC.",Non-OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Autophagy 2017; 13(5); http://dx.doi.org/ 10.1080/15548627.2017.1291470 [14] Nordgren M, Francisco T, Lismont C, Hennebel L, Brees C, Wang B, Van Veldhoven PP, Azevedo JE, Fransen M. Export-de ﬁcient monoubiquitinated PEX5 trigge rs peroxisome removal in SV40 large T antigen-transformed mouse embryonic ﬁbroblasts.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Auto- phagy 2015; 11(8):1326-40; PMID:26086376; http://dx.doi.org/10.1080/15548627.2015.1061846 [15] Zhang J, Tripathi DN, Jing J, Alexander A, Kim J, Powell RT, Dere R, Tait-Mulder J, Lee JH, Paull TT, et al.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Nat Cell Biol 2015;17(10):1259-69; PMID:26344566; http://dx.doi.org/10.1038/ncb3230 [16] Khaminets A, Behl C, Dikic I. Ubiquitin-Dependent And Independent Signals In Selective Autophagy.",Non-OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Trends Cell Biol 2016;26(1):6-16; PMID:26437584; http://dx.doi.org/10.1016/j.tcb.2015.08.010 [17] Xie Q, Tzfadia O, Levy M, Weithorn E, Peled-Zehavi H, Van Parys T ,V a nd eP e e rY ,G a l i l iG .h f A I M :Ar e l i a b l eb i o i n f o r m a t i c sapproach for in silico genome-wide identi ﬁcation of autophagy- associated Atg8-interacting mo tifs in various organisms.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Auto- phagy 2016; 12(5):876-87; PMID:27071037; http://dx.doi.org/ 10.1080/15548627.2016.1147668 [18] Klouwer FC, Berendse K, Ferdinandusse S, Wanders RJ, Engelen M, Poll-The BT.",Non-OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Orphanet J Rare Dis 2015; 10:151; PMID:26627182; http://dx.doi.org/10.1186/s13023-015-0368-9 [19] Braverman NE, Raymond GV, Rizzo WB, Moser AB, Wilkinson ME, Stone EM, Steinberg SJ, Wangler MF, Rush ET, Hacia JG, et al.",Non-OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Mol Genet Metab 2016; 117(3):313-21; PMID:26750748; http://dx.doi.org/10.1016/j.ymgme.2015.12.009 [20] Wei H, Kemp S, McGuinness MC, Moser AB, Smith KD.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Pharmaco- logical induction of peroxisomes in peroxisome biogenesis disorders.Ann Neurol 2000; 47(3):286-96; PMID:10716247; http://dx.doi.org/ 10.1002/1531-8249(200003)47:3%3c286::AID-ANA3%3e3.0.CO;2-B [21] Zhang R, Chen L, Jiralerspong S, Snowden A, Steinberg S, Braverman N. Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-AUTOPHAGY 993",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Orphanet J Rare Dis 2013; 8:138; PMID:24016303; http://dx.doi.org/10.1186/1750-1172-8-138 [23] Kim DS, Li B, Rhew KY, Oh HW, Lim HD, Lee W, Chae HJ, Kim HR.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Arch Pharm Res 2012; 35(7):1269-78; PMID:22864750; http://dx.doi.org/10.1007/ s12272-012-0718-2 [24] Xia X, Che Y, Gao Y, Zhao S, Ao C, Yang H, Liu J, Liu G, Han W, Wang Y, et al.",Non-OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Mol Cells 2016; 39(5):410-7;PMID:27025389; http://dx.doi.org/10.14348/molcells.2016.2358[25] Manjithaya R, Jain S, Farr /C19e JC, Subramani S. A yeast MAPK cascade regulates pexophagy but not other autophagy pathways.",Non-OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"J Cell Biol2010; 189(2):303-10; PMID:20385774; http://dx.doi.org/10.1083/jcb.200909154 [26] Chen JL, Lin HH, Kim KJ, Lin A, Forman HJ, Ann DK.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"J Biol Chem 2008; 283(49):34432- 44; PMID:18836180; http://dx.doi.org/10.1074/jbc.M804239200 [27] Walter KM, Sch €onenberger MJ, Tr €otzm €uller M, Horn M, Els €asser HP, Moser AB, Lucas MS, Schwarz T, Gerber PA, Faust PL, et al.Hif-2apromotes degradation of mammalian peroxisomes by selec- tive autophagy.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"Cell Metab 2014; 20(5):882-97; PMID:25440060; http://dx.doi.org/10.1016/j.cmet.2014.09.017 [28] Hiebler S, Masuda T, Hacia JG, Moser AB, Faust PL, Liu A, Chowd- hury N, Huang N, Lauer A, Bennett J, et al.",OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
Mol Genet Metab 2014; 111(4):522-32; PMID:24503136; http://dx.doi.org/10.1016/j.ymgme.2014.01.008994 T. Y. NAZARKO,OADS,/arxiv_data1/oa_pdf/cf/11/kaup-13-05-1291480.PMC5446054.pdf
"5, 900 –913 http://dx.doi.org/10.1080/15548627.2017.1291479",Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Hepatology 2013; 57:171-82; PMID:22859216; http://dx.doi.org/10.1002/hep.25991 [2] Zhang C, He H, Zhang H, Yu D, Zhao W, Chen Y, Shao R. The blockage of Ras/ERK pathway augments the sensitivity of SphK1inhibitor SKI II in human hepatoma HepG2 cells.",Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Biochem Biophys Res Commun 2013; 434:35-41; PMID:23545258; http://dx.doi.org/ 10.1016/j.bbrc.2013.03.070 [3] Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, McGinn CM, DePeralta DK, Chen X, Kuroda T, et al.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Hepatology 2014; 59:1577-90;PMID:24677197; http://dx.doi.org/10.1002/hep.26898 [4] Huang YL, Huang WP, Lee H. Roles of sphingosine 1-phosphate on tumorigenesis.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"World J Biol Chem 2011; 2:25-34; PMID:21537487; http://dx.doi.org/10.4331/wjbc.v2.i2.25 [5] Liu H, Zhang CX, Ma Y, He HW, Wang JP, Shao RG.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Life Sci 2016; 151:23-29; PMID:26944438; http://dx.doi.org/10.1016/j.lfs.2016.02.098 [6] Zhang Z, Yan Z, Yuan Z, Sun Y, He H, Mai C. SPHK1 inhibitor sup- presses cell proliferation and invasion associated with the inhibition of NF-kappaB pathway in hepatocellular carcinoma.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Tumour Biol2015; 36:1503-39; PMID:25537088; http://dx.doi.org/10.1007/s13277-014-2665-7 [7] Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, Liu L, Chen T, Li J, Tu H, et al.",Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Liver Int 2012; 32:331-38; PMID:22098666; http://dx.doi.org/ 10.1111/j.1478-3231.2011.02666.x [8] Zhang H, Ma Y, Zhang S, Liu H, He H, Li N, Gong Y, Zhao S, Jiang JD, Shao RG.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Oncotarget 2015; 6:17039-53; PMID:25962958; http://dx.doi.org/10.18632/oncotarget.3636 [9] Lv Q, Wang W, Xue J, Hua F, Mu R, Lin H, Yan J, Lv X, Chen X, Hu ZW.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Can-cer Res 2012; 72:3238-50; PMID:22719072; http://dx.doi.org/ 10.1158/0008-5472.CAN-11-3832 [10] Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
Cancer Res 2008; 68:3645-54; PMID:18483246; http://dx.doi.org/10.1158/0008-5472.CAN-07-2938912 H. LIU ET AL.,Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"World J Gastroenterol 2008; 14:5665-73; PMID:18837082;http://dx.doi.org/10.3748/wjg.14.5665 [12] Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking trans- forming growth factor-beta up-regulates E-cadherin and reducesmigration and invasion of hepatocellular carcinoma cells.",Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Hepatol- ogy 2008; 47:1557-66; PMID:18318443; http://dx.doi.org/10.1002/ hep.22201 [13] Hsieh S, L PY, Hsieh CW, Li IT, Hsieh SL, Wu CC, Y SH, Huang Ys, Huay MW, Tu LW, et al.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"J Chin Chem Soc 2012; 59:929-33; http://dx.doi.org/10.1002/jccs.201200129 [14] Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M. Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lyso- somal degradation of E-cadherin.",Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Oncogene 2006; 25:7117-30; PMID:16751808; http://dx.doi.org/10.1038/sj.onc.1209701 [15] Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R, Botti J, Codogno P. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"J Biol Chem 2006; 281:8518-27; PMID:16415355; http://dx.doi.org/10.1074/jbc.M506182200 [16] Liu H, Ma Y, He HW, Wang JP, Jiang JD, Shao RG.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Autophagy 2015; 11:2323-34; PMID:26218645; http://dx.doi.org/10.1080/15548627.2015.1074372 [17] Li J, Yang B, Zhou Q, Wu Y, Shang D, Guo Y, Song Z, Zheng Q, Xiong J. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition.",Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Carcino-genesis 2013; 34:1343-51; PMID:23430956; http://dx.doi.org/10.1093/carcin/bgt063 [18] Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, Maceyka M, Jiang H, Luo C, Kordula T, et al.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Nature 2010; 465:1084-88; PMID:20577214; http://dx.doi.org/10.1038/ nature09128 [19] Shi CS, Kehrl JH.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Mol Immuno 2010; 47:1283-91; http://dx.doi.org/10.1016/j.molimm.2009.12.002 [22] Pan J, Tao YF, Zhou Z, Cao BR, Wu SY, Zhang YL, Hu SY, Zhao WL, Wang J, Lou GL, et al.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"JTransl Med 2011; 9:157; PMID:21936950; http://dx.doi.org/10.1186/ 1479-5876-9-157 [23] Liu SQ, Su YJ, Qin MB, Mao YB, Huang JA, Tang GD.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Radiother Oncol 2011; 101:158-64; PMID:21665310; http://dx.doi.org/10.1016/j.radonc.2011.05.042 [25] Cicchini C, Laudadio I, Citarella F, Corazzari M, Steindler C, Conigliaro A, Fantoni A, Amicone L, Tripodi M. TGFbeta-induced EMT requiresfocal adhesion kinase (FAK) signaling.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Exp Cell Res 2008; 314:143-52; PMID:17949712; http://dx.doi.org/10.1016/j.yexcr.2007.09.005 [26] Heo MJ, Kim YM, Koo JH, Yang YM, An J, Lee SK, Lee SJ, Kim KM, Park JW, Kim SG.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Oncotarget 2014; 5:2792-806; PMID:24798342; http://dx.doi.org/10.18632/oncotarget.1920 [27] Catalano M, D ’Alessandro G, Lepore F, Corazzari M, Caldarola S, Valacca C, Faienza F, Esposito V, Limatola C, Cecconi F, Di Bartolo- meo S. Autophagy induction impairs migration and invasion byreversing EMT in glioblastoma cells.",Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Mol Oncol 2015; 9:1612-25;PMID:26022108; http://dx.doi.org/10.1016/j.molonc.2015.04.016 [28] Sun T, Sun BC, Zhao XL, Zhao N, Dong XY, Che N, Yao Z, Ma YM, Gu Q, Zong WK, et al.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Hepatology 2011; 54:1690-706; PMID:21748764; http://dx.doi.org/10.1002/hep.24543 [29] Liu H, Mi S, Li Z, Hua F, Hu ZW.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
Autophagy 2013; 9:730-42; PMID:23514933; http://dx.doi.org/10.4161/auto.24039 [30] Mizushima N. Autophagy: process and function.,OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"Genes Dev 2007; 21:2861-73; PMID:18006683; http://dx.doi.org/10.1101/gad.1599207 [31] Lamb CA, Dooley HC, Tooze SA.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"BioEssays 2013; 35:34-45;PMID:23147242; http://dx.doi.org/10.1002/bies.201200130 [32] Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, Wang XX, Liu HZ, Sun W, Hu ZW.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"J Immunol 2011; 187:3003-14; PMID:21841134; http://dx.doi.org/10.4049/jimmunol.1004081 [33] Liu H, Mi S, Li Z, Lv XX, Li K, Hua F, Hu ZW.",OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
Acta Pharmaceutica Sinica B 2013; 4:226-33; http://dx.doi.org/ 10.1016/j.apsb.2013.05.004AUTOPHAGY 913,Non-OADS,/arxiv_data1/oa_pdf/c7/57/kaup-13-05-1291479.PMC5446059.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"5, 781 –819 http://dx.doi.org/10.1080/15548627.2017.1290751",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Common somatic mutations in colorectal cancer (data extracted from: https://civic.genome.wustl.edu/ ).,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"ORCID Pooneh Mokarram http://orcid.org/0000-0002-9717-0473 Mohammed Albokashy http://orcid.org/0000-0002-0933-9110 Maryam Zarghooni http://orcid.org/0000-0002-7586-0967 Mohammad Amin Moosavi http://orcid.org/0000-0001-9958-2220 Zahra Sepehri http://orcid.org/0000-0002-3331-0924 Aliyeh Sargazi http://orcid.org/0000-0002-9037-6639 Javad Alizadeh http://orcid.org/0000-0001-9082-3083 Mohammad Hashemi http://orcid.org/0000-0002-6074-7101 Hesam Movassagh http://orcid.org/0000-0002-0205-1069 Thomas Klonisch http://orcid.org/0000-0003-0448-6741 Marek J. Łos http://orcid.org/0000-0001-9518-1411 Saeid Ghavami http://orcid.org/0000-0001-5948-508X References [1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
CA Cancer J Clin 2011; 61:69-90; PMID:21296855;http://dx.doi.org/10.3322/caac.20107 [2] Canada CCSNCIo.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
CA Cancer J Clin 2009; 59:366-78; PMID:19897840; http://dx.doi.org/10.3322/caac.20038 [4] Saudi Moh.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Cancer Epidemiol 2015;2015:643020; PMID:25685149; http://dx.doi.org/10.1155/2015/ 643020 [6] Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
CA Cancer J Clin 2005; 55:74-108; PMID:15761078; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Eur J Cancer 2013; 49:1374-403; PMID:23485231; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Gut 2008; 57:704-13; PMID:18194984; http://dx.doi.org/10.1136/gut.2007.136127 [9] Burt RW.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Gastroenterology 2000; 119:837- 53; PMID:10982778; http://dx.doi.org/10.1053/gast.2000.16508 [10] Rustgi AK.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Genes Dev 2007; 21:2525-38; PMID:17938238; http://dx.doi.org/10.1101/ gad.1593107AUTOPHAGY 805,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Gastroenterology 2010; 138:2044-58;PMID:20420945; http://dx.doi.org/10.1053/j.gastro.2010.01.054 [12] Lynch HT, de la Chapelle A.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"N Engl J Med 2003; 348:919-32; PMID:12621137; http://dx.doi.org/10.1056/ NEJMra012242 [13] Knudsen AL, Bisgaard ML, Bulow S. Attenuated familial adenoma- tous polyposis (AFAP).",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Fam Cancer 2003; 2:43-55; PMID:14574166; http://dx.doi.org/10.1023/A:1023286520725 [14] Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltom €aki P, Mecklin JP, J €arvinen HJ.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Int J Cancer1999; 81:214-8; PMID:10188721; http://dx.doi.org/10.1002/(SICI)1097-0215(19990412)81:2%3c214::AID-IJC8%3e3.0.CO;2-L [15] Broaddus RR, Lynch PM, Lu KH, Luthra R, Michelson SJ.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mod Pathol 2004; 17:981-9; PMID:15143336; http://dx.doi.org/10.1038/modpathol.3800150 [16] Mokarram P, Asghari Estiar M, Ashktorab H. Epigenetics Territory and Cancer (methylation in colorectal cancer).",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Gastroenterology 2015; 149:1177- 90 e3; PMID:26216840; http://dx.doi.org/10.1053/j.gastro.2015.06.047 [19] Yusof AS, Isa ZM, Shah SA.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Asian Pac J Cancer Prev 2012; 13:4713-7; PMID:23167408; http://dx.doi.org/10.7314/APJCP.2012.13.9.4713 [20] Vanio H, Bianchini F. IARC handbooks of cancer prevention.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Ann Oncol 2015; 26:272-8; PMID:25009011; http://dx.doi.org/10.1093/annonc/mdu250 [22] Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Lancet 2010; 376:1741-50; PMID:20970847; http://dx.doi.org/ 10.1016/S0140-6736(10)61543-7 [23] Tarraga Lopez PJ, Albero JS, Rodriguez-Montes JA.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Med Insights Gas-troenterol 2014; 7:33-46; PMID:25093007; http://dx.doi.org/ 10.4137/CGast.S14039 [24] Tsoi KK, Pau CY, Wu WK, Chan FK, Grif ﬁths S, Sung JJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Gastroenterol Hepatol 2009; 7:682-8. e1–5; PMID:19245853; http://dx.doi.org/10.1016/j.cgh.2009.02.016 [25] Rhodes JM, Campbell BJ.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Trend Mol Med 2002;8:10-6; PMID:11796261; http://dx.doi.org/10.1016/S1471-4914(01) 02194-3 [26] Mattar MC, Lough D, Pishvaian MJ, Charabaty A.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Gastroenterology 2010; 138:746-74, 74.e1-4; quiz e12-3; PMID:20141809; http://dx.doi.org/10.1053/j.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Expert Rev Gastroenterol Hepatol 2011; 5:25-32; PMID:21309669; http://dx.doi.org/10.1586/egh.10.86 [29] Whitlock E, Lin J, Liles E, Beil T, Fu R, O ’Connor E, Thompson RN, Cardenas T. Screening for colorectal cancer: An updated systematicreview.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Ann Intern Med 2011; 154:22-30; PMID:21200035; http://dx.doi.org/10.7326/0003-4819-154-1-201101040-00004 [31] Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Lancet 1996;348:1472-7; PMID:8942775; http://dx.doi.org/10.1016/S0140-6736 (96)03386-7 [32] Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"N Eng J Med 2000; 343:1603- 7;PMID:11096167;http://dx.doi.org/10.1056/ NEJM200011303432203 [33] Wu CW, Sung JJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Annal Oncol 2010; 21 Suppl 5:70-7; http://dx.doi.org/10.1093/annonc/mdq168 [36] Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J ClinOncol 2012; 30:1926-33; PMID:22529255; http://dx.doi.org/ 10.1200/JCO.2011.40.1836 [37] Sebag-Monte ﬁore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Lancet 2009; 373:811-20;PMID:19269519; http://dx.doi.org/10.1016/S0140-6736(09)60484-0 [38] Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic- Jelic L, Daban A, Bardet E, Beny A, Ollier JC, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"N Engl J Med 2006;355:1114-23;PMID:16971718;http://dx.doi.org/10.1056/ NEJMoa060829 [39] Haller DG, Catalano PJ, Macdonald JS, O ’Rourke MA, Frontiera MS, Jackson DV, Mayer RJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Clin Oncol 2005; 23:8671-8; PMID:16314627; http://dx.doi.org/10.1200/JCO.2004.00.5686 [40] Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM, Gibson F. A review of the evolution of systemic che- motherapy in the management of colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Colorectal Cancer 2015; 14:1-10; PMID:25579803; http://dx.doi.org/10.1016/j.clcc.2014.11.002 [41] Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yosh- ino T, Paul J, Sobrero A, Taieb J, Shields AF, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr Colorectal Cancer Rep 2013; 9:261-9; PMID:24032000; http://dx.doi.org/10.1007/s11888-013-0181-6 [42] Sargent D, Sobrero A, Grothey A, O ’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O ’Callaghan C, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
J Clin Oncol 2009; 27:872-7; PMID:19124803; http://dx.doi.org/10.1200/JCO.2008.19.5362806 P. MOKARRAM ET AL.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Biol Ther 2005; 4:1159- 67; PMID:16294035; http://dx.doi.org/10.4161/cbt.4.10.2206 [45] Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery- Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Clin Oncol 2004; 22:229-37; PMID:14657227; http://dx.doi.org/10.1200/JCO.2004.05.113 [46] Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouch /C19e O, Mineur L, Barone C, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Lancet 2013; 381:303-12; PMID:23177514; http://dx.doi.org/10.1016/S0140-6736(12)61900-X [47] Liu EY, Ryan KM.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Cell Sci 2012; 125:2349-58; PMID:22641689; http://dx.doi.org/ 10.1242/jcs.093708 [48] Mah LY, Ryan KM.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cold Spring Harb Per- spect Biol 2012; 4:a008821; PMID:22166310; http://dx.doi.org/10.1101/cshperspect.a008821 [49] Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell Death Dis 2013; 4:e838; PMID:24113172; http://dx.doi.org/10.1038/ cddis.2013.350 [50] Chen N, Debnath J. Autophagy and tumorigenesis.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
FEBS Lett 2010; 584:1427-35; PMID:20035753; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Semin Immuno- pathol 2010; 32:383-96; PMID:20589500; http://dx.doi.org/10.1007/s00281-010-0213-0 [52] Tsai WT, Lo YC, Wu MS, Li CY, Kuo YP, Lai YH, Tsai Y, Chen KC, Chuang TH, Yao CH, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Biol Chem 2016; 291(37):19299-311; PMID:27458013; http://dx.doi.org/10.1074/jbc.M115.686683 [53] Stranks AJ, Hansen AL, Panse I, Mortensen M, Ferguson DJ, Pules- ton DJ, Shenderov K, Watson AS, Veldhoen M, Phadwal K, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"JInnate Immun 2015; 7:375-91; PMID:25764971; http://dx.doi.org/10.1159/000370112 [54] Kim YH, Baek SH, Kim EK, Ha JM, Jin SY, Lee HS, Ha HK, Song SH, Kim SJ, Shin HK, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"FEBS Lett 2016; 590:1365-74; PMID:27062295; http://dx.doi.org/10.1002/1873-3468.12172 [55] Zhou Y, Rucker EB, 3rd, Zhou BP.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Acta Biochim Biophys Sin (Shanghai) 2016; 48:60-74; PMID:26637829; http://dx.doi.org/ 10.1093/abbs/gmw063 [56] Zarzynska JM.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Biomed Res Int 2014; 2014:710345; PMID:25317422; http://dx.doi.org/10.1155/2014/ 710345 [57] Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature 2008; 456:259-63; PMID:18849966; http://dx.doi.org/10.1038/nature07416[58] Lopez P, Alonso-Perez E, Rodriguez-Carrio J, Suarez A.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"PloSone 2013; 8:e78756; PMID:24205307; http://dx.doi.org/10.1371/journal.pone.0078756 [59] Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Immunity 2013; 39:211-27; PMID:23973220;http://dx.doi.org/10.1016/j.immuni.2013.07.017 [60] Madia F, Grossi V, Peserico A, Simone C. Updates from the intesti- nal front line: Autophagic weapons against in ﬂammation and can- cer.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cells 2012; 1:535-57; PMID:24710489; http://dx.doi.org/10.3390/cells1030535 [61] Liton PB.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Exp Eye Res 2016; 144:29-37;http://dx.doi.org/10.1016/j.exer.2015.07.013 [62] Wen X, Klionsky DJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2016; 12:617-8;PMID:27050452; http://dx.doi.org/10.1080/15548627.2016.1158373 [63] Wasik AM, Grabarek J, Pantovic A, Cieslar-Pobuda A, Asgari HR, Bundgaard-Nielsen C, Rafat M, Dixon IM, Ghavami S, ºos MJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Expert Rev Mol Med 2016; 18:e1; PMID:26781343; http://dx.doi.org/10.1017/erm.2015.19 [65] Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo- Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496 [66] Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehr- pour M, Christoffersson J, Chaabane W, Moghadam AR, Kashani HH, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Prog Neurobiol 2014; 112:24-49; PMID:24211851;http://dx.doi.org/10.1016/j.pneurobio.2013.10.004 [67] Yeganeh B, Ghavami S, Kroeker AL, Mahood TH, Stelmack GL, Klonisch T, Coombs KM, Halayko AJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Am J Physiol Lung Cell Mol Physiol 2015; 308:L270-86; PMID:25361566; http://dx.doi.org/10.1152/ ajplung.00011.2014 [68] Gong C, Bauvy C, Tonelli G, Yue W, Delomenie C, Nicolas V, Zhu Y, Domergue V, Marin-Esteban V, Tharinger H, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Oncogene 2013; 32:2261-72, 72e 1 –11; PMID:22733132; http://dx.doi.org/10.1038/onc.2012.252 [69] Zeki AA, Yeganeh B, Kenyon NJ, Post M, Ghavami S. Autophagy in airway diseases: a new frontier in human asthma?.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Allergy 2016;71:5-14; PMID:26335713; http://dx.doi.org/10.1111/all.12761 [70] Sou YS, Tanida I, Komatsu M, Ueno T, Kominami E. Phosphatidyl- serine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modi ﬁers, LC3, GABARAP, and GATE-16.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Biol Chem 2006; 281:3017-24; PMID:16303767; http://dx.doi.org/10.1074/jbc.M505888200 [71] Le Grand JN, Chakrama FZ, Seguin-Py S, Fraichard A, Delage- Mourroux R, Jouvenot M, Boyer-Guittaut M. GABARAPL1(GEC1): Original or copycat?.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2011; 7:1098-107; PMID:21597319; http://dx.doi.org/10.4161/auto.7.10.15904 [72] Tanida I, Sou YS, Ezaki J, Minematsu-Ikeguchi N, Ueno T, Komi- nami E. HsAtg4B/HsApg4B/autophagin-1 cleaves the carboxyl ter-mini of three human Atg8 homologues and delipidates microtubule-associated protein light chain 3- and GABAA recep- tor-associated protein-phospholipid conjugates.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Biol Chem 2004;279:36268-76; PMID:15187094; http://dx.doi.org/10.1074/jbc.M401461200 [73] Yeganeh B, Moghadam AR, Tran AT, Rahim MN, Ande SR, Hashemi M, Coombs KM, Ghavami S. Asthma and in ﬂuenza virus infection: Focusing on cell death and stress pathways in in ﬂuenzaAUTOPHAGY 807",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nat Rev Mol Cell Biol 2007; 8:519-29; PMID:17565364; http://dx.doi.org/10.1038/nrm2199 [75] Iranpour M, Moghadam AR, Yazdi M, Ande SR, Alizadeh J, Wie- chec E, Lindsay R, Drebot M, Coombs KM, Ghavami S. Apoptosis, autophagy and unfolded protein response pathways in Arbovirus replication and pathogenesis.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Expert Rev Mol Med 2016; 18:e1;PMID:26781343; http://dx.doi.org/10.1017/erm.2015.19 [76] Cao SS, Kaufman RJ.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Curr Biol 2012; 22:R622-R6;PMID:22917505;http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cancer Discov 2015; 5:586-97; PMID:25977222; http://dx.doi.org/10.1158/2159-8290.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Science 2011; 334:1081-6; PMID:22116877; http://dx.doi.org/10.1126/science.1209038 [79] Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM, Walter P. IRE1 signaling affects cell fate during the unfolded protein response.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Science 2007; 318:944-9; PMID:17991856; http://dx.doi.org/10.1126/science.1146361 [80] Forman MS, Lee VM, Trojanowski JQ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Trends Neurosci 2003; 26:407-10; PMID:12900170; http://dx.doi.org/10.1016/S0166-2236(03)00197-8 [81] Hetz C. The unfolded protein response: Controlling cell fate deci- sions under ER stress and beyond.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature Rev Mol Cell Biol 2012;13:89-102 [82] Namba T, Ishihara T, Tanaka KI, Hoshino T, Mizushima T. Tran- scriptional activation of ATF6 by endoplasmic reticulum stressors.Biochem Biophys Res Commun 2007; 355:543-8; PMID:17307147; http://dx.doi.org/10.1016/j.bbrc.2007.02.004 [83] Sovolyova N, Healy S, Samali A, Logue SE.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Biol Chem 2014; 395:1-13;PMID:24002662; http://dx.doi.org/10.1515/hsz-2013-0174 [84] Kaufman RJ.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Trends Biochem Sci 2004; 29:152-8; PMID:15003273; http://dx.doi.org/10.1016/j.tibs.2004.01.004 [85] Hetz C, Chevet E, Harding HP.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature Rev Drug Discov 2013; 12:703-19;http://dx.doi.org/10.1038/nrd3976 [86] Deegan S, Saveljeva S, Gorman AM, Samali A. Stress-induced self- cannibalism: on the regulation of autophagy by endoplasmic reticu-lum stress.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell Mol Life Sci 2013; 70:2425-41; PMID:23052213;http://dx.doi.org/10.1007/s00018-012-1173-4 [87] Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Cell Biol 2003; 23:7198-209; PMID:14517290;http://dx.doi.org/10.1128/MCB.23.20.7198-7209.2003 [88] Sato M, Seki T, Konno A, Hirai H, Kurauchi Y, Hisatsune A, Kat- suki H. Fluorescent-based evaluation of chaperone-mediated auto-phagy and microautophagy activities in cultured cells.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Genes Cells2016; 21:861-73; PMID:27377049; http://dx.doi.org/10.1111/ gtc.12390 [89] Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofen- geim D, Coloff JL, Pan L, Ince TA, Kroemer G, Brugge JS, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Genes Dev 2016; 30:870; PMID:27036968; http://dx.doi.org/10.1101/gad.280453.116 [90] Kaushik S, Massey AC, Mizushima N, Cuervo AM.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Biol Cell 2008; 19:2179-92; PMID:18337468;http://dx.doi.org/10.1091/mbc.E07-11-1155 [91] Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofen- geim D, Coloff JL, Pan L, Ince TA, Kroemer G, Brugge JS, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Genes Dev2013; 27:1718-30; PMID:23913924; http://dx.doi.org/10.1101/ gad.220897.113 [92] Zhou J, Yang J, Fan X, Hu S, Zhou F, Dong J, Zhang S, Shang Y, Jiang X, Guo H, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2016; 12:515-28;PMID:26761524;http://dx.doi.org/10.1080/15548627.2015.1136770 [93] Kon M, Kif ﬁn R, Koga H, Chapochnick J, Macian F, Varticovski L, Cuervo AM.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Sci Transl Med 2011; 3:109ra17-ra17; http://dx.doi.org/10.1126/scitranslmed.3003182 [94] Eskelinen EL, Cuervo AM, Taylor MR, Nishino I, Blum JS, Dice JF, Sandoval IV, Lippincott-Schwartz J, August JT, Saftig P. Unifyingnomenclature for the isoforms of the lysosomal membrane proteinLAMP-2.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Traf ﬁc 2005; 6:1058-61; PMID:16190986; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Cell Biol 2014; 205:435-45;PMID:24862571; http://dx.doi.org/10.1083/jcb.201402054 [96] Jangamreddy JR, Los MJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mitoptosis, a novel mitochondrial death mechanism leading predominantly to activation of autophagy.Hepat Mon 2012; 12:e6159; PMID:23087751; http://dx.doi.org/ 10.5812/hepatmon.6159 [97] Zhang T, Xue L, Li L, Tang C, Wan Z, Wang R, Tan J, Tan Y, Han H, Tian R, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Biol Chem 2016; 291(41):21616-629; PMID:27528605; http://dx.doi.org/10.1074/jbc.M116.733410 [98] McWilliams TG, Prescott AR, Allen GF, Tamjar J, Munson MJ, Thomson C, Muqit MM, Ganley IG.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Cell Biol 2016; 214:333-45; PMID:27458135; http://dx.doi.org/10.1083/ jcb.201603039 [99] Bondanese VP, Lamboux A, Simon M, Lafont JE, Albalat E, Pichat S, Vanacker JM, Telouk P, Balter V, Oger P, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Metallomics 2016; 8(11):1177-84;PMID:27500357; http://dx.doi.org/10.1039/C6MT00102E [100] Ko YS, Cho SJ, Park J, Choi Y, Lee JS, Youn HD, Kim WH, Kim MA, Park JW, Lee BL.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"APMIS 2016; 124 (9):748-56; PMID:27365055; http://dx.doi.org/10.1111/apm.12569 [101] Lock R, Roy S, Keni ﬁc CM, Su JS, Salas E, Ronen SM, Debnath J. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Biol Cell 2011; 22:165-78; PMID:21119005; http://dx.doi.org/10.1091/mbc.E10-06-0500 [102] Kim JH, Kim HY, Lee YK, Yoon YS, Xu WG, Yoon JK, Choi SE, Ko YG, Kim MJ, Lee SJ, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2011; 7:1187-98; PMID:21738012; http://dx.doi.org/10.4161/auto.7.10.16643 [103] Kirkin V, McEwan DG, Novak I, Dikic I.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Cell 2009; 34:259-69; PMID:19450525; http://dx.doi.org/10.1016/j.molcel.2009.04.026 [104] Dikic I, Johansen T, Kirkin V. Selective autophagy in cancer devel- opment and therapy.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Res 2010; 70:3431-4; PMID:20424122; http://dx.doi.org/10.1158/0008-5472.CAN-09-4027 [105] Gao C, Cao W, Bao L, Zuo W, Xie G, Cai T, Fu W, Zhang J, Wu W, Zhang X, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature cell biology 2010; 12:781-90; PMID:20639871; http://dx.doi.org/10.1038/ncb2082 [106] Yang ZJ, Chee CE, Huang S, Sinicrope FA.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Cancer Ther 2011; 10:1533- 41; PMID:21878654; http://dx.doi.org/10.1158/1535-7163.MCT-11- 0047 [107] Ghavami S, Mutawe MM, Hauff K, Stelmack GL, Schaafsma D, Sharma P, McNeill KD, Hynes TS, Kung SK, Unruh H, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"cytochrome c. Biochim Biophys Acta 2010; 1803:452-67; PMID:20045437; http://dx.doi.org/10.1016/j.bbamcr.2009.12.005 [108] Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D’Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nat Cell Biol 2008; 10:676-87; PMID:18454141; http://dx.doi.org/10.1038/ncb1730 [109] Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baeh- recke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, KarantzaV, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
EMBO J 2015; 34:856-80; PMID:25712477; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Semin Oncol 2016; 43:97-106; PMID:26970128;http://dx.doi.org/10.1053/j.seminoncol.2015.09.001 [111] Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, O’Riordain M, Shanahan F, O ’Toole PW.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Genome Res 2012; 22:292-8; PMID:22009990; http://dx.doi.org/ 10.1101/gr.126573.111 [113] Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Genome Res 2012; 22:299-306; PMID:22009989;http://dx.doi.org/10.1101/gr.126516.111 [115] Fearon ER.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Annu Rev Pathol 2011; 6:479-507; PMID:21090969; http://dx.doi.org/10.1146/annurev-pathol-011110-130235 [116] Tjalsma H, Boleij A, Marchesi JR, Dutilh BE.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nat Rev Microbiol 2012; 10:575-82; PMID:22728587; http://dx.doi.org/10.1038/nrmicro2819 [117] Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"mBio 2013; 4:e00692-13; PMID:24194538; http://dx.doi.org/10.1128/mBio.00692-13 [118] Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Zhong Z, Sanchez-Lopez E, Wu LW, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Immunity 2014; 41:1052-63; PMID:25526314; http://dx.doi.org/10.1016/j.immuni.2014.11.009 [119] Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, Harrison O, Powrie F. Innate lymphoid cells sustaincolon cancer through production of interleukin-22 in a mouse model.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
J Exp Med 2013; 210:917-31; PMID:23589566; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Cell 2014; 54:224-33; PMID:24766886; http://dx.doi.org/10.1016/j.molcel.2014.03.009 [122] Donohoe DR, Garge N, Zhang X, Sun W, O ’Connell TM, Bunger MK, Bultman SJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cell Metab2011; 13:517-26; PMID:21531334; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Ther 2015; 37:996-1009 e7; PMID:26046242; http://dx.doi.org/10.1016/j.clinthera.2015.04.004 [125] Brech A, Ahlquist T, Lothe RA, Stenmark H. Autophagy in tumour suppression and promotion.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Oncol 2009; 3:366-75; PMID:19559660; http://dx.doi.org/10.1016/j.molonc.2009.05.007 [126] Grimm WA, Messer JS, Murphy SF, Nero T, Lodolce JP, Weber CR, Logsdon MF, Bartulis S, Sylvester BE, Springer A, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Immunol 2015; 66:78-88; PMID:25725948; http://dx.doi.org/10.1016/j.molimm.2015.02.001 [129] Boelens J, Lust S, Offner F, Bracke ME, Vanhoecke BW.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cancer Sci 2011; 102:999-1006; PMID:21299716; http://dx.doi.org/10.1111/j.1349- 7006.2011.01902.x [131] Khan S. Potential role of Escherichia coli DNA mismatch repair proteins in colon cancer.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Am J Physiol Gastrointest LiverPhysiol 2015; 308:24; http://dx.doi.org/10.1152/ajpgi.00360.2012 [133] Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER stress-induced in ﬂammation: does it aid or impede disease progression?.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Trend Mol Med 2012; 18:589-98;PMID:22883813; http://dx.doi.org/10.1016/j.molmed.2012.06.010 [134] Wirth MD, Shivappa N, Steck SE, Hurley TG, Hebert JR.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Br J Nutr 2015; 113:1819-27; PMID:25871645; http://dx.doi.org/10.1017/S000711451500104X [135] Wang D, Fu L, Sun H, Guo L, DuBois RN.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Epige- netics 2015; 7:015-0110; http://dx.doi.org/10.1186/s13148-015- 0110-4 [137] Mehta RS, Chong DQ, Song M, Meyerhardt JA, Ng K, Nishihara R, Qian Z, Morikawa T, Wu K, Giovannucci EL, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Gastroenterology2015; 149:614-22; PMID:26026393; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr Med Chem 2009;16:506-21; PMID:19199918; http://dx.doi.org/10.2174/ 092986709787315568 [139] Liesenfeld DB, Grapov D, Fahrmann JF, Salou M, Scherer D, Toth R, Habermann N, B €ohm J, Schrotz-King P, Gigic B, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Am J Clin Nutr 2015; 102:433-43;PMID:26156741; http://dx.doi.org/10.3945/ajcn.114.103804AUTOPHAGY 809,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Br J Cancer 2015; 113:669-79; PMID:26196182;http://dx.doi.org/ 10.1038/bjc.2015.263 [141] Yeganeh B, Jager R, Gorman AM, Samali A, Ghavami S. Induction of autophagy: Role of endoplasmic reticulum stress and unfolded protein response.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Lett 2013; 332:249- 64; PMID:20732741; http://dx.doi.org/10.1016/j.canlet.2010.07.016 [143] Grivennikov SI, Greten FR, Karin M. Immunity, in ﬂammation, and cancer.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/ 10.1016/j.cell.2010.01.025 [144] Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Nat Rev Immunol 2008; 8:923-34; PMID:19029988; http://dx.doi.org/10.1038/nri2449 [146] Hotamisligil GS.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell 2010; 140:900-17; PMID:20303879; http://dx.doi.org/10.1016/j.cell.2010.02.034 [147] Zhang K, Kaufman RJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature 2008; 454:455-62; PMID:18650916; http://dx.doi.org/10.1038/nature07203 [148] Gregory AD, Houghton AM.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Research 2011; 71:2411-6;PMID:21427354; http://dx.doi.org/10.1158/0008-5472.CAN-10-2583 [149] Coppola A, Arriga R, Lauro D, Del Principe M, Buccisano F, Mau- rillo L, Palomba P, Venditti A, Sconocchia G. NK Cell In ﬂamma- tion in the Clinical Outcome of Colorectal Carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Front Med2015; 2; http://dx.doi.org/10.3389/fmed.2015.00033 [150] Elinav E, Henao-Mejia JF, Flavell RA.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Integrative in ﬂammasome activity in the regulation of intestinal mucosal immune responses.Mucosal Immunol 2013; 6:4-13; PMID:23212196; http://dx.doi.org/10.1038/mi.2012.115 [151] Trusevych EF, MacNaughton WK.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr Pharm Des 2015; 21:2983-92; PMID:26004412; http://dx.doi.org/10.2174/ 1381612821666150514104800 [152] Yu C, Wen XD, Zhang Z, Zhang CF, Wu X, He X, Liao Y, Wu N, Wang CZ, Du W, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Ginseng Res 2015; 39:230-7; PMID:26199554; http://dx.doi.org/10.1016/j.jgr.2014.12.004 [153] Lu J-J, Chen S-M, Zhang X-W, Ding J, Meng LH.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Invest New Drugs 2011; 29:1276-83;PMID:20607588; http://dx.doi.org/10.1007/s10637-010-9481-8 [154] Mhaidat NM, Alali FQ, Matalqah SM, Matalka II, Jaradat SA, Al- sawalha NA, Thorne RF.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Anticancer Drugs 2009; 20:601-6; PMID:19521235; http://dx.doi.org/10.1097/CAD.0b013e32832e3120 [155] Thornton M, Aslam MA, Tweedle EM, Ang C, Campbell F, Jackson R, Costello E, Rooney PS, Vlatkovi /C19c N, Boyd MT.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Int J Cancer 2013; 133:1408-18; PMID:23456958; http://dx.doi.org/10.1002/ijc.28137 [156] Mhaidat NM, Alzoubi KH, Khabour OF, Banihani MN, Al-Balas QA, Swaidan S. GRP78 regulates sensitivity of human colorectal cancer cells to DNA targeting agents.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cytotechnology 2016; 68:459- 67; PMID:25399254; http://dx.doi.org/10.1007/s10616-014-9799-8[157] Rouschop KM, Van Den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, Keulers T, Mujcic H, Landuyt W, Voncken JW,et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Clin Invest 2010; 120:127-41; PMID:20038797; http://dx.doi.org/10.1172/JCI40027 [158] Sutherland A, Kim D-H, Relton C, Ahn Y-O, Hesketh J. Polymor- phisms in the selenoprotein S and 15-kDa selenoprotein genes are associated with altered susceptibility to colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"GenesNutr 2010; 5:215-23; PMID:21052528; http://dx.doi.org/10.1007/s12263-010-0176-8 [159] Fujimoto T, Yoshimatsu K, Watanabe K, Yokomizo H, Otani T, Matsumoto A, Osawa G, Onda M, Ogawa K. Overexpression ofhuman X-box binding protein 1 (XBP-1) in colorectal adenomasand adenocarcinomas.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Int J Cancer 2009; 125:926-31; PMID:19415750; http://dx.doi.org/ 10.1002/ijc.24453 [161] Du H, Li W, Wang Y, Chen S, Zhang Y. Celecoxib induces cell apo- ptosis coupled with up-regulation of the expression of VEGF by a mechanism involving ER stress in human colorectal cancer cells.Oncol Rep 2011; 26:495-502; PMID:21567098 [162] Lu M, Sun L, Zhou J, Zhao Y, Deng X. Dihydroartemisinin-induced apoptosis is associated with inhibition of sarco/endoplasmic reticu- lum calcium ATPase activity in colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell Biochem Bio-phys 2015; 73:137-45; PMID:25701954; http://dx.doi.org/10.1007/s12013-015-0643-3 [163] Jin C, Jin Z, Chen N-z, Lu M, Liu CB, Hu W-L, Zheng CG.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Biochem Biophys Res Commun 2016; 470:75-81; PMID:26742428; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Chemother 2015; 27:167-73; PMID:25692573; http://dx.doi.org/10.1179/ 1973947815Y.0000000006 [165] Bao W, Gu Y, Ta L, Wang K, Xu Z.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature 2000;405:354-60; PMID:10830965; http://dx.doi.org/10.1038/35012626 [167] Ohmori H, Luo Y, Kuniyasu H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Expert Opin Ther Targets 2011; 15:183-93; PMID:21204727; http://dx.doi.org/10.1517/14728222.2011.546785 [168] Scaf ﬁdi P, Misteli T, Bianchi ME.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature 2002; 418:191-5; PMID:12110890; http://dx.doi.org/10.1038/nature00858 [169] Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"EMBO Rep2002; 3:995-1001; PMID:12231511; http://dx.doi.org/10.1093/ embo-reports/kvf198 [170] Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associ-ates closely with metastasis of colorectal cancer.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Pathobiology 2010; 77:210-7; PMID:20616616; http://dx.doi.org/10.1159/000296305810 P. MOKARRAM ET AL.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Neu-roscience 2016; 315:286-95; PMID:26705737; http://dx.doi.org/ 10.1016/j.neuroscience.2015.12.020 [174] Ioannou S, Voulgarelis M. Toll-like receptors, tissue injury, and tumourigenesis.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mediators In ﬂamm; Epub 2010 Sep. 14; Article ID:581837; PMID:20871832; http://dx.doi.org/10.1155/ 2010/581837 [175] Delgado MA, Deretic V. Toll-like receptors in control of immuno- logical autophagy.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell Death Differ 2009; 16:976-83;PMID:19444282; http://dx.doi.org/10.1038/cdd.2009.40 [176] Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, 3rd, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Cell Biol 2010; 190:881-92;PMID:20819940; http://dx.doi.org/10.1083/jcb.200911078 [177] Luo Y, Yoneda J, Ohmori H, Sasaki T, Shimbo K, Eto S, Kato Y, Miyano H, Kobayashi T, Sasahira T, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Research 2014; 74:330-40; PMID:24197136; http://dx.doi.org/10.1158/0008-5472.CAN-13- 1052 [178] Jung CH, Ro SH, Cao J, Otto NM, Kim DH.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Dev Cell 2004;6:463-77; PMID:15068787; http://dx.doi.org/10.1016/S1534-5807 (04)00099-1 [180] Bluemlein K, Gluckmann M, Gruning NM, Feichtinger R, Kruger A, Wamelink M, Lehrach H, Tate S, Neureiter D, Ko ﬂer B, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Oncotarget 2012; 3:1356-69; PMID:23154538;http://dx.doi.org/10.18632/oncotarget.730 [181] Dang CV.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Sci Signal 2009; 2: pe75; PMID:19920249; http://dx.doi.org/10.1126/scisignal.297pe75 [182] Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H, Kuniyasu H. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Eur J Cancer 2013; 49:741-51;PMID:23040637; http://dx.doi.org/10.1016/j.ejca.2012.09.016 [183] Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC, Kroemer G. Anti- and pro-tumor functions of autophagy.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Biochi-mica Et Biophysica Acta 2009; 1793:1524-32; PMID:19371598;http://dx.doi.org/10.1016/j.bbamcr.2009.01.006 [184] Yang Z, Ghoorun RA, Fan X, Wu PC, Bai Y, Li J, Yang Z, Ghoorun RA, Fan X, Wu P, Bai Y, Li J.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Biochimica Et Biophysica Acta 2009; 1793:1516-23;PMID:19167434; http://dx.doi.org/10.1016/j.bbamcr.2008.12.013 [186] Chen Z, Li Y, Zhang C, Yi H, Wu C, Wang J, Liu Y, Tan J, Wen J. Downregulation of Beclin 1 and impairment of autophagy in asmall population of colorectal cancer.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Dig Dis Sci 2013; 58:2887-94; PMID:23812859; http://dx.doi.org/10.1007/s10620-013-2732-8 [187] Wu S, Sun C, Tian D, Li Y, Gao X, He S, Li T. Expression and clini- cal signi ﬁcances of Beclin1, LC3 and mTOR in colorectal cancer.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
World J Gastroenterol 2011; 17:4779-86; PMID:22147978; http://dx.doi.org/10.3748/wjg.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"BioDatamining 2015; 8:1; PMID:25621011; http://dx.doi.org/10.1186/ s13040-015-0058-0 [190] Jo YK, Kim SC, Park IJ, Park SJ, Jin DH, Hong SW, Cho DH, Kim JC.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"PloS One 2012; 7:e52705; PMID:23285162; http://dx.doi.org/10.1371/journal.pone.0052705 [191] Choi JH, Cho Y-S, Ko YH, Hong SU, Park JH, Lee MA.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Gastroenterol ResPract 2014; 2014:10; http://dx.doi.org/10.1155/2014/179586 [192] Qian Q, Zhou H, Chen Y, Shen C, He S, Zhao H, Wang L, Wan D, Gu W. VMP1 related autophagy and apoptosis in colorectal cancercells: VMP1 regulates cell death.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Biochem Biophys Res Commun2014; 443:1041-7; PMID:24365149; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Oncotarget 2015; 6:19735-46; PMID:25980495; http://dx.doi.org/10.18632/ oncotarget.3771 [194] Li X, Zhang K, Li Z.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Hematol Oncol 2011; 4:8; PMID:21345215; http://dx.doi.org/10.1186/1756-8722-4-8 [195] Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Tar- geting the endoplasmic reticulum-stress response as an anticancer strategy.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Eur J Pharmacol 2009; 625:234-46; PMID:19835867; http://dx.doi.org/10.1016/j.ejphar.2009.06.064 [196] Ashktorab H, Green W, Finzi G, Sessa F, Nouraie M, Lee EL, Mor- gano A, Moschetta A, Cattaneo M, Mariani-Costantini R, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Dig Dis Sci 2012; 57:905-12; PMID:22350780;http://dx.doi.org/10.1007/s10620-011-2026-y [197] Akbari-Birgani S, Paranjothy T, Zuse A, Janikowski T, Cieslar- Pobuda A, Likus W, Urasi /C19nska E, Schweizer F, Ghavami S, Klonisch T, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Drug Discov today 2016; 21:836-42; PMID:26976692; http://dx.doi.org/10.1016/j.drudis.2016.03.004 [198] Cieslar-Pobuda A, Back M, Magnusson K, Jain MV, Rafat M, Ghavami S, Nilsson KP, ºos MJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cytometry A 2014; 85:628-35; PMID:24500794; http://dx.doi.org/10.1002/cyto.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"PloS One 2014; 9:e87386; PMID:24498091; http://dx.doi.org/10.1371/journal.pone.0087386 [200] Munro S, Pelham HR.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell 1986; 46:291-300;PMID:3087629; http://dx.doi.org/10.1016/0092-8674(86)90746-4 [201] Zorbas M, Sicurella C, Bertoncello I, Venter D, Ellis S, Mucenski ML, Ramsay RG.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"c-Myb is critical for murine colon development.Oncogene 1999; 18:5821-30; PMID:10523863; http://dx.doi.org/10.1038/sj.onc.1202971 [202] Ramsay RG, Ciznadija D, Mantamadiotis T, Anderson R, Pear- son R. Expression of stress response protein glucose regulatedprotein-78 mediated by c-Myb.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Int J Biochem Cell Biol 2005; 37:1254-68; PMID:15778089; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Pathol Res Pract 2013; 209:237-43; PMID:23538046; http://dx.doi.org/10.1016/j.prp.2013.02.007 [204] Zhang JC, Kim S, Helmke BP, Yu WW, Du KL, Lu MM, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Mol Cell Biol 2001; 21:1336-44; PMID:11158319; http://dx.doi.org/10.1128/MCB.2001.21.4.1336-1344.2001AUTOPHAGY 811,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2016; 12:1-222; PMID:26799652; http://dx.doi.org/10.1080/15548627.2015.1100356 [207] Ren F, Shu G, Liu G, Liu D, Zhou J, Yuan L, Zhou J. Knockdown of p62/sequestosome 1 attenuates autophagy and inhibits colorectalcancer cell growth.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Cell Biochem 2014; 385:95-102; PMID:24065390; http://dx.doi.org/10.1007/s11010-013-1818-0 [208] McKnight NC, Zhenyu Y. Beclin 1, an essential component and master regulator of PI3K-III in health and disease.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr PathobiolRep 2013; 1:231-8; PMID:24729948; http://dx.doi.org/10.1007/ s40139-013-0028-5 [209] Ko YH, Cho YS, Won HS, An HJ, Sun DS, Hong SU, Park JH, Lee MA.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Inter J Biol Macromol 2015; 81:370-4;PMID:26277751; http://dx.doi.org/10.1016/j.ijbiomac.2015.08.027 [212] Wu X-Y, Chen J, Cao Q-H, Dong M, Lin Q, Fan XJ, Xia Q, Chen ZH, Liu Q, Wan X. Beclin 1 activation enhances chemosensitivity and predicts a favorable outcome for primary duodenal adenocarci-noma.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Genes Cancer 2010; 1:764-78; PMID:21331300; http://dx.doi.org/10.1177/ 1947601910383011 [215] Jain MV, Shareef A, Likus W, Cieslar-Pobuda A, Ghavami S, Los MJ.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Oncotarget 2016; 7(15):20953-65;PMID:26967567; http://dx.doi.org/10.18632/oncotarget.7996 [216] Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. Dis- tinct classes of phosphatidylinositol 3 0-kinases are involved in sig- naling pathways that control macroautophagy in HT-29 cells.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J BiolChem 2000; 275:992-8; PMID:10625637; http://dx.doi.org/10.1074/ jbc.275.2.992 [217] Won SJ, Yen CH, Liu HS, Wu SY, Lan SH, Jiang-Shieh YF, Lin CN, Su CL.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Cell Physiol 2015; 230:930-46; PMID:25216025; http://dx.doi.org/ 10.1002/jcp.24825 [218] Roberts HR, Smartt HJM, Greenhough A, Moore AE, Williams AC, Paraskeva C. Colon tumour cells increase PGE2 by regulating COX-2 and 15-PGDH to promote survival during the microenvi-ronmental stress of glucose deprivation.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Carcinogenesis 2011;32:1741-7; PMID:21926111; http://dx.doi.org/10.1093/carcin/ bgr210 [219] De Pergola G, Silvestris F. Obesity as a major risk factor for cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Obesity 2013; 2013:291546; PMID:24073332; http://dx.doi.org/10.1155/2013/291546 [220] Pfalzer AC, Nesbeth PD, Parnell LD, Iyer LK, Liu Z, Kane AV, Chen CY, Tai AK, Bowman TA, Obin MS, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"PLoS One 2015; 10; PMID:26284788; http://dx.doi.org/10.1371/journal.pone.0135758 [221] Diaz-Algorri Y, Lozada ME, Lopez SM, Bertran-Rodriguez CE, Gonzalez-Hernandez CM, Gonzalez D, P /C19erez-Cardona CM, Hern /C19andez J, Pedrosa C, Toro DH, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr Nutr Rep 2013; 2:19-26;PMID:23396869; http://dx.doi.org/10.1007/s13668-012-0038-7 [223] Pietrzyk L, Torres A, Maciejewski R, Torres K. Obesity and Obese-related Chronic Low-grade in ﬂammation in promotion of colorectal cancer development.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Asian Pac J Cancer Prev2015; 16:4161-8; PMID:26028066; http://dx.doi.org/10.7314/APJCP.2015.16.10.4161 [224] Tae CH, Kim SE, Jung SA, Joo YH, Shim KN, Jung HK, Kim TH, Cho MS, Kim KH, Kim JS.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"BMC Cancer 2014; 14:811; PMID:25370174; http://dx.doi.org/10.1186/1471-2407-14-811 [225] Kourelis TV, Siegel RD.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Med Oncol 2012; 29:1314-27; PMID:21301998;http://dx.doi.org/10.1007/s12032-011-9846-7 [226] Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR, Dunlop MG. Aspirin inhibits mTOR signaling, acti-vates AMP-activated protein kinase, and induces autophagy in colo-rectal cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Gastroenterology 2012; 142:1504-15 e3; PMID:22406476; http://dx.doi.org/10.1053/j.gastro.2012.02.050 [227] Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, Ueno T, Ochiai A, Esumi H. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Can- cer Res 2007; 67:9677-84; PMID:17942897; http://dx.doi.org/10.1158/0008-5472.CAN-07-1462 [228] Kauntz H, Bousserouel S, Gosse F, Raul F. Silibinin triggers apopto- tic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Apo-ptosis 2011; 16:1042-53; PMID:21779837; http://dx.doi.org/10.1007/s10495-011-0631-z [229] Kantara C, O ’Connell M, Sarkar S, Moya S, Ullrich R, Singh P. Cur- cumin promotes autophagic survival of a subset of colon cancerstem cells, which are ablated by DCLK1-siRNA.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cancer Res 2014; 74:2487-98; PMID:24626093; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"BMC Complementary AlternMed 2015; 15:246; PMID:26199067; http://dx.doi.org/10.1186/s12906-015-0773-6 [231] Talero E, Avila-Roman J, Motilva V. Chemoprevention with phyto- nutrients and microalgae products in chronic in ﬂammation and colon cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr Pharm Des 2012; 18:3939-65; PMID:22632755;http://dx.doi.org/10.2174/138161212802083725 [232] Sui X, Kong N, Wang X, Fang Y, Hu X, Xu Y, Chen W, Wang K, Li D, Jin W, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Lett 2008; 265:16-26; PMID:18395970; http://dx.doi.org/10.1016/j.canlet.2008.02.061 [234] Comes F, Matrone A, Lastella P, Nico B, Susca FC, Bagnulo R, Ingravallo G, Modica S, Lo Sasso G, Moschetta A, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cell Death Differ 2007; 14:693-702;PMID:17159917; http://dx.doi.org/10.1038/sj.cdd.4402076812 P. MOKARRAM ET AL.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell Death Differ 2009; 16:1203-14; PMID:19343039; http://dx.doi.org/ 10.1038/cdd.2009.36 [236] Chiacchiera F, Simone C. Inhibition of p38alpha unveils an AMPK- FoxO3A axis linking autophagy to cancer-speci ﬁc metabolism.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Autophagy 2009; 5:1030-3; PMID:19587525; http://dx.doi.org/10.4161/auto.5.7.9252 [237] Simone C. Signal-dependent control of autophagy and cell death in colorectal cancer cell: the role of the p38 pathway.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2007; 3:468-71; PMID:17495519; http://dx.doi.org/10.4161/auto.4319 [238] Yang WL, Perillo W, Liou D, Marambaud P, Wang P. AMPK inhib- itor compound C suppresses cell proliferation by induction of apo- ptosis and autophagy in human colorectal cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Surg Oncol 2012; 106:680-8; PMID:22674626; http://dx.doi.org/10.1002/jso.23184 [239] Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, N a k a g a w aY ,I t oY ,O t s u k iY ,U n oB ,U c h i y a m aK ,e ta l .M i c r o - RNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cancer Lett 2015; 363:17-27; PMID:25818238; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Oncogene 2012; 31:1073-85;PMID:21841826; http://dx.doi.org/10.1038/onc.2011.321 [241] Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Saito K, Ito Z, Kobayashi H, Kajihara M, Uchiyama K, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"World J Gastroenterol 2013; 19:8531-42; PMID:24379570; http://dx.doi.org/10.3748/wjg.v19.i46.8531 [242] Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J ClinOncol 2005; 23:720-31; PMID:15613691; http://dx.doi.org/10.1200/ JCO.2005.10.206 [243] Noguchi T, Ritter G, Nishikawa H. Antibody-based therapy in colo- rectal cancer.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Immunotherapy 2013; 5:533-45; PMID:23638747; http://dx.doi.org/10.2217/imt.13.35 [244] Sanchez-Castanon M, Er TK, Bujanda L, Herreros-Villanueva M. Immunotherapy in colorectal cancer: What have we learned so far?Clin Chim Acta 2016; 460:78-87; PMID:27350293; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Cancer Res 2005; 11:7891-900;PMID:16278414; http://dx.doi.org/10.1158/1078-0432.CCR-05-1330 [246] Gonzalez G, Crombet T, Catala M, Mirabal V, Hernandez JC, Gon- zalez Y, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Annal Oncol 1998; 9:431-5; http://dx.doi.org/ 10.1023/A:1008261031034 [247] Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Cancer Res 2009; 15:1086-95;PMID:19188184; http://dx.doi.org/10.1158/1078-0432.CCR-08- 2227 [248] Paulsen JE, Bjorheim J, Roe J, Eide TJ, Alexander J, Gaudernack G. Effect of vaccination with mutant KRAS peptides on rat coloncarcinogenesis induced by azoxymethane.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nat Rev Immunol 2005; 5:296-306; PMID:15803149; http://dx.doi.org/10.1038/nri1592 [250] Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD, Jr. Peptide-pulsed dendritic cells induce antigen-speci ﬁc CTL-medi- ated protective tumor immunity.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Exp Med 1996; 183:283-7; PMID:8551233; http://dx.doi.org/10.1084/jem.183.1.283 [251] Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Res 2012; 72:2791-801; PMID:22472122; http://dx.doi.org/10.1158/0008-5472.CAN-12-0320 [267] Likus W, Siemianowicz K, Markowski J, Wiaderkiewicz J, Kostrzab- Zdebel A, Jura-Szoltys E, Dziubdziela W, Wiaderkiewicz R, ºos MJ, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Archivum Immunol Ther Exp 2016, 64:241-7; PMID:26584851; http://dx.doi.org/10.1007/s00005- 015-0373-7 [268] Jin HR, Zhao J, Zhang Z, Liao Y, Wang CZ, Huang WH, Li SP, He TC, Yuan CS, Du W. The antitumor natural compound falcarindiol promotes cancer cell death by inducing endoplasmic reticulum stress.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell Death Dis 2012; 3:e376; PMID:22914324; http://dx.doi.org/10.1038/cddis.2012.122 [269] Bravo R, Parra V, Gatica D, Rodriguez AE, Torrealba N, Paredes F, Wang ZV, Zorzano A, Hill JA, Jaimovich E, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Toxicol- ogy 2007; 229:253-61; PMID:17161515; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Natl Cancer Inst 2004; 96:1300-10; PMID:15339968; http://dx.doi.org/10.1093/jnci/djh243 [272] Suh DH, Kim MK, Kim HS, Chung HH, Song YS.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Ann N Y Acad Sci 2012; 1271:20-32; PMID:23050960;http://dx.doi.org/10.1111/j.1749-6632.2012.06739.x [273] Schleicher SM, Moretti L, Varki V, Lu B.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Drug Resist Updat2010; 13:79-86; PMID:20471904; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Oncotarget 2015; 6:18891-904; PMID:25970773; http://dx.doi.org/10.18632/oncotarget.3783 [275] Moretti L, Yang ES, Kim KW, Lu B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Drug Resist Updat 2007; 10:135-43; PMID:17627865; http://dx.doi.org/10.1016/j.drup.2007.05.001 [276] Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, Olson M, Koong AC, Koumenis C. Preferential cytotoxicity of bortezomib toward hyp- oxic tumor cells via overactivation of endoplasmic reticulum stresspathways.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Res 2008; 68:9323-30; PMID:19010906; http://dx.doi.org/10.1158/0008-5472.CAN-08-2873 [277] Fasano E, Serini S, Piccioni E, Toesca A, Monego G, Cittadini AR, Ranelletti FO, Calviello G. DHA induces apoptosis by altering theexpression and cellular location of GRP78 in colon cancer cell lines.Biochimica Et Biophysica Acta 2012; 1822:1762-72; PMID:22898250; http://dx.doi.org/10.1016/j.bbadis.2012.08.003 [278] Jakobsen CH, Storvold GL, Bremseth H, Follestad T, Sand K, Mack M, Olsen KS, Lundemo AG, Iversen JG, Krokan HE, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Lipid Res2008; 49:2089-100; PMID:18566476; http://dx.doi.org/10.1194/jlr.M700389-JLR200 [279] Lundemo AG, Pettersen CH, Berge K, Berge RK, Schonberg SA.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Lipids Health Dis 2011; 10:190; PMID:22027281; http://dx.doi.org/10.1186/1476-511X-10-190 [280] Adwan H, Bayer H, Pervaiz A, Sagini M, Berger MR. Riproximin is a recently discovered type II ribosome inactivating protein withpotential for treating cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Biotechnol Adv 2014; 32:1077-90; PMID:24699434; http://dx.doi.org/10.1016/j.biotechadv.2014.03.008 [281] Guichard C, Pedruzzi E, Fay M, Marie JC, Braut-Boucher F, Daniel F, Grodet A, Gougerot-Pocidalo MA, Chastre E, Kotelevets L, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Car- cinogenesis 2006; 27:1812-27; PMID:16524888; http://dx.doi.org/ 10.1093/carcin/bgl009 [282] Trondl R, Flocke LS, Kowol CR, Heffeter P, Jungwirth U, Mair GE, Steinborn R, Enyedy /C19EA, Jakupec MA, Berger W, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Pharmacol 2014; 85:451-9;PMID:24378333; http://dx.doi.org/10.1124/mol.113.090605 [283] Zhang X, Lee SH, Min KW, McEntee MF, Jeong JB, Li Q, Baek SJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Prev Res(Phila) 2013; 6:1337-47; PMID:24104354; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0220 [284] Symonds EL, Konczak I, Fenech M. The Australian fruit Illawarra plum (Podocarpus elatus Endl., Podocarpaceae) inhibits telomerase,increases histone deacetylase activity and decreases proliferation of colon cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Br J Nutr 2013; 109:2117-25; PMID:23069328; http://dx.doi.org/10.1017/S0007114512004333 [285] Wiersma VR, de Bruyn M, Wei Y, van Ginkel RJ, Hirashima M, N i k iT ,N i s h iN ,Z h o uJ ,P o u w e l sS D ,S a m p l o n i u sD F ,e ta l .",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2015; 11:1373-88; PMID:26086204; http://dx.doi.org/10.1080/ 15548627.2015.1063767 [286] Oliveira CS, Pereira H, Alves S, Castro L, Baltazar F, Chaves SR, Preto A, C ^orte-Real M. Cathepsin D protects colorectal cancer cells from acetate-induced apoptosis through autophagy-independent degradation of damaged mitochondria.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr Pharm Des 2012; 18:3853-73; PMID:22632751; http://dx.doi.org/10.2174/ 138161212802083653 [288] Francipane MG, Lagasse E. Selective targeting of human colon can- cer stem-like cells by the mTOR inhibitor Torin-1.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Oncotarget 2013; 4:1948-62; PMID:24185040; http://dx.doi.org/10.18632/oncotarget.1310 [289] Huo HZ, Zhou ZY, Wang B, Qin J, Liu WY, Gu Y.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Biochem Biophys Res Commun2014; 443:406-12; PMID:24309100; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Apoptosis 2012; 17:1300-15; PMID:23011180; http://dx.doi.org/10.1007/s10495-012-0757-7 [291] Chekhonin VP, Shein SA, Korchagina AA, Gurina OI.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr Cancer Drug Targets 2013; 13:423-43; PMID:23167597; http://dx.doi.org/10.2174/15680096113139990074 [292] Koehler BC, Jager D, Schulze-Bergkamen H. Targeting cell death signaling in colorectal cancer: current strategies and future perspec-tives.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"World J Gastroenterol 2014; 20:1923-34; PMID:24587670;http://dx.doi.org/10.3748/wjg.v20.i8.1923 [293] Hong Y, Won J, Lee Y, Lee S, Park K, Chang K-T, Hong Y. Melato- nin treatment induces interplay of apoptosis, autophagy, and senes-cence in human colorectal cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Pineal Res 2014; 56:264-74; PMID:24484372; http://dx.doi.org/10.1111/jpi.12119 [294] Ricci MS, Zong WX.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Oncologist 2006; 11:342-57; PMID:16614230;http://dx.doi.org/10.1634/theoncologist.11-4-342814 P. MOKARRAM ET AL.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Proc Natl Acad Sci U S A 2010; 107(43):18511-6; PMID:20937856; http://dx.doi.org/ 10.1073/pnas.1006124107 [297] Hiss DC, Gabriels GA.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Expert Opin Drug Discov2009; 4:799-821; PMID:23496268; http://dx.doi.org/10.1517/17460440903052559 [298] Koukourakis MI, Giatromanolaki A, Sivridis E, Pitiakoudis M, Gat- ter KC, Harris AL.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"BrJ Cancer 2010; 103:1209-14; PMID:20842118; http://dx.doi.org/ 10.1038/sj.bjc.6605904 [299] Goel A, Aggarwal BB.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nutr Cancer 2010; 62:919-30; PMID:20924967; http://dx.doi.org/10.1080/01635581.2010.509835 [300] Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishi- kawa T, Shuno Y, Hongo K, Hiyoshi M, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"BMC Cancer 2010; 10:1-11; PMID:20047689; http://dx.doi.org/10.1186/1471-2407-10-370 [301] Hiss DC, Gabriels GA.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Exp Opin Drug Dis 2009; 4:907-21; PMID:23480539; http://dx.doi.org/10.1517/17460440903055032 [302] Nishikawa T, Tsuno NH, Okaji Y, Shuno Y, Sasaki K, Hongo K, Sunami E, Kitayama J, Takahashi K, Nagawa H. Inhibition of auto- phagy potentiates sulforaphane-induced apoptosis in human colon cancer cells.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Ann Surg Oncol 2010; 17:592-602; PMID:19830499;http://dx.doi.org/10.1245/s10434-009-0696-x [303] Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M, Kruyt FA.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Anticancer Drugs 2012; 23:675-82; PMID:22561420; http://dx.doi.org/10.1097/CAD.0b013e328353f8c7 [305] Schonewolf CA, Mehta M, Schiff D, Wu H, Haffty BG, Karantza V, Jabbour SK.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"PloS one 2012; 7:e51076; PMID:23226467; http://dx.doi.org/10.1371/journal.pone.0051076 [307] Xie CM, Chan WY, Yu S, Zhao J, Cheng CH.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Free RadicBiol Med 2011; 51:1365-75; PMID:21763418; http://dx.doi.org/10.1016/j.freeradbiomed.2011.06.016 [308] Wu YN, Wu PC, Yang LX, Ratinac KR, Thordarson P, Jahn KA, Chen DH, Shieh DB, Braet F. The anticancer properties of ironcore-gold shell nanoparticles in colorectal cancer cells.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Int J Nano-medicine 2013; 8:3321-31; PMID:24039416; http://dx.doi.org/ 10.2147/IJN.S47742 [309] Fels DR, Koumenis C. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Biol Ther2006; 5:723-8; PMID:16861899; http://dx.doi.org/10.4161/ cbt.5.7.2967 [310] Paridaens A, Laukens D, Vandewynckel YP, Coulon S, Van Vlierberghe H, Geerts A, Colle I. Endoplasmic reticulum stress and angiogenesis: is there an interaction between them?",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Liver Int 2014; 34:e10-8; PMID:24393274; http://dx.doi.org/10.1111/liv.12457 [311] Tai CJ, Wang CK, Tai CJ, Lin YF, Lin CS, Jian JY, Chang YJ, Chang CC.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Biochem Pharmacol 2014; 88:178-88; PMID:24486574; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Cancer Res Clin Oncol 2014; 140:769-81;PMID:24619662; http://dx.doi.org/10.1007/s00432-014-1628-0 [314] Szokalska A, Makowski M, Nowis D, Wilczynski GM, Kujawa M, Wojcik C, Mlynarczuk-Bialy I, Salwa P, Bil J, Janowska S, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Res 2009; 69:4235-43; PMID:19435917; http://dx.doi.org/10.1158/0008-5472.CAN-08-3439 [315] Wei M-F, Chen M-W, Chen K-C, Lou P-J, Lin SY-F, Hung S-C, Hsiao M, Yao CJ, Shieh MJ.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Autophagy 2014; 10:1179-92; PMID:24905352; http://dx.doi.org/10.4161/auto.28679 [316] Likus W, Siemianowicz K, Bie /C19nk K, Paku »a M, Pathak H, Dutta C, Wang Q, Shojaei S, Assaraf YG, Ghavami S, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Drug Resist Updat 2016; 25:13-25; PMID:27155373; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Neoplasia (New York, NY) 2014; 16:679-93; http://dx.doi.org/10.1016/j.neo.2014.08.001 [318] Jain MV, Jangamreddy JR, Grabarek J, Schweizer F, Klonisch T, Cieslar-Pobuda A, ºos MJ.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell Cycle (Georgetown, Tex) 2015; 14:2109- 20; PMID:26030190; http://dx.doi.org/10.1080/ 15384101.2015.1041692 [319] Savelyeva A, Ghavami S, Davoodpour P, Asoodeh A, Los MJ.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"PloS One 2014; 9:e90607;PMID:24594804; http://dx.doi.org/10.1371/journal.pone.0090607 [321] Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M,et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Clin Oncol 2015; 33:4023-31; PMID:26392102; http://dx.doi.org/10.1200/ JCO.2015.63.2471 [322] Kopetz S, Desai J, Chan E, Hecht JR, O ’Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
J Clin Oncol 2015; 33:4032-8; PMID:26460303; http://dx.doi.org/10.1200/JCO.2015.63.2497AUTOPHAGY 815,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Lancet 2012; 379:1893-901; PMID:22608338; http://dx.doi.org/10.1016/S0140- 6736(12)60398-5 [324] Yaeger R, Cercek A, O ’Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Cancer Res 2015; 21:1313-20;PMID:25589621; http://dx.doi.org/10.1158/1078-0432.CCR-14- 2779 [325] Rad R, Cadinanos J, Rad L, Varela I, Strong A, Kriegl L, Con- stantino-Casas F, Eser S, Hieber M, Seidler B, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Cell 2013; 24:15-29; PMID:23845441; http://dx.doi.org/10.1016/j.ccr.2013.05.014 [326] Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Cancer Res 2013; 19:2688-98; PMID:23549875; http://dx.doi.org/10.1158/1078- 0432.CCR-12-2556 [327] Karapetis CS, Khambata-Ford S, Jonker DJ, O ’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385 [328] De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent- Puig P, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Lancet Oncol 2010; 11:753-62;PMID:20619739; http://dx.doi.org/10.1016/S1470-2045(10)70130-3 [329] De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Genet 2013; 206:26-31; PMID:23313110; http://dx.doi.org/10.1016/j.cancergen.2012.12.003 [332] Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Res 2009; 69:1851-7; PMID:19223544; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-2466 [333] Cushman SM, Jiang C, Hatch AJ, Shterev I, Sibley AB, Niedzwiecki D, Venook AP, Owzar K, Hurwitz HI, Nixon AB.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"CliniCancer Res 2015; 21:1078-86; PMID:25520391; http://dx.doi.org/10.1158/1078-0432.CCR-14-2313 [334] Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox- Fogel N, Forg /C19o E, Rajendran PS, Miranda SP, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"N Engl JMed 2016; 374:211-22; PMID:26789870; http://dx.doi.org/10.1056/ NEJMoa1506597 [335] Sanchez-Martin FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Canadas I, Vidal J, Martinez A, Argil /C19es G, Siravegna G, Arena S, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Clin Cancer Res 2016; 22:3260-7; PMID:26888827; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Cancer 2014; 13:141; PMID:24894453;http://dx.doi.org/10.1186/1476-4598-13-141 [337] Shen WD, Chen HL, Liu PF.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Res 2013; 73:3132-44; PMID:23539443; http://dx.doi.org/10.1158/0008-5472.CAN-12-4562 [339] Boidot R, Chevrier S, Julie V, Ladoire S, Ghiringhelli F. HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Int J Colorectal Dis2016; 31:1245-6; PMID:26561417; http://dx.doi.org/10.1007/s00384-015-2448-7 [340] Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, Chng WJ, Zeng Q. Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Clin Invest 2013; 123:3459-71; PMID:23867504; http://dx.doi.org/10.1172/JCI66824 [341] Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Fal- tejskova P, Svoboda M, Sabbioni S, Nemecek R, Slaby O, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"BMC Cancer 2015; 15:808; PMID:26508446; http://dx.doi.org/10.1186/s12885-015-1752-5 [342] Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, Wanherdrick K, Dorard C, Taieb A, Saget A, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Gastroenterology 2014; 146:401-11 e1; PMID:24512910; http://dx.doi.org/10.1053/j.gastro.2013.10.054 [343] Lee SJ, Li GG, Kim ST, Hong ME, Jang J, Yoon N, Ahn SM, Murphy D, Christiansen J, Wei G, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Mol Oncol2012; 6:370-81; PMID:22521243; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Anticancer Drugs 2014; 25:1175-81; PMID:25089570; http://dx.doi.org/10.1097/ CAD.0000000000000151 [346] Nygard SB, Christensen IJ, Nielsen SL, Nielsen HJ, Brunner N, Spindler KL.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Scand J Gastroenterol 2014; 49:84-91;PMID:24256029; http://dx.doi.org/10.3109/00365521.2013.856464 [347] Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5- ﬂuorodeoxyuridylate.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Biochemistry 1974; 13:471-81; PMID:4203910; http://dx.doi.org/10.1021/bi00700a012816 P. MOKARRAM ET AL.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature Rev Cancer 2003; 3:330-8;http://dx.doi.org/10.1038/nrc1074 [349] Abdallah EA, Fanelli MF, Buim MEC, Machado Netto MC, Gaspar- ini Junior JL, Souza e Silva V, Dettino AL, Mingues NB, Romero JV, Ocea LM, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Inter J Cancer 2015; 137:1397- 405; PMID:25721610; http://dx.doi.org/10.1002/ijc.29495 [350] Wyatt MD, Wilson DM, III.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cell Mol Life Sci 2009; 66:788-99; PMID:18979208; http://dx.doi.org/10.1007/s00018-008-8557-5 [351] Ghoshal K, Jacob ST. An alternative molecular mechanism of action of 5- ﬂuorouracil, a potent anticancer drug.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Biochem Pharmacol 1997; 53:1569-75; PMID:9264308; http://dx.doi.org/10.1016/S0006- 2952(97)00040-3 [352] Zhou X, Wang W, Li P, Zheng Z, Tu Y, Zhang Y, You T. Curcumin Enhances the effects of 5-Fluorouracil and oxaliplatin in inducinggastric cancer cell apoptosis both in vitro and in vivo .",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Oncol Res 2016; 23:29-34; PMID:26802648; http://dx.doi.org/10.3727/ 096504015X14452563486011 [353] Amankwatia E, Chakravarty P, Carey F, Weidlich S, Steele R, Munro A, Wolf CR, Smith G. MicroRNA-224 is associated with colorectal cancer progression and response to 5- ﬂuorouracil-based chemotherapy by KRAS-dependent and-independent mechanisms.Br J Cancer 2015; 112:1480-90; PMID:25919696; http://dx.doi.org/ 10.1038/bjc.2015.125 [354] Sun Z, Zhou N, Han Q, Zhao L, Bai C, Chen Y, Zhou J, Zhao RC.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Transl Oncol 2015; 17:876-83; PMID:26055341; http://dx.doi.org/10.1007/s12094-015-1318-7 [355] Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E, Jones A, Howarth K, Freeman-Mills L, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Gut 2015; 64:111-20; PMID:24647007;http://dx.doi.org/10.1136/gutjnl-2013-306571 [356] Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M. Resveratrol induces chemosensitization to 5- ﬂuorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymaltransition and apoptosis in colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Biochem Pharmacol 2015; 98:51-68; PMID:26310874; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Annal Surg Oncol 2012; 19:3065-71; PMID:22322955; http://dx.doi.org/10.1245/s10434-012-2246-1 [359] Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, Gordon MA, Lenz HJ, Van Schaeybroeck S, Longley DB, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Immunol 2015; 194:1868-82; http://dx.doi.org/10.4049/jimmunol.1402243 [363] Lourencao BC, Medeiros RA, Thomasi SS, Ferreira AG, Rocha- Filho RC, Fatibello-Filho O. Amperometric ﬂow-injection determi- nation of the anthelmintic drugs ivermectin and levamisole using electrochemically pretreated boron-doped diamond electrodes.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Sen- sors and Actuators B: Chemical 2016; 222:181-9; http://dx.doi.org/ 10.1016/j.snb.2015.08.036 [364] Maude RJ, Silamut K, Plewes K, Charunwatthana P, Ho M, Faiz MA, Hassan MU, Bin Yunus E, Hoque G, Islam F, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Infect Dis 2014; 209:120-9; PMID:23943850; http://dx.doi.org/10.1093/infdis/jit410 [365] Patil U, Jaydeokar A, Bandawane D. Immunomodulators: A phar- macological review.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"CurrOpin Hematol 2012; 19:27-31; PMID:22143075; http://dx.doi.org/ 10.1097/MOH.0b013e32834da9ef [367] Sakurai H, Kubota K, Inaba S-i, Takanaka K, Shinagawa A. Identi ﬁ- cation of a metabolizing enzyme in human kidney by proteomic correlation pro ﬁling.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Cell Proteomics 2013; 12:2313-23; PMID:23674616; http://dx.doi.org/10.1074/mcp.M112.023853 [368] Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O ’Connell MJ, Levitt R, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J ClinOncol 2002; 20:1735-43; PMID:11919229; http://dx.doi.org/10.1200/JCO.2002.07.080 [369] McLeod H, Murray G. Tumour markers of prognosis in colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Br J Cancer 1999; 79:191; PMID:9888457; http://dx.doi.org/10.1038/sj.bjc.6690033 [370] Liao VH-C, Liu J-T, Li W-H, Yu C-W, Hsieh Y-C. Caenorhabditis elegans bicarbonate transporter ABTS-1 is involved in arsenite tox-icity and cholinergic signaling.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Chem Res Toxicol 2010; 23:926-32;PMID:20423156; http://dx.doi.org/10.1021/tx100016e [371] Kozlenkov A, Le Du MH, Cuniasse P, Ny T, Hoylaerts MF, Mill /C19an JL.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Bone Miner Res 2004; 19:1862-72; PMID:15476587; http://dx.doi.org/10.1359/ JBMR.040608 [372] Sakai H, Kokura S, Ishikawa T, Tsuchiya R, Okajima M, Matsuyama T, Adachi S, Katada K, Kamada K, Uchiyama K, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Clin BiochemNutr 2013; 52:64; PMID:23341700; http://dx.doi.org/10.3164/jcbn.12-60 [373] Chia WK, Ali R, Toh HC.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nat Rev Clin Oncol 2012; 9:561- 70; PMID:22910681; http://dx.doi.org/10.1038/nrclinonc.2012.137 [374] Kandioler D, Mittlb €ock M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"EBioMedicine 2015; 2:823-8; http://dx.doi.org/10.1016/j.ebiom.2015.06.003 [375] Siegelin MD, Altieri DC.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"DrugMetab Rev 2012; 44:148-72; PMID:22497631; http://dx.doi.org/ 10.3109/03602532.2011.638303 [377] Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Clin Cancer Res 2006; 12:4315-30; PMID:16857807; http://dx.doi.org/10.1158/1078-0432.CCR-06-0162AUTOPHAGY 817,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Mol Cell Biol 2008; 28:4261- 74; PMID:18458060; http://dx.doi.org/10.1128/MCB.02252-07 [379] Li W, Zou W, Yang Y, Chai Y, Chen B, Cheng S, Tian D, Wang X, Vale RD, Ou G. Autophagy genes function sequentially to promote apoptotic cell corpse degradation in the engul ﬁng cell.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Cell Biol 2012; 197:27-35; PMID:22451698; http://dx.doi.org/10.1083/jcb.201111053 [380] Latheef S, Devanabanda M, Sankati S, Madduri R. Differential expression of alkaline phosphatase gene in proliferating primary lymphocytes and malignant lymphoid cell lines.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Immunol Lett2016; 170:37-41; PMID:26730846; http://dx.doi.org/10.1016/j.imlet.2015.12.008 [381] Staab TA, Griffen TC, Corcoran C, Evgrafov O, Knowles JA, Sie- burth D. The conserved SKN-1/Nrf2 stress response pathway regu-lates synaptic function in Caenorhabditis elegans.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
PLoS Genet 2013;9:e1003354; PMID:23555279; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Clin Endocrinol Metab 2000; 85:4347-53; PMID:11095478; http://dx.doi.org/10.1210/jcem.85.11.6991 [383] Bennett MK, Gross MI, Bromley SD, Li J, Chen L, Goyal B, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Nature Rev Cancer 2007; 7:573-84; http://dx.doi.org/10.1038/ nrc2167 [385] Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"CancerResearch 2006; 66:8847-57; PMID:16951202; http://dx.doi.org/10.1158/0008-5472.CAN-06-0769 [386] Maclean D, Khokhar A, Tyle P, Perez-Soler R. Intraliposomal chemical activation patterns of liposomal cis-bis-neodeca-noato-trans-R, R-1, 2-diamino cyclohexane platinum (II)(L- NDDP)-a potential antitumo ur agent.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Microencapsul 2000; 17:307-22; PMID:10819419; http://dx.doi.org/10.1080/ 026520400288283 [387] Cui X, Clark DN, Liu K, Xu X-D, Guo J-T, Hu J.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Virol 2016; 90:486-96; http://dx.doi.org/10.1128/JVI.01263-15 [388] Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimo- kata T, Sugishita M, Nakayama G, Uehara K, Hasegawa Y, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cancer 2012; 118:2828-36; PMID:22020760; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Invest 2015; 33:89-97;PMID:25723812;http://dx.doi.org/10.3109/ 07357907.2014.998834 [391] Perego P, Robert J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical ef ﬁcacy.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer Chemother Pharmacol 2016; 77:5-18; PMID:26589793; http://dx.doi.org/ 10.1007/s00280-015-2901-x [392] Tang D, Kang R, Cheh C-W, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, et al.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Oncogene 2010; 29:5299-310; PMID:20622903; http://dx.doi.org/10.1038/onc.2010.261 [393] Ishtikhar M, Khan MV, Khan S, Chaturvedi SK, Badr G, Mahmoud MH, Khan RH.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Biomol Struct Dyn 2016; 34 (7):1545-60; PMID:26309154; http://dx.doi.org/10.1080/07391102.2015.1082504 [394] Chaniyara R, Tala S, Chen C-W, Zang X, Kakadiya R, Lin LF, Chen CH, Chien SI, Chou TC, Tsai TH, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Med Chem 2013; 56:1544-63; PMID:23360284; http://dx.doi.org/10.1021/jm301788a [395] Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, ZielinskiCC, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Colorectal Cancer 2015; 14:91-8;PMID:25666295; http://dx.doi.org/10.1016/j.clcc.2014.12.003 [396] Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1 /C3 28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Pharmacogenomics J 2014;14:120-9; PMID:23529007; http://dx.doi.org/10.1038/tpj.2013.10 [397] Zhang G, Wang Z, Qian F, Zhao C, Sun C. Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in humangastric cancer.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Pharmacogenomics 2012; 13:1445; PMID:23057543; http://dx.doi.org/10.2217/pgs.12.134 [399] Van Cutsem E, Lenz H-J, K €ohne C-H, Heinemann V, Tejpar S, Melez /C19ınek I, Beier F, Stroh C, Rougier P, van Krieken JH, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"J Clin Oncol 2015; 33:692-700; PMID:25605843; http://dx.doi.org/10.1200/JCO.2014.59.4812 [400] Chaudhuri AR, Hashimoto Y, Herrador R, Neelsen KJ, Fachinetti D, Bermejo R, Cocito A, Costanzo V, Lopes M. Topoisomerase Ipoisoning results in PARP-mediated replication fork reversal.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Nat Struct Mol Biol 2012; 19:417-23; PMID:22388737; http://dx.doi.org/ 10.1038/nsmb.2258 [401] Saif MW.,OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Onco Targets Ther 2009; 2:29; PMID:20616892; http://dx.doi.org/10.2147/OTT.S3469 [402] Abd-Elzaher MM, Labib AA, Mousa HA, Moustafa SA, Abdallah MM.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Res Chem Intermed- iat 2014; 40:1923-36; http://dx.doi.org/10.1007/s11164-013-1090-7 [403] Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, et al.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Clin Cancer Res 2011; 17:3455-68; PMID:21498394; http://dx.doi.org/10.1158/1078-0432.CCR-10-2209 [404] O ’Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ, Dolan ME.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Cancer 2012; 118:4063-73; PMID:22864933; http://dx.doi.org/ 10.1002/cncr.26737 [405] Luo B, Lee AS.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
Cancer 2010; 116:5200-6;PMID:20669326; http://dx.doi.org/10.1002/cncr.25303818 P. MOKARRAM ET AL.,Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Lung Cancer 2002; 38:217-27; PMID:12445742; http://dx.doi.org/10.1016/S0169-5002(02)00224-6 [408] Honeywell RJ, van Haperen VWR, Veerman G, Smid K, Peters GJ.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Int J Biochem Cell Biol 2015; 60:73-81; PMID:25562513; http://dx.doi.org/10.1016/j.biocel.2014.12.010 [409] Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R. Cellular and pharmacogenetics foundation ofsynergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Curr Drug Discov Technol 2007; 4:48-58; PMID:17630928; http://dx.doi.org/10.2174/157016307781115494 [411] Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhib- itor, trichostatin A, increases the chemosensitivity of anticancerdrugs in gastric cancer cell lines.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"ClinCancer Res 2012; 18:577-84; PMID:22142827; http://dx.doi.org/ 10.1158/1078-0432.CCR-11-1387 [413] Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunode ﬁcient mice: a systematic review.",OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Immunol Cell Biol 2012; 90:85-94; PMID:22124371; http://dx.doi.org/10.1038/ icb.2011.100 [415] Porcelli L, E Quatrale A, Mantuano P, Silvestris N, E Brunetti A, Calvert H, Paradiso A, Azzariti A.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"Currnt Med Chem 2012; 19:3858-73; PMID:22788762; http://dx.doi.org/10.2174/092986712802002563 [416] Marzban H, Del Bigio MR, Alizadeh J, Ghavami S, Zachariah RM, Rastegar M. Cellular commitment in the developing cerebellum.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/kaup-13-05-1290751.PMC5446063.pdf
"eLife 2016,5:e21167; http://dx.doi.org/10.7554/eLife.21167 © 2017 Juan Wang, Saralin Davis, Ming Zhu, Elizabeth A. Miller, and Susan Ferro-Novick.",Non-OADS,/arxiv_data1/oa_pdf/66/2b/kaup-13-05-1287657.PMC5446067.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.AUTOPHAGY 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/66/2b/kaup-13-05-1287657.PMC5446067.pdf
"5, 973 –974 http://dx.doi.org/10.1080/15548627.2017.1287657",Non-OADS,/arxiv_data1/oa_pdf/66/2b/kaup-13-05-1287657.PMC5446067.pdf
"5, 868 –884 http://dx.doi.org/10.1080/15548627.2017.1291470",Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"ORCID Peter K. Kim http://orcid.org/0000-0001-6626-0575 References [1] Yorimitsu T, Klionsky DJ.",Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Avail- able from: http://www.ncbi.nlm.nih.gov/pubmed/16247502 ; http:// dx.doi.org/10.1038/sj.cdd.4401765 [2] Okamoto K. Organellophagy: eliminating cellular building blocks via selective autophagy.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/24862571 ; PMID: 24862571; http://dx.doi.org/10.1083/jcb.201402054 [3] Stolz A, Ernst A, Dikic I.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"from: http://www.ncbi.nlm.nih.gov/pubmed/24875736 ; PMID: 24875736; http://dx.doi.org/10.1038/ncb2979 [4] Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/21189453 ; PMID: 21189453; http://dx.doi.org/10.4161/auto.7.3.14487 [5] Pickrell AM, Youle RJ.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/25611507; http://dx.doi.org/10.1016/j.neuron.2014.12.007 [6] Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://jcb.rupress.org/content/191/5/933 PMID: 21115803; http://dx.doi.org/10.1083/jcb.201008084 [7] Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA, Banerjee S, Youle RJ.",Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"J Cell Biol [Internet] 2014; 205:143-53.Available from: http://jcb.rupress.org/content/205/2/143 ; PMID: 24751536; http://dx.doi.org/10.1083/jcb.201402104 [8] Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS, Hofmann K, Alessi DR, Knebel A, Trost M, Muqit MMK.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.nature.com/nature/journal/ vnfv/ncurrent/full/nature13392.html [10] Deosaran E, Larsen KB, Hua R, Sargent G, Wang Y, Kim S, Lamark T, Jauregui M, Law K, Lip pincott-Schwartz J, et al.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
nlm.nih.gov/pubmed/23239026 ; PMID: 23239026 http://dx.doi.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Proc Natl Acad Sci U S A [Internet] 2008; 105:20567-74.Available from: http://www.ncbi.nlm.nih.gov/pubmed/19074260 ; http://dx.doi.org/10.1073/pnas.0810611105 [12] Hettema EH, Distel B, Tabak HF.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"gov/pubmed/24345375 ; PMID: 24345375; http://dx.doi.org/10.1016/ j.biochi.2013.12.009 [14] Blok NB, Tan D, Wang RY-R, Penczek PA, Baker D, DiMaio F, Rapoport TA, Walz T. Unique double-ring structure of the peroxi-somal Pex1/Pex6 ATPase complex revealed by cryo-electron micros-copy.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/26170309 ; PMID: 26170309; http://dx.doi.org/10.1073/pnas.1500257112 [15] Ciniawsky S, Grimm I, Saf ﬁan D, Girzalsky W, Erdmann R, Wendler P. Molecular snapshots of the Pex1/6 AAA Ccomplex in action.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"nlm.nih.gov/pubmed/26066397 ; PMID: 26066397; http://dx.doi.org/ 10.1038/ncomms8331 [16] Gardner BM, Chowdhury S, Lander GC, Martin A.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"J Mol Biol [Internet] 2015; 427:1375-88.Available from: http://www.ncbi.nlm.nih.gov/pubmed/25659908 ; PMID: 25659908; http://dx.doi.org/10.1016/j.jmb.2015.01.019 [17] Steinberg SJ, Dodt G, Raymond G V, Braverman NE, Moser AB, Moser HW.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
ncbi.nlm.nih.gov/pubmed/17055079 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/26750748 ; PMID: 26750748; http://dx.doi.org/10.1016/j.ymgme.2015.12.009 [19] Waterham HR, Ferdinandusse S, Wanders RJA.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
ncbi.nlm.nih.gov/pubmed/26611709 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from:http://www.ncbi.nlm.nih.gov/pubmed/14709540 ; PMID: 14709540; http://dx.doi.org/10.1083/jcb.200304111 [21] Nordgren M, Francisco T, Lismont C, Hennebel L, Brees C, Wang B, Van Veldhoven PP, Azevedo JE, Fransen M. Export-de ﬁcient mono- ubiquitinated PEX5 triggers peroxisome removal in SV40 large T antigen-transformed mouse embryonic ﬁbroblasts.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"nih.gov/pubmed/26086376 ; PMID: 26086376; http://dx.doi.org/ 10.1080/15548627.2015.1061846 [22] Zhang J, Tripathi DN, Jing J, Alexander A, Kim J, Powell RT, Dere R, Tait-Mulder J, Lee J-H, Paull TT, et al.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/ pubmed/26344566 ; PMID: 26344566; http://dx.doi.org/10.1038/ ncb3230 [23] Kamijo K, Taketani S, Yokota S, Osumi T, Hashimoto T. The 70-kDa peroxisomal membrane protein is a member of the Mdr (P-glycopro-tein)-related ATP-binding protein superfamily.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22966490 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://linkinghub.elsevier.com/retrieve/pii/S0925443912000932 ; PMID: 22871920; http://dx.doi.org/10.1016/j.bbadis.2012.04.006 [27] Braverman NE, Raymond G V., Rizzo WB, Moser AB, Wilkinson ME, Stone EM, Steinberg SJ, Wangler MF, Rush ET, Hacia JG, et al.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/23524572 ; PMID: 23524572; http://dx.doi.org/10.1038/aps.2013.5 [29] Fujiki Y, Nashiro C, Miyata N, Tamura S, Okumoto K. New insights into dynamic and functional assembly of the AAA peroxins, Pex1p and Pex6p, and their membrane receptor Pex26p in shuttling of PTS1-receptor Pex5p during peroxisome biogenesis.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.AUTOPHAGY 883,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
ncbi.nlm.nih.gov/pubmed/22079764 ; PMID: 22079764; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Availablefrom: http://www.ncbi.nlm.nih.gov/pubmed/15536088 ; PMID: 15536088; http://dx.doi.org/10.1074/jbc.M403632200 [31] Okumoto K, Misono S, Miyata N, Matsumoto Y, Mukai S, Fujiki Y. Cysteine ubiquitination of PTS1 receptor Pex5p regulatesPex5p recycling.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.nlm.n ih.gov/pubmed/21554508 ; http://dx.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/17452527 ; PMID: 17452527; http://dx.doi.org/10.1083/jcb.200611012 [33] Miyata N, Fujiki Y. Shuttling mechanism of peroxisome targeting signal type 1 receptor Pex5: ATP-independent import and ATP- dependent export.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Avail-able from: http://www.ncbi.nlm.nih.gov/pubmed/16314507 ; http:// dx.doi.org/10.1128/MCB.25.24.10822-10832.2005 [34] Zhang R, Chen L, Jiralerspong S, Snowden A, Steinberg S, Braverman N. Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.pubmedcen tral.nih.gov/articlerender .fcgi?artid equals;2851769&tool Dpmcentrez& rendertype Dabstract ; PMID: 20212125; http://dx.doi.org/10.1073/ pnas.0914960107 [35] Sumantran VN.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/21516411 ; PMID: 21516411 [36] Zhang R, Chen L, Jiralerspong S, Snowden A, Steinberg S, Braverman N. Recovery of PEX1-Gly843Asp peroxi some dysfunction by small-mole- cule compounds.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih .gov/pubmed/20212125 ; PMID: 20212125; http://dx.doi.org/10.1073/pnas.0914960107 [37] Brocard CB, Boucher KK, Jedeszko C, Kim PK, Walton PA. Require- ment for microtubules and dynein motors in the earliest stages ofperoxisome biogenesis.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15813749 ; http://dx.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Availablefrom: http://www.ncbi.nlm.nih.gov/pubmed/17302559 ; PMID: 17302559; http://dx.doi.org/10.1042/BJ20061489[39] Nuttall JM, Motley AM, Hettema EH.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Autophagy [Internet] 2014; 10:835-45.Available from: http://www.ncbi.nlm.nih.gov/pubmed/24657987 ; PMID: 24657987; http://dx.doi.org/10.4161/auto.28259 [40] Motley AM, Nuttall JM, Hettema EH.",Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"nih.gov/pubmed/22643220 ; PMID: 22643220; http://dx.doi.org/ 10.1038/emboj.2012.151 [41] Yamashita S, Abe K, Tatemichi Y, Fujiki Y.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"nlm.nih.gov/pubmed/25007327 ; PMID: 25007327; http://dx.doi.org/ 10.4161/auto.29329 [42] Yorimitsu T, Klionsky DJ.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"nlm.nih.gov/pubmed/15659643 ; PMID: 15659643; http://dx.doi.org/ 10.1091/mbc.E04-11-1035 [43] Knoops K, Manivannan S, Cepinska MN, Krikken AM, Kram AM, Veenhuis M, van der Klei IJ.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/24590171 ; PMID: 24590171;http://dx.doi.org/10.1083/jcb.201310148 [44] van der Zand A, Gent J, Braakman I, Tabak HF.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"Available from: http://www.ncbi.nlm.nih.gov/pubmed/25440060 ; PMID: 25440060; http://dx.doi.org/10.1016/j.cmet.2014.09.017 [46] van Zutphen T, Ciapaite J, Bloks VW, Ackereley C, Gerding A, Jurdzinski A, Allgayer de Moraes R, Zhang L, Wolters JC, Bischoff R, et al.",OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
nlm.nih.gov/pubmed/24503136 ; PMID: 24503136; http://dx.doi.org/ 10.1016/j.ymgme.2014.01.008884 K. B.,OADS,/arxiv_data1/oa_pdf/20/b7/kaup-13-05-1291470.PMC5446072.pdf
"5, 885 –899 http://dx.doi.org/10.1080/15548627.2017.1291471",Non-OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Nat Med 2013; 19:983-97; PMID:23921753; http://dx.doi.org/10.1038/ nm.3232 [2] Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, et al.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Nature 2006; 441:880-4; PMID:16625205; http://dx.doi.org/10.1038/nature04723 [3] Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki- Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, et al.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Nat Rev Neurosci 2015; 16:345-57;PMID:25991442; http://dx.doi.org/10.1038/nrn3961 [5] Hannun YA, Obeid LM.",Non-OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Nat Rev Mol Cell Biol 2008; 9:139-50;PMID:18216770; http://dx.doi.org/10.1038/nrm2329 [6] Taniguchi M, Kitatani K, Kondo T, Hashimoto-Nishimura M, Asano S, Hayashi A, Mitsutake S, Igarashi Y, Umehara H, Takeya H, et al.Regulation of autophagy and its associated cell death by “sphingoli- pid rheostat: ”reciprocal role of ceramide and sphingosine 1-phos- phate in the mammalian target of rapamycin pathway.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"J Biol Chem 2012; 287:39898-910; PMID:23035115; http://dx.doi.org/10.1074/jbc.M112.416552 [7] Harvald EB, Olsen AS, Faergeman NJ.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Apoptosis 2015; 20:658-70; PMID:25682163; http://dx.doi.org/10.1007/s10495-015-1108-2 [8] Moruno Manchon JF, Uzor NE, Dabaghian Y, Furr-Stimming EE, Finkbeiner S, Tsvetkov AS.",Non-OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Scienti ﬁc Rep 2015; 5:15213; http://dx.doi.org/10.1038/srep15213 [9] Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signal- ling lipid.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Nat Rev Mol Cell Biol 2003; 4:397-407; PMID:12728273; http://dx.doi.org/10.1038/nrm1103 [10] Lepine S, Allegood JC, Park M, Dent P, Milstien S, Spiegel S. Sphin- gosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Cell Death Differ 2011; 18:350-61; PMID:20798685; http://dx.doi.org/10.1038/cdd.2010.104 [11] Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R, Botti J, Codogno P. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation.",Non-OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"J Biol Chem 2006; 281:8518-27;PMID:16415355;http://dx.doi.org/10.1074/jbc.M506182200 [12] Maeurer C, Holland S, Pierre S, Potstada W, Scholich K. Sphingo- sine-1-phosphate induced mTOR-activation is mediated by the E3-898 D. N. MITROI ET AL.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Cell Signal 2009; 21:293-300; PMID:19000755; http://dx.doi.org/10.1016/j.cellsig.2008.10.016 [13] Fyrst H, Saba JD.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
Biochim Biophys Acta 2008; 1781:448-58; PMID:18558101; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"bbalip.2008.05.005 [14] Rockenfeller P, Koska M, Pietrocola F, Minois N, Knittelfelder O, Sica V, Franz J, Carmona-Gutierrez D, Kroemer G, Madeo F. Phos- phatidylethanolamine positively regulates autophagy and longevity.Cell Death Differ 2015; 22:499-508; PMID:25571976; http://dx.doi.org/10.1038/cdd.2014.219 [15] Mitroi DN, Deutschmann AU, Raucamp M, Karunakaran I, Gle- b o vK ,H a n sM ,W a l t e rJ ,S a b aJ ,G r €aler M, Ehninger D, et al.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
Adv Enzyme Regul 2010; 50:349-62; PMID:19914275; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
Science 2002; 298:789-91; PMID:12399581; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"FASEB J 2004; 18:617-26; PMID:15054084; http://dx.doi.org/10.1096/fj.03-0338rev [20] Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem ﬂuorescent- tagged LC3.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Oncotarget2014; 5:7886-901; PMID:25226616; http://dx.doi.org/10.18632/oncotarget.2318 [22] Merrill AH Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway.",Non-OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"J Biol Chem 2002; 277:25843-6; PMID:12011104; http://dx.doi.org/10.1074/jbc.R200009200 [23] Hannun YA, Luberto C, Argraves KM.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Biochemistry 2001; 40:4893-903; PMID:11305904; http://dx.doi.org/10.1021/bi002836k [24] Zhang K, Pompey JM, Hsu FF, Key P, Bandhuvula P, Saba JD, Turk J, Beverley SM.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
EMBO J 2007;26:1094-104; PMID:17290222; http://dx.doi.org/10.1038/sj.emboj.7601565 [25] Kihara A. Sphingosine 1-phosphate is a key metabolite linking sphin- golipids to glycerophospholipids.,Non-OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Biochim Biophys Acta 2014;1841:766-72; PMID:23994042; http://dx.doi.org/10.1016/j.bbalip.2013.08.014 [26] Hagen-Euteneuer N, Lutjohann D, Park H, Merrill AH, Jr., van Echten-Deckert G. Sphingosine 1-phosphate (S1P) lyase de ﬁciency increases sphingolipid formation via recycling at the expense of de novo biosynthesis in neurons.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"J Biol Chem 2012; 287:9128-36; PMID:22291021; http://dx.doi.org/10.1074/jbc.M111.302380 [27] Hagen N, Hans M, Hartmann D, Swandulla D, van Echten-Deckert G. Sphingosine-1-phosphate links glycosphingolipid metabolism toneurodegeneration via a calpain-mediated mechanism.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Cell Death Differ 2011; 18:1356-65; PMID:21331079; http://dx.doi.org/10.1038/cdd.2011.7 [28] Yang Z, Klionsky DJ.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Curr Opin Cell Biol 2010; 22:124-31; PMID:20034776; http://dx.doi.org/10.1016/j.ceb.2009.11.014 [29] Wang H, Sun RQ, Camera D, Zeng XY, Jo E, Chan SM, Herbert TP, Molero JC, Ye JM.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"FASEB J 2016; 30:2549-56;PMID:27022162; http://dx.doi.org/10.1096/fj.201500119 [30] Sims K, Haynes CA, Kelly S, Allegood JC, Wang E, Momin A, Leipelt M, Reichart D, Glass CK, Sullards MC, et al.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Nat Cell Biol 2010; 12:207-9; PMID:20190829; http://dx.doi.org/10.1038/ ncb0310-207 [32] Elrick MJ, Yu T, Chung C, Lieberman AP.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
Hum Mol Genet 2012; 21:4876-87; PMID:22872701; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Hum Mol Genet 2012; 21:2651-62; PMID:22437840; http://dx.doi.org/10.1093/hmg/dds090 [34] Hoglinger D, Haberkant P, Aguilera-Romero A, Riezman H, Porter FD, Platt FM, Galione A, Schultz C. Intracellular sphingosine releases calcium from lysosomes.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"eLife 2015; 4:e10616; PMID:26613410; http://dx.doi.org/10.7554/eLife.10616 [35] Karaca I, Tamboli IY, Glebov K, Richter J, Fell LH, Grimm MO, Haupenthal VJ, Hartmann T, Gr €aler MH, van Echten-Deckert G, et al.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"J Clin Invest 2014; 124:5368-84; PMID:25347472; http://dx.doi.org/ 10.1172/JCI74188 [37] van Echten-Deckert G, Zschoche A, Bar T, Schmidt RR, Raths A, Heinemann T, Sandhoff K. cis-4-Methylsphingosine decreases sphingolipid biosynthesis by speci ﬁcally interfering with serine pal- mitoyltransferase activity in primary cultured neurons.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"J Biol Chem1997; 272:15825-33; PMID:9188480; http://dx.doi.org/10.1074/ jbc.272.25.15825 [38] Kaech S, Banker G. Culturing hippocampal neurons.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"Nat Protoc 2006; 1:2406-15;PMID:17406484;http://dx.doi.org/10.1038/nprot.2006.356 [39] Ullrich C, Daschil N, Humpel C. Organotypic vibrosections: novel whole sagittal brain cultures.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"J Neurosci Methods 2011; 201:131-41; PMID:21835204; http://dx.doi.org/10.1016/j.jneumeth.2011.07.021 [40] Bode C, Graler MH.",OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
Neural Plast 2012; 2012:467251; PMID:22848851; http://dx.doi.org/10.1155/2012/467251AUTOPHAGY 899,Non-OADS,/arxiv_data1/oa_pdf/32/af/kaup-13-05-1291471.PMC5446076.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"5, 854 –867 http://dx.doi.org/10.1080/15548627.2017.1287653",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"The New England journal of medicine 2013; 368:651-62; PMID: 23406030; http://dx.doi.org/10.1056/NEJMra1205406 [2] Hale CM, Cheng Q, Ortuno D, Huang M, Nojima D, Kassner PD, Wang S, Ollmann MM, Carlisle HJ.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Auto- phagy 2016; 12:713-26; PMID: 27050463; http://dx.doi.org/10.1080/15548627.2016.1147669 [3] Orvedahl A, Sumpter R, Jr., Xiao G, Ng A, Zou Z, Tang Y, Narimatsu M, Gilpin C, Sun Q, Roth M, et al.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Nature 2011; 480:113-7; PMID: 22020285; http://dx.doi.org/10.1038/nature10546 [4] Rubinsztein DC, Bento CF, Deretic V. Therapeutic targeting of autophagy in neurodegenerative and infectious diseases.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"J ExpMed 2015; 212:979-90; PMID: 26101267; http://dx.doi.org/10.1084/jem.20150956 [5] Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Nat Rev Drug Discov2012; 11:709-30; PMID: 22935804; http://dx.doi.org/10.1038/ nrd3802 [ 6 ] Z h a n gL ,Y uJ ,P a nH ,H uP ,H a oY ,C a iW ,Z h uH ,Y uA D ,X i e X, Ma D, et al.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Cell Research 2014; 24:24-41; PMID:24366339; https://dx.doi.org/10.1038/cr.2013.168 [8] Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Autophagy 2016; 12:1-222; PMID: 26799652; http://dx.doi.org/10.1080/15548627.2015.1100356 [9] Florey O, Kim SE, Sandoval CP, Haynes CM, Overholtzer M. Auto- phagy machinery mediates macroendocytic processing and entoticcell death by targeting single membranes.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Nature cell biology 2011; 13:1335-43; PMID: 22002674; http://dx.doi.org/10.1038/ncb2363 [10] Florey O, Overholtzer M. Autophagy proteins in macroendocytic engulfment.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Trends in cell biology 2012; 22:374-80; PMID:22608991; http://dx.doi.org/10.1016/j.tcb.2012.04.005 [11] Sanjuan MA, Dillon CP, Tait SW, Moshiach S, Dorsey F, Connell S, Komatsu M, Tanaka K, Cleveland JL, Withoff S, et al.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Nature 2007; 450:1253-7; PMID: 18097414; http://dx.doi.org/ 10.1038/nature06421 [12] Huang J, Canadien V, Lam GY, Steinberg BE, Dinauer MC, Magalhaes MA, Glogauer M, Grinstein S, Brumell JH.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"The Journal of biological chemistry 2012; 287:34149-56; PMID: 22902620; http://dx.doi.org/10.1074/jbc.M112.382812 [14] Martinez J, Almendinger J, Oberst A, Ness R, Dillon CP, Fitzgerald P, Hengartner MO, Green DR. Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the ef ﬁ- cient clearance of dead cells.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"The Journal of cell biology 2013; 203:757-66; PMID: 24322427; http://dx.doi.org/10.1083/jcb.201308173 [16] Martinez J, Cunha LD, Park S, Yang M, Lu Q, Orchard R, Li QZ, Yan M, Janke L, Guy C, et al.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Nature 2016; 533:115-9; PMID: 27096368; http://dx.doi.org/10.1038/nature17950 [17] Martinez J, Malireddi RK, Lu Q, Cunha LD, Pelletier S, Gingras S, Orchard R, Guan JL, Tan H, Peng J, et al.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Nature cell biology 2015; 17:893-906;PMID: 26098576; http://dx.doi.org/10.1038/ncb3192 [18] Florey O, Gammoh N, Kim SE, Jiang X, Overholtzer M. V-ATPase and osmotic imbalances activate endolysosomal LC3 lipidation.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
Autophagy 2015; 11:88-99; PMID: 25484071; http://dx.doi.org/10.4161/15548627.2014.984277 [19] Mindell JA.,Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Annu Rev Physiol 2012; 74:69-86; PMID: 22335796; http://dx.doi.org/10.1146/annurev- physiol-012110-142317 [20] Tapper H, Sundler R. Role of lysosomal and cytosolic pH in the regu- lation of macrophage lysosomal enzyme secretion.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Biochem J 1990; 272:407-14; PMID: 2268269; http://dx.doi.org/10.1042/bj2720407 [21] de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Commentary.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Biochem Pharmacol 1974; 23:2495-531; http://dx.doi.org/10.1016/0006-2952(74)90174-9 [22] Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
Eur J Pharmacol2009; 625:220-33; PMID: 19836374; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Acta Otolar- yngol 2015; 135:1205-11; PMID: 26245698; http://dx.doi.org/10.3109/00016489.2015.1072873 [24] Marceau F, Bawolak MT, Lodge R, Bouthillier J, Gagne-Henley A, Gaudreault RC, Morissette G. Cation trapping by cellular acidic com- partments: beyond the concept of lysosomotropic drugs.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"ToxicolAppl Pharmacol 2012; 259:1-12; PMID: 22198553; http://dx.doi.org/ 10.1016/j.taap.2011.12.004 [25] Ganley IG, Lam du H, Wang J, Ding X, Chen S, Jiang X. ULK1.ATG13.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Mol Cell Biol 2015; 36:585-95; PMID:26644405; http://dx.doi.org/10.1128/MCB.01005-15 [27] Mari M, Grif ﬁth J, Rieter E, Krishnappa L, Klionsky DJ, Reggiori F. An Atg9-containing compartment that functions in the early steps of autophagosome biogenes i s .T h eJ o u r n a lo fc e l lb i o l o g y 2010; 190:1005-22; PMID: 20855505; http://dx.doi.org/10.1083/jcb.200912089 [28] Maejima I, Takahashi A, Omori H, Kimura T, Takabatake Y, Saitoh T, Yamamoto A, Hamasaki M, Noda T, Isaka Y, et al.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"The EMBO journal 2013; 32:2336-47; PMID: 23921551; http://dx.doi.org/10.1038/emboj.2013.171 [29] Thurston TL, Wandel MP, von Muhlinen N, Foeglein A, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Nature 2012; 482:414-8; PMID: 22246324; http://dx.doi.org/10.1038/nature10744 [30] Cazes A, Prost-Squarcioni C, Bodemer C, Heller M, Brousse N, Fraitag S. Histologic cutaneous modi ﬁcations after the use of EMLA cream, a diagnostic pitfall: review of 13 cases.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Arch Der- matol 2007; 143:1074-6; PMID: 17709674; http://dx.doi.org/10.1001/archderm.143.8.1074 [31] Vallance H, Chaba T, Clarke L, Taylor G. Pseudo-lysosomal storage dis- ease caused by EMLA cream.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"J Inh erit Metab Dis 2004; 27:507-11; PMID: 15303008; http://dx.doi.org/10.1023/B:BOLI.0000037352.98317.5a [32] Chikh A, Sanza P, Raimondi C, Akinduro O, Warnes G, Chiorino G, Byrne C, Harwood CA, Bergamaschi D. iASPP is a novel autophagy inhibitor in keratinocytes.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Journal of cell science 2014; 127:3079-93;PMID: 24777476; http://dx.doi.org/10.1242/jcs.144816 [33] Rossiter H, Konig U, Barresi C, Buchberger M, Ghannadan M, Zhang CF, Mlitz V, Gmeiner R, Sukseree S, Fodinger D, et al.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"J Dermatol Sci 2013; 71:67-75; PMID: 23669018; http://dx.doi.org/10.1016/j.jdermsci.2013.04.015 [34] Ishida-Yamamoto A, Simon M, Kishibe M, Miyauchi Y, Takahashi H, Yoshida S, O ’Brien TJ, Serre G, Iizuka H. Epidermal lamellar granules transport different cargoes as distinct aggregates.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"J Invest Dermatol 2004; 122:1137-44; PMID: 15140216; http://dx.doi.org/ 10.1111/j.0022-202X.2004.22515.x [35] Chapman SJ, Walsh A. Membrane-coating granules are acidic organelles which possess proton pumps.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"J Invest Dermatol 1989; 93:466-70; PMID: 2550559; http://dx.doi.org/10.1111/1523-1747.ep12284032 [36] Kasianowicz J, Benz R, McLaughlin S. The kinetic mechanism by which CCCP (carbonyl cyanide m-chlorophenylhydrazone) trans-ports protons across membranes.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"J Membr Biol 1984; 82:179-90; PMID: 6096547; http://dx.doi.org/10.1007/BF01868942 [37] Narendra D, Tanaka A, Suen DF, Youle RJ.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Biochem Biophys Res Commun 2011; 416:343- 8; PMID: 22119190; http://dx.doi.org/10.1016/j.bbrc.2011.11.038 [40] Padman BS, Bach M, Lucarelli G, Prescott M, Ramm G. The proto- nophore CCCP interferes with lysosomal degradation of autophagiccargo in yeast and mammalian cells.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Autophagy 2013; 9:1862-75; PMID: 24150213; http://dx.doi.org/10.4161/auto.26557 [41] Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, Proud CG, Nabi IR, Roberge M. Screen for chemical modulators of autophagyreveals novel therapeutic inhibitors of mTORC1 signaling.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
PLoS One 2009; 4:e7124; PMID: 19771169; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Nat Chem Biol 2008; 4:295-305; PMID: 18391949; http://dx.doi.org/10.1038/nchembio.79 [43] Morissette G, Ammoury A, Rusu D, Marguery MC, Lodge R, Pou- belle PE, Marceau F. Intracellular sequestration of amiodarone: roleof vacuolar ATPase and macroautophagic transition of the resultingvacuolar cytopathology.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Br J Pharmacol 2009; 157:1531-40; PMID: 19594752; http://dx.doi.org/10.1111/j.1476-5381.2009.00320.x [44] Chen D, Chen X, Li M, Zhang H, Ding WX, Yin XM.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Biochem Biophys Res Com- mun 2013; 432:226-30; PMID: 23402761; http://dx.doi.org/ 10.1016/j.bbrc.2013.02.010 [45] Lee KY, Oh S, Choi YJ, Oh SH, Yang YS, Yang MJ, Lee K, Lee BH.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Toxicol Sci 2013;136:193-204; PMID: 23912912; http://dx.doi.org/10.1093/toxsci/kft168 [46] Renna M, Jimenez-Sanchez M, Sarkar S, Rubinsztein DC.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
The Journal of biological chemistry2010; 285:11061-7; PMID: 20147746; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Sci Rep 2015; 5:15807;PMID: 26515640; http://dx.doi.org/10.1038/srep15807 [48] Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS.",OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
"Hepatology 2014; 59:505-17; PMID: 23913306; http://dx.doi.org/10.1002/hep.26659 [49] Barrow-McGee R, Kishi N, Joffre C, Menard L, Hervieu A, Bakhouche BA, Noval AJ, Mai A, Guzman C, Robert-Masson L,et al.",Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
Nature commu- nications 2013; 4:2799; PMID: 24240988; http://dx.doi.org/10.1038/ ncomms3799AUTOPHAGY 867,Non-OADS,/arxiv_data1/oa_pdf/b5/16/kaup-13-05-1287653.PMC5446083.pdf
Keywords: Inf ormation Science http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
Fractional  citation counting apportions  credit based on the number  of aut hors  of  2 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
3 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
4 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"As many as 85 categories  cite at least one article older than 300 y and  8 categories  cite more than 100 articles  older than that (the number  of  reference articles  older than 300 y are in parentheses):  classics  (687),   romance literature  (414),  literar y theory criticism (397),  history (344),   theatre  (283),  multidisciplinary humanities  (141),  philosophy of science  5 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"The a verage of the number  of citations  to the top 500 papers  per categories, ̄𝑁cit,  correlates  with ℎcat(Figure 1 ): ℎcat=4.5̄𝑁0.71 cit,𝑅2=0.997 (3) Iglesias  and Pecharromán (2007) derived  a theoretical relationship  that they apply to  individuals  that takes into account both the category productivity and an individual’s   productivity based on ℎ=3√ 𝑁art 4̄𝑁2∕3 cit(4) 6 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
The categories  that deviate  7 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
Articles  in categories  that  cite proportionately more often than the number  of articles  that WoS assigns  to  8 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"An inverse cubed relation accounts  for 66% of  the variance in the data: ̄𝑁cit= 35000∕ 𝛽3,𝑅2=0.66 (7) 9 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"Excluding 12 categories  related  to psychology,  business  and  management (Iglesias  and Pecharromán,  2007), the following expression accounts   for 95% of the variance: ̄𝑁cit=( 1.5+0.33𝜂(1+𝑁fund)5∕4)𝑁0.5 art 𝛽(9) 10 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
11 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"133 141 14.2 127297 4.8 6 0.74 2.315 Nanoscience nanotechnology 337 274 15.4 126462 6.4 4.4 0.81 3.316 Biotechnology, microbiology 220 188 19.8 123573 7.7 5.6 0.66 3.117 Optics 125 136 14.0 122955 6.1 6.4 0.78 2.5 18 Mathematics 46 68 1.8 119243 2.1 12.3 0.39 1.6 19 Public occupational health 110 124 5.8 118333 6.5 7.3 0.29 220 Applied mathematics 70 86 1.9 117549 2.4 9 0.37 1.621 Clinical neurology 146 149 10.9 111086 11.7 7.6 0.45 5.822 Multidisciplinary physics 215 197 12.8 109406 6.4 8.6 0.93 5.423 Cell biology 272 238 25.9 108662 12.8 5.3 0.67 4.8 24 Energy, fuels 154 157 14.0 101404 5.2 5.6 0.69 2.3 25 Organic chemistry 100 113 5.4 101007 4.4 5.8 0.67 2.426 Analytical chemistry 99 113 5.2 100161 4.7 5.5 0.69 2.327 Plant sciences 93 106 7.4 95409 7.8 7.7 0.63 2.928 Food science technology 65 81 3.2 95236 4.6 8.1 0.52 1.429 Multidisciplinary geosciences 98 115 6.6 93070 6.4 9.5 0.47 2.430 Immunology 170 171 14.6 92018 10.8 5.9 0.63 4.7 12 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
134 126 4.1 60469 3.8 7.7 0.61 1.8 57 Infectious diseases 110 121 9.1 59151 10.3 6.1 0.59 4.1 58 Telecommunications 83 105 3.3 58937 3.7 5.3 0.47 1.4 59 Water resources 69 88 4.2 57784 4.7 8.2 0.7 1.9 60 Biophysics 107 113 8.3 57391 6.3 6.8 0.4 3.1 13 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
55 73 2.6 42083 2.8 9 0.46 1.6 89 Crystallography 78 84 4.2 41570 5.7 6.4 0.94 2.5 90 Spectroscopy 53 72 2.5 41260 5.3 8.4 0.39 2.5 14 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"47 66 2.1 37596 3.4 7.5 0.28 1.4 99 Health care science services 71 89 3.9 37155 6.0 7.2 0.44 1.3 100 Respiratory system 98 115 9.1 36915 10.5 7.2 0.7 4.1101 Pathology 75 95 6.3 36251 9.4 6.6 0.54 2.7 102 Multidisciplinary psychology 81 99 7.8 35326 2.8 10.8 0.5 0.4 103 Computer science theory 59 81 3.0 33601 3.2 7.6 0.33 2 104 Rehabilitation 44 63 2.8 33403 5.1 8.7 0.34 1.1 105 History 10 21 1.1 33312 1.4 19.6 0.28 0 106 Dairy, animal science 37 58 2.3 32548 5.5 9.6 0.7 1.8 107 Nursing 28 43 1.9 32082 3.9 8.1 0.26 0.9 108 Clinical psychology 68 86 4.8 31743 5.1 9.3 0.33 1.6 109 Virology 91 109 7.0 31649 10.1 6.2 0.85 3.4 110 Nuclear Physics 82 100 4.7 31571 4.7 12.2 0.85 10.9111 Experimental psychology 67 85 3.5 31321 3.3 10.1 0.34 0.9 112 Coatings, ﬁlms 52 69 2.8 30783 4.8 7.4 0.98 1.7 113 Dermatology 48 65 5.3 30474 7.2 8.3 0.62 2.1 114 Political science 39 57 3.1 29881 1.7 10.1 0.3 0 115 Psychology 73 92 8.1 29628 4.1 10.3 0.4 1.7 116 Environmental studies 70 90 6.2 29625 3.3 7.2 0.63 1.5 117 Computational biology 122 121 4.5 29329 4.2 6.5 0.81 2.3 118 Entomology 34 49 2.4 29266 4.6 10.9 0.3 1.9 119 Oceanography 50 68 2.8 29259 4.8 10 0.4 2.4 120 Business 67 87 5.1 27946 2.5 11.9 0.29 0 15 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"34 51 2.2 22216 2.8 10.1 0.5 0.2 137 Law 25 41 3.5 22148 1.9 10.9 0.23 0 138 Linguistics 28 44 2.7 22057 2.5 11.9 0.38 0.5 139 Computer science hardware 48 71 3.3 21756 3.4 6.4 0.5 1.9 140 Critical care medicine 97 111 9.0 21483 10.4 8 0.8 4.4141 Biodiversity, conservation 62 84 6.0 20992 5.3 8.1 0.68 2.9 142 Acoustics 41 59 2.8 20857 4.2 8.7 0.49 1.4 143 Reproductive biology 54 73 4.3 20769 6.4 7.8 0.7 1.8144 Geriatrics, gerontology 58 77 5.0 20695 7.6 7.8 0.57 3 145 Rheumatology 80 96 7.9 20565 10.0 7.4 0.84 5.1 146 Industrial engineering 43 62 2.3 20473 2.9 8.9 0.58 1147 Developmental psychology 59 76 4.8 20417 4.5 9.7 0.45 1.3 148 Language, linguistics 16 31 1.2 20102 1.9 12.6 0.34 0 149 Soil science 45 66 3.1 20077 4.9 9.6 0.64 1.9 150 Business ﬁnance 44 66 3.4 19688 2.4 10.2 0.54 0 16 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
41 63 4.9 13860 7.2 7.1 0.76 2 174 Ethics 21 37 2.0 13768 2.2 10.2 0.64 0.4 175 Transportation 31 47 2.5 13688 2.8 9.1 0.61 0.7 176 Communication 28 47 2.1 13327 2.1 9.8 0.36 0 177 Biomedical social science 34 52 3.0 13187 4.9 8.2 0.71 0.7 178 Aaerospace engineering 19 34 1.2 13077 3.0 11.3 0.71 1.1 179 Literary theory criticism 3 10 0.0 12970 1.1 18.5 0.25 0 180 Planning development 36 57 2.7 12802 2.0 9.3 0.49 0 17 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"26 46 3.4 9736 4.9 7.6 0.95 2200 Educational psychology 38 59 3.4 9692 3.2 11.2 0.57 0201 Social work 20 33 1.8 9670 2.9 9.6 0.51 0 202 Limnology 38 56 3.2 9578 4.3 10.4 0.86 2.3 203 Criminology, penology 23 38 2.2 9572 2.7 11.1 0.34 0 204 Mycology 33 52 4.0 9402 5.6 10.9 0.5 2.1 205 Anatomy morphology 24 41 2.5 9343 5.1 11.1 0.54 2206 Hospitality, leisure, sport 27 44 2.3 9328 2.4 10.4 0.61 0.1 207 Allergy 63 86 9.6 9201 9.5 7.1 0.91 6 208 Architecture 4 14 0.5 8993 2.0 15 0.48 0.3 209 Urban studies 25 42 2.2 8965 2.4 9 0.55 0.5 210 Petroleum engineering 12 27 1.1 8874 3.5 13.7 0.77 1.2 18 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"Other  factors  that  correlate with citations  include the  age of  the references, journal  impact factor  and  19 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
20 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
Article No~e00300 Additional  information Supplementary content  related  to this article has been published online at http://dx.doi.org/10.1016/j.heliyon.2017.e00300 .,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
21 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
22 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"Accessed on 15 June 2015,  https://www.nsf.gov/ statistics/2016/nsf16300/digest/nsf16300.pdf .",Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
23 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
24 http://dx.doi.org/10.1016/j.heliyon.2017.e00300 2405-8440/ ©2017 Published  by Elsevier  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
This is an open access article under the CC BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/2f/main.PMC5446096.pdf
"For reprints and permission queries, plea se visit SAGE’s website at http://www.sagepub.com/journalsPermissions.nav.",Non-OADS,/arxiv_data1/oa_pdf/72/eb/10.1177_2325967117707703.PMC5446105.pdf
http://www.baseballjapan.org/jpn/ uploaded_data/bfj_news/doc/0125/undoki2.pdf.,Non-OADS,/arxiv_data1/oa_pdf/72/eb/10.1177_2325967117707703.PMC5446105.pdf
"For reprints and permission queries, plea se visit SAGE’s website at http://www.sagepub.com/journalsPermissions.nav.",Non-OADS,/arxiv_data1/oa_pdf/fb/b8/10.1177_2325967117707213.PMC5446106.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/5/e1602991/DC1 Supplementary Textfig.,Non-OADS,/arxiv_data1/oa_pdf/b9/f9/1602991.PMC5446212.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/5/e1602902/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/6a/97/1602902.PMC5446213.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/5/e1603171/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/56/c6/1603171.PMC5446214.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/5/e1603137/DC1section S1.,Non-OADS,/arxiv_data1/oa_pdf/28/c5/1603137.PMC5446215.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/5/e1601684/DC1discussion S1.,Non-OADS,/arxiv_data1/oa_pdf/95/e0/1601684.PMC5446216.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/5/e1601555/DC1table S1.,Non-OADS,/arxiv_data1/oa_pdf/59/e3/1601555.PMC5446217.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/5/e1700298/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/5d/7e/1700298.PMC5446218.pdf
https://doi.org/10.1016/ j.neuroscience.2016.04.034.,OADS,/arxiv_data1/oa_pdf/9c/c2/NYAS-1396-126.PMC5446287.pdf
https://doi.org/10.1016/j.neuroscience.2016.09.026.,OADS,/arxiv_data1/oa_pdf/9c/c2/NYAS-1396-126.PMC5446287.pdf
https://doi.org/10.1016/j.neuroimage.,OADS,/arxiv_data1/oa_pdf/9c/c2/NYAS-1396-126.PMC5446287.pdf
Rep. 6:30770. https://doi.org/10.1038/srep30770.,Non-OADS,/arxiv_data1/oa_pdf/9c/c2/NYAS-1396-126.PMC5446287.pdf
"Classical (Ly-6C high CX3CR1low, CCR2high) monocytes are high- ly responsive to inflammatory signals, invade inflamed tissues Integrative Physiology Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.117.310739Rationale:  Nonclassical mouse monocyte (CX3CR1high, Ly-6Clow) patrolling along the vessels of the microcirculation  is critical for endothelial homeostasis and inflammation.",Non-OADS,/arxiv_data1/oa_pdf/c1/7f/res-120-1789.PMC5446289.pdf
*These authors shared senior authorship.The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.,Non-OADS,/arxiv_data1/oa_pdf/c1/7f/res-120-1789.PMC5446289.pdf
"HEV GT3 is usually transmitted through consump- tion of undercooked meat from infected ani- mals, such as pork, deer and wild boar [ 4–6].Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 8197F060326C5FD5 .",Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Availablefrom: http://www.ncbi.nlm.nih.gov/pubmed/ 23829163 .,OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Available from:http://content.wkhealth.com/linkback/openurl?sid =WKPTLP:landingpage&an=00007890-201002150- 00015 .294 Infect Dis Ther (2017) 6:291–295,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Available from:http://www.sciencedirect.,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Available from: http://www.ncbi.nlm.nih.gov/pubmed/23158522 .,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
2013;381: 817–24.Available from: http://www.ncbi.nlm.nih.gov/ pubmed/23312829 .,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Available from: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
Available from: http://www.sciencedirect.com/science/ article/pii/S0168827814003730 .,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
2014;146: 1775–83.Available from: http://www.ncbi.nlm.nih.gov/ pubmed/24582714 .,Non-OADS,/arxiv_data1/oa_pdf/dc/4c/40121_2017_Article_147.PMC5446360.pdf
"For the treatment of MSSA infections, use of beta-lactams antibiotics compared to vancomycin therapy is associated with about a 35% lower rate ofEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ E197F06020A00B5D .",Non-OADS,/arxiv_data1/oa_pdf/b6/17/40121_2017_Article_148.PMC5446361.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/b6/17/40121_2017_Article_148.PMC5446361.pdf
Keywords: Antimicrobial stewardship; Acinetobacter ; Combination therapy; Outcomes; Pipeline; Resistance; Susceptibility; Synergy; TreatmentEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 62F7F060122AE447 .,Non-OADS,/arxiv_data1/oa_pdf/68/44/40121_2017_Article_149.PMC5446362.pdf
"This article is distributed under the terms of the Creative Commons Attribu- tion-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use,distribution, and reproduction in any med- ium, provided you give appropriate credit tothe original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/68/44/40121_2017_Article_149.PMC5446362.pdf
2013. http://www.cdc.gov/drugre sistance/threat-report- 2013/pdf/ar-threats-2013-508.pdf .,OADS,/arxiv_data1/oa_pdf/68/44/40121_2017_Article_149.PMC5446362.pdf
Keywords: Antimicrobial; Fosfomycin; Urinary tract infectionEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 04F7F06050FD1A20 .,Non-OADS,/arxiv_data1/oa_pdf/14/c5/40121_2017_Article_150.PMC5446363.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/14/c5/40121_2017_Article_150.PMC5446363.pdf
"Prospective, epi- demiologic studies consistently demonstrated that RSV LRTI is a signiﬁcant risk factor for on-going respiratory morbidity characterized by transient early wheezing and recurrent wheez- ing and asthma within the ﬁrst decade of life and possibly into adolescence and adulthoodEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ F6E4F06044E2A44B .",Non-OADS,/arxiv_data1/oa_pdf/4b/61/40121_2017_Article_151.PMC5446364.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/4b/61/40121_2017_Article_151.PMC5446364.pdf
http://www.cebm.net/ index.aspx?o=5653 Accessed Mar 2016.,Non-OADS,/arxiv_data1/oa_pdf/4b/61/40121_2017_Article_151.PMC5446364.pdf
Oxford Centre for Evidence-Based Medicine http://www.cebm.net/ oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ Accessed Mar 2016.26.,Non-OADS,/arxiv_data1/oa_pdf/4b/61/40121_2017_Article_151.PMC5446364.pdf
The emergence of antimicrobial resistance in E. coli hasEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 09F7F0604089D8D0 .,Non-OADS,/arxiv_data1/oa_pdf/d7/fb/40121_2017_Article_152.PMC5446365.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/d7/fb/40121_2017_Article_152.PMC5446365.pdf
"Antibiotic Resistance Threats in the United States, 2013. http://www.cdc.",Non-OADS,/arxiv_data1/oa_pdf/d7/fb/40121_2017_Article_152.PMC5446365.pdf
Its ability to resist environmental stress and cleaningEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 29F7F0607D680466 .,Non-OADS,/arxiv_data1/oa_pdf/d2/fb/40121_2017_Article_153.PMC5446366.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide208 Infect Dis Ther (2017) 6:199–211",Non-OADS,/arxiv_data1/oa_pdf/d2/fb/40121_2017_Article_153.PMC5446366.pdf
2013. http://www.cdc.gov/hai/ organisms/cre/TrackingCRE.html .,OADS,/arxiv_data1/oa_pdf/d2/fb/40121_2017_Article_153.PMC5446366.pdf
The purpose of this review is to perform a practical approach by selecting cases from real life as examples of challenges relatedEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ A9F7F06018C7A9AA .,Non-OADS,/arxiv_data1/oa_pdf/9b/35/40121_2017_Article_154.PMC5446367.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/9b/35/40121_2017_Article_154.PMC5446367.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/e0/5f/40121_2017_Article_155.PMC5446368.pdf
"HCV guidance: rec- ommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full- report/ .",Non-OADS,/arxiv_data1/oa_pdf/e0/5f/40121_2017_Article_155.PMC5446368.pdf
"https://www.cdc.gov/ knowmorehepatitis/media/pdfs/factsheet-boomers.pdf(Updated 2015, 2016) .",OADS,/arxiv_data1/oa_pdf/e0/5f/40121_2017_Article_155.PMC5446368.pdf
"Bloodstream infections with S. aureus are rife with complications such as osteomyelitis and endocarditis, and treatment courses tend toEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 3708F0602569295B .",Non-OADS,/arxiv_data1/oa_pdf/e5/b4/40121_2017_Article_156.PMC5446369.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any non- commercial use, distribution, and reproduction in any medium, provided you give appropriatecredit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/e5/b4/40121_2017_Article_156.PMC5446369.pdf
"Keywords: Acyclovir; Shortage; Valacyclovir; Viral encephalitis; Viral meningitis INTRODUCTION Drug shortages continue to be a problem in the United States, causing numerous difﬁculties forEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ FD08F06077F449A2 .",Non-OADS,/arxiv_data1/oa_pdf/9d/98/40121_2017_Article_157.PMC5446370.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/9d/98/40121_2017_Article_157.PMC5446370.pdf
"Mean patient-reported adherence to study drugs was [89% at Week 4, Week 12 and end of treatment.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 9A18F0602C81E0BE .",Non-OADS,/arxiv_data1/oa_pdf/5d/d2/40121_2017_Article_158.PMC5446371.pdf
Requests for access to datasets can be made via http://yoda.yale.,OADS,/arxiv_data1/oa_pdf/5d/d2/40121_2017_Article_158.PMC5446371.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/5d/d2/40121_2017_Article_158.PMC5446371.pdf
Available at: https://www.eiseverywhere.com/ﬁle_uploads/1a0a6 aab975530ed73e635f394654af3_139_MarkHull.pdf .,Non-OADS,/arxiv_data1/oa_pdf/5d/d2/40121_2017_Article_158.PMC5446371.pdf
Available at: https://www.eisevery where.com/ﬁle_uploads/ec626d74ab97207d900dd c93eeb18144_166_AlainLitwin.pdf .,Non-OADS,/arxiv_data1/oa_pdf/5d/d2/40121_2017_Article_158.PMC5446371.pdf
Many patients do not have proper access to sharpsEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ A2F7F0605653FD50 .,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
2015. http://www.idf.org/membership/sea/india .,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
http://www.mayoclinicprocee dings.org/ar ticle/S0025- 6196(16)30322-6/fulltext .,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
2016;91(9):1224–1230.http://www.mayoclinicproceedings.org/article/S00 25-6196(16)30326-3/fulltext .,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
http://www.mayoclinic proceedings.org/article/S0025-6196(16)30321-4/full text.,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
http://www.mayoclinicproceedings.,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
Tableau Public Adam Young’s Proﬁle website: http://tabsoft.co/23V6oﬁ .,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
English version available at http://docplayer.net/2966550-Evidence- based-clinicalguidelines-for-injection-of-insulin-for- adults-with-diabetes-mellitus.html .,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
2008. http://www.google.co.in/url?sa= t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwjdgd3ZqMPSAhXKr48KHcWZDAUQFggbMAA&url=http%3A%2F%2Fwww.eadv.nl%2Fmodule%2F1530%2F196%2FGuideline-The-administration- of-insulin-with-the-insulin-pen.pdf&usg=AFQjCNE FHElByntR2GlsmvfxTJULMipgyQ&cad=rja .,Non-OADS,/arxiv_data1/oa_pdf/d7/1d/13300_2017_Article_243.PMC5446372.pdf
"Of these, 4 outEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ A2F7F0605653FD50 .",Non-OADS,/arxiv_data1/oa_pdf/4c/27/13300_2017_Article_244.PMC5446373.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/4c/27/13300_2017_Article_244.PMC5446373.pdf
http://www.mayoclinicproceedings.org/article/S00 25-6196(16)30326-3/fulltext .,Non-OADS,/arxiv_data1/oa_pdf/4c/27/13300_2017_Article_244.PMC5446373.pdf
http://tabsoft.co/23V6oﬁ .,Non-OADS,/arxiv_data1/oa_pdf/4c/27/13300_2017_Article_244.PMC5446373.pdf
Achieving the glycemic controlEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 06F7F060022F228A .,Non-OADS,/arxiv_data1/oa_pdf/9a/20/13300_2017_Article_247.PMC5446374.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any non- commercial use, distribution, and reproduction in any medium, provided you give appropriatecredit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/9a/20/13300_2017_Article_247.PMC5446374.pdf
2015; http://www.idf.org/ diabetesatlas .,Non-OADS,/arxiv_data1/oa_pdf/9a/20/13300_2017_Article_247.PMC5446374.pdf
This suggests that the increase in UGE might not beEnhanced Content To view enhanced content for this article go to http://www.medengine.com/Redeem/ A6F7F0607498CA43 .,Non-OADS,/arxiv_data1/oa_pdf/05/17/13300_2017_Article_248.PMC5446375.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/05/17/13300_2017_Article_248.PMC5446375.pdf
Keywords: Diabetes management; Diabetes therapy; GLP1 receptor agonist; Insulin glargine; Lixisenatide; Long acting insulin; Premixed insulin; Type 2 diabetes mellitusEnhanced Content To view enhanced content for this article go to http://www.medengine.com/Redeem/46F7 F0602FD50329 .,Non-OADS,/arxiv_data1/oa_pdf/02/f5/13300_2017_Article_249.PMC5446376.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/02/f5/13300_2017_Article_249.PMC5446376.pdf
2016. http://www.diabetesatlas.,Non-OADS,/arxiv_data1/oa_pdf/02/f5/13300_2017_Article_249.PMC5446376.pdf
Keywords: Cost-effectiveness analysis; Glucagon-like peptide 1; Sodium-glucose transporter 2; Type 2 diabetes mellitusEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 17F7F060606BDCD7 .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ Fig.,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
IDF diabetes atlas 2015. http://www.diabetesatlas.org .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
https://www.nice.,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
http://www.who.int/ entity/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_2.pdf?ua=1 .,OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
Available from:http://www.whocc.no/atc_ddd_index/?showdescription=yes&code=A10AE04 .,OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
http://www.mims.co.uk/ .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
Personal Social ServicesResearch Unit 2014. http://www.pssru.ac.uk/ project-pages/unit-costs/2015/ .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
National Institute for Health and Care Excellence 2015. https://www.nice.org.uk/ article/pmg9/chapter/ foreword .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
Scottish Medicines Consortium 2009 December 7. http://www.scottish medicines.org.uk/SMC_Advice/Advice/585_09_liraglutide___Victoza_/liraglutide__Victoza_ .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
NHS Reference Costs 2014 to 2015. https://www.gov.uk/government/publications/ nhs-reference-costs-2014-to-2015 .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
Available from: http://www.nice.org.uk/ guidance/cg48 .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
National Institute of Health and Care Excellence 2008.http://www.nice.org.uk/guidance/cg73 .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
National Institute for Health and CareExcellence 2014. http://www.nice.org.uk/guidance/ cg87 .,Non-OADS,/arxiv_data1/oa_pdf/35/3a/13300_2017_Article_250.PMC5446377.pdf
"An ICER within the range described as high care value was cal- culated, suggesting IDegLira is a cost-effective treatment option in the US.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/08F7 F0601436691B .",Non-OADS,/arxiv_data1/oa_pdf/59/76/13300_2017_Article_251.PMC5446378.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/59/76/13300_2017_Article_251.PMC5446378.pdf
http://www.wolterskluwercdi.,Non-OADS,/arxiv_data1/oa_pdf/59/76/13300_2017_Article_251.PMC5446378.pdf
https://oig.hhs.gov/oei/reports/oei-02-10- 00170.pdf .,Non-OADS,/arxiv_data1/oa_pdf/59/76/13300_2017_Article_251.PMC5446378.pdf
http://www.amputee-coalition.org/ senior_step/older_prosthesis_users.html .A c c e s s e d 16 Oct 2017.544 Diabetes Ther (2017) 8:531–544,Non-OADS,/arxiv_data1/oa_pdf/59/76/13300_2017_Article_251.PMC5446378.pdf
"Hypoglycemia rates were 1.98, 1.08 and 0.37 events/patient-years of exposure (PYE) for IDegLira, insulin degludec and liraglutide in DUAL I, 4.06 and 0.36 events/PYE for IDegLira and placebo in DUAL IV and 1.16 and 0.83Enhanced content To view enhanced content for this article go to: http://www.medengine.com/Redeem/ 39F7F0600921A8B9 .",Non-OADS,/arxiv_data1/oa_pdf/6a/42/13300_2017_Article_252.PMC5446379.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/6a/42/13300_2017_Article_252.PMC5446379.pdf
"Keywords: Insulin antibody response; Insulin glargine; LY2963016 insulin glargine INTRODUCTION LY2963016 insulin glargine (LY IGlar; Eli Lilly and Company, Indianapolis, IN, USA) is the ﬁrst biosimilar insulin approved in the EuropeanEnhanced Content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 79F7F0601290EA61 .",Non-OADS,/arxiv_data1/oa_pdf/8e/22/13300_2017_Article_253.PMC5446380.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/8e/22/13300_2017_Article_253.PMC5446380.pdf
"Indianapolis, IN: Eli Lilly and Com-pany, Boehringer Ingelheim; September 10, 2014.http://lilly.mediaroom.com/index.php?s=9042&item= 137348 .",Non-OADS,/arxiv_data1/oa_pdf/8e/22/13300_2017_Article_253.PMC5446380.pdf
New drugs approved in FY 2014. http://www.pmda.go.,Non-OADS,/arxiv_data1/oa_pdf/8e/22/13300_2017_Article_253.PMC5446380.pdf
"December 16, 2015. http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm477734.htm .",Non-OADS,/arxiv_data1/oa_pdf/8e/22/13300_2017_Article_253.PMC5446380.pdf
http://www.ema.europa.eu/docs/en_GB/ document_library/Scientiﬁc_guideline/2012/06/WC 500129256.pdf .,Non-OADS,/arxiv_data1/oa_pdf/8e/22/13300_2017_Article_253.PMC5446380.pdf
http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/8e/22/13300_2017_Article_253.PMC5446380.pdf
"Nocturnal hypo- glycemia [2300 to 0600 hours, \3.9 mmol/LEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 99F7F06029979785 .",Non-OADS,/arxiv_data1/oa_pdf/85/ca/13300_2017_Article_255.PMC5446381.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/85/ca/13300_2017_Article_255.PMC5446381.pdf
Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/4508 F06042A677F0 .,Non-OADS,/arxiv_data1/oa_pdf/d9/53/13300_2017_Article_256.PMC5446382.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/d9/53/13300_2017_Article_256.PMC5446382.pdf
Diabetes prevalence in the elderly is higher than in theEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 8708F06044E00CB3 .,Non-OADS,/arxiv_data1/oa_pdf/b6/05/13300_2017_Article_258.PMC5446383.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any non- commercial use, distribution, and reproduction in any medium, provided you give appropriatecredit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/b6/05/13300_2017_Article_258.PMC5446383.pdf
The FCI appears to capture the frequency and tone ofEnhanced Content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 8C08F0601556E12B .,Non-OADS,/arxiv_data1/oa_pdf/d8/5d/13300_2017_Article_259.PMC5446384.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/d8/5d/13300_2017_Article_259.PMC5446384.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,provide a link to the Creative Commons license, and indicate if changes were made.Table 2 Changes in clinical parameters after 24 weeks’ basal-plus treatment ParametersaWeek 12 ( n563) Week 36 ( n563) Mean difference (SD) pvalue HbA1c (%) 8.06 (0.71) 7.17 (0.54) 0.89 (0.56)* \0.001 FBG (mmol/L) 6.23 (0.15) 6.20 (0.16) 0.03 (0.14) 0.118PBG (mmol/L) 13.17 (1.72) 10.14 (2.20) 3.03 (1.53)* \0.001 Basal insulin dosage (IU/kg/day) 0.36 (0.06) 0.35 (0.05) 0.01 (0.02) 0.073 Prandial insulin dosage (IU/kg/day) 0 (0) 0.14 (0.04) 0.14 (0.04)* \0.001 Total insulin dosage (IU/kg/day) 0.36 (0.06) 0.50 (0.08) 0.14 (0.03)* \0.001 Weight (kg) 73.19 (6.82) 73.28 (6.90) 0.08 (0.76) 0.379 Number of OADs used 2.71 (0.46) 2.12 (0.42) 0.60 (0.61)* \0.001 OADs, n(%) a-glycosidase inhibitor 63 (100) 22 (34.9) Metformin 18 (28.6) 63 (100)Insulin secretagogue 59 (93.7) 10 (15.9) Hypoglycemic events, n(%) 2 (3.2) 3 (4.8) 0.500 Other adverse events, n(%) 0 (0) 0 (0) HbA1c glycated hemoglobin A1c, FBG fasting blood glucose, PBG postprandial blood glucose, OADs oral antidiabetic drugs *p\0.01 aParameters are summarized as mean (SD) unless speciﬁed624 Diabetes Ther (2017) 8:623–624",Non-OADS,/arxiv_data1/oa_pdf/66/7c/13300_2017_Article_260.PMC5446385.pdf
Funding : AstraZeneca.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1818F0601962B3CC .,Non-OADS,/arxiv_data1/oa_pdf/74/48/13300_2017_Article_261.PMC5446386.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/74/48/13300_2017_Article_261.PMC5446386.pdf
Available from: http://www.idf.org/diabetesatlas/ 5e/the-global-burden .,Non-OADS,/arxiv_data1/oa_pdf/74/48/13300_2017_Article_261.PMC5446386.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/5c/5c/13300_2017_Article_262.PMC5446387.pdf
"Although this search and screening strategy was far from infallible, we believe that it found most of the studies published during this period that delivered outpatient closed-loop data dur- ing the day or both the day and night for at leasta ﬁve-day period, and we also performed a cross-check with the online database of the Doyle group ( http://thedoylegroup.org/ apdatabase/ ).",OADS,/arxiv_data1/oa_pdf/46/67/13300_2017_Article_263.PMC5446388.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/46/67/13300_2017_Article_263.PMC5446388.pdf
Rochester: ADA;2016. p. 907. https://ada.scientiﬁcposters.com/ epsAbstractADA.cfm?id=1 .,OADS,/arxiv_data1/oa_pdf/46/67/13300_2017_Article_263.PMC5446388.pdf
Rochester: ADA; 2016. p. 870.https://ada.scientiﬁcposters.com/epsAbstractADA.cfm?id=1 .,OADS,/arxiv_data1/oa_pdf/46/67/13300_2017_Article_263.PMC5446388.pdf
"After cleavage of proinsulin, insulin and theEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1E18F06019514A5F .",Non-OADS,/arxiv_data1/oa_pdf/e4/7e/13300_2017_Article_265.PMC5446389.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any non- commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/e4/7e/13300_2017_Article_265.PMC5446389.pdf
2013. http://www.who.int/diabetes/ publications/diagnosis_diabetes2006/en/ .,Non-OADS,/arxiv_data1/oa_pdf/e4/7e/13300_2017_Article_265.PMC5446389.pdf
American Association of Clinical Endocrinologists andAmerican College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus compre- hensive care plan – 2015. https://www.aace.com/ﬁles/ dm-guidelines-ccp.pdf .,Non-OADS,/arxiv_data1/oa_pdf/e4/7e/13300_2017_Article_265.PMC5446389.pdf
Results : Forty-ﬁve out of 71 subjects in the sitagliptin group and 41 out of 62 subjects inEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 7848F060253101E5 .,Non-OADS,/arxiv_data1/oa_pdf/ac/5c/13300_2017_Article_267.PMC5446390.pdf
This article is distributed under the terms of the Creative Commons Attribu- tion-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.,Non-OADS,/arxiv_data1/oa_pdf/ac/5c/13300_2017_Article_267.PMC5446390.pdf
"6 Findings of a systematic review of clinical trials  of tranexamic acid in surgery showed that the drug Lancet 2017; 389: 2105–16 Published Online  April 26, 2017 http://dx.doi.org/10.1016/S0140-6736(17)30638-4 This online publication has  been corrected.",Non-OADS,/arxiv_data1/oa_pdf/d9/1d/main.PMC5446563.pdf
For the protocol see  http://www.txacentral.org/,Non-OADS,/arxiv_data1/oa_pdf/d9/1d/main.PMC5446563.pdf
"We recorded fewer deaths from all causes with tranexamic acid but the reduction was not significant To access data at freeBIRD see  http://freebird.Lshtm.ac.ukFigure 2: Cause of death by hours since randomisation (A) and cause of hysterectomy by hours since  randomisation (B)*Excludes data for 311 women who had a hysterectomy before randomisation.A B0102030405060Number of deaths 0 1 2 3 4 5 6 7 8 9 10 11 12 13 15 17 18 19 20 21 22 23 14 16050100150200250Number of hysterectomies* Hours since randomisationDeaths due to all other causes Deaths due to bleeding Hysterectomies for other causesHysterectomies for bleeding Tranexamic acid group  (n=10  036)Placebo group  (n=9985)RR (95% CI) p value (two-sided) Bleeding 155 (1·5%) 191 (1·9 %) 0·81 (0·65–1·00) 0·045 Pulmonary embolism 10 (0·1%) 11 (0·1) 0·90 (0·38–2·13) 0·82 Organ failure 25 (0·3%) 18 (0·2%) 1·38 (0·75–2·53) 0·29 Sepsis 15 (0·2%) 8 (0·1%) 1·87 (0·79–4·40) 0·15 Eclampsia 2 (0·02%) 8 (0·1%) 0·25 (0·05–1·17) 0·057 Other 20 (0·2%) 20 (0·2%) 0·99 (0·54–1·85) 0·99 Any cause of death 227 (2·3%) 256 (2·6%) 0·88 (0·74–1·05) 0·16 Data are n (%), unless otherwise indicated.",Non-OADS,/arxiv_data1/oa_pdf/d9/1d/main.PMC5446563.pdf
"http://www.medicines.org.uk/emc/medicine/1489 (accessed March 3, 2017).",Non-OADS,/arxiv_data1/oa_pdf/d9/1d/main.PMC5446563.pdf
"1996 June 10. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4.pdf (accessed March 3, 2017).",Non-OADS,/arxiv_data1/oa_pdf/d9/1d/main.PMC5446563.pdf
View Video 1 at http://movie-usa.glencoesoftware.,Non-OADS,/arxiv_data1/oa_pdf/35/dd/erp-4-I5.PMC5446592.pdf
View Video 5 at  http://movie-usa.glencoesoftware.com/video/10.1530/ ERP-17-0003/video-5.,Non-OADS,/arxiv_data1/oa_pdf/e9/0f/erp-4-I7.PMC5446593.pdf
View Video 7 at http://movie-usa.glencoesoftware.,Non-OADS,/arxiv_data1/oa_pdf/e9/0f/erp-4-I7.PMC5446593.pdf
View Video 8 at  http://movie-usa.glencoesoftware.com/video/10.1530/ ERP-17-0003/video-8.,Non-OADS,/arxiv_data1/oa_pdf/e9/0f/erp-4-I7.PMC5446593.pdf
View Video 6 at http://movie-usa.glencoesoftware.com/ video/10.1530/ERP-17-0004/video-6.Video 7 Three-dimensional en face view (left atrial perspective).,Non-OADS,/arxiv_data1/oa_pdf/dc/8e/erp-4-I1.PMC5446594.pdf
View  Video 7 at http://movie-usa.glencoesoftware.com/ video/10.1530/ERP-17-0004/video-7.Video 2 Mid-esophageal long axis TEE image reveals a massive  left atrial mural thrombus and markedly thickened  bioprosthetic mitral leaflets.,Non-OADS,/arxiv_data1/oa_pdf/dc/8e/erp-4-I1.PMC5446594.pdf
View  Video 5 at http://movie-usa.glencoesoftware.com/ video/10.1530/ERP-17-0004/video-5.,Non-OADS,/arxiv_data1/oa_pdf/dc/8e/erp-4-I1.PMC5446594.pdf
Am J Hosp Palliat Care 2016 [Epub ahead of print]; http://dx.doi.org/ 10.1177/1049909116653733 6.,Non-OADS,/arxiv_data1/oa_pdf/97/9b/acm.2016.0289.PMC5446597.pdf
Online document at http://nccam.nih.gov/health integrative-health.,Non-OADS,/arxiv_data1/oa_pdf/97/9b/acm.2016.0289.PMC5446597.pdf
"ªJeane Ann Grisso et al., 2017; Published by Mary Ann Liebert, Inc. Th is article is available under the Creative Commons License CC-BY-NC (http://creativecommons.org/licenses/by-nc/4.0).",OADS,/arxiv_data1/oa_pdf/fa/7c/jwh.2016.6025.PMC5446599.pdf
The study meets the exclusion criteria listed in: https://clinicaltrials.gov/ct2/managerecs/fdaaa#WhichTrialsMustBeRegistered.,Non-OADS,/arxiv_data1/oa_pdf/fa/7c/jwh.2016.6025.PMC5446599.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.AIDS PATIENT CARE and STDs Volume 31, Number 5, 2017Mary Ann Liebert, Inc.DOI: 10.1089/apc.2016.0291 205",Non-OADS,/arxiv_data1/oa_pdf/33/e4/apc.2016.0291.PMC5446602.pdf
This article is available under the Creative Commons License CC-BY-NC (http://creativecommons.org/licenses/by-nc/4.0).,Non-OADS,/arxiv_data1/oa_pdf/a0/78/jwh.2016.5830.PMC5446610.pdf
"Available at: http://bhpr.hrsa.gov/healthworkforce/data/ primarycareserviceareas/index.html Accessed July 6, 2016.",Non-OADS,/arxiv_data1/oa_pdf/a0/78/jwh.2016.5830.PMC5446610.pdf
"Available at: http://healthcarereform.procon .org/sourceﬁles/crs-physician- supply-and-affordable-care- act.pdf Accessed July 6, 2016.",Non-OADS,/arxiv_data1/oa_pdf/a0/78/jwh.2016.5830.PMC5446610.pdf
Keywords: Endocarditis; Risk assessment; Valvular heart disease INTRODUCTION The original concept of antibiotic prophylaxis for infective endocarditis (IE) led to theEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ E327F06005DF3AF0 .,Non-OADS,/arxiv_data1/oa_pdf/1a/f5/40119_2016_Article_74.PMC5446807.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/1a/f5/40119_2016_Article_74.PMC5446807.pdf
"The overall odds ratio (OR) of all-cause mortality [OR =0.72, 95% conﬁdence interval (CI) 0.60–0.86, P\0.001, I2=0%], and cardiovascular mortality (OR =0.67, 95% CI 0.53–0.84, P=0.001, I2=23%) were lowerEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/1627 F06050529D91 .",Non-OADS,/arxiv_data1/oa_pdf/dd/c2/40119_2016_Article_75.PMC5446808.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/dd/c2/40119_2016_Article_75.PMC5446808.pdf
http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisory Committee/UCM508422.pdf .A c c e s s e d2 8J u n e 2016.,Non-OADS,/arxiv_data1/oa_pdf/dd/c2/40119_2016_Article_75.PMC5446808.pdf
Keywords: Cardiac; Echocardiography; Mortality; Sub-arachnoid hemorrhageEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 6237F0602739B8E3 .,Non-OADS,/arxiv_data1/oa_pdf/37/a6/40119_2016_Article_76.PMC5446809.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/37/a6/40119_2016_Article_76.PMC5446809.pdf
"Our case illustrates that late recoil needs to be systematically evaluated in future studies, especially when trans-catheter aortic valve replacement is being expanded to lower risk and younger patients for whom the longevity and long-term performance of these valves is of critical importance.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 0237F0602E31F4A7 .",Non-OADS,/arxiv_data1/oa_pdf/25/8a/40119_2016_Article_77.PMC5446810.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/25/8a/40119_2016_Article_77.PMC5446810.pdf
http://www.edwards.com/eu/products/ transcathetervalves/Pages/sapien3.aspx .,Non-OADS,/arxiv_data1/oa_pdf/25/8a/40119_2016_Article_77.PMC5446810.pdf
Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ DA47F06002A3D3E3 .,Non-OADS,/arxiv_data1/oa_pdf/5e/85/40119_2016_Article_78.PMC5446811.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/5e/85/40119_2016_Article_78.PMC5446811.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit tothe original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/fa/0f/40119_2016_Article_79.PMC5446812.pdf
The reduction of eGFR and the increase of serum creatinine and potassium levels in imidaprilEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ BF47F06042596BF7 .,Non-OADS,/arxiv_data1/oa_pdf/7f/4c/40119_2016_Article_80.PMC5446813.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/7f/4c/40119_2016_Article_80.PMC5446813.pdf
http://www.mayo.edu/research/departments-divi sions/department-health-sciences-research/division- biomedical-statistics-info rmatics/software/locally- written-sas-macros .,Non-OADS,/arxiv_data1/oa_pdf/7f/4c/40119_2016_Article_80.PMC5446813.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/8b/90/40119_2016_Article_81.PMC5446814.pdf
This article is based on previously conducted studies and does not involve any new studies ofEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/1D77 F0603E8B4DEF .,Non-OADS,/arxiv_data1/oa_pdf/06/91/40119_2017_Article_82.PMC5446815.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any non- commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/06/91/40119_2017_Article_82.PMC5446815.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any non- commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/bc/b4/40119_2017_Article_83.PMC5446816.pdf
"Since symptomatic severe AS is lethal with high 2-year mortality, surgical aortic valve replacement has been traditionally offered to these patients in order to improve survival.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ E387F06022413BB8 .",Non-OADS,/arxiv_data1/oa_pdf/e6/4f/40119_2017_Article_84.PMC5446817.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/e6/4f/40119_2017_Article_84.PMC5446817.pdf
The proportion ofEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ A487F0607C763559 .,Non-OADS,/arxiv_data1/oa_pdf/aa/49/40119_2017_Article_85.PMC5446818.pdf
Clinical trials number : http://www.controlled-trials.com ISRCTN: 16442558.,Non-OADS,/arxiv_data1/oa_pdf/aa/49/40119_2017_Article_85.PMC5446818.pdf
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/Cardiol Ther (2017) 6:91–104 101,Non-OADS,/arxiv_data1/oa_pdf/aa/49/40119_2017_Article_85.PMC5446818.pdf
We present a 63-year-old female who presented to the emergencyEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ BF87F0607133DAE7 .,Non-OADS,/arxiv_data1/oa_pdf/61/b4/40119_2017_Article_86.PMC5446819.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/61/b4/40119_2017_Article_86.PMC5446819.pdf
Keywords: Angiotensin II receptor blockers; Blood pressure control; Combination drug treatment; Hypertension; Olmesartan medoxomilEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ E097F0602FD64106 .,Non-OADS,/arxiv_data1/oa_pdf/b9/36/40119_2017_Article_87.PMC5446820.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/b9/36/40119_2017_Article_87.PMC5446820.pdf
"Daiichi Sankyo, Inc. Reference ID:3335147. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021532s022lbl.pdf .",OADS,/arxiv_data1/oa_pdf/b9/36/40119_2017_Article_87.PMC5446820.pdf
https://www.pharma.us.no vartis.com/sites/www.,Non-OADS,/arxiv_data1/oa_pdf/b9/36/40119_2017_Article_87.PMC5446820.pdf
http://www.fda.,Non-OADS,/arxiv_data1/oa_pdf/b9/36/40119_2017_Article_87.PMC5446820.pdf
"Nonetheless, in real life practice, there are patients with severe aorticEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ E8F7F0605B873386 .",Non-OADS,/arxiv_data1/oa_pdf/24/51/40119_2017_Article_88.PMC5446821.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/24/51/40119_2017_Article_88.PMC5446821.pdf
http://www.nejm.org/doi/suppl/10.1056/NEJMoa11035 10/suppl_ﬁle/nejmoa1103510_appendix.pdf .,OADS,/arxiv_data1/oa_pdf/24/51/40119_2017_Article_88.PMC5446821.pdf
2016. https://www.pcronline.com/ Cases-resources-images/Cases/Read-share-cases .A c c e s - sed 10 Dec 2016.150 Cardiol Ther (2017) 6:145–150,Non-OADS,/arxiv_data1/oa_pdf/24/51/40119_2017_Article_88.PMC5446821.pdf
"The most fre- quent prescribed statins were rosuvastatinEnhanced content To view enhanced content for this article, go to http://www.medengine.com/Redeem/ 9408F0603D4A3C5E .",Non-OADS,/arxiv_data1/oa_pdf/49/b6/40119_2017_Article_89.PMC5446822.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/49/b6/40119_2017_Article_89.PMC5446822.pdf
http://dx.doi.org/10.1371/ journal.pone.0073592 .,Non-OADS,/arxiv_data1/oa_pdf/47/ba/nihms861502.PMC5446894.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Diseasehttp://e-aair.org   285For all infants, breast-feeding is recommended for at least first  4 to 6 months of life.1-4 Breast-feeding has many physiological  and psychological benefits in both mothers and infants, and  the World Health Organization recommends that infants be ex - clusively breast-fed for the first 6 months of life to achieve opti-mal growth development and health.",Non-OADS,/arxiv_data1/oa_pdf/21/62/aair-9-285.PMC5446942.pdf
"15 A 2009 systematic re-Role of Breast-feeding in the Development of Atopic Dermatitis in  Early Childhood  Jeong Hee Kim1,2 1Department of Pediatrics, School of Medicine, Inha University Hospital, Incheon, Korea 2Environmental Health Center for Allergic Rhinitis, Inha University Hospital, Ministry of Environment, Incheon, Korea  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/21/62/aair-9-285.PMC5446942.pdf
2017 July;9(4):285-287. https://doi.org/10.4168/aair.2017.9.4.285 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/21/62/aair-9-285.PMC5446942.pdf
"2017 July;9(4):285-287. https://doi.org/10.4168/aair.2017.9.4.285 Volume 9, Number 4, July 2017 286  http://e-aair.orgview and meta-analysis of prospective cohort studies in devel- oped countries compared breast-feeding with conventional in-fant formula feeding or partial breast-feeding in the develop-ment of AD, and revealed that exclusive breast-feeding for at least 3 months was not significantly protective against the de-velopment of AD compared with partial breast-feeding or con-ventional formula.",Non-OADS,/arxiv_data1/oa_pdf/21/62/aair-9-285.PMC5446942.pdf
ORCID Jeong Hee Kim  http://orcid.org/0000-0002-7054-8552 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/21/62/aair-9-285.PMC5446942.pdf
2017 July;9(4):285-287. https://doi.org/10.4168/aair.2017.9.4.285 AAIR http://e-aair.org   287munol Res 2017;9:307-13.,Non-OADS,/arxiv_data1/oa_pdf/21/62/aair-9-285.PMC5446942.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease288  http://e-aair.orgINTRODUCTION Antibiotics may be classified as β-lactams (BLs) or non- β- lactams (NBLs).",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"IR usually oc - cur within 1 hour after drug intake 6, NIR appear later than 1 In Vitro  Diagnostic Testing for Antibiotic Allergy Inmaculada Doña,1 Maria J. Torres,1,3 Maria I. Montañez,2,3* Tahía D. Fernández2* 1Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, Málaga, Spain 2Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA, Málaga, Spain 3Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Málaga, Spain This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial License (http://creativecommons.org/licenses/bync/4.0/) which permits  unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 AAIR http://e-aair.org   289hour.7 Allergic reactions to antibiotics can also be classified ac - cording to different mechanisms involved, into 4 categories7: 1)   Type I, mediated by drug-specific immunoglobulin E (IgE) an- tibodies, occur less than 1 hour after drug administration.",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 Volume 9, Number 4, July 2017 290  http://e-aair.orgworkup of a suspected drug allergy requires the appropriate use  of diagnostic tests, if available, including clinical history, physi-cal examination, 27 skin tests, and drug provocation testing.28 A  detailed history is the most essential step toward an accurate diagnosis of allergic reactions.",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 AAIR http://e-aair.org   291an improvement in sensitivity.,Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 Volume 9, Number 4, July 2017 292  http://e-aair.orgproaches have been standardized and evaluated in detail.",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 AAIR http://e-aair.org   293moxifloxacin has a higher rate of photo-degradation than cip- rofloxacin.,Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 Volume 9, Number 4, July 2017 294  http://e-aair.orggroup of patients with positive skin tests,63 showing a sensitivity  of 55% and a specificity of 85%.",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 AAIR http://e-aair.org   295inclusion of drug metabolites that could be the recognized de- terminant, the depletion of FoxP3+ regulatory T cells that can suppress activation, and the evaluation of isolated effector cells.",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 Volume 9, Number 4, July 2017 296  http://e-aair.orgAL RD16/0006/0001), Andalusian Regional Ministry of Econo- my and Knowledge (grants co-funded from European Regional Development Fund : CTS-06603), Andalusian Regional Minis - try Health (grants: PI-0699-2011, PI-0352-2012, PI-0179-2014, and PI-0241-2016), and MerckSerono Research Grant from Fundacion Salud 2000.",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 AAIR http://e-aair.org   297al.,Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"2017 July;9(4):288-298. https://doi.org/10.4168/aair.2017.9.4.288 Volume 9, Number 4, July 2017 298  http://e-aair.orgof the lymphocyte transformation test in the diagnosis of drug sen- sitivity: dependence on its timing and the type of drug eruption.",Non-OADS,/arxiv_data1/oa_pdf/48/ce/aair-9-288.PMC5446943.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Diseasehttp://e-aair.org   299INTRODUCTION Chronic rhinosinusitis (CRS) is one of the common diseases  affecting about 10% of the general population, causing signifi- cant socioeconomic burden.1,2 The phenotypes of CRS, clinical- ly observable characteristics, have been classified based on en-doscopic or computed tomographic findings of nasal polyps (NP), 3 the presence of lower airway disease (e.g.",Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
"Endo- typing also helps determine optimal primary therapeutic mo-dality, select a good responder to a specific treatment, and pre-dict treatment outcomes and risks for comorbidities, such as asthma.Emerging Endotypes of Chronic Rhinosinusitis and Its Application  to Precision Medicine Dae Woo Kim,1 Seong H. Cho2* 1Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Boramae Medical Center, Seoul, Korea 2Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, USA This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
"2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299 Volume 9, Number 4, July 2017 300  http://e-aair.orgWe herein summarize pathophysiology and potential endo- types of CRS with NP (CRSwNP) and introduce biologicals  available now or under investigation in CRS.",Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299 AAIR http://e-aair.org   301flammatory condition like eosinophilic NP .,Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
"2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299 Volume 9, Number 4, July 2017 302  http://e-aair.orgRemodeling CRS is characterized by edematous remodeling patterns, base- ment membrane thickening, and goblet cell hyperplasia.58,59  TGF-β is not only a chemoattractant for fibroblasts, enhancing  their proliferation and collagen deposition, but also an inducer  for Treg.",Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
"2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299 AAIR http://e-aair.org   303Th2 cytokinebacteria PRR PARfungusvirus allergens TSLP IL-25 IL-33S100, Lactoferin ECPElastase IgENeutrophilILC2 Mast cell M2 Fibrin cross -linkingFXIIIAt-PA  TGF-β Treg Fibroblast collagenBacterial Biofilm Superantigen TryptaseIL-5 IL-4ILC1 IL-4 IL-12 virusIL-8, IL-33 EosinophilBAFF B cell Epithelial cell ExtravasatedFibrinogen  Fibrin D-dimerplasmin  IL-17A AutoAb Remodeling Inflammation Th2Th2 cytokine M1Th17Junction  protein Damage  IFN-γ thrombin  Under investigation  targets in NP Under investigation targets in allergic diseasesIL-13 Potential targets in NP Figure.",Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
"2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299 Volume 9, Number 4, July 2017 304  http://e-aair.orgDupilumab targeting IL-4R α has inhibitory effects on the sig- naling of IL-4 and IL-13 since both cytokines signaled through  IL-4Rα as a common subunit.",Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299 AAIR http://e-aair.org   30520.,Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
"2017 July;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299 Volume 9, Number 4, July 2017 306  http://e-aair.orgkanishi K. Interleukin 18 acts on memory T helper cells type 1 to  induce airway inflammation and hyperresponsiveness in a naive host mouse.",Non-OADS,/arxiv_data1/oa_pdf/f7/06/aair-9-299.PMC5446944.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Diseasehttp://e-aair.org   307INTRODUCTION Atopic dermatitis (AD) begins in early childhood, and 60% of  the cases develop in children before 2 years of age.1 It has dis - tinctive chronicity and is the gateway of atopic march.2 To re - duce potential public health implications, intervention for the  prevention of AD has been considered.2 Breast-feeding is commonly known as a preventive factor  against the development of allergic diseases including AD.3  However, recent studies demonstrated that breast-feeding does not have a protective effect against AD but actually increases the risk of AD.",Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
": Based on the Fourth and Fifth Korea National Health and Nutrition Examination Survey 2007–2012 Kyung Suk Lee,1 Yeong-Ho Rha,2 In-Hwan Oh,3 Yong Sung Choi,2 Young-Eun Kim,3 Sun Hee Choi4* 1Department of Pediatrics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea 2Department of Pediatrics, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea 3Department of Preventive Medicine, School of Medicine, Kyung Hee University, Seoul, Korea 4Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
2017 July;9(4):307-313. https://doi.org/10.4168/aair.2017.9.4.307 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
"2017 July;9(4):307-313. https://doi.org/10.4168/aair.2017.9.4.307 Volume 9, Number 4, July 2017 308  http://e-aair.orgterviewers or examiners who were not provided with any prior  information about participants conducted the survey.",Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
"From 2007 to 2012, 50,404 individuals participated in the KNHANES (detailed information about KNHANES: http://khanes.cdc.go.kr/).",Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
2017 July;9(4):307-313. https://doi.org/10.4168/aair.2017.9.4.307 AAIR http://e-aair.org   309The relationship between feeding and the parental history of  allergic diseases Feeding types and breast-feeding duration were analyzed in  relation to the history of parental allergic diseases (Table 2).,Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
"2017 July;9(4):307-313. https://doi.org/10.4168/aair.2017.9.4.307 Volume 9, Number 4, July 2017 310  http://e-aair.orgThe relationship between AD and feeding Exclusive breast-feeding was a significant risk factor for AD in  feeding type I (P =0.043; crude odds ratio [OR], 1.882; 95% con- fidence interval [CI], 1.020-3.475) by univariate logistic regres - sion.",Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
"2017 July;9(4):307-313. https://doi.org/10.4168/aair.2017.9.4.307 AAIR http://e-aair.org   311was not associated with the development of AD in early child- hood, and multiple regression analysis showed the definite dis - connection between breast-feeding and the prevalence of AD.",Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
"2017 July;9(4):307-313. https://doi.org/10.4168/aair.2017.9.4.307 Volume 9, Number 4, July 2017 312  http://e-aair.orgthese factors into consideration, it is an appropriate study to an- alyze the association between breast-feeding and the preva-lence of AD in young children from the Korean national repre-sentative data.",Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
Available from: http://www.who.Int/topics/breastfeeding/en/.,Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
2017 July;9(4):307-313. https://doi.org/10.4168/aair.2017.9.4.307 AAIR http://e-aair.org   313and development of atopic diseases in infants.,Non-OADS,/arxiv_data1/oa_pdf/d2/19/aair-9-307.PMC5446945.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease314  http://e-aair.orgINTRODUCTION Allergic rhinitis (AR) is a common chronic disease in child- hood and adolescence.1,2 AR negatively impacts physical, so- cial, and psychological well-being, and these effects can also  extend to other family members.1,3 Children with AR complain  of disruptive sneezing, itching, watery rhinorrhea, and nasal blockage; these symptoms can indirectly cause sleep distur -Allergic Rhinitis in Preschool Children and the Clinical Utility of  FeNO Jisun Yoon,1 Yean Jung Choi,1 Eun Lee,2 Hyun-Ju Cho,1 Song-I Yang,3 Young-Ho Kim,4 Young-Ho Jung,5 Ju-Hee Seo,6  Ji-won Kwon,7 Hyo-Bin Kim,8 So-Yeon Lee,3 Bong-Seong Kim,9 Jung Yeon Shim,10 Eun-Jin Kim,11 Joo-Shil Lee,11   Soo-Jong Hong1* 1 Department of Pediatrics, Childhood Asthma Atopy Center, Research Center for the Standardization of Allergic Diseases, University of Ulsan College of  Medicine, Asan Medical Center, Seoul, Korea 2Department of Pediatrics, Chonnam National University Hospital, Gwangju, Korea 3Department of Pediatrics, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea 4Department of Pediatrics, Gyeongsang National University Changwon Hospital, Gyeongsang, Korea 5Department of Pediatrics, CHA Bundang Medical Center, College of Medicine, CHA University, Seongnam, Korea 6Department of Pediatrics, Dankook University Hospital, Cheonan, Korea 7Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea 8Department of Pediatrics, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea 9Department of Pediatrics, Gangneung Asan Hospital, Gangneung, Korea 10Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea 11 Division of Allergy and Chronic Respiratory Diseases, Center for Biomedical Sciences, Korea National Institute of Health, Korea Center for Disease Control and  Prevention, Cheongju, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
2017 July;9(4):314-321. https://doi.org/10.4168/aair.2017.9.4.314 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
"2017 July;9(4):314-321. https://doi.org/10.4168/aair.2017.9.4.314 AAIR http://e-aair.org   315bances and daily fatigue, thereby resulting in impaired school  performance.4 The prevalence of AR is increasing worldwide.5 The Interna- tional Study of Asthma and Allergies in Childhood (ISAAC) I studies revealed that the median average prevalence of rhino-conjunctivitis in the past year for 6- to 7-year-old children was 6.9% (range 0.8%-14.9%) in 1997.",Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
"2017 July;9(4):314-321. https://doi.org/10.4168/aair.2017.9.4.314 Volume 9, Number 4, July 2017 316  http://e-aair.organy allergic disease, including asthma, AR, or AD, was reported  for 49.0% of individuals, while a parental history of AR was not - ed for 44.0%.",Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
"2017 July;9(4):314-321. https://doi.org/10.4168/aair.2017.9.4.314 AAIR http://e-aair.org   3171.73-5.08), a history of wheezing in the last 12 months (aOR,  2.09; 95% CI, 1.21-3.59), a history of AD diagnosis (aOR, 1.61; 95% CI, 1.11-2.34), and a parental history of asthma (aOR, 2.10; 95% CI, 1.08-4.08).",Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
"2017 July;9(4):314-321. https://doi.org/10.4168/aair.2017.9.4.314 Volume 9, Number 4, July 2017 318  http://e-aair.orgLevels of FeNO and total serum IgE, and blood eosinophil  counts in current atopic AR patients without asthma or atopy The geometric mean levels of FeNO were significantly higher  in children with current atopic AR without asthma than in ei-ther control individuals or those with non-atopic rhinitis with-out asthma groups (12.43; 95% CI, 10.07-15.49 vs 8.25; 95% CI, 7.39-9.39, P=0.001).",Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
"2017 July;9(4):314-321. https://doi.org/10.4168/aair.2017.9.4.314 AAIR http://e-aair.org   319sinophil percentage was observed (r =0.244, P<0.001 for serum  IgE and r =0.296, P<0.001 for blood eosinophilia; Supplemen- tary Figs.",Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
"2017 July;9(4):314-321. https://doi.org/10.4168/aair.2017.9.4.314 Volume 9, Number 4, July 2017 320  http://e-aair.orgtective effect of having an older sibling on AR in preschool-aged  children was observed, which was consistent with an inverse association between the number of siblings and hay fever.",Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
2017 July;9(4):314-321. https://doi.org/10.4168/aair.2017.9.4.314 AAIR http://e-aair.org   321disposition as risk factors for asthma in China.,Non-OADS,/arxiv_data1/oa_pdf/24/88/aair-9-314.PMC5446946.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease322  http://e-aair.orgINTRODUCTION An increasing prevalence of food allergy (FA) has recently  been reported among children.1,2 However, the true prevalence  of FA, as based on an oral food challenge test (OFC), is relative- ly unknown.3 Rona et al.4 reported that many studies of the  prevalence of FA have been based only on perception of food reactions, and compared with studies that include objective di-agnostic tools, most of these studies seem to have overestimat - ed the prevalence of FA.",Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
"Therefore, this study aimed to identify the prevalence of FA and to determine the proportion of children who unnecessarily eliminate food in Nii - jima village.Accurate Determination of Childhood Food Allergy Prevalence and  Correction of Unnecessary Avoidance Yuki Okada,1,2,3* Takumi Yamashita,4,5 Hideki Kumagai,3 Yoshihiko Morikawa,6 Akira Akasawa7 1Department of General Pediatrics, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan 2Niijima Clinic, Tokyo, Japan 3Department of Pediatrics, Jichi Medical University, Tochigi, Japan 4Shikinejima Clinic, Tokyo, Japan 5Department of Pediatrics, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan 6Clinical Research Support Center, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan 7Department of Allergy, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
2017 July;9(4):322-328. https://doi.org/10.4168/aair.2017.9.4.322 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
"2017 July;9(4):322-328. https://doi.org/10.4168/aair.2017.9.4.322 AAIR http://e-aair.org   323MATERIALS AND METHODS Primary survey To determine patients with suspected FA, a primary survey  was conducted via a questionnaire among all children aged  0-18 years (high school students and younger) in Niijima vil- lage.",Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
"2017 July;9(4):322-328. https://doi.org/10.4168/aair.2017.9.4.322 Volume 9, Number 4, July 2017 324  http://e-aair.orgmately 1 month to determine if the same symptoms occurred.",Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
"2017 July;9(4):322-328. https://doi.org/10.4168/aair.2017.9.4.322 AAIR http://e-aair.org   325children, 20 were too young to consume some foods and were  therefore regarded as FA negative.",Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
"2017 July;9(4):322-328. https://doi.org/10.4168/aair.2017.9.4.322 Volume 9, Number 4, July 2017 326  http://e-aair.orgFig.",Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
2017 July;9(4):322-328. https://doi.org/10.4168/aair.2017.9.4.322 AAIR http://e-aair.org   327and outcomes are summarized in Fig.,Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
"2017 July;9(4):322-328. https://doi.org/10.4168/aair.2017.9.4.322 Volume 9, Number 4, July 2017 328  http://e-aair.orgperiods to undergo an OFC because low-risk children also have  to undergo OFCs at these facilities.",Non-OADS,/arxiv_data1/oa_pdf/75/66/aair-9-322.PMC5446947.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Diseasehttp://e-aair.org   329INTRODUCTION The pathogenesis of allergic diseases is multifactorial.",Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"The Korea National Health and Nutrition Examination Survey  (KNHANES) is a large-scale cross-sectional survey, conducted Prevalence of Self-reported Allergic Diseases and IgE Levels:   A 2010 KNHANES Analysis Hye Jung Park,1 Eun-Jin Kim,2 Dankyu Yoon,2 Jeom Kyu Lee,2 Woo-Sung Chang,2 Yoen-Mi Lim,2 Jung-Won Park,3*   Joo-Shil Lee2* 1Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea 2 Division of Allergy and Chronic Respiratory Diseases, Center for Biomedical Sciences, Korea National Institute of Health, Korea Center for Diseases Control and  Prevention, Osong, Korea  3Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 Volume 9, Number 4, July 2017 330  http://e-aair.orgby the Korea Centers for Disease Control and Prevention  (KCDC), which collects a significant amount of demographic and environmental data.",Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"In the present study, to ob-tain appropriate estimates, we followed the guidelines for re-porting sample weight (sampling weights) and stratification designated by the KCDC; this information is available on the KNHANES website (http://knhanes.cdc.go.kr).",OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 AAIR http://e-aair.org   331Table 1.,Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 Volume 9, Number 4, July 2017 332  http://e-aair.org37.6% (Table 1).",Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 AAIR http://e-aair.org   333Univariate analyses of factors associated with the tIgE level The geometric mean tIgE level was 94.8 kU/L (95% confi - dence interval [CI], 87.9-102.3).",OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 Volume 9, Number 4, July 2017 334  http://e-aair.orgcupation (P =0.008), glucose intolerance (P =0.023), and sensiti- zation to dog (P =0.007) were found to be significant indepen- dent risk factors for allergic rhinitis.",Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 AAIR http://e-aair.org   335DISCUSSION This large cross-sectional study aimed to identify demograph- ic and environmental factors associated with the prevalence of  allergic diseases and allergen sensitization in the non-institu-tionalized Korean general population.,Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 Volume 9, Number 4, July 2017 336  http://e-aair.orgvice and sales occupations (20.4%) was significantly lower than  that for those in other occupations (31.9%-36.5%; data not shown).",OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 AAIR http://e-aair.org   337lationship between these conditions is still lacking.,Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 Volume 9, Number 4, July 2017 338  http://e-aair.organ general population.",Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
2017 July;9(4):329-339. https://doi.org/10.4168/aair.2017.9.4.329 AAIR http://e-aair.org   339associated with a subsequent risk of peripheral artery disease: a  longitudinal population-based study.,Non-OADS,/arxiv_data1/oa_pdf/3b/38/aair-9-329.PMC5446948.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease340  http://e-aair.orgINTRODUCTION Mycoplasma pneumoniae is an important cause of communi- ty-acquired pneumonia (CAP) in children and young adults.",Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
"Therefore, continuous surveillance of the change in prevalence of MRMP pneumonia and the influence of MRMP on disease outcome are inevitably needed to define its clinical relevance and to develop appropriate treatment strategies at a Macrolide Resistance and Its Impacts on M. Pneumoniae   Pneumonia in Children: Comparison of Two Recent Epidemics in  Korea Jong Hyun Kim,1 Jee Yong Kim,2 Chang Hoon Yoo,3 Won Hee Seo,1 Young Yoo,1,4 Dae Jin Song,1,4* Ji Tae Choung1,4 1Department of Pediatrics, Korea University College of Medicine, Seoul, Korea 2Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea 3Nanobiosys Inc., Seoul, Korea 4Environmental Health Center for Childhood Asthma, Korea University Anam Hospital, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
2017 July;9(4):340-346. https://doi.org/10.4168/aair.2017.9.4.340 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
2017 July;9(4):340-346. https://doi.org/10.4168/aair.2017.9.4.340 AAIR http://e-aair.org   341time when MRMP is increasingly being detected.,Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
"2017 July;9(4):340-346. https://doi.org/10.4168/aair.2017.9.4.340 Volume 9, Number 4, July 2017 342  http://e-aair.orgtest.",Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
2017 July;9(4):340-346. https://doi.org/10.4168/aair.2017.9.4.340 AAIR http://e-aair.org   343rized in Tables 2 and 3.,Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
"2017 July;9(4):340-346. https://doi.org/10.4168/aair.2017.9.4.340 Volume 9, Number 4, July 2017 344  http://e-aair.orgmore than 72 hours after initiation of macrolides and who re- ceived corticosteroid treatment were higher in MRMP pneu-monia during 2 epidemics.",Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
"2017 July;9(4):340-346. https://doi.org/10.4168/aair.2017.9.4.340 AAIR http://e-aair.org   345increased as MRMP pneumonia in children increased.8 The  reason for the difference in the influence of MRMP on clinical  outcomes in previous studies could be partially explained by the fact that patients with MRMP pneumonia had more persis - tent signs and symptoms, which in turn led physicians to add an adjunctive treatment, such as corticosteroids, or to replace antibiotics in order to obtain a more rapid clinical improve-ment.",Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
"2017 July;9(4):340-346. https://doi.org/10.4168/aair.2017.9.4.340 Volume 9, Number 4, July 2017 346  http://e-aair.orgplasma pneumoniae: characteristics of isolates and clinical aspects  of community-acquired pneumonia.",Non-OADS,/arxiv_data1/oa_pdf/2d/80/aair-9-340.PMC5446949.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Diseasehttp://e-aair.org   347INTRODUCTION Quinolones are the synthetic broad spectrum antimicrobial  agents which are frequently used for various gram positive and  gram negative bacterial infections.1 The most frequently used  quinolones are classified into 4 generations according to their main antibacterial activity and chemical structures.",Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"3 In parallel to the increased quinolone  consumption, the frequency of hypersensitivity reactions has significantly increased over the past decade and quinolones represent the most frequent reason for hypersensitivity reac -Usefulness of In Vivo  and In Vitro  Diagnostic Tests in the Diagnosis  of Hypersensitivity Reactions to Quinolones and in the Evaluation  of Cross-Reactivity: A Comprehensive Study Including the Latest Quinolone Gemifloxacin Semra Demir,1* Asli Gelincik,1 Nilgun Akdeniz,2 Esin Aktas-Cetin,2 Muge Olgac,1 Derya Unal,1 Belkis Ertek,1 Raif Coskun,1  Bahattin Colako ğlu,1 Gunnur Deniz,2 Suna Buyukozturk1 1Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 2Department of Immunology, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 Volume 9, Number 4, July 2017 348  http://e-aair.orgtions among non beta-lactam antibiotics.4 Quinolones induce  hypersensitivity reactions primarily by immunoglobulin E (IgE)  and T cell-mediated mechanisms.5-7 The most common hyper - sensitivity reaction types are urticaria and anaphylaxis.5-8 Non- immediate hypersensitivity reactions to quinolones including maculopapular exanthemas, fixed drug eruptions, acute gener - alized exanthematic pustulosis, Stevens-Johnson syndrome, and toxic epidermal necrolysis are less often seen.",Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 AAIR http://e-aair.org   349persensitivity reaction occurred up to 24 hours after the last  dose.,Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 Volume 9, Number 4, July 2017 350  http://e-aair.orgChemical Co.).",Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 AAIR http://e-aair.org   351and the most common atopic agents were house dust mites  and pollen (25.9%).,Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 Volume 9, Number 4, July 2017 352  http://e-aair.orgTable 4.",Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 AAIR http://e-aair.org   353Table 4.,Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 Volume 9, Number 4, July 2017 354  http://e-aair.orgEvaluation of in vivo  tests with the alternative drugs In 5 of the 30 CFX-hypersensitive patients STs were found  positive with LFX (n =4) and GFX (n =1).",Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 AAIR http://e-aair.org   355(CI, 0.90-0.97), the positive predictive value was 20% (CI,2.52- 55.61), the negative predictive value was 74.6% (CI,68.25-80.34), false positive results were 8% and false negative results were 25%.",OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 Volume 9, Number 4, July 2017 356  http://e-aair.orgues of LTT with CFX, LFX, MFX, and OFX were 1.05 ±0.04,  1.04±0.08, 1.05 ±0.03, and 1.04 ±0.40 respectively.",OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 AAIR http://e-aair.org   357clic ring structure, LFX is the active L-isomer form of OFX.",Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 Volume 9, Number 4, July 2017 358  http://e-aair.orgperformed in different visits, some patients could not attend to  every part of the studydue to special reasons such as living in another city or being afraid of donating blood.",Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
2017 July;9(4):347-359. https://doi.org/10.4168/aair.2017.9.4.347 AAIR http://e-aair.org   35933.,Non-OADS,/arxiv_data1/oa_pdf/c1/37/aair-9-347.PMC5446950.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease360  http://e-aair.orgINTRODUCTION Eosinophilic gastroenteritis (EGE) is a member of eosinophil- ic gastrointestinal diseases (EGIDs) which include eosinophilic  esophagitis, eosinophilic gastritis, EGE, and eosinophilic colitis.",Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
"Eotaxin-3 is a key player in the eosinophilia observed in eosinophilic esophagitis, while eotax -CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation  and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis Dae Jin Song,1,2* Mun Hee Shim,1 Nahyun Lee,1 Young Yoo,1,2 Ji Tae Choung1,2 1Department of Pediatrics, Korea University College of Medicine, Seoul, Korea 2Environmental Health Center for Childhood Asthma, Korea University Anam Hospital, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
2017 July;9(4):360-367. https://doi.org/10.4168/aair.2017.9.4.360 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
"2017 July;9(4):360-367. https://doi.org/10.4168/aair.2017.9.4.360 AAIR http://e-aair.org   361in-1 is involved in the lower GI eosinophilic diseases.9 Eosino- phils express cysteine-cysteine chemokine receptor-3 (CCR3),  a specific receptor for eotaxin, which is involved in selective re-cruitment of this leukocyte to sites of inflammation.",Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
"2017 July;9(4):360-367. https://doi.org/10.4168/aair.2017.9.4.360 Volume 9, Number 4, July 2017 362  http://e-aair.orgnohistochemistry Kit (Chemicon, Temecula, CA, USA) accord- ing to the manufacturer’s instructions.",Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
"2017 July;9(4):360-367. https://doi.org/10.4168/aair.2017.9.4.360 AAIR http://e-aair.org   363Effects of anti-CCR3 antibody on the numbers of eosinophils  and mast cells in intestinal mucosa The number of eosinophils in the intestinal mucosa signifi- cantly increased in OVA-challenged mice compared with non-OVA-challenged ones (358.20 ±12.40 vs 179.90 ±8.12 eosino- phils/mm 2, P<0.001).",Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
"2017 July;9(4):360-367. https://doi.org/10.4168/aair.2017.9.4.360 Volume 9, Number 4, July 2017 364  http://e-aair.orgof control antibody (43.88% ±7.93% vs 69.03% ±6.54% BrdU-la- beled intestinal epithelial cells, P =0.030; Fig.",Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
2017 July;9(4):360-367. https://doi.org/10.4168/aair.2017.9.4.360 AAIR http://e-aair.org   365Effect of CCR3 antibody on weight loss Baseline body weight at day 0 was not different between the  experimental groups.,Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
"2017 July;9(4):360-367. https://doi.org/10.4168/aair.2017.9.4.360 Volume 9, Number 4, July 2017 366  http://e-aair.orgtoms was modest in this study.",Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
2017 July;9(4):360-367. https://doi.org/10.4168/aair.2017.9.4.360 AAIR http://e-aair.org   367bodies specific for C-C chemokine receptor 3 (CCR3).,Non-OADS,/arxiv_data1/oa_pdf/d2/f8/aair-9-360.PMC5446951.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease368  http://e-aair.orgINTRODUCTION Severe asthma affects about 10% of all patients with asthma  and is associated with high-risk of asthma-related hospitaliza- tion, substantial morbidity, high utilization of healthcare re - sources, and negative impact on the quality of life (QoL).1 Gen- erally, long-term management is focused on controlling the clinical aspects of the disease.",Non-OADS,/arxiv_data1/oa_pdf/be/15/aair-9-368.PMC5446952.pdf
"11 (4 years), Zazzali Real-life Efficacy of Omalizumab After 9 Years of Follow-up Francesco Menzella,1* Carla Galeone,1 Debora Formisano,2 Claudia Castagnetti,1 Patrizia Ruggiero,1 Anna Simonazzi,1   Luigi Zucchi1 1Department of Cardio-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy 2Scientific Directorate, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/be/15/aair-9-368.PMC5446952.pdf
2017 July;9(4):368-372. https://doi.org/10.4168/aair.2017.9.4.368 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/be/15/aair-9-368.PMC5446952.pdf
"2017 July;9(4):368-372. https://doi.org/10.4168/aair.2017.9.4.368 AAIR http://e-aair.org   369et al.12 (5 years), Pace et al.13 (7 years), and our group14 (4 years).",Non-OADS,/arxiv_data1/oa_pdf/be/15/aair-9-368.PMC5446952.pdf
"2017 July;9(4):368-372. https://doi.org/10.4168/aair.2017.9.4.368 Volume 9, Number 4, July 2017 370  http://e-aair.orgparticular for corticosteroids and anti-leukotrienes at 9 years  (Table).",Non-OADS,/arxiv_data1/oa_pdf/be/15/aair-9-368.PMC5446952.pdf
2017 July;9(4):368-372. https://doi.org/10.4168/aair.2017.9.4.368 AAIR http://e-aair.org   371be a trend toward use of a lower dose of ICS at prolonged fol- low-up times.,Non-OADS,/arxiv_data1/oa_pdf/be/15/aair-9-368.PMC5446952.pdf
"2017 July;9(4):368-372. https://doi.org/10.4168/aair.2017.9.4.368 Volume 9, Number 4, July 2017 372  http://e-aair.orgment and prevention.",Non-OADS,/arxiv_data1/oa_pdf/be/15/aair-9-368.PMC5446952.pdf
Available from: http://www.hse.ie/eng/about/Who/clinical/natclinprog/asthma/ workstreams/asthmacontrol.pdf.18.,Non-OADS,/arxiv_data1/oa_pdf/be/15/aair-9-368.PMC5446952.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Diseasehttp://e-aair.org   373INTRODUCTION Chronic urticaria (CU) is a disorder defined as transient and  itchy wheals for more than 6 weeks and is experienced by 0.1%  of the general population.1 CU is classified in to chronic sponta- neous urticaria (CSU) and inducible urticaria by physical stim-uli.",Non-OADS,/arxiv_data1/oa_pdf/51/7e/aair-9-373.PMC5446953.pdf
"However, to our knowledge, only 2 population-based studies investigated the association between AITD and CSU, in Increased Risk of Chronic Spontaneous Urticaria in Patients With  Autoimmune Thyroid Diseases: A Nationwide, Population-based Study Yoon Seob Kim,1 Kyungdo Han,2 Ji Hyun Lee,1 Nack In Kim,3 Joo Young Roh,4 Seong Jun Seo,5 Hae Jun Song,6   Min-Geol Lee,7 Jee Ho Choi,8 Young Min Park1* 1Department of Dermatology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 2Department of Medical Statistics, The Catholic University of Korea College of Medicine, Seoul, Korea 3Department of Dermatology, Kyung Hee University School of Medicine, Seoul, Korea 4Department of Dermatology, Gachon University Gil Medical Center, Incheon, Korea 5Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea 6Department of Dermatology, Korea University College of Medicine, Seoul, Korea 7Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea 8Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/51/7e/aair-9-373.PMC5446953.pdf
2017 July;9(4):373-377. https://doi.org/10.4168/aair.2017.9.4.373 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/51/7e/aair-9-373.PMC5446953.pdf
"2017 July;9(4):373-377. https://doi.org/10.4168/aair.2017.9.4.373 Volume 9, Number 4, July 2017 374  http://e-aair.orgwhich they did not use an age- and gender-matched controls.6,7 The aim of this study was to investigate the relative risk of CSU  in the AITD group compared to the control group using nation- al registry data of Korea.",Non-OADS,/arxiv_data1/oa_pdf/51/7e/aair-9-373.PMC5446953.pdf
"2017 July;9(4):373-377. https://doi.org/10.4168/aair.2017.9.4.373 AAIR http://e-aair.org   375portions of patients with type 2 DM, hypertension, dyslipid- emia, allergic rhinitis, atopic dermatitis, or asthma was signifi-cantly higher in the AITD group compared with the control group (P <0.001).",Non-OADS,/arxiv_data1/oa_pdf/51/7e/aair-9-373.PMC5446953.pdf
"2017 July;9(4):373-377. https://doi.org/10.4168/aair.2017.9.4.373 Volume 9, Number 4, July 2017 376  http://e-aair.organd type 1 type 2 DM was reported.19,20 Evolving evidence of in- teractions between thyroid hormone and basal mechanisms  controlling appetite and energy expenditure, as well as between the regulation of insulin sensitivity and secretion, explains the possible association between AITD and metabolic diseases.",Non-OADS,/arxiv_data1/oa_pdf/51/7e/aair-9-373.PMC5446953.pdf
2017 July;9(4):373-377. https://doi.org/10.4168/aair.2017.9.4.373 AAIR http://e-aair.org   37719.,Non-OADS,/arxiv_data1/oa_pdf/51/7e/aair-9-373.PMC5446953.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease378  http://e-aair.orgINTRODUCTION The geriatric population is increasing worldwide and the bur - den of asthma is more significant in elderly asthmatics com- pared to younger ones.",Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
"One of the most im-portant risk factors for AE is the history of ≥1 exacerbation in Plasma LTE 4/PGF 2α Ratio and Blood Eosinophil Count Are Increased  in Elderly Asthmatics With Previous Asthma Exacerbation Ga-Young Ban,1 Young-Min Ye,1 Sang-Ha Kim,2 Gyu-Young Hur,3 Joo-Hee Kim,4 Jae-Jung Shim,3 Kumsun Cho,5   Joo-Youn Cho,5 Hae-Sim Park,1* and PRANA group 1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea  2Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea  3Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea  4 Department of Internal Medicine, Hallym University School of Medicine, Anyang, Korea  5Department of Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
2017 July;9(4):378-382. https://doi.org/10.4168/aair.2017.9.4.378 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
"2017 July;9(4):378-382. https://doi.org/10.4168/aair.2017.9.4.378 AAIR http://e-aair.org   379the previous year; therefore, patients should recall their AE his - tory to evaluate the future risk for AE.6 Spirometry which is rec - ommended in assessing the future risk for AE requires proper  coordination, and cognitive function and effort.1 The tools for  asthma control recommended by the current guideline6 are de- pendent on cognitive function and effort which is substantially impaired in elderly.",Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
"2017 July;9(4):378-382. https://doi.org/10.4168/aair.2017.9.4.378 Volume 9, Number 4, July 2017 380  http://e-aair.orgweek 12 than group 2 subjects (LTE 4 level: 20.83 ±23.37 vs  13.49±11.04 pg/mL, P =0.023; LTE 4/PGF 2α ratio: 1.43 ±1.76 vs  0.79±0.82, P=0.010) (Figure).",Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
2017 July;9(4):378-382. https://doi.org/10.4168/aair.2017.9.4.378 AAIR http://e-aair.org   381previous 1 to 4 weeks.,Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
"ACKNOWLEDGMENTS This research was supported by a grant of the Korea Health  Technology R&D Project through the Korea Health Industry De-velopment Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0992) and Dong-A ST Co., Ltd. ORCID Hae-Sim Park  http://orcid.org/0000-0003-2614-0303 REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
Available from: http://ginasthma.org/gina-reports.,Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
"2017 July;9(4):378-382. https://doi.org/10.4168/aair.2017.9.4.378 Volume 9, Number 4, July 2017 382  http://e-aair.orgChild 1995;73:221-5.",Non-OADS,/arxiv_data1/oa_pdf/81/22/aair-9-378.PMC5446954.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3a/b4/copd-12-1519.PMC5446957.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2017:12 1519–1525International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1519OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S13227 6 Proteasome activity related with the daily physical  activity of COPD patients Kang-Yun lee1,2,* Tzu-Tao Chen1,* ling-ling Chiang1,3 hsiao-Chi Chuang1,3 Po-hao Feng1,2 Wen-T e liu1–3 Kuan-Yuan Chen1 shu-Chuan ho1,3 1Division of Pulmonary Medicine,   Department of Internal Medicine,   shuang ho hospital, Taipei Medical  University, new Taipei City, 2Division  of Pulmonary Medicine, Department  of Internal Medicine, school of  Medicine, College of Medicine,   Taipei Medical University, 3school  of respiratory Therapy, College of  Medicine, Taipei Medical University,   Taipei, Taiwan *These authors contributed equally  to this workBackground:  COPD is a debilitating disease that affects patients’ daily lives.",Non-OADS,/arxiv_data1/oa_pdf/3a/b4/copd-12-1519.PMC5446957.pdf
"Calf circumference (CC) is highly associated with exercise tolerance,  and it might be of value in predicting exercise intolerance in COPD patients.6 Patients Correspondence: shu-Chuan ho school of respiratory Therapy, College  of Medicine, Taipei Medical University,  250 Wu-Xing st, Taipei 11031, Taiwan Tel +886 22 736 1661 ext 3512 Fax +886 22 739 1143 email shu-chuan@tmu.edu.t w Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Lee et al Running head recto: Proteasome activity in COPD patients DOI: http://dx.doi.org/10.2147/COPD.S132276",Non-OADS,/arxiv_data1/oa_pdf/3a/b4/copd-12-1519.PMC5446957.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/3a/b4/copd-12-1519.PMC5446957.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/3a/b4/copd-12-1519.PMC5446957.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Cancer Management and Research 2017:9 179–187Cancer Management and Research Dovepress submit your manuscript | www.dovepress.com Dovepress  179 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CMAR.S129059APF530 versus ondansetron, each in a  guideline-recommended three-drug regimen,  for the prevention of chemotherapy-induced  nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic  chemotherapy regimens: a post hoc subgroup  analysis of the Phase III randomized MAGIC trial  Ian D Schnadig1, Richy  Agajanian2, Christopher  Dakhil3, Nashat Gabrail4,  Jeffrey Vacirca5, Charles  Taylor6, Sharon Wilks7,  Eduardo Braun8, Michael C  Mosier9, Robert B Geller10,  Lee Schwartzberg11,  Nicholas  Vogelzang12 1Compass Oncology, US Oncology  Research, T ualatin, OR, 2The Oncology  Institute of Hope and Innovation,   Whittier, CA, 3Cancer Center of  Kansas, Wichita, KS, 4Gabrail Cancer  Center, Canton, OH, 5North Shore  Hematology Oncology, East Setauket,  NY,  6T ulsa Cancer Institute, T ulsa, OK,   7Cancer Care Centers of South T exas,   San Antonio, TX, 8Michiana Hematology  Oncology, Westville, IN, 9Biostatistics,   EMB Statistical Solutions, LLC, Overland Park, KS,  10Medical Affairs, Heron  Therapeutics, Inc., San Diego, CA,   11West Cancer Center, Germantown,   TN, 12Comprehensive Cancer Centers of  Nevada, Las Vegas, NV, USABackground: APF530, a novel extended-release granisetron injection, was superior to  ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase  chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic  chemotherapy (HEC) in the double-blind Phase III Modified Absorption of Granisetron In the  prevention of CINV (MAGIC) trial.",Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
"Keywords: APF530, extended release granisetron, chemotherapy-induced nausea and vomiting  (CINV), highly emetogenic chemotherapy (HEC), anthracycline, cyclophosphamide  Correspondence: Ian D Schnadig Compass Oncology, US Oncology Research,  19260 SW 65th Ave., Suite 435, Tualatin,  OR, 97062, USATel +1 503 692 2032 Fax +1 503 692 4450Email Ian.Schnadig@USONCOLOGY.comJournal name: Cancer Management and Research Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Schnadig et alRunning head recto: APF530 vs ondansetron in CINV due to AC regimensDOI: http://dx.doi.org/10.2147/CMAR.S129059",Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.,Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
Available from: http://www.mascc.org/antiemetic-guidelines.,Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
Available from: http://www.gene.com/download/pdf/kytril_injection_prescribing.pdf.,Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
Available from: http://www.herontx.com/sustol.,Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
Available from: http://www.pharma.us.novartis.com/product/pi/pdf/zofran_inj.pdf.,Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
Available from: https://www.nccn.org/professionals/physi-cian_gls/f_guidelines.asp.,Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
"Cancer Management and Research 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress Cancer Management and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journalCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 187 APF530 vs ondansetron in CINV due to AC regimens 32.,Non-OADS,/arxiv_data1/oa_pdf/07/15/cmar-9-179.PMC5446958.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/56/11/copd-12-1503.PMC5446959.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2017:12 1503–1506International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1503ShO rt rePO rtopen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/COPD.S13786 5 Clinical characteristics of COPD patients with  tidal expiratory flow limitation James Dean1 Umme Kolsum1,2 Paul hitchen1 Vandana Gupta1 Dave Singh1,2 1Medicines evaluation Unit,   Manchester, 2Division of Infection,   Immunity and respiratory Medicine,   School of Biological Sciences, Faculty  of Biology, Medicine and health,   Manchester Academic health Science  Centre, the University of Manchester  and University hospital of South  Manchester N hS Foundation trust,   Manchester, UKAbstract:  We have used impulse oscillometry to identify COPD patients with tidal expiratory  flow limitation (EFL), which is a measurement related to small airway disease.",Non-OADS,/arxiv_data1/oa_pdf/56/11/copd-12-1503.PMC5446959.pdf
"We also  studied whether the presence of EFL is stable after 2 years of follow-up.Correspondence: Dave Singh Medicines evaluation Unit, University  of Manchester, Southmoor road,  Manchester M23 9QZ, UK tel +44 161 946 4073 Fax +44 161 946 1459 email dsingh@meu.org.u k Journal name: International Journal of COPD Article Designation: Short Report Y ear: 2017 Volume: 12 Running head verso: Dean et al Running head recto: Tidal expiratory flow limitation in COPD DOI: http://dx.doi.org/10.2147/COPD.S137865",Non-OADS,/arxiv_data1/oa_pdf/56/11/copd-12-1503.PMC5446959.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/56/11/copd-12-1503.PMC5446959.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/56/11/copd-12-1503.PMC5446959.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a6/cd/ijwh-9-365.PMC5446960.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2017:9 365–372International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  365OrIg Inal researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJWH.S13220 2 Knowledge about cervical cancer screening and  its practice among female health care workers  in southern ethiopia: a cross-sectional study Dubale Dulla1 Deresse Daka2 negash Wakgari1 1school of n ursing and Midwifery,   2Department of Medical science,   college of Medicine and Health  sciences, Hawassa University,   Hawassa, ethiopiaBackground:  Cervical cancer remains a major cause of morbidity and mortality among the  women in the world.",Non-OADS,/arxiv_data1/oa_pdf/a6/cd/ijwh-9-365.PMC5446960.pdf
"Keywords:  cervical cancer, health care workers, southern Ethiopia Background Globally, cervical cancer is the third most frequent cancer among women.1 Each year,  an estimated half million new cases are diagnosed with ~275,000 deaths in 2008  alone.2–5 Low-resource countries account for 85% of the cases, yet very little is spent  in preventing and treating cervical cancers.1–3 Similarly, it is the most common and  most lethal cancer among the women of sub-Saharan Africa.6 A considerable reduc - tion in cervical cancer incidence and deaths has been achieved in developed countries correspondence: negash Wakgari school of nursing and Midwifery,  college of Medicine and Health sciences,  Hawassa University, Hawassa, ethiopia email negashwakgari@yahoo.co m Journal name: International Journal of Women’s Health Article Designation: Original Research Y ear: 2017 Volume: 9 Running head verso: Dulla et al Running head recto: Knowledge about cervical cancer screening DOI: http://dx.doi.org/10.2147/IJWH.S132202",Non-OADS,/arxiv_data1/oa_pdf/a6/cd/ijwh-9-365.PMC5446960.pdf
"Available from: http://screening.iarc.fr/doc/Human%20Papilloma - virus%20and%20Related%20Cancers.pd f. Accessed September 23,  2010.",Non-OADS,/arxiv_data1/oa_pdf/a6/cd/ijwh-9-365.PMC5446960.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/a6/cd/ijwh-9-365.PMC5446960.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a6/cd/ijwh-9-365.PMC5446960.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/4c/cb/ceor-9-295.PMC5446961.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/4c/cb/ceor-9-295.PMC5446961.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).ClinicoEconomics and Outcomes Research 2017:9 295–306ClinicoEconomics and Outcomes Research Dovepress submit your manuscript | www.dovepress.com Dovepress  295 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEOR.S127760Evaluation of the treatment patterns and  economic burden of dysmenorrhea in Japanese  women, using a claims database Sayako Akiyama1 Erika Tanaka2 Olivier Cristeau3 Y oshie Onishi4 Yutaka Osuga5 1Health Economics and Outcomes  Research, 2Advocacy and External  Affairs, Market Access, Bayer  Yakuhin, Ltd., T okyo, Japan; 3Health  Economics and Outcome Research,  Creativ-Ceutical, Paris, France;   4Creativ-Ceutical K.K., T okyo, Japan;   5Obstetrics and Gynecology, Graduate  School of Medicine, The University of T okyo, T okyo, JapanPurpose: This study aimed to describe treatment patterns and estimate health care resource utili- zation and associated costs among Japanese women with dysmenorrhea, using a claims database.",Non-OADS,/arxiv_data1/oa_pdf/4c/cb/ceor-9-295.PMC5446961.pdf
"4 It has also been reported that one-third of Japanese women require analgesic  therapy for dysmenorrhea.5Correspondence: Erika Tanaka Advocacy and External Affairs, Market Access, Bayer Yakuhin, Ltd., 6-5 Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-8625, JapanEmail erika.tanaka@bayer.comJournal name: ClinicoEconomics and Outcomes Research Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Akiyama et alRunning head recto: Evaluation of the treatment patterns and economic burden of dysmenorrheaDOI: http://dx.doi.org/10.2147/CEOR.S127760",Non-OADS,/arxiv_data1/oa_pdf/4c/cb/ceor-9-295.PMC5446961.pdf
"ClinicoEconomics and Outcomes Research 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinicoeconomics-and-outcomes-research-journalClinicoEconomics and Outcomes Research is an international, peer- reviewed open-access journal focusing on health technology assess-ment, pharmacoeconomics and outcomes research in the areas of   diagnosis, medical devices, and clinical, surgical and pharmacological intervention.",Non-OADS,/arxiv_data1/oa_pdf/4c/cb/ceor-9-295.PMC5446961.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 306 Akiyama et al  9.,Non-OADS,/arxiv_data1/oa_pdf/4c/cb/ceor-9-295.PMC5446961.pdf
Avail- able from: http://www.jaaww.or.jp/index.php.,Non-OADS,/arxiv_data1/oa_pdf/4c/cb/ceor-9-295.PMC5446961.pdf
Available from: http://www.iryohoken.go.jp/shinryohoshu/.,Non-OADS,/arxiv_data1/oa_pdf/4c/cb/ceor-9-295.PMC5446961.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/04/42/ijn-12-3899.PMC5446962.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2017:12 3899–3911International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3899OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S13316 6 aptamer-conjugated Pegylated quantum dots  targeting epidermal growth factor receptor  variant III for fluorescence imaging of glioma Jiaze Tang,1 Ning huang,1  Xiang Zhang,1,2 Tao Zhou,3  Ying Tan,1,4 Jiangli Pi,5 li Pi,1  si cheng,6 huzhi Zheng,5  Yuan cheng1 1Department of Neurosurgery,   The second affiliated hospital  of chongqing Medical University,   2chongqing Key laboratory of  Ultrasound Molecular Imaging,   Institute of Ultrasound Imaging,   3chongqing Key laboratory of  Biochemistry and Molecular  Pharmacology, 4Institute of life  sciences, chongqing Medical  University, 5Key laboratory on  luminescent and real-Time analytical  chemistry, Ministry of education,   college of chemistry and chemical  engineering, southwest University,   6Department of Orthopaedics,   The second affiliated hospital  of chongqing Medical University,   chongqing, People’s republic of chinaAbstract:  The extent of resection is a significant prognostic factor in glioma patients.",Non-OADS,/arxiv_data1/oa_pdf/04/42/ijn-12-3899.PMC5446962.pdf
"Over 90% of  recurrent tumors develop within a 2–3 cm margin of the primary site and are thought  to arise from microscopic glioma cells that infiltrate the area surrounding the original correspondence: Yuan cheng Department of Neurosurgery, The  Second Affiliated Hospital of Chongqing  Medical University, chongqing 400010,  People’s republic of china email chengyuan023@aliyun.co m huzhi Zheng Key laboratory on luminescent and  real-Time analytical chemistry, Ministry  of education, college of chemistry  and chemical engineering, southwest  University, chongqing 400715,  People’s republic of china  email zhenghz@swu.edu.c nJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Tang et al Running head recto: Aptamer-conjugated PEGylated quantum dots for glioma imaging DOI: http://dx.doi.org/10.2147/IJN.S133166",Non-OADS,/arxiv_data1/oa_pdf/04/42/ijn-12-3899.PMC5446962.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/04/42/ijn-12-3899.PMC5446962.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/04/42/ijn-12-3899.PMC5446962.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/2b/d9/copd-12-1507.PMC5446963.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2017:12 1507–1518International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1507OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S13533 8 ampicillin resistance in Haemophilus influenzae   from COPD patients in the UK satyanarayana Maddi1 Umme Kolsum1 sarah Jackson1 richard Barraclough2 Barbara Maschera3 Karen D simpson3 Thierry g Pascal4 serge Durviaux4 edith M hessel3 Dave singh1 1Division of Infection, Immunity and  respiratory Medicine, Medicines  evaluation Unit, University hospital  of south Manchester Foundation  Trust, University of Manchester,   2Department of respiratory  Medicine, University hospital of  south Manchester Foundation Trust,   Manchester, 3refractory respiratory  Inflammation DPU, glaxo smithKline  Medicines research Centre,   stevenage, hertfordshire, UK; 4Clinical  laboratory sciences, glaxosmithKline  Vaccines, Wavre, BelgiumBackground:  Haemophilus influenzae  is commonly isolated from the airways of COPD patients.",Non-OADS,/arxiv_data1/oa_pdf/2b/d9/copd-12-1507.PMC5446963.pdf
"Bacterial infection increases the levels of airway inflammation.2 Haemophilus influenzae  is one of the most commonly isolated bacterial pathogens  from COPD patients.2,4 It can be capsulated or noncapsulated based on the presence Correspondence: Dave singh Medicines evaluation Unit, University  of Manchester, The langley Building,  southmoor road, Wythenshawe,  Manchester M23 9QZ, UK Tel +44 161 946 4073 Fax +44 161 946 1459 email dsingh@meu.org.u k Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Maddi et al Running head recto: Ampicillin resistance in Haemophilus influenzae DOI: http://dx.doi.org/10.2147/COPD.S135338",Non-OADS,/arxiv_data1/oa_pdf/2b/d9/copd-12-1507.PMC5446963.pdf
Allele numbers and ST were assigned  using H. influenzae  MLST website ( http://pubmlst.org/ hinfluenzae /).,OADS,/arxiv_data1/oa_pdf/2b/d9/copd-12-1507.PMC5446963.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/2b/d9/copd-12-1507.PMC5446963.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/2b/d9/copd-12-1507.PMC5446963.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Multidisciplinary Healthcare 2017:10 205–215Journal of Multidisciplinary Healthcare Dovepress submit your manuscript | www.dovepress.com Dovepress 205 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JMDH.S134992Amyotrophic lateral sclerosis: improving care with  a multidisciplinary approach Anne Hogden1 Geraldine Foley2 Robert D Henderson3 Natalie James4 Samar M Aoun5 1Australian Institute of Health  Innovation, Macquarie University,   Sydney, NSW, Australia; 2Discipline  of Occupational Therapy, School of Medicine, Trinity College Dublin, the University of Dublin, Republic of Ireland;  3Neurology, Royal Brisbane  & Women’s Hospital, Brisbane, QLD,   4Motor Neurone Disease (MND)  Service, Communication and Assistive T echnology (CAT) Clinic, St Joseph’s Hospital, St Vincent’s Health Network,  Sydney, NSW,  5School of Nursing,   Midwifery and Paramedicine, Faculty of Health Sciences, Curtin University,  Perth, WA, AustraliaAbstract:  Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease,  leading to death within an average of 2–3 years.",Non-OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
"11,12 However, such work does not illuminate  the wider complexity of processes that underpin service delivery in multidisciplinary Correspondence: Anne Hogden Australian Institute of Health Innovation, Faculty of Medicine and Health Sciences, Level 1, 75 Talavera Rd, Macquarie University, NSW, Australia 2109Tel +61 2 9850 2417Fax +61 2 9850 2499Email anne.hogden@mq.edu.au Journal name: Journal of Multidisciplinary Healthcare Article Designation: REVIEWY ear: 2017V olume: 10Running head verso: Hogden et alRunning head recto: Multidisciplinary care in ALSDOI: http://dx.doi.org/10.2147/JMDH.S134992",Non-OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
Available from: https://www.nice.org.uk/guidance/ng42.,Non-OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
Available from http://www.mndaust.asn.au/Influencing-policy/Economic-analysis-of-MND-(1)/Economic-analysis-of-MND-in-Australia.aspx.,Non-OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
Available from: http://www.mndassociation.org/forprofessionals/information-for-gps/diagnosis-of-mnd/red-flag-diagnosis-tool/.,OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
Available from: http://www.als-centrum.nl/over-het-als-centrum.,Non-OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
"Journal of Multidisciplinary Healthcare 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Multidisciplinary Healthcare Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-multidisciplinary-healthcare-journalThe Journal of Multidisciplinary Healthcare is an international, peer- reviewed open-access journal that aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines.",Non-OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
Visit http://www.dovepress.com/   testimonials.php to read real quotes from published authors.Dovepress 215 Multidisciplinary care in ALS,Non-OADS,/arxiv_data1/oa_pdf/8f/79/jmdh-10-205.PMC5446964.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/7b/43/cmar-9-189.PMC5446965.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/7b/43/cmar-9-189.PMC5446965.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Cancer Management and Research 2017:9 189–196Cancer Management and Research Dovepress submit your manuscript | www.dovepress.com Dovepress  189 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CMAR.S126136Multiple myeloma in Niger Delta, Nigeria:  complications and the outcome of palliative  interventions Ogbonna Collins  Nwabuko1,2  Elizabeth Eneikido Igbigbi3  Innocent Ijezie  Chukwuonye4  Martin Anazodo Nnoli5 1Department of Haematology,   Federal Medical Center, Umuahia,   2Department of Haematology,   College of Health Science, Abia  State University, Aba, Abia State,   3Department of Haematology, Blood  Transfusion and Immunology, Faculty of Basic Medical Sciences, University of Port Harcourt, Port Harcourt,   4Department of Internal Medicine,   Federal Medical Center, Umuahia,   5Department of Anatomic Pathology,   University of Calabar, Calabar, NigeriaBackground: Multiple myeloma (MM) is one of the hematological malignancies that require  palliative care.",Non-OADS,/arxiv_data1/oa_pdf/7b/43/cmar-9-189.PMC5446965.pdf
"It accounts Correspondence: Ogbonna Collins  Nwabuko   Department of Hematology, Federal Medical Center, Aba Road, PMB 7001, Umuahia, Abia State, Nigeria   Tel +234 80 3704 6537   Email ogbollins2002@yahoo.comJournal name: Cancer Management and Research Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Nwabuko et alRunning head recto: Multiple myeloma in Niger Delta, NigeriaDOI: http://dx.doi.org/10.2147/CMAR.S126136",Non-OADS,/arxiv_data1/oa_pdf/7b/43/cmar-9-189.PMC5446965.pdf
Available from: http://seer.cancer.gov/csr/1975_2002/.,Non-OADS,/arxiv_data1/oa_pdf/7b/43/cmar-9-189.PMC5446965.pdf
"Cancer Management and Research 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress Cancer Management and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journalCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/7b/43/cmar-9-189.PMC5446965.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 196 Nwabuko et al 15.,Non-OADS,/arxiv_data1/oa_pdf/7b/43/cmar-9-189.PMC5446965.pdf
Available from http://www.nddc.gov.ng/NDRMP%20Chapter%201.pdf.,OADS,/arxiv_data1/oa_pdf/7b/43/cmar-9-189.PMC5446965.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/a7/b1/ccid-10-199.PMC5446966.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/a7/b1/ccid-10-199.PMC5446966.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical, Cosmetic and Investigational Dermatology 2017:10 199–204Clinical, Cosmetic and Investigational Dermatology Dovepress submit your manuscript | www.dovepress.com Dovepress 199 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S131323 Pollution and acne: is there a link?",Non-OADS,/arxiv_data1/oa_pdf/a7/b1/ccid-10-199.PMC5446966.pdf
"Some anecdotal evidence emerged during an International Dermatology Conference in Beijing, where Correspondence: Sophie Seité La Roche-Posay Dermatological Laboratories, 110 Avenue Henri Barbusse, 92600 Asnières, FranceTel +33 14 688 6544Fax +33 14 688 6688Email sophie.seite@loreal.comJournal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: REVIEWY ear: 2017V olume: 10Running head verso: Krutmann et alRunning head recto: Pollution and acne: a state-of-the-art reviewDOI: http://dx.doi.org/10.2147/CCID.S131323",Non-OADS,/arxiv_data1/oa_pdf/a7/b1/ccid-10-199.PMC5446966.pdf
"Clinical, Cosmetic and Investigational Dermatology 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal Clinical, Cosmetic and Investigational Dermatology is an interna- tional, peer-reviewed, open access, online journal that focuses on   the latest clinical and experimental research in all aspects of skin   disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/a7/b1/ccid-10-199.PMC5446966.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authorsDovepress 204 Krutmann et al,Non-OADS,/arxiv_data1/oa_pdf/a7/b1/ccid-10-199.PMC5446966.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/47/cb/amep-8-337.PMC5446967.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/47/cb/amep-8-337.PMC5446967.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2017:8 337–345Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 337 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S135172 Innovative curriculum for second-year  Harvard-MIT medical students: practicing  communication skills with volunteer patients  giving immediate feedback Nadaa B Ali1 Stephen R Pelletier2 Helen M Shields1 1Department of Medicine, Brigham  and Women’s Hospital, 2Center for  Evaluation, Harvard Medical School,   Boston, MA, USAPurpose: Medical students are expected to develop excellent communication skills.",Non-OADS,/arxiv_data1/oa_pdf/47/cb/amep-8-337.PMC5446967.pdf
"2 However, studies have shown that good communication Correspondence: Nadaa B Ali Department of Medicine, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USATel +1 617 732 6047Email nbali@bwh.harvard.eduJournal name: Advances in Medical Education and Practice Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 8Running head verso: Ali et alRunning head recto: Communication skills practice for medical studentsDOI: http://dx.doi.org/10.2147/AMEP .S135172",Non-OADS,/arxiv_data1/oa_pdf/47/cb/amep-8-337.PMC5446967.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/47/cb/amep-8-337.PMC5446967.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2017:8submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 345 Communication skills practice for medical students  26.,Non-OADS,/arxiv_data1/oa_pdf/47/cb/amep-8-337.PMC5446967.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/c9/94/amep-8-347.PMC5446968.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/c9/94/amep-8-347.PMC5446968.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2017:8 347–351Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 347 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S133681 Medicons: toward clinical examination diagrams  standardization in medical documentation Georgios Pafitanis1 Michalis Hadjiandreou2 Leo Withers1 Helen Dent3 1The Royal London Hospital,    Barts Health NHS Trust, London, UK;    2Barts and the London School of  Medicine and Dentistry, London, UK;   3St Richard’s Hospital, Chichester, UKBackground: Electronic patient records (EPRs) allow efficient and accurate medical documen- tation.",Non-OADS,/arxiv_data1/oa_pdf/c9/94/amep-8-347.PMC5446968.pdf
"4–9 The introduction  of EPRs provides an exciting opportunity to standardize the commonly used method Correspondence: Georgios Pafitanis The Royal London Hospital, Barts Health NHS Trust, 4 Newark Street, Whitechapel, London E12AT, UKEmail g.pafitanis@qmul.ac.ukJournal name: Advances in Medical Education and Practice Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 8Running head verso: Pafitanis et alRunning head recto: Digitalization of hand-drawn clinical examination diagrams – MediconsDOI: http://dx.doi.org/10.2147/AMEP .S133681",Non-OADS,/arxiv_data1/oa_pdf/c9/94/amep-8-347.PMC5446968.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/c9/94/amep-8-347.PMC5446968.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2017:8submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 351 Digitalization of hand-drawn clinical examination diagrams – Medicons  2.,Non-OADS,/arxiv_data1/oa_pdf/c9/94/amep-8-347.PMC5446968.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/50/93/ijn-12-3865.PMC5446969.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2017:12 3865–3879International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3865OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S13271 9 aTP synthesis in the energy metabolism pathway:  a new perspective for manipulating cdse quantum  dots biosynthesized in Saccharomyces cerevisiae rong Zhang1–3 Ming shao1–3 Xu han1–3 chuan Wang3–4 Y ong li3–4 Bin hu3–4 Daiwen Pang3–4 Zhixiong Xie1–3 1hubei Key laboratory of cell  homeostasis, 2college of life  sciences, Wuhan University, 3Key  laboratory of analytical chemistry  for Biology and Medicine (Ministry of  education), 4college of chemistry and  Molecular science, Wuhan University,   Wuhan, People’s republic of chinaAbstract:  Due to a growing trend in their biomedical application, biosynthesized nanomaterials  are of great interest to researchers nowadays with their biocompatible, low-energy consump - tion, economic, and tunable characteristics.",Non-OADS,/arxiv_data1/oa_pdf/50/93/ijn-12-3865.PMC5446969.pdf
"There have been many investigations on the biosynthesis of nanomaterials,  mainly concerning their applications.21 In order to obtain nanoparticles with a defined  expectation in the biosynthesis, whether through optimizing the culture conditions  or adjusting the concentrations of primary substrates, former studies were devoted correspondence: Zhixiong Xie college of life sciences, Wuhan  University, 299 Bayi road, Wuhan  430072, People’s republic of china Tel +86 27 6875 2090 Fax +86 27 6875 2560 email zxxie@whu.edu.c n Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Zhang et al Running head recto: ATP synthesis manipulates CdSe QDs biosynthesis in yeast DOI: http://dx.doi.org/10.2147/IJN.S132719",Non-OADS,/arxiv_data1/oa_pdf/50/93/ijn-12-3865.PMC5446969.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/50/93/ijn-12-3865.PMC5446969.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/50/93/ijn-12-3865.PMC5446969.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/47/7b/cia-12-847.PMC5446970.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2017:12 847–858Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  847OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S13476 0 effects of a giant exercising board game  intervention on ambulatory physical activity  among nursing home residents: a preliminary study Alexandre Mouton,1 nicolas  gillet,1 Flore Mouton,1 Dave  Van Kann,2,3 Olivier Bruyère,1,4  Marc Cloes,1 Fanny Buckinx4 1Department of sport and rehabilitation  sciences, Multidisciplinary research Unit  on health and society, University of liège,   liège, Belgium; 2Department of health  Promotion, Maastricht University Medical  Center (MUMC +), Maastricht, 3school of  sport studies, Fontys University of Applied  sciences, eindhoven, the netherlands;   4Department of Public health, epidemiology  and health economics, University of liège  T eaching hospital (ChU), liège, BelgiumPurpose:  This study examined the effects of a giant (4 ×3 m) exercising board game intervention  on ambulatory physical activity (PA) and a broader array of physical and psychological outcomes  among nursing home residents.",Non-OADS,/arxiv_data1/oa_pdf/47/7b/cia-12-847.PMC5446970.pdf
"Keywords:  exercise, nursing home, elderly, ambulatory physical activity, autonomy, game Background The majority of nursing home residents are physically inactive.1,2 In the existing  literature, physical activity (PA) levels among nursing home residents are much lower  than existing recommended levels, which advocate a minimum of 3,000 steps/day.3,4  Most of their time is spent sleeping, doing nothing or watching TV in a lying or sit - ting position.5 Therefore, this population is among the most sedentary segment of the  society, with an increased risk of physical and neurocognitive impairment leading to  frailty and increased mortality.6–9 Promoting regular PA is considered to be an effective Correspondence: Alexandre Mouton Department of sports sciences, University of  liège, Blanc gravier, Allée des sports, 4, 4000  liège, Belgium Tel +32 4366 3896 Fax +32 4366 2901 email alexandre.mouton@ulg.ac.b e Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Mouton et al Running head recto: Exercising board game intervention among nursing home residents DOI: http://dx.doi.org/10.2147/CIA.S134760 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/47/7b/cia-12-847.PMC5446970.pdf
Or use: http://youtu.be/O5RIPpfcyJ U Video abstract,Non-OADS,/arxiv_data1/oa_pdf/47/7b/cia-12-847.PMC5446970.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/47/7b/cia-12-847.PMC5446970.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/47/7b/cia-12-847.PMC5446970.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).ClinicoEconomics and Outcomes Research 2017:9 281–293ClinicoEconomics and Outcomes Research Dovepress submit your manuscript | www.dovepress.com Dovepress  281 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEOR.S129859Cost per care of the first year of direct antiviral  agents in the Liguria Region: a multicenter analysis Giovanni Cenderello1 Caterina Fanizza2 Simona Marenco3 Laura Ambra Nicolini4 Stefania Artioli5 Isabella Baldissarro3 Chiara Dentone6 Pasqualina De Leo7 Antonio Di Biagio4 1SC Malattie Infettive, EO Ospedali  Galliera, 2Rete ligure HIV, 3SSD  Epatologia, AOU S. Martino, 4Clinica  Malattie Infettive, AOU S. Martino,   Genoa, 5SC Malattie Infettive ASL5  La Spezia, 6SC Malattie Infettive,   ASL‑1, Sanremo, 7SC Malattie Infettive  ASL2, San Paolo, Savona, ItalyAims:  Despite the remarkable efficacy shown in clinical practice, concerns have been raised  about the costs associated with direct antiviral agent (DAA) therapy.",Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
"To this end, antiviral Correspondence: Giovanni Cenderello SC Malattie Infettive, EO Ospedali Galliera, Via volta 8, 16128 Genoa, ItalyTel +39 010 563 4475Fax +39 010 5748 1295Email giovanni.cenderello@galliera.itJournal name: ClinicoEconomics and Outcomes Research Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Cenderello et alRunning head recto: Cost per care of DAAs in LinguriaDOI: http://dx.doi.org/10.2147/CEOR.S129859",Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Available from:  http://espresso.repubblica.it/visioni/scienze/2015/02/27/news/quel- farmaco-costa-troppo-1.201536.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Avail - able from: http://www.salute.regione.emilia-romagna.it/documenti.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Available from: http://salute.regione.emilia-romagna.it/documentazi-one/ptr/ptr/archivio/PTR_229_maggio_2015.pdf.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Available from: http://salute.regione.emilia-romagna.it/documentazione/ptr/ptr/archivio/229_nuovi-antivirali-epatiteC-luglio-2015.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Documento di indirizzo per la definizione delle strategie terapeutiche da applicare sul breve termine per “Nuovi antivirali diretti nella tera-pia dell’epatite C cronica” aggiornamento Dicembre 2015 Available from: http://salute.regione.emilia-romagna.it/documentazione/ptr/ptr/archivio/229_nuovi-antivirali-epatiteC-dicembre-2015.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1094_allegato.pdf.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Available from: http://salute.regione.emilia-romagna.it/documentazione/ptr/elaborati/229-epatite-c-cronica-settembre-2016.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Available from: http://www.quadernidifarmacoeconomia.com/component/content/article/118-archivio-qf-preview/611-qf10.html.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
"ClinicoEconomics and Outcomes Research 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinicoeconomics‑and‑outcomes‑research‑journalClinicoEconomics and Outcomes Research is an international, peer- reviewed open-access journal focusing on health technology assess-ment, pharmacoeconomics and outcomes research in the areas of   diagnosis, medical devices, and clinical, surgical and pharmacological intervention.",Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 293 Cost per care of DAAs in Linguria Table S7 Correlates of the total cost: results of multivariate analyses Variables b 95% CI p-value HCV treatment PTVr/OBV+DSV+RBV – – – PTVr/OBV+DSV 1,863 −752; 4,477 0.16 PTVr/OBV+RBV −2,222 −4,980; 536 0.11 SOF+DCV 29,988 26,724; 33,253 <0.0001 SOF+DCV+RBV 31,922 29,161; 34,683 <0.0001 SOF+LDP 16,392 14,277; 18,506 <0.0001 SOF+LDP+RBV 16,954 15,537; 18,372 <0.0001 SOF+RBV 10,091 6,754; 13,429 <0.0001 SOF+SIM 30,481 28,415; 32,546 <0.0001 SOF+SIM+RBV 30,173 28,365; 31,981 <0.0001 Gender (female vs male) −510 −1,405; 386 0.26 Fibrosis grade  1 – – –  2 2,422 −2,067; 6,912 0.29  3 2,152 −1,435; 5,738 0.24  4 1,825 −1,772; 5,422 0.32 Genotype 1 – – –  2 2,563 −583; 5,708 0.11  3 749 −1,891; 3,389 0.58  4 573 −787; 1,932 0.41 Comorbidites (yes vs no) 623 −201; 1,446 0.14 Prior anti-HCV treatment (yes vs no) 712 −100; 1,525 0.09 Time start treatment −4,726 −5,682; −3,769 <0.0001 Abbreviations:  CI, confidence interval; DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; LDP, ledipasvir; OBV, ombitasvir; PTVr, ritonavir boosted  paritaprevir;  RBV, ribavirin; SIM, simeprevir; SOF,  sofosbuvir.",Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
Available from: http://www.webaisf.org/pubblicazioni/documento-aisf-hcv-2016.aspx.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/ceor-9-281.PMC5446971.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/84/48/ijn-12-3881.PMC5446972.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2017:12 3881–3898International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3881OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S13190 1 capsaicin-loaded nanolipoidal carriers for topical  application: design, characterization, and in vitro/ in vivo evaluation Xia-rong Wang1 si-Qian gao1 Xiao-Qian Niu1 long-Jian li2 Xiao-Ying Ying1 Zhong-Jie hu2 Jian-Qing gao1,3 1Institute of Pharmaceutics, college  of Pharmaceutical sciences, Zhejiang  University, hangzhou, 2Zhejiang  Provincial corps hospital of  chinese People’s armed Police  Forces, Jiaxing, Zhejiang, 3Jiangsu  engineering research center for  New-Type external and Transdermal  Preparations, Jiangsu, People’s  republic of chinaAbstract:  Capsaicin has been used in clinical applications for the treatment of pain disorders  and inflammatory diseases.",Non-OADS,/arxiv_data1/oa_pdf/84/48/ijn-12-3881.PMC5446972.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/84/48/ijn-12-3881.PMC5446972.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/84/48/ijn-12-3881.PMC5446972.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/41/1f/bctt-9-347.PMC5446973.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/41/1f/bctt-9-347.PMC5446973.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Breast Cancer - Targets and Therapy 2017:9 347–357Breast Cancer - Targets and Therapy Dovepress submit your manuscript | www.dovepress.com Dovepress 347 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/BCTT .S135371 Natural and synthetic progestins enrich cancer  stem cell-like cells in hormone-responsive human  breast cancer cell populations in vitro Sandy Goyette1,2 Yayun Liang1,2 Benford Mafuvadze1,2 Matthew T Cook1,2 Moiz Munir1,2 Salman M Hyder1,2 1Department of Biomedical Sciences,   2Dalton Cardiovascular Research  Center, University of Missouri,   Columbia, MO, USAAbstract:  Clinical trials and studies have shown that combination estrogen/progestin hormone  replacement therapy, but not estrogen therapy alone or placebo, increases breast cancer risk in  postmenopausal women.",Non-OADS,/arxiv_data1/oa_pdf/41/1f/bctt-9-347.PMC5446973.pdf
"6 Unfortunately, clinical Correspondence: Salman M Hyder Department of Biomedical Sciences, Dalton Cardiovascular Research Center, University of Missouri, 134 Research Park Drive, Columbia, MO 65211, USATel +1 573 882 1266Fax +1 573 884 4232Email hyders@missouri.eduJournal name: Breast Cancer - Targets and Therapy Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Goyette et alRunning head recto: Progestins enrich cancer stem cell-like population of breast cancer cellsDOI: http://dx.doi.org/10.2147/BCTT.S135371",Non-OADS,/arxiv_data1/oa_pdf/41/1f/bctt-9-347.PMC5446973.pdf
"Breast Cancer - Targets and Therapy 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress Breast Cancer - Targets and Therapy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/breast-cancer---targets-and-therapy-journal Breast Cancer - Targets and Therapy is an international, peer-   reviewed open access journal focusing on breast cancer research,  identification of therapeutic targets and the optimal use of preven-tative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/41/1f/bctt-9-347.PMC5446973.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 357 Progestins enrich cancer stem cell-like population of breast cancer cells 22.,Non-OADS,/arxiv_data1/oa_pdf/41/1f/bctt-9-347.PMC5446973.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/81/23/ijgm-10-151.PMC5446974.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/81/23/ijgm-10-151.PMC5446974.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Journal of General Medicine 2017:10 151–159International Journal of General Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress 151 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJGM.S129710The impact of internet-based cognitive behavior  therapy on work ability in patients with  depression – a randomized controlled study Dominique Hange1 Nashmil Ariai1 Marie Kivi2 Maria CM Eriksson1 Shabnam Nejati1 Eva-Lisa Petersson1,3 1Department of Public Health  and Community Medicine/ Primary Health Care, Sahlgrenska Academy, University of Gothenburg,   Gothenburg, Sweden;  2Department of  Psychology, University of Gothenburg,  Gothenburg, Sweden;  3Narhalsan  Research and Development Primary Health Care, Region Vastra Gotaland,  Gothenburg, SwedenObjectives:  The aim of this randomized controlled trial (RCT) was to investigate the effects  of internet-based cognitive behavior therapy (ICBT) treatment for depression compared to  treatment-as-usual (TAU) on improving work ability and quality of life in patients with mild- to-moderate depression.",Non-OADS,/arxiv_data1/oa_pdf/81/23/ijgm-10-151.PMC5446974.pdf
"4–6 Depression is more related to poor work performance than Correspondence: Dominique Hange Department of Public Health and Community Medicine/Primary Health Care, University of Gothenburg,   PO Box 454, SE 405 30, Gothenburg, SwedenTel +46 31 773 6849Fax +46 31 778 1704Email dominique.hange@vgregion.seJournal name: International Journal of General Medicine Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Hange et alRunning head recto: Impact of internet-based cognitive behavior therapy on work abilityDOI: http://dx.doi.org/10.2147/IJGM.S129710",Non-OADS,/arxiv_data1/oa_pdf/81/23/ijgm-10-151.PMC5446974.pdf
"International Journal of General Medicine 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress International Journal of General Medicine Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/international-journal-of-general-medicine-journalThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/81/23/ijgm-10-151.PMC5446974.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 159 Impact of internet-based cognitive behavior therapy on work ability,Non-OADS,/arxiv_data1/oa_pdf/81/23/ijgm-10-151.PMC5446974.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fb/58/dddt-11-1567.PMC5446975.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 1567–1583Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1567Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S13345 3 Past and current perspective on new therapeutic  targets for Type-ii diabetes Pradip D Patil1,* Umesh B Mahajan1,* Kalpesh R Patil2,* Sandip Chaudhari1 Chandragouda R Patil1 Y ogeeta O Agrawal3 Shreesh Ojha4 Sameer N Goyal1 1Department of Pharmacology,   R. C. Patel institute of Pharmaceutical  education and Research, 2Department  of Pharmacology, H. R. Patel institute  of Pharmaceutical education  and Research, 3Department of  Pharmaceutics and Quality Assurance,   R. C. Patel institute of Pharmaceutical  education and Research, Shirpur,   Dhule, Maharashtra, india;   4Department of Pharmacology and  Therapeutics, College of Medicine and  Health Sciences, United Arab emirates  University, Abu Dhabi, UAe *These authors contributed equally  to this workAbstract:  Loss of pancreatic β-cell function is a hallmark of Type-II diabetes mellitus (DM).",Non-OADS,/arxiv_data1/oa_pdf/fb/58/dddt-11-1567.PMC5446975.pdf
"Activation of advanced glycation end products, stimulation Correspondence: Sameer N Goyal Department of Pharmacology, R. C. Patel  institute of Pharmaceutical education and  Research, Karwand Naka, Shirpur, Dhule,  Maharashtra, india 425 405 Tel +91 025 6325 5189 Fax +91 025 6325 1808 email goyal.aiims@gmail.co m  Shreesh Ojha Department of Pharmacology and  Therapeutics, College of Medicine and  Health Sciences, United Arab emirates,  University, PO Box 17666, Al Ain,  Abu Dhabi, UAe Tel +971 3 137 524 Fax +971 3 767 2033 email shreeshojha@uaeu.ac.a e Journal name: Drug Design, Development and Therapy Article Designation: Review Y ear: 2017 Volume: 11 Running head verso: Patil et al Running head recto: New therapeutic targets for Type-II diabetes DOI: http://dx.doi.org/10.2147/DDDT.S133453",Non-OADS,/arxiv_data1/oa_pdf/fb/58/dddt-11-1567.PMC5446975.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/fb/58/dddt-11-1567.PMC5446975.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/fb/58/dddt-11-1567.PMC5446975.pdf
"MeSH Keywords:  Pulmonary Embolism • Recurrence • Risk Factors • Venous Thrombosis  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/901924Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Surgery, Clinical Research, Trauma Surgery Section, Hamad  General Hospital, Doha, Qatar 2 Department of Vascular Surgery, Hamad General Hospital, Doha, Qatar 3 Department of Clinical Medicine, Weill Cornell Medical College, Doha, Qatar 4 Cardiology Unit, Internal Medicine, Ahmed Maher Teaching Hospital, Cairo, Egypte-ISSN 1643-3750 © Med Sci Monit, 2017; 23: 2391-2399 DOI: 10.12659/MSM.901924 2391 Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]   [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]   [Chemical Abstracts/CAS] [Index Copernicus]CLINICAL RESEARCH This work is licensed under Creative Common Attribution- NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/1d/ec/medscimonit-23-2391.PMC5446976.pdf
"MeSH Keywords:  Apoptosis • Carcinoma, Squamous Cell • Cell Migration Assays • Cell Proliferation  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/903380Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Thoracic Surgery, The First Affiliated Hospital of Xinjiang Medical  University, Urumqi, Xinjiang, P.R.",Non-OADS,/arxiv_data1/oa_pdf/f3/ee/medscimonit-23-2382.PMC5446977.pdf
"As Allen could  not disclose his status as a missionary openly, he worked as a  physician affiliated in the U.S. legation on the surface, taking  care of foreigners living in Joseon.Allen (Horace N. Allen, 安連 , 1858 –1932) In-Sok Yeo1 and Do Heum Yoon2  Departments of 1Medical History and 2Neurosurgery, Yonsei University College of Medicine, Seoul, Korea.Yonsei Med J 2017 Jul;58(4):685-688 https://doi.org/10.3349/ymj.2017.58.4.685Editorial pISSN: 0513-5796 · eISSN: 1976-2437 Received:  April 18, 2017 Corresponding author:  Dr. Do Heum Yoon, Department of Neurosurgery, Yonsei  University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.",Non-OADS,/arxiv_data1/oa_pdf/c3/3e/ymj-58-685.PMC5447096.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Editorial Series: Frontiers of Medicine in Korea",Non-OADS,/arxiv_data1/oa_pdf/c3/3e/ymj-58-685.PMC5447096.pdf
"686 Allen (Horace N. Allen, 安連 , 1858–1932) https://doi.org/10.3349/ymj.2017.58.4.685Due to the situation of Joseon in which missionary activities  were not free, he had difficulty in performing as a missionary  actively.",Non-OADS,/arxiv_data1/oa_pdf/c3/3e/ymj-58-685.PMC5447096.pdf
687In-Sok Yeo and Do Heum Yoon https://doi.org/10.3349/ymj.2017.58.4.685Confucian customs regarding distinction between the sexes.,Non-OADS,/arxiv_data1/oa_pdf/c3/3e/ymj-58-685.PMC5447096.pdf
"688 Allen (Horace N. Allen, 安連 , 1858–1932) https://doi.org/10.3349/ymj.2017.58.4.685Concluding remarks At the end of 19th century, Allen appeared in the modern histo - ry in Korea and performed various roles as a missionary, phy - sician, and diplomat in this land.",Non-OADS,/arxiv_data1/oa_pdf/c3/3e/ymj-58-685.PMC5447096.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):689-696 https://doi.org/10.3349/ymj.2017.58.4.689",Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
"690Alcohol, ALDH2, and Cardiovascular Health https://doi.org/10.3349/ymj.2017.58.4.689incidence of alcohol-related accidents.",Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
https://doi.org/10.3349/ymj.2017.58.4.689the ADH1B*47Arg  allele and the susceptible ALDH2*487Glu  al- lele at either loci had 11 times greater risk for alcoholism.,Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
"692Alcohol, ALDH2, and Cardiovascular Health https://doi.org/10.3349/ymj.2017.58.4.689individuals after alcohol consumption relative to those with  the ALDH2*1/*1 genotype.",Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
https://doi.org/10.3349/ymj.2017.58.4.689Table 1.,Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
Papers included  in Table 1 were collected from MEDLINE (http://www.ncbi.nlm.nih.gov/PubMed) using the following keywords: “Aldehyde dehydrogenase 2” and “ALDH2” in  combination with “Mendelian randomization” and “alcohol.” The abstracts of the collected articles were scanned for inclusion of any cardiovascular-related  outcomes of interest.,OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
"694Alcohol, ALDH2, and Cardiovascular Health https://doi.org/10.3349/ymj.2017.58.4.689elevated risk for cancer with the same amount of alcohol.8 In  support of this, an animal study demonstrated that maternal  deficiency in ALDH2 due to the ALDH2*2  allele resulted in ex - tensive developmental malformations, particularly in cases of  alcohol consumption during pregnancy.",Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
https://doi.org/10.3349/ymj.2017.58.4.689lian randomisation analysis based on individual participant data.,OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
Available at: http://monographs.iarc.fr/ENG/Classification/Clas - sificationsAlphaOrder.pdf.,OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
"696Alcohol, ALDH2, and Cardiovascular Health https://doi.org/10.3349/ymj.2017.58.4.68957.",Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
https://doi.org/10.1093/ije/dyw237.,Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
https://doi.org/10.1093/ije/ dyw327.,Non-OADS,/arxiv_data1/oa_pdf/1b/5d/ymj-58-689.PMC5447097.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):697-702 https://doi.org/10.3349/ymj.2017.58.4.697",Non-OADS,/arxiv_data1/oa_pdf/92/c7/ymj-58-697.PMC5447098.pdf
"698MicroRNA-34c in Triple-Negative Breast Cancer https://doi.org/10.3349/ymj.2017.58.4.697many aspects of cancer biology, including invasion, metasta - sis, proliferation, cell survival, apoptosis, cell growth, cell cycle,  migration, senescence, angiogenesis, and silencing, by regu - lating the expression of their target genes.5-7 However, most of  these studies are tissue- and cell-based miR-34 family expres - sions.",Non-OADS,/arxiv_data1/oa_pdf/92/c7/ymj-58-697.PMC5447098.pdf
https://doi.org/10.3349/ymj.2017.58.4.697ed into high (n=87) and low (n=86) expression groups by the  median value of miR-34a/b/c.,OADS,/arxiv_data1/oa_pdf/92/c7/ymj-58-697.PMC5447098.pdf
700MicroRNA-34c in Triple-Negative Breast Cancer https://doi.org/10.3349/ymj.2017.58.4.697strate the correlation between miR-34 family expressions and  OS.,Non-OADS,/arxiv_data1/oa_pdf/92/c7/ymj-58-697.PMC5447098.pdf
https://doi.org/10.3349/ymj.2017.58.4.697DISCUSSION This publication was designed to study the relationship of cir - culating miR-34 family expressions with prognosis in TNBC  patients and to evaluate its possibility of becoming a novel non - invasive prognostic biomarker.,Non-OADS,/arxiv_data1/oa_pdf/92/c7/ymj-58-697.PMC5447098.pdf
"702MicroRNA-34c in Triple-Negative Breast Cancer https://doi.org/10.3349/ymj.2017.58.4.697sive breast tumor phenotype,13 and low expression of miR-34a  suppressed breast cancer cells to proliferate.14 As for circulating  miR-34a, a previous study showed it was significantly reduced  in breast cancer without association with stage or grade of tu - mors.15 However, our results showed downregulation of miR- 34a to be associated with worse tumor grade.",Non-OADS,/arxiv_data1/oa_pdf/92/c7/ymj-58-697.PMC5447098.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fb/60/ymj-58-703.PMC5447099.pdf
Yonsei Med J 2017 Jul;58(4):703-709 https://doi.org/10.3349/ymj.2017.58.4.703,Non-OADS,/arxiv_data1/oa_pdf/fb/60/ymj-58-703.PMC5447099.pdf
704Cardiac Resynchronization Therapy for Pacing-Induced Cardiomyopathy https://doi.org/10.3349/ymj.2017.58.4.703in patients with PiCM (upgrade CRT for PiCM) than in those  without PiCM (upgrade CRT for non-PiCM) or those treated by  de novo  implantation ( de novo  CRT).,Non-OADS,/arxiv_data1/oa_pdf/fb/60/ymj-58-703.PMC5447099.pdf
https://doi.org/10.3349/ymj.2017.58.4.703RESULTS Patients and baseline characteristics We identified 82 patients who underwent a CRT procedure dur -ing the enrollment period.,Non-OADS,/arxiv_data1/oa_pdf/fb/60/ymj-58-703.PMC5447099.pdf
706Cardiac Resynchronization Therapy for Pacing-Induced Cardiomyopathy https://doi.org/10.3349/ymj.2017.58.4.703more frequent in the upgrade groups.,Non-OADS,/arxiv_data1/oa_pdf/fb/60/ymj-58-703.PMC5447099.pdf
"https://doi.org/10.3349/ymj.2017.58.4.703ratio 10.4, 95% confidence interval 1.08 –99.4, p=0.043) (Table 3).",OADS,/arxiv_data1/oa_pdf/fb/60/ymj-58-703.PMC5447099.pdf
"708Cardiac Resynchronization Therapy for Pacing-Induced Cardiomyopathy https://doi.org/10.3349/ymj.2017.58.4.703a prospective observational study including 135 CRT cases,  the authors showed that upgrade CRT had more favorable out - comes than de novo  CRT over a period of 4 years in terms of  death, heart transplantation, or LV assist devices.15 However, no  significant differences were observed in functional class change,  QRS narrowing, and mortality at 1-year follow-up in the Euro - pean CRT Survey, which compared 692 cases of upgrade CRT  against 1675 of de novo  CRT.14 This conflicting data might re - sult from the fact none of the previous researchers specified  the efficacy of upgrade CRT according to initial pre-PPM LV  systolic function.",Non-OADS,/arxiv_data1/oa_pdf/fb/60/ymj-58-703.PMC5447099.pdf
https://doi.org/10.3349/ymj.2017.58.4.7039.,Non-OADS,/arxiv_data1/oa_pdf/fb/60/ymj-58-703.PMC5447099.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):710-719 https://doi.org/10.3349/ymj.2017.58.4.710",Non-OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
"https://doi.org/10.3349/ymj.2017.58.4.710INTRODUCTION Prompt reperfusion therapy, including percutaneous coronary  intervention (PCI) and fibrinolytic therapy in patients with ST- segment elevation myocardial infarction (STEMI) is very im - portant.",Non-OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
712Gender Differences of Prehospital Delay in STEMI Patients https://doi.org/10.3349/ymj.2017.58.4.710Table 1.,Non-OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
"https://doi.org/10.3349/ymj.2017.58.4.710were asked about the following symptoms, consisting of 5 di - chotomous Yes/No items: chest pain, radiating pain, dyspnea,  sweating, and weakness/dizziness.",Non-OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
714Gender Differences of Prehospital Delay in STEMI Patients https://doi.org/10.3349/ymj.2017.58.4.710Factors associated with a prolonged delay in deciding  to seek medical assistance at a hospital Factors that led to the decision to seek medical assistance at a hospital were separately analyzed for male and female patients  using univariate and multivariate logistic regression.,OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
"https://doi.org/10.3349/ymj.2017.58.4.710ous CVD and PCI, symptoms onset time, knowledge of disease  and symptoms for AMI, and major symptoms), the OR for a  delay ≥60 minutes in deciding to seek medical assistance at a  hospital increased to 33.28 (95% CI, 3.78–293.04) in female pa - tients with low education (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
716Gender Differences of Prehospital Delay in STEMI Patients https://doi.org/10.3349/ymj.2017.58.4.710pital and receive treatment as soon as possible after symptom  onset.,Non-OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
"https://doi.org/10.3349/ymj.2017.58.4.710vious studies,7,10,27,36,42 which reported that the arrival and treat - ment delay times are prolonged when patients visit other hospitals  that are unable to treat their conditions.",Non-OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
718Gender Differences of Prehospital Delay in STEMI Patients https://doi.org/10.3349/ymj.2017.58.4.7106.,Non-OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
https://doi.org/10.3349/ymj.2017.58.4.710diovasc Nurs 2016;31:142-50.,OADS,/arxiv_data1/oa_pdf/e3/05/ymj-58-710.PMC5447100.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
Yonsei Med J 2017 Jul;58(4):720-730 https://doi.org/10.3349/ymj.2017.58.4.720,Non-OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
https://doi.org/10.3349/ymj.2017.58.4.720coronary intervention (PCI) is restenosis.,Non-OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
722Routine CAG Follow-Up vs. Clinical Follow-Up in AMI https://doi.org/10.3349/ymj.2017.58.4.720center participated in our registry.,OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
"https://doi.org/10.3349/ymj.2017.58.4.720ables that could be of potential relevance: sex (men), age, left  ventricular ejection fraction, STEMI, cardiogenic shock, cardio - vascular diseases risk factors [hypertension, diabetes, dyslipid - emia, chronic kidney disease, cerebrovascular accident (CVA), peripheral vascular disease (PVD), history of coronary artery  disease, current smokers, and current alcoholics], laboratory  findings [hemoglobin, CK-MB, troponin-T, high sensitivity C- reactive protein (hs-CRP), lipid profiles, fasting serum glucose,  Table 1.",Non-OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
"724Routine CAG Follow-Up vs. Clinical Follow-Up in AMI https://doi.org/10.3349/ymj.2017.58.4.720hemoglobin A1c and serum creatinine], number of target ves - sels, number of diseased vessels, total number of stent per pa - tient, American College of Cardiology (ACC)/American Heart Association (AHA) B1/B2/C lesions, type of DES, and post-PCI  medications (aspirin, clopidogrel, cilostazol, prasugrel, BB, CCB,  ACEI, ARB, diuretics, lipid lowering agents, and proton pump  Table 2.",Non-OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
https://doi.org/10.3349/ymj.2017.58.4.720inhibitors).,Non-OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
"726Routine CAG Follow-Up vs. Clinical Follow-Up in AMI https://doi.org/10.3349/ymj.2017.58.4.720mean age (mean±SD) of the RAF group was 59.8±11.5 years, and  that of the CF group was 63.6±12.7 years ( p<0.001).",OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
https://doi.org/10.3349/ymj.2017.58.4.720We deemed that RAF may have no beneficial effects and could  potentially be harmful.,Non-OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
728Routine CAG Follow-Up vs. Clinical Follow-Up in AMI https://doi.org/10.3349/ymj.2017.58.4.720cases occurred after one year (after the nested control period).,OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
https://doi.org/10.3349/ymj.2017.58.4.720ysis also showed cardiac death and MI at 3-years to not signif - icantly differ between the two groups (Fig.,Non-OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
"730Routine CAG Follow-Up vs. Clinical Follow-Up in AMI https://doi.org/10.3349/ymj.2017.58.4.720JW, van’t Veer M, et al.",OADS,/arxiv_data1/oa_pdf/d1/e1/ymj-58-720.PMC5447101.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):731-736 https://doi.org/10.3349/ymj.2017.58.4.731",Non-OADS,/arxiv_data1/oa_pdf/37/64/ymj-58-731.PMC5447102.pdf
"732Sex Hormone-Binding Globulin, Alanine Aminotransferase, and Hepatic Steatosis https://doi.org/10.3349/ymj.2017.58.4.731This study aimed to investigate the association between  SHBG and hepatocyte damage represented by ALT among Ko - rean male patients with hepatic steatosis, enrolled in a health  examination program.",Non-OADS,/arxiv_data1/oa_pdf/37/64/ymj-58-731.PMC5447102.pdf
https://doi.org/10.3349/ymj.2017.58.4.731Multivariate logistic regression models were used to evalu - ate the relationship between hepatic steatosis and elevated  ALT levels with the risk of low SHBG levels (Table 3).,OADS,/arxiv_data1/oa_pdf/37/64/ymj-58-731.PMC5447102.pdf
"734Sex Hormone-Binding Globulin, Alanine Aminotransferase, and Hepatic Steatosis https://doi.org/10.3349/ymj.2017.58.4.731of BMI and metabolic profiles.",Non-OADS,/arxiv_data1/oa_pdf/37/64/ymj-58-731.PMC5447102.pdf
https://doi.org/10.3349/ymj.2017.58.4.731sonography is a non-invasive and preferred modality for mass  screening for hepatic steatosis with a reasonable sensitivity  and specificity.,Non-OADS,/arxiv_data1/oa_pdf/37/64/ymj-58-731.PMC5447102.pdf
"736Sex Hormone-Binding Globulin, Alanine Aminotransferase, and Hepatic Steatosis https://doi.org/10.3349/ymj.2017.58.4.73127.",Non-OADS,/arxiv_data1/oa_pdf/37/64/ymj-58-731.PMC5447102.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):737-742 https://doi.org/10.3349/ymj.2017.58.4.737",Non-OADS,/arxiv_data1/oa_pdf/e0/17/ymj-58-737.PMC5447103.pdf
"738Surgical Resection for BCLC B HCC https://doi.org/10.3349/ymj.2017.58.4.737transarterial chemoembolization (TACE) as the main treatment  option.4 A previous study showed that TACE provided a better  2-year survival rate than supportive treatment;12 however, it is  unclear whether TACE provides any long-term survival benefit.",Non-OADS,/arxiv_data1/oa_pdf/e0/17/ymj-58-737.PMC5447103.pdf
739Suk-Won Suh and Yoo Shin Choi https://doi.org/10.3349/ymj.2017.58.4.737Hepatic arterial angiography was performed using fluoroscopy  to guide the catheter into the celiac artery.,OADS,/arxiv_data1/oa_pdf/e0/17/ymj-58-737.PMC5447103.pdf
"740Surgical Resection for BCLC B HCC https://doi.org/10.3349/ymj.2017.58.4.737often in patients with AFP ≥110 or PIVKA-II ≥800; however,  most patients who had AFP <110 and PIVKA-II <800 showed  only single tumor recurrence of less than 2 cm (Table 3).",Non-OADS,/arxiv_data1/oa_pdf/e0/17/ymj-58-737.PMC5447103.pdf
"741Suk-Won Suh and Yoo Shin Choi https://doi.org/10.3349/ymj.2017.58.4.737fore, the identification of patients suitable for SR is of critical  importance.7,22,23 Based on the clinical observation of a marked  heterogeneity in the clinical benefit of TACE, one study has  proposed a subclassification of the BCLC stage B score into  four stages (B1–B4) to facilitate therapeutic decisions, and pa - tients who classified as the B1 subgroup showed acceptable  survival rates after SR.24 Among the patients who underwent SR, patients who had an identified risk factor had significant earlier tumor recur - rence, compared with other patients (14.5±21.8 months vs.  36.7±28.5 months; p=0.011).",Non-OADS,/arxiv_data1/oa_pdf/e0/17/ymj-58-737.PMC5447103.pdf
"742Surgical Resection for BCLC B HCC https://doi.org/10.3349/ymj.2017.58.4.737ACKNOWLEDGEMENTS This work was supported by Samjin Pharm Co., Ltd., Seoul, Korea.",Non-OADS,/arxiv_data1/oa_pdf/e0/17/ymj-58-737.PMC5447103.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ce/69/ymj-58-743.PMC5447104.pdf
Yonsei Med J 2017 Jul;58(4):743-748 https://doi.org/10.3349/ymj.2017.58.4.743,Non-OADS,/arxiv_data1/oa_pdf/ce/69/ymj-58-743.PMC5447104.pdf
"744Central Obesity as a Risk Factor for NERD https://doi.org/10.3349/ymj.2017.58.4.743and in 32% in 2011.14,15 Population-based studies have shown  that overweight or obesity are both positively associated with  GERD symptoms.16-19 Many studies have also found a positive  correlation between obesity and GERD-associated esophageal  erosion (e.g., erosive esophagitis, Barrett’s esophagus).6,18,20,21  However, information regarding the relationship between obe - sity and NERD is still scarce and inconsistent.",Non-OADS,/arxiv_data1/oa_pdf/ce/69/ymj-58-743.PMC5447104.pdf
745Ki Ju Kim and Ban Seok Lee https://doi.org/10.3349/ymj.2017.58.4.743data were then repeated to assess the association between obe - sity/central obesity and NERD after adjusting for propensity  scores and all covariates.,OADS,/arxiv_data1/oa_pdf/ce/69/ymj-58-743.PMC5447104.pdf
"746Central Obesity as a Risk Factor for NERD https://doi.org/10.3349/ymj.2017.58.4.743ate analysis, there was also no association between gallbladder  stone and NERD (OR=1.242, p=0.121).",Non-OADS,/arxiv_data1/oa_pdf/ce/69/ymj-58-743.PMC5447104.pdf
747Ki Ju Kim and Ban Seok Lee https://doi.org/10.3349/ymj.2017.58.4.743another possible explanation.,Non-OADS,/arxiv_data1/oa_pdf/ce/69/ymj-58-743.PMC5447104.pdf
748Central Obesity as a Risk Factor for NERD https://doi.org/10.3349/ymj.2017.58.4.743of acid reflux in functional dyspepsia and its association with  symptom profile.,Non-OADS,/arxiv_data1/oa_pdf/ce/69/ymj-58-743.PMC5447104.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):749-755 https://doi.org/10.3349/ymj.2017.58.4.749",Non-OADS,/arxiv_data1/oa_pdf/04/d7/ymj-58-749.PMC5447105.pdf
750Lack of Aberrant Methylation in Cancer Field https://doi.org/10.3349/ymj.2017.58.4.749diction and whether these differentially methylated genes  (DMGs) have a rate-limiting stage of methylation change in  the evolution process of colorectal carcinogenesis remains  uncertain.,Non-OADS,/arxiv_data1/oa_pdf/04/d7/ymj-58-749.PMC5447105.pdf
"https://doi.org/10.3349/ymj.2017.58.4.749Bisulfite PCR and pyrosequencing analysis of DNA  methylation Genomic DNA extracted from colorectal tissues were modi - fied by sodium bisulfite treatment16 using Wizard DNA purifi - cation resin (Promega, Madison, WI, USA) according to the  manufacturer’s instructions.",Non-OADS,/arxiv_data1/oa_pdf/04/d7/ymj-58-749.PMC5447105.pdf
752Lack of Aberrant Methylation in Cancer Field https://doi.org/10.3349/ymj.2017.58.4.749in cancers that could be considered as potential field methyla - tion markers.,Non-OADS,/arxiv_data1/oa_pdf/04/d7/ymj-58-749.PMC5447105.pdf
https://doi.org/10.3349/ymj.2017.58.4.749ylation marker (data not shown).,OADS,/arxiv_data1/oa_pdf/04/d7/ymj-58-749.PMC5447105.pdf
754Lack of Aberrant Methylation in Cancer Field https://doi.org/10.3349/ymj.2017.58.4.749morphological change.,Non-OADS,/arxiv_data1/oa_pdf/04/d7/ymj-58-749.PMC5447105.pdf
https://doi.org/10.3349/ymj.2017.58.4.749lenced by methylation in human colon aberrant crypt foci and can - cers.,Non-OADS,/arxiv_data1/oa_pdf/04/d7/ymj-58-749.PMC5447105.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/34/f0/ymj-58-756.PMC5447106.pdf
Yonsei Med J 2017 Jul;58(4):756-762 https://doi.org/10.3349/ymj.2017.58.4.756,Non-OADS,/arxiv_data1/oa_pdf/34/f0/ymj-58-756.PMC5447106.pdf
"https://doi.org/10.3349/ymj.2017.58.4.756In one-third of NASH patients, progression to liver fibrosis was  found within 5 years of diagnosis, and the prevalence of cirrho - sis development was found to be 11 times higher in patients  with NASH than in patients with simple hepatic steatosis.6 Ad- ditionally, NAFLD in children may be associated with signifi - cantly shorter survival than the general population because of  liver failure or cirrhosis, especially in NASH patients.7 To evalu - ate the severity of NASH, a liver biopsy is required, in which fi - brosis is an important factor.",Non-OADS,/arxiv_data1/oa_pdf/34/f0/ymj-58-756.PMC5447106.pdf
"758Effect of Insulin Resistance on Pathologic Severity of NASH https://doi.org/10.3349/ymj.2017.58.4.756inflammation, and ballooning change scores and the group with  score ≥5 were defined as NASH.",Non-OADS,/arxiv_data1/oa_pdf/34/f0/ymj-58-756.PMC5447106.pdf
https://doi.org/10.3349/ymj.2017.58.4.756The tendencies of TG level and mean age were considered sig - nificant.,OADS,/arxiv_data1/oa_pdf/34/f0/ymj-58-756.PMC5447106.pdf
760Effect of Insulin Resistance on Pathologic Severity of NASH https://doi.org/10.3349/ymj.2017.58.4.756increased synthesis in liver cells.,Non-OADS,/arxiv_data1/oa_pdf/34/f0/ymj-58-756.PMC5447106.pdf
https://doi.org/10.3349/ymj.2017.58.4.756IR in pediatric nonalcoholic steatohepatitis and nonalcoholic  fatty liver disease; IR is an important factor in the first hit of  the two-hit model of NASH.,Non-OADS,/arxiv_data1/oa_pdf/34/f0/ymj-58-756.PMC5447106.pdf
762Effect of Insulin Resistance on Pathologic Severity of NASH https://doi.org/10.3349/ymj.2017.58.4.756and pathological severity.,Non-OADS,/arxiv_data1/oa_pdf/34/f0/ymj-58-756.PMC5447106.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/74/ymj-58-763.PMC5447107.pdf
Yonsei Med J 2017 Jul;58(4):763-769 https://doi.org/10.3349/ymj.2017.58.4.763,Non-OADS,/arxiv_data1/oa_pdf/82/74/ymj-58-763.PMC5447107.pdf
"764γ-Glutamyltransferase Levels on Incident Metabolic Syndrome https://doi.org/10.3349/ymj.2017.58.4.763sity, hypertriglyceridemia, high blood pressure, low high den - sity lipoprotein (HDL) cholesterol, and elevated blood glucose.",Non-OADS,/arxiv_data1/oa_pdf/82/74/ymj-58-763.PMC5447107.pdf
https://doi.org/10.3349/ymj.2017.58.4.763Statistical methods Data are expressed as means±SDs.,OADS,/arxiv_data1/oa_pdf/82/74/ymj-58-763.PMC5447107.pdf
"766γ-Glutamyltransferase Levels on Incident Metabolic Syndrome https://doi.org/10.3349/ymj.2017.58.4.763RESULTS Patient characteristics After a mean follow-up of 2.6 years, 558 participants (21.6%)  developed metabolic syndrome (Fig.",Non-OADS,/arxiv_data1/oa_pdf/82/74/ymj-58-763.PMC5447107.pdf
https://doi.org/10.3349/ymj.2017.58.4.763GGT change over the 2.6 years is shown in Table 3.,OADS,/arxiv_data1/oa_pdf/82/74/ymj-58-763.PMC5447107.pdf
"768γ-Glutamyltransferase Levels on Incident Metabolic Syndrome https://doi.org/10.3349/ymj.2017.58.4.763of metabolic syndrome.18,25 Our study clearly showed that a  stepwise increase in baseline GGT levels significantly increas - es the risk of incident metabolic syndrome (from 13.7 to 27.6%)  and the incidence of each component of metabolic syndrome.",Non-OADS,/arxiv_data1/oa_pdf/82/74/ymj-58-763.PMC5447107.pdf
"https://doi.org/10.3349/ymj.2017.58.4.763Gamma-glutamyltransferase as a risk factor for cardiovascular  disease mortality: an epidemiological investigation in a cohort of  163,944 Austrian adults.",Non-OADS,/arxiv_data1/oa_pdf/82/74/ymj-58-763.PMC5447107.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
Yonsei Med J 2017 Jul;58(4):770-777 https://doi.org/10.3349/ymj.2017.58.4.770,Non-OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
"https://doi.org/10.3349/ymj.2017.58.4.770cern of long-term use of TDF .6,8,9 TDF accumulates in the cyto - plasm of proximal renal tubular epithelial cells, inhibiting mi - tochondrial DNA polymerase and causing dysfunction of the  oxidative respiratory chain and energy deprivation.6,10,11 This  acquired renal tubular mitochondriopathy eventually drives ep - ithelial cells to apoptosis, resulting in proximal tubular dam - age and renal injury.10-12 The long-term adverse outcomes of antiretroviral drugs or  their indirect effects are becoming major factors in the deteri - orating quality of life of HIV-infected individuals in a highly ac - tive ART era.",Non-OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
"772Renal Dysfunction by TDF in HIV-Infected Koreans https://doi.org/10.3349/ymj.2017.58.4.770sel, Switzerland), and SCr, serum uric acid, and serum inor - ganic phosphate (IP) using an automatic chemistry spectro - photometric analyzer, Hitachi 7600 (Hitachi, Ltd., Tokyo, Japan)  every 3 months during the first year and every 6 months dur - ing the last 2 years.",OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
https://doi.org/10.3349/ymj.2017.58.4.770ies received TDF-based ART with TDF as a co-formulation of  TDF/FTC.,OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
"774Renal Dysfunction by TDF in HIV-Infected Koreans https://doi.org/10.3349/ymj.2017.58.4.770DISCUSSION In our study, parameters indicating renal function were SCr  level, eGFR from SCr as MDRD and CKD-EPI, and eGFR from  plasma cystatin-C.",OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
"https://doi.org/10.3349/ymj.2017.58.4.770had mild CKD (stage 2).30 A considerable number of patients  had clinically meaningful, mild CKD, with no patients with  moderate or severe CKD or kidney failure (≥stage 3) CKD in  this 3-year follow-up study.",Non-OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
"776Renal Dysfunction by TDF in HIV-Infected Koreans https://doi.org/10.3349/ymj.2017.58.4.770Schandelmaier S, et al.",OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
https://doi.org/10.3349/ymj.2017.58.4.770weight.,Non-OADS,/arxiv_data1/oa_pdf/34/d3/ymj-58-770.PMC5447108.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
Yonsei Med J 2017 Jul;58(4):778-785 https://doi.org/10.3349/ymj.2017.58.4.778,Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
https://doi.org/10.3349/ymj.2017.58.4.778Oseltamivir (F .,Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
The search used keywords related to peramivir: BCX-1812;  RWJ 270201; oseltamivir; tamiflu; influenza; flu; H1N1; antivi - rals; and neuramidase inhibitors; search filters provided by  SIGN (http://www.sign.ac.uk/methodology/filters.html) were  used.,OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
780Peramivir versus Oseltamivir for Flu Treatments  https://doi.org/10.3349/ymj.2017.58.4.778RESULTS Study search A total of 19155 published articles were initially identified through  database searches.,OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
https://doi.org/10.3349/ymj.2017.58.4.778 Table 1.,Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
"782Peramivir versus Oseltamivir for Flu Treatments  https://doi.org/10.3349/ymj.2017.58.4.778the time to alleviation of symptoms.8 However, due to the scar - city of clinical comparisons, we sought to determine which an - tiviral agent was superior through a meta-analysis of previous  trials.",Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
https://doi.org/10.3349/ymj.2017.58.4.778mivir.,Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
784Peramivir versus Oseltamivir for Flu Treatments  https://doi.org/10.3349/ymj.2017.58.4.778 Fig.,Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
https://doi.org/10.3349/ymj.2017.58.4.778ruses is a major concern.,Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
Available at:  https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.,Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
Available at: http://www.ohri.ca/programs/clinical_epidemi - ology/oxford.asp.,Non-OADS,/arxiv_data1/oa_pdf/25/53/ymj-58-778.PMC5447109.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):786-792 https://doi.org/10.3349/ymj.2017.58.4.786",Non-OADS,/arxiv_data1/oa_pdf/1e/6a/ymj-58-786.PMC5447110.pdf
"https://doi.org/10.3349/ymj.2017.58.4.786the proficiency of the operator, the test site, or underlying medi - cal illnesses, especially skin diseases.4,5  In Korea, multiplex sIgE detection is commonly used to  screen for allergic diseases.",Non-OADS,/arxiv_data1/oa_pdf/1e/6a/ymj-58-786.PMC5447110.pdf
"788AlloScreen versus ImmunoCAP in Allergic Patients  https://doi.org/10.3349/ymj.2017.58.4.786lergy, chronic urticarial, and anaphylaxis (Table 1).",Non-OADS,/arxiv_data1/oa_pdf/1e/6a/ymj-58-786.PMC5447110.pdf
https://doi.org/10.3349/ymj.2017.58.4.786Quantitative comparison: sIgE titer determination The ICCs for each allergen are shown in Table 5.,OADS,/arxiv_data1/oa_pdf/1e/6a/ymj-58-786.PMC5447110.pdf
790AlloScreen versus ImmunoCAP in Allergic Patients  https://doi.org/10.3349/ymj.2017.58.4.786Fig.,Non-OADS,/arxiv_data1/oa_pdf/1e/6a/ymj-58-786.PMC5447110.pdf
https://doi.org/10.3349/ymj.2017.58.4.786allergens that employs a semi-quantitative enzyme immunoas - say (EIA).,Non-OADS,/arxiv_data1/oa_pdf/1e/6a/ymj-58-786.PMC5447110.pdf
"792AlloScreen versus ImmunoCAP in Allergic Patients  https://doi.org/10.3349/ymj.2017.58.4.786played no role in the study design; in the collection, analysis,  and interpretation of data; in the writing of the report; or in  the decision to submit the report for publication.",Non-OADS,/arxiv_data1/oa_pdf/1e/6a/ymj-58-786.PMC5447110.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):793-799 https://doi.org/10.3349/ymj.2017.58.4.793",Non-OADS,/arxiv_data1/oa_pdf/d5/40/ymj-58-793.PMC5447111.pdf
"794High Dose Erythropoietin and Fistula Failure https://doi.org/10.3349/ymj.2017.58.4.793ment of anemia in patients with chronic kidney disease (CKD),  but it has some adverse effects, such as hypertension and car - diovascular and cerebrovascular events.7 Interestingly, several  experimental studies have shown that ESA could stimulate  vascular smooth muscle cells8 and induce neointimal hyper - plasia.9 However, the role of ESA in the process of late AVF loss  in patients on chronic hemodialysis is still inconclusive.10 The  aim of the present study was to determine whether ESA treat - ment is associated with late loss of AVF function after success - ful maturation in patients receiving chronic hemodialysis.",Non-OADS,/arxiv_data1/oa_pdf/d5/40/ymj-58-793.PMC5447111.pdf
"https://doi.org/10.3349/ymj.2017.58.4.793ents, or vitamin D analogues), heparin dose, and other comor- bidities (ischemic heart disease, cerebrovascular disease, or  peripheral vascular disease), were obtained by medical record  review.",OADS,/arxiv_data1/oa_pdf/d5/40/ymj-58-793.PMC5447111.pdf
796High Dose Erythropoietin and Fistula Failure https://doi.org/10.3349/ymj.2017.58.4.793ables were compared using the χ2 test or Fisher’s exact test.,Non-OADS,/arxiv_data1/oa_pdf/d5/40/ymj-58-793.PMC5447111.pdf
"https://doi.org/10.3349/ymj.2017.58.4.793DISCUSSION In this study, we retrospectively compared 51 cases and con - trols.",Non-OADS,/arxiv_data1/oa_pdf/d5/40/ymj-58-793.PMC5447111.pdf
798High Dose Erythropoietin and Fistula Failure https://doi.org/10.3349/ymj.2017.58.4.793bin increase and the risk of adverse cardiovascular outcomes.24  The third possibility is an increased platelet count or reactivi - ty.,Non-OADS,/arxiv_data1/oa_pdf/d5/40/ymj-58-793.PMC5447111.pdf
https://doi.org/10.3349/ymj.2017.58.4.793alysis patients.,Non-OADS,/arxiv_data1/oa_pdf/d5/40/ymj-58-793.PMC5447111.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/32/5d/ymj-58-800.PMC5447112.pdf
Yonsei Med J 2017 Jul;58(4):800-806 https://doi.org/10.3349/ymj.2017.58.4.800,Non-OADS,/arxiv_data1/oa_pdf/32/5d/ymj-58-800.PMC5447112.pdf
"https://doi.org/10.3349/ymj.2017.58.4.800affinity for this subtype than for α1A and α1B subtypes, respec - tively.8,9 Although several clinical trials9-12 demonstrating the  efficacy of this drug for BPH patients have been reported, there  are few reports of the cardiovascular responses associated with  this drug during BPH treatment.",Non-OADS,/arxiv_data1/oa_pdf/32/5d/ymj-58-800.PMC5447112.pdf
"802Naftopidil and Blood Pressure in BPH Patients https://doi.org/10.3349/ymj.2017.58.4.80027 patients completed the study, and one discontinued because  of loss during follow-up.",Non-OADS,/arxiv_data1/oa_pdf/32/5d/ymj-58-800.PMC5447112.pdf
"https://doi.org/10.3349/ymj.2017.58.4.800differences between the four treatment groups in regards to age,  height, weight, prostate volume, level of PSA, total IPSS scores,  IPSS obstructive or irritative subscore, QoL due to urinary symp - toms, Qmax, or post-void residual urine volume.",Non-OADS,/arxiv_data1/oa_pdf/32/5d/ymj-58-800.PMC5447112.pdf
"804Naftopidil and Blood Pressure in BPH Patients https://doi.org/10.3349/ymj.2017.58.4.800The majority of these reports, however, concern doxazosin  treatment.",Non-OADS,/arxiv_data1/oa_pdf/32/5d/ymj-58-800.PMC5447112.pdf
https://doi.org/10.3349/ymj.2017.58.4.800tolic and diastolic BP in baseline HT patients (Fig.,Non-OADS,/arxiv_data1/oa_pdf/32/5d/ymj-58-800.PMC5447112.pdf
806Naftopidil and Blood Pressure in BPH Patients https://doi.org/10.3349/ymj.2017.58.4.800system in patients with benign prostatic hyperplasia with or with - out concomitant hypertension.,Non-OADS,/arxiv_data1/oa_pdf/32/5d/ymj-58-800.PMC5447112.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
Yonsei Med J 2017 Jul;58(4):807-815 https://doi.org/10.3349/ymj.2017.58.4.807,Non-OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
"808Neural Correlates of CTG Expansion Size in DM1 https://doi.org/10.3349/ymj.2017.58.4.807Cognitive deficits have been observed in 24 –75% of DM1 pa - tients,2-4 including reduced visuospatial/constructional abili - ties, attention, verbal memory, and even severe cognitive de - cline.",Non-OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
https://doi.org/10.3349/ymj.2017.58.4.807combination of the verbal and performance scores.,Non-OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
810Neural Correlates of CTG Expansion Size in DM1 https://doi.org/10.3349/ymj.2017.58.4.807with cortical thickness as the dependent variable.,OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
"https://doi.org/10.3349/ymj.2017.58.4.807Cortical changes Cortical thickness was significantly reduced in the clusters of  the bilateral superior temporal cortices (including the supra - marginal cortex), precuneus, lateral occipital cortex, superior  frontal, precentral, and postcentral cortices in the patient group,  compared to controls.",OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
812Neural Correlates of CTG Expansion Size in DM1 https://doi.org/10.3349/ymj.2017.58.4.807tically significant correlation was found between IQ scores and  the size of CTG repeats.,OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
"https://doi.org/10.3349/ymj.2017.58.4.807including dysexecutive syndrome, apathy, depression, anxi - ety, obsessive-compulsive, avoidant, and passive-aggressive  behavior, which was observed in DM1.6 In the present study, we  also found changes in diffusion metrics in the external capsule,  which might be related to decreased verbal fluency resulting  from impairment in semantic processing.22  We also observed pronounced changes in cortical thickness  and white matter integrity, mainly in the temporo-occipital and  parietal areas in the medial side, including the precuneus.",Non-OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
"814Neural Correlates of CTG Expansion Size in DM1 https://doi.org/10.3349/ymj.2017.58.4.807ACKNOWLEDGEMENTS This study was supported by a faculty research grant from  Yonsei University College of Medicine for 2011(6-2011-0131)  and by the Basic Science Research Program through the Na - tional Research Foundation of Korea (NRF) funded by the Min - istry of Education, Science and Technology (2009-0089481) and  (2013R1A1A2012562).",OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
https://doi.org/10.3349/ymj.2017.58.4.80735.,Non-OADS,/arxiv_data1/oa_pdf/4f/ef/ymj-58-807.PMC5447113.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):816-822 https://doi.org/10.3349/ymj.2017.58.4.816",Non-OADS,/arxiv_data1/oa_pdf/f9/31/ymj-58-816.PMC5447114.pdf
"https://doi.org/10.3349/ymj.2017.58.4.816treatments.5 The prevalence of emotional distress is high in pa - tients diagnosed with cancer in general.6 Despite general agree - ment that cancer and its treatment can be stressful for pa - tients, few studies have directly addressed the specific factors  that affect children and adolescents diagnosed with cancer  during early treatment.",Non-OADS,/arxiv_data1/oa_pdf/f9/31/ymj-58-816.PMC5447114.pdf
818Emotional Distress during Early Treatment for Cancer https://doi.org/10.3349/ymj.2017.58.4.816p-values<0.05 were considered significant.,Non-OADS,/arxiv_data1/oa_pdf/f9/31/ymj-58-816.PMC5447114.pdf
https://doi.org/10.3349/ymj.2017.58.4.816Fig.,Non-OADS,/arxiv_data1/oa_pdf/f9/31/ymj-58-816.PMC5447114.pdf
820Emotional Distress during Early Treatment for Cancer https://doi.org/10.3349/ymj.2017.58.4.816Patients aged 13–17 years We conducted analyses of the association between patient  emotional distress and other variables (Table 3).,OADS,/arxiv_data1/oa_pdf/f9/31/ymj-58-816.PMC5447114.pdf
"https://doi.org/10.3349/ymj.2017.58.4.816maternal age, coping strategies and attachment types of moth - ers would provide advanced results.",Non-OADS,/arxiv_data1/oa_pdf/f9/31/ymj-58-816.PMC5447114.pdf
822Emotional Distress during Early Treatment for Cancer https://doi.org/10.3349/ymj.2017.58.4.816recovery within mother-infant dyads.,Non-OADS,/arxiv_data1/oa_pdf/f9/31/ymj-58-816.PMC5447114.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):823-828 https://doi.org/10.3349/ymj.2017.58.4.823",Non-OADS,/arxiv_data1/oa_pdf/b6/e9/ymj-58-823.PMC5447115.pdf
"824Synthetic Surfactant Using SP-B and C Analogues https://doi.org/10.3349/ymj.2017.58.4.823after, various commercial agents were developed, and many  randomized controlled trials confirmed the use of surfactants  as a standard treatment of choice.4 Such practice have enabled  markedly improved survival in preterm infants.5 Artificial surfactants can be categorized into two different  compositional features according to type of surfactant pro - teins (SPs).",Non-OADS,/arxiv_data1/oa_pdf/b6/e9/ymj-58-823.PMC5447115.pdf
https://doi.org/10.3349/ymj.2017.58.4.823cheostomy and gentle forced ventilation of 0.3 –0.5 cc air with  a syringe over 30 cycles.,Non-OADS,/arxiv_data1/oa_pdf/b6/e9/ymj-58-823.PMC5447115.pdf
"826Synthetic Surfactant Using SP-B and C Analogues https://doi.org/10.3349/ymj.2017.58.4.823or physical properties in the mixture of surfactant.14 It is im - possible to reconstruct intact human SPs based on the known  full sequences, because of their instability and complicated  structure.",Non-OADS,/arxiv_data1/oa_pdf/b6/e9/ymj-58-823.PMC5447115.pdf
"https://doi.org/10.3349/ymj.2017.58.4.823sis was conducted at 15 cm H2O; however, we also noted a dif - ference at 0 cm H2O as well.",Non-OADS,/arxiv_data1/oa_pdf/b6/e9/ymj-58-823.PMC5447115.pdf
"828Synthetic Surfactant Using SP-B and C Analogues https://doi.org/10.3349/ymj.2017.58.4.823include that we could not evaluate the efficacy of our Synsurfs  in comparison to other available commercial preparations, for  example Curosurf® (Chiesi Farmaceutici, Parma, Italy) (por - cine SP) or Surfaxin® (synthetic SP).",Non-OADS,/arxiv_data1/oa_pdf/b6/e9/ymj-58-823.PMC5447115.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
Yonsei Med J 2017 Jul;58(4):829-836 https://doi.org/10.3349/ymj.2017.58.4.829,Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
"830Indications for Open Reduction Only  https://doi.org/10.3349/ymj.2017.58.4.829sults without open reduction.17-22 Moreover, several papers have  reported satisfactory results with open reduction alone in some  patients with missed Monteggia fracture.1,4,6,25,26 Although these  reports could not suggest the indications for open reduction  alone for missed Monteggia fracture, open reduction alone might  be the ideal procedure in select patients.",Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
https://doi.org/10.3349/ymj.2017.58.4.829(Fig.,Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
832Indications for Open Reduction Only  https://doi.org/10.3349/ymj.2017.58.4.829used as measures of the interobserver and intraobserver re - peatability for all evaluations.,Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
https://doi.org/10.3349/ymj.2017.58.4.829additional ulnar osteotomy fixed with a plate.,Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
834Indications for Open Reduction Only  https://doi.org/10.3349/ymj.2017.58.4.829quence of surgical treatment for missed Monteggia fracture.,Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
"https://doi.org/10.3349/ymj.2017.58.4.829by open reduction only, then an additional procedure for the  ulna is not necessary.",Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
836Indications for Open Reduction Only  https://doi.org/10.3349/ymj.2017.58.4.829of ulnar bowing in radiography.,Non-OADS,/arxiv_data1/oa_pdf/58/ef/ymj-58-829.PMC5447116.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):837-841 https://doi.org/10.3349/ymj.2017.58.4.837",Non-OADS,/arxiv_data1/oa_pdf/60/63/ymj-58-837.PMC5447117.pdf
838Cerclage Cables in Humeral Shaft Fracture https://doi.org/10.3349/ymj.2017.58.4.837lowed by an intramedullary nail to gain greater stability.,Non-OADS,/arxiv_data1/oa_pdf/60/63/ymj-58-837.PMC5447117.pdf
https://doi.org/10.3349/ymj.2017.58.4.837RESULTS The patients’ demographic data are provided in Table 1.,OADS,/arxiv_data1/oa_pdf/60/63/ymj-58-837.PMC5447117.pdf
"840Cerclage Cables in Humeral Shaft Fracture https://doi.org/10.3349/ymj.2017.58.4.837reported in which a plate/cable system for the humeral shaft  was used.16 One study reported that, of 125 cases with a humer - al shaft fracture, 20% of patients with an extended oblique or  spiral type of fracture were fixed with cerclage wiring followed  by IMN; however, no subgroup results were reported.2 We compared the clinical results of the open cerclage cable  technique followed by nailing to the traditional closed nailing  technique in humeral shaft fractures.",Non-OADS,/arxiv_data1/oa_pdf/60/63/ymj-58-837.PMC5447117.pdf
https://doi.org/10.3349/ymj.2017.58.4.837sure time during the operation can be decreased compared to  the conventional nailing technique.,Non-OADS,/arxiv_data1/oa_pdf/60/63/ymj-58-837.PMC5447117.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):842-847 https://doi.org/10.3349/ymj.2017.58.4.842",Non-OADS,/arxiv_data1/oa_pdf/0a/1a/ymj-58-842.PMC5447118.pdf
"https://doi.org/10.3349/ymj.2017.58.4.842Scale (SSQ) is a representative questionnaire.8 However, the  SSQ consist of 49 questions, compared to 24 questions in the  SHQ, and the SSQ takes more time than the SHQ.",Non-OADS,/arxiv_data1/oa_pdf/0a/1a/ymj-58-842.PMC5447118.pdf
844The Korean Version of the Spatial Hearing Questionnaire https://doi.org/10.3349/ymj.2017.58.4.842tions number 1 to 12 from the questionnaire.,Non-OADS,/arxiv_data1/oa_pdf/0a/1a/ymj-58-842.PMC5447118.pdf
https://doi.org/10.3349/ymj.2017.58.4.842metry as an interaural difference of less than 15 dB of the aver - age value of PTA.,OADS,/arxiv_data1/oa_pdf/0a/1a/ymj-58-842.PMC5447118.pdf
846The Korean Version of the Spatial Hearing Questionnaire https://doi.org/10.3349/ymj.2017.58.4.842from 0.686 to 0.910.,Non-OADS,/arxiv_data1/oa_pdf/0a/1a/ymj-58-842.PMC5447118.pdf
"https://doi.org/10.3349/ymj.2017.58.4.842Spatial hearing is co-influenced by many factors, including  the severity and symmetry of the hearing impairment.6,7 It is  expected that the more severe the hearing loss, the lower the  K-SHQ.",Non-OADS,/arxiv_data1/oa_pdf/0a/1a/ymj-58-842.PMC5447118.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):848-858 https://doi.org/10.3349/ymj.2017.58.4.848",Non-OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
https://doi.org/10.3349/ymj.2017.58.4.848ability to prevent early and late postoperative vomiting (POV)  better than ondansetron.,Non-OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
"850Palonosetron vs. Ramosetron for PONV Prophylaxis https://doi.org/10.3349/ymj.2017.58.4.848an, low and high end of the range for samples less than 25, and  the median value itself was regarded as the mean value for  samples more than 25.",OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
https://doi.org/10.3349/ymj.2017.58.4.848 Table 1.,Non-OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
"852Palonosetron vs. Ramosetron for PONV Prophylaxis https://doi.org/10.3349/ymj.2017.58.4.848ue was 0.79 (95% CI, 0.66 to 0.93; p<0.001), suggesting substan - tial agreement between the two raters that evaluated risk of bias.",OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
https://doi.org/10.3349/ymj.2017.58.4.848Table 4 shows pooled analyses for POV .,OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
"854Palonosetron vs. Ramosetron for PONV Prophylaxis https://doi.org/10.3349/ymj.2017.58.4.848data for the early, late, and delayed periods but not for the total  study period.",Non-OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
https://doi.org/10.3349/ymj.2017.58.4.848cant differences in POV were observed for the early and de - layed periods.,OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
"856Palonosetron vs. Ramosetron for PONV Prophylaxis https://doi.org/10.3349/ymj.2017.58.4.848DISCUSSION There have been recent previous meta-analyses comparing ei - ther palonosetron4 or ramosetron3,23 with ondansetron, but a di - rect comparison between each other has not yet been made.",OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
https://doi.org/10.3349/ymj.2017.58.4.848tic intervention or drug.,Non-OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
858Palonosetron vs. Ramosetron for PONV Prophylaxis https://doi.org/10.3349/ymj.2017.58.4.84813.,Non-OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
https://doi.org/10.1097/ANA.0000000000000361.,Non-OADS,/arxiv_data1/oa_pdf/4d/0d/ymj-58-848.PMC5447119.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):859-866 https://doi.org/10.3349/ymj.2017.58.4.859",Non-OADS,/arxiv_data1/oa_pdf/ad/90/ymj-58-859.PMC5447120.pdf
"860Paraquat Ban and Herbicide Mortality https://doi.org/10.3349/ymj.2017.58.4.859INTRODUCTION Paraquat is a non-selective herbicide that is widely used in agri - culture, because it is fast acting and non-persistent in the envi - ronment.",Non-OADS,/arxiv_data1/oa_pdf/ad/90/ymj-58-859.PMC5447120.pdf
"https://doi.org/10.3349/ymj.2017.58.4.859cide products or fungicides, as well as those with unknown  outcomes (death or survival), were excluded.",Non-OADS,/arxiv_data1/oa_pdf/ad/90/ymj-58-859.PMC5447120.pdf
862Paraquat Ban and Herbicide Mortality https://doi.org/10.3349/ymj.2017.58.4.859Statistical analysis  Data are presented as the mean±standard deviation or per - centages.,OADS,/arxiv_data1/oa_pdf/ad/90/ymj-58-859.PMC5447120.pdf
"https://doi.org/10.3349/ymj.2017.58.4.859quat ban (78.8% vs. 70.3%, p=0.004) (Table 1).",Non-OADS,/arxiv_data1/oa_pdf/ad/90/ymj-58-859.PMC5447120.pdf
864Paraquat Ban and Herbicide Mortality https://doi.org/10.3349/ymj.2017.58.4.859has some limitations on reducing mortality.,Non-OADS,/arxiv_data1/oa_pdf/ad/90/ymj-58-859.PMC5447120.pdf
"https://doi.org/10.3349/ymj.2017.58.4.859fore, it appears that after the paraquat ban the mortality rate  tended to decline (Table 3).",Non-OADS,/arxiv_data1/oa_pdf/ad/90/ymj-58-859.PMC5447120.pdf
866Paraquat Ban and Herbicide Mortality https://doi.org/10.3349/ymj.2017.58.4.859to standardize and reflect the past medical history and health  status of the individual patients.,Non-OADS,/arxiv_data1/oa_pdf/ad/90/ymj-58-859.PMC5447120.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):867-871 https://doi.org/10.3349/ymj.2017.58.4.867",Non-OADS,/arxiv_data1/oa_pdf/a5/16/ymj-58-867.PMC5447121.pdf
868Early Plasma Exchange in SFTS https://doi.org/10.3349/ymj.2017.58.4.867This retrospective cohort study was conducted at nine Kore - an hospitals.,Non-OADS,/arxiv_data1/oa_pdf/a5/16/ymj-58-867.PMC5447121.pdf
https://doi.org/10.3349/ymj.2017.58.4.867and diabetes mellitus.,Non-OADS,/arxiv_data1/oa_pdf/a5/16/ymj-58-867.PMC5447121.pdf
"870Early Plasma Exchange in SFTS https://doi.org/10.3349/ymj.2017.58.4.8672.171, p=0.003), early PE implementation (adjusted HR 0.052,  95% CI 0.004 –0.678, p=0.024), and late PE implementation  (adjusted HR 5.513, 95% CI 1.121 –27.10, p=0.036) were identi - fied as independent risk factors for 30-day mortality (model II  in Table 2).",Non-OADS,/arxiv_data1/oa_pdf/a5/16/ymj-58-867.PMC5447121.pdf
"https://doi.org/10.3349/ymj.2017.58.4.867study, larger randomized trials with early PE implementation  in high-risk SFTS patients for death are needed.",Non-OADS,/arxiv_data1/oa_pdf/a5/16/ymj-58-867.PMC5447121.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):872-877 https://doi.org/10.3349/ymj.2017.58.4.872",Non-OADS,/arxiv_data1/oa_pdf/1f/f9/ymj-58-872.PMC5447122.pdf
"https://doi.org/10.3349/ymj.2017.58.4.872of gut motor function, whereas CRF antagonist administration  prevents the effects of various stressors.12 In addition to the  brain, CRF ligands and receptors are widely expressed in en - teric nervous system neurons and other cells of the GI tract in  animals and humans.19-22 Remarkably, peripheral administra - tion of CRF ligands was found to mimic changes similar to that  induced by stress, while its antagonists alleviate stress-induced  alteration of GI function.23,24 This indicates the co-existence of  a peripheral and central CRF signaling pathway, and together,  they might play critical role in stress-related alterations of gut  function.",Non-OADS,/arxiv_data1/oa_pdf/1f/f9/ymj-58-872.PMC5447122.pdf
874Effect of Peripheral CRF and Stress on Gastrocolonic Transit https://doi.org/10.3349/ymj.2017.58.4.872peptide on lower GI transit was analyzed by FPO assay.,OADS,/arxiv_data1/oa_pdf/1f/f9/ymj-58-872.PMC5447122.pdf
"https://doi.org/10.3349/ymj.2017.58.4.872Emerging evidence links the activation of CRF receptors with  stress-related alterations of gastric and colonic motor func - tion.34-37 In order to establish an experimental animal model of  overlap syndrome, the present study targeted CRF receptors to  analyze its effects on upper and lower GI transit in conscious  guinea pigs.",Non-OADS,/arxiv_data1/oa_pdf/1f/f9/ymj-58-872.PMC5447122.pdf
"876Effect of Peripheral CRF and Stress on Gastrocolonic Transit https://doi.org/10.3349/ymj.2017.58.4.872the selective CRF action on the activation of CRF2 receptors in  the inhibition of gastric emptying and CRF1 receptors in the  stimulation of colonic transit.34,38,39 Thus, these results strongly  suggest that CRF receptor subtypes 2 and 1 may be activated si - multaneously during stress or during central and peripheral  administration of CRF .34-37 The WAS model was applied to analyze the role of central CRF  pathways in GI motility.",Non-OADS,/arxiv_data1/oa_pdf/1f/f9/ymj-58-872.PMC5447122.pdf
https://doi.org/10.3349/ymj.2017.58.4.872in stress-related alterations of gut motility and mucosal function.,Non-OADS,/arxiv_data1/oa_pdf/1f/f9/ymj-58-872.PMC5447122.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):878-883 https://doi.org/10.3349/ymj.2017.58.4.878",Non-OADS,/arxiv_data1/oa_pdf/34/ef/ymj-58-878.PMC5447123.pdf
"https://doi.org/10.3349/ymj.2017.58.4.878valgum deformity, both of which are commonly associated  with patellar instability.1,2 Furthermore, biplanar closing-wedge  DFO (CWDFO) provides better stability and promotes bone  healing, due to increased cancellous bone surface area at the  osteotomy site.9,10,14,15 For these reasons, CWDFO could be a  valuable procedure in a chronic patellar instability patient with  excessive Q-angle stemming from significant genu valgum,  Additional medial reefing with lateral release could be helpful  when instability would be potentially intractable in the pa - tient.10-13,16 The purpose of this study was to analyze the short-term re - sults of single-incision CWDFO combined with medial reefing  and lateral release for recurrent patellar instability with genu  valgum.",Non-OADS,/arxiv_data1/oa_pdf/34/ef/ymj-58-878.PMC5447123.pdf
https://doi.org/10.3349/ymj.2017.58.4.878to confirm the patellofemoral alignment through full range of  motion.,Non-OADS,/arxiv_data1/oa_pdf/34/ef/ymj-58-878.PMC5447123.pdf
882DFO Reefing https://doi.org/10.3349/ymj.2017.58.4.878DISCUSSION This paper describes the advantages of single-incision medial  biplanar CWDFO combined with medial retinaculum reefing  and lateral release for treatment of recurrent dislocation of the  patella with genu valgus knee.,Non-OADS,/arxiv_data1/oa_pdf/34/ef/ymj-58-878.PMC5447123.pdf
https://doi.org/10.3349/ymj.2017.58.4.878method of biplanar lateral OWDFO for patellofemoral ma - lalignment.,OADS,/arxiv_data1/oa_pdf/34/ef/ymj-58-878.PMC5447123.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):884-887 https://doi.org/10.3349/ymj.2017.58.4.884",Non-OADS,/arxiv_data1/oa_pdf/72/71/ymj-58-884.PMC5447124.pdf
https://doi.org/10.3349/ymj.2017.58.4.884pacing with or without isoproterenol infusion.,Non-OADS,/arxiv_data1/oa_pdf/72/71/ymj-58-884.PMC5447124.pdf
886IVC Focal Atrial Tachycardia https://doi.org/10.3349/ymj.2017.58.4.884ing 3D mapping.,Non-OADS,/arxiv_data1/oa_pdf/72/71/ymj-58-884.PMC5447124.pdf
"https://doi.org/10.3349/ymj.2017.58.4.884lou A, Kyriakides Z. Electroanatomical mapping of a right atrial  tachycardia originating within the inferior vena cava.",Non-OADS,/arxiv_data1/oa_pdf/72/71/ymj-58-884.PMC5447124.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):888-890 https://doi.org/10.3349/ymj.2017.58.4.888",Non-OADS,/arxiv_data1/oa_pdf/81/6f/ymj-58-888.PMC5447125.pdf
https://doi.org/10.3349/ymj.2017.58.4.888they had no obvious complications.,Non-OADS,/arxiv_data1/oa_pdf/81/6f/ymj-58-888.PMC5447125.pdf
890DUOX2/DUOXA2  Mutations in CH https://doi.org/10.3349/ymj.2017.58.4.888trols.,Non-OADS,/arxiv_data1/oa_pdf/81/6f/ymj-58-888.PMC5447125.pdf
"© Copyright: Yonsei University College of Medicine 2017 This is an Open Access article distributed under the terms of the Creative Com - mons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.Yonsei Med J 2017 Jul;58(4):891-893 https://doi.org/10.3349/ymj.2017.58.4.891",Non-OADS,/arxiv_data1/oa_pdf/4c/a2/ymj-58-891.PMC5447126.pdf
"892PLE as a Complication of KD https://doi.org/10.3349/ymj.2017.58.4.891trogen 9.2 mg/dL, creatinine 0.2 mg/dL, aspartate aminotrans - ferase 16 IU/L, alanine aminotrasnferase 5 IU/L, and normal  thyroid function.",Non-OADS,/arxiv_data1/oa_pdf/4c/a2/ymj-58-891.PMC5447126.pdf
"https://doi.org/10.3349/ymj.2017.58.4.891proximately 10% of the patients: 12 of 129 patients (9.3%) and  39 of 317 patients (12.3%), respectively.",Non-OADS,/arxiv_data1/oa_pdf/4c/a2/ymj-58-891.PMC5447126.pdf
1/10 https://ejgo.orgABSTRACT Objective:  To evaluate the prevalence and risk factors for unrecognized invasive carcinoma  in a series of patients undergoing surgical excision after an office biopsy of vulvar high-grade  squamous intraepithelial lesion (VHSIL).,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
"2017 Jul;28(4):e27 https://doi.org/10.3802/jgo.2017.28.e27 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  May 29, 2016 Revised:  Dec 22, 2016 Accepted:  Jan 5, 2017 Correspondence to Mario Preti Department of Obstetrics and Gynecology,  University of Torino, Via Ventimiglia 3, Torino  10128, Italy.",Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
"ORCID Mario Preti https://orcid.org/0000-0002-1573-3114 Lauro Bucchi https://orcid.org/0000-0002-6771-8119 Bruno Ghiringhello https://orcid.org/0000-0003-1357-3660 Silvana Privitera https://orcid.org/0000-0003-2753-1314 Valentina Frau https://orcid.org/0000-0002-1868-5066 Elisabetta Corvetto https://orcid.org/0000-0001-8661-2902 Chiara Benedetto https://orcid.org/0000-0003-1514-4771Mario Preti,1 Lauro Bucchi,2 Bruno Ghiringhello,3 Silvana Privitera,3   Valentina Frau,1 Elisabetta Corvetto,1 Chiara Benedetto,1 Leonardo Micheletti1 1Department of Obstetrics and Gynecology, University of Torino, Torino, Italy 2Romagna Cancer Registry, Romagna Cancer Institute (IRST) IRCCS, Meldola, Forlì, Italy 3 Department of Pathology and Cytology of Female Cancer, Childhood Cancer, and Rare Cancers, AOU Città  della Salute e della Scienza, Torino, ItalyRisk factors for unrecognized invasive  carcinoma in patients with vulvar  high-grade squamous intraepithelial  lesion at vulvoscopy-directed biopsy",Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
Leonardo Micheletti https://orcid.org/0000-0002-0337-8637 Conflict of Interest No potential conflict of interest relevant to this  article was reported.,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
In order to minimize the variability of clinical  2/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
3/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
4/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL Total patients Patients with unrecognized invasive carcinoma Patient age (yr)0No.,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
"As shown in Table 3 , this was significantly  increased for patients in the highest tertile of age, for patients with a lesion size ≥20 mm,  5/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL Table 2.",Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
It must be noted that our result  6/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL Table 3.,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
7/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
PUBMED 8/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
PUBMED  | CROSSREF 9/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
PUBMED  | CROSSREF 10/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e27Vulvoscopy in vulvar high-grade SIL,Non-OADS,/arxiv_data1/oa_pdf/92/3a/jgo-28-e27.PMC5447137.pdf
1/2 https://ejgo.orgABSTRACT Objective:  Sentinel lymph node (SLN) mapping is being adapted to gynecologic cancer.,Non-OADS,/arxiv_data1/oa_pdf/b5/54/jgo-28-e29.PMC5447138.pdf
"2017 Jul;28(4):e29 https://doi.org/10.3802/jgo.2017.28.e29 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Dec 25, 2016 Revised:  Jan 10, 2017 Accepted:  Jan 22, 2017 Correspondence to Eun Ji Nam Department of Obstetrics and Gynecology,  Institute of Women's Medical Life Science,  Yonsei University College of Medicine, 50-1  Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.",Non-OADS,/arxiv_data1/oa_pdf/b5/54/jgo-28-e29.PMC5447138.pdf
"ORCID In Ok Lee https://orcid.org/0000-0003-3189-701X Jung-Yun Lee https://orcid.org/0000-0001-7948-1350In Ok Lee, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Eun Ji Nam Department of Obstetrics and Gynecology, Institute of Women's Medical Life Science, Yonsei University  College of Medicine, Seoul, KoreaSentinel lymph node mapping with  indocyanine green in vaginal cancer",Non-OADS,/arxiv_data1/oa_pdf/b5/54/jgo-28-e29.PMC5447138.pdf
2/2 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e29 SLN Mapping with ICG in vaginal cancerVIDEO CLIP Sentinel lymph node mapping with indocyanine green in vaginal cancer.,Non-OADS,/arxiv_data1/oa_pdf/b5/54/jgo-28-e29.PMC5447138.pdf
Video can be found with this article online at https://ejgo.org/src/sm/jgo-28-e29-s001.mp4 .,Non-OADS,/arxiv_data1/oa_pdf/b5/54/jgo-28-e29.PMC5447138.pdf
Sunghoon Kim https://orcid.org/0000-0002-1645-7473 Sang Wun Kim https://orcid.org/0000-0002-8342-8701 Eun Ji Nam https://orcid.org/0000-0003-0189-3560 Conflict of Interest No potential conflict of interest relevant to this  article was reported.,Non-OADS,/arxiv_data1/oa_pdf/b5/54/jgo-28-e29.PMC5447138.pdf
"1/11 https://ejgo.orgABSTRACT Objective: To explore the genotype distribution of high-risk human papillomavirus (HR- HPV) and its attribution to different grades of cervical lesions in rural China, which will contribute to type-specific HPV screening tests and the development of new polyvalent HPV vaccines among the Chinese population.Methods: One thousand two hundred ninety-two subjects were followed based on the Shanxi Province Cervical Cancer Screening Study I (SPOCCS-I), and screened by HPV DNA testing (hybrid capture ® 2 [HC2]), liquid-based cytology (LBC), and if necessary, directed  or random colposcopy-guided quadrant biopsies.",Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
"2017 Jul;28(4):e30 https://doi.org/10.3802/jgo.2017.28.e30pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Sep 19, 2016 Revised: Jan 12, 2017 Accepted: Jan 29, 2017 Correspondence to Fang-Hui ZhaoDepartment of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, Beijing 100021, China.E-mail: zhaofangh@cicams.ac.cn Copyright © 2017.",Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
ORCID Fang-Hui Zhaohttps://orcid.org/0000-0001-9294-0005 Funding This was supported by National Natural Science Foundation of China (No.,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
All women who did not receive a hysterectomy  2/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
"After excluding 18 cases which lacked colposcopy and biopsy results (2 cases with HR-HPV  positive and ASC-US, 2 cases with LSIL, 13 cases with unsatisfactory cytology results, and   3/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions",Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
"Standard χ 2 tests were conducted to compare  4/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions /one.LP/five.LPth-year follow-up group of SPOCCS-I (n=/one.LP,/two.LP/seven.LP/four.LP ) LBC, HC/two.LP, and genotype testing Normal (n=/one.LP,/one.LP/nine.LP/nine.LP) CIN/two.LP/plus.cap (n=/three.LP/five.LP) Follow-up  TreatmentCIN/one.LP (n=/four.LP/zero.LP ) Informed consent, surveys on risk factors and history of cervical or uterine treatment Normal cytology and negative HC/two.LP (n=/eight.LP/nine.LP/four.LP)Abnormal cytology (≥ASC-US) or positive HC/two.LP (n=/three.LP/eight.LP/zero.LP) Colposcopy (n=/three.LP/five.LP/two.LP) (/two.LP/nine.LP/nine.LP normal; /five.LP/three.LP abnormal) Pathological diagnosis (n=/one.LP/four.LP/six.LP) (/four.LP/nine.LP directed biopsy, /nine.LP/seven.LP/four.LP -quadrant punch biopsy, and /one.LP/zero.LP/five.LP ECC) Determine the ﬁnal outcomes according to LBC and HCt/two.LP  resultsOthers (n=/two.LP/zero.LP/six.LP)Others (n=/two.LP/eight.LP) Fig.",Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
5/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions Table 1.,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
"In total, HPV52, 31, 16, 33, 39, and 56 combined  6/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions Table 2.",Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
7/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions 10 All types0Prevalence (%)A HPVMultiple infection Single infectionNormal pathology (n=/one.LP/three.LP/three.LP) 20304050 60708090100 58 52 56 51 33 16 18 31 39 59/five.LP./three.LP /one.LP/two.LP./zero.LP/three.LP./eight.LP /five.LP./three.LP/three.LP./eight.LP /four.LP./five.LP/six.LP./eight.LP /zero.LP./eight.LP /zero.LP./zero.LP /three.LP./zero.LP/six.LP./zero.LP /five.LP./zero.LP/four.LP./five.LP /nine.LP./zero.LP/seven.LP./five.LP /six.LP./eight.LP/six.LP./eight.LP /seven.LP./five.LP/six.LP./eight.LP /one.LP/two.LP./eight.LP/two.LP/two.LP./six.LP /seven.LP/seven.LP./four.LP B 10 All types0Prevalence (%) HPVMultiple infection Single infectionCIN/one.LP /parenleft.capn=/two.LP/nine.LP) 20304050 60708090100 52 31 16 33 39 56 18 68 35 58/one.LP/seven.LP./two.LP /eight.LP/two.LP./eight.LP /three.LP./four.LP /two.LP/zero.LP./seven.LP /six.LP./nine.LP /one.LP/three.LP./eight.LP/three.LP./four.LP /one.LP/zero.LP./three.LP/three.LP./four.LP /six.LP./nine.LP/three.LP./four.LP /three.LP./four.LP/three.LP./four.LP /three.LP./four.LP/zero.LP./zero.LP /one.LP/three.LP./eight.LP /zero.LP./zero.LP /one.LP/zero.LP./three.LP/three.LP./four.LP /zero.LP./zero.LP /three.LP./four.LP /zero.LP./zero.LP C 90100 10 All types0Prevalence (%) HPVMultiple infection Single infectionCIN/two.LP/plus.cap /parenleft.cap n=/three.LP/two.LP)/one.LP/two.LP./five.LP /eight.LP/seven.LP./five.LP 20304050 607080 16 58 33 51 52 31 35 45 56/six.LP./three.LP /four.LP/six.LP./nine.LP /six.LP./three.LP /nine.LP./four.LP/zero.LP./zero.LP /one.LP/two.LP./five.LP/three.LP./one.LP /six.LP./three.LP/zero.LP./zero.LP /six.LP./three.LP/three.LP./one.LP/zero.LP./zero.LP/three.LP./one.LP/zero.LP./zero.LP /three.LP./one.LP/zero.LP./zero.LP/zero.LP./zero.LP/three.LP./one.LP Fig.,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
"As a result, its prevalence and attribution  8/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions",Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
Available from: http://globocan.iarc.fr.,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
Available from: http://www.who.int/cancer/publications/9241547006/en/.,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
PUBMED | CROSSREF 9/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
PUBMED | CROSSREF 10/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
PUBMED | CROSSREF 11/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e30HR-HPV genotype distribution in cervical lesions,Non-OADS,/arxiv_data1/oa_pdf/5f/b2/jgo-28-e30.PMC5447139.pdf
"1/9 https://ejgo.orgABSTRACT Objective:  Some, but not all, granulosa cell tumors are characterized by estrogen production.",Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
"2017 Jul;28(4):e31 https://doi.org/10.3802/jgo.2017.28.e31 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Oct 11, 2016 Revised:  Dec 8, 2016 Accepted:  Jan 29, 2017 Correspondence to Kaoru Abiko Department of Obstetrics and Gynecology,  Kyoto University Graduate School of Medicine,  54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto  606-8507, Japan.",Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
"ORCID Sachiko Kitamura https://orcid.org/0000-0001-9127-3781 Kaoru Abiko https://orcid.org/0000-0001-9648-158X Noriomi Matsumura https://orcid.org/0000-0002-4512-7975 Hidekatsu Nakai https://orcid.org/0000-0002-9994-2131 Yumiko Akimoto https://orcid.org/0000-0002-3206-0222 Hirotoshi Tanimoto https://orcid.org/0000-0002-0463-8760 Ikuo Konishi https://orcid.org/0000-0002-4284-9569Sachiko Kitamura,1 Kaoru Abiko,1 Noriomi Matsumura,1 Hidekatsu Nakai,2   Yumiko Akimoto,3 Hirotoshi Tanimoto,3 Ikuo Konishi1 1Department of Obstetrics and Gynecology, Kyoto University Graduate School of Medicine, Kyoto, Japan 2Department of Obstetrics and Gynecology, Kinki University Hospital, Osaka, Japan 3Department of Obstetrics and Gynecology, Hiroshima City Asa Citizens Hospital, Hiroshima, JapanAdult granulosa cell tumors of the  ovary: a retrospective study of 30  cases with respect to the expression  of steroid synthesis enzymes",Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
"Abnormal genital bleeding,  2/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e31Adult granulosa cell tumors of the ovary",Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
"In  the former group, the mean endometrial thickness was 4.0 mm, whereas a large uterus  3/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e31Adult granulosa cell tumors of the ovary Table 1.",Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
4/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e31Adult granulosa cell tumors of the ovary A B Age* 20 10 5 0 <50 ≥50Em thickness (mm)1525 Fig.,Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
"Collectively, our data  5/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e31Adult granulosa cell tumors of the ovary H&E Inhibin ɑ P/four.LP/five.LP/zero.LP aromatase Fig.",Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
6/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e31Adult granulosa cell tumors of the ovary A B Cns 40 0 NegativeAge60 2080 Weakly positive Strongly positive 100 0 NegativeSerum E /two.LP (pg/mL)150200 50250 Weakly positive Strongly positiveH&E  H&E H&EP/four.LP/five.LP/zero.LPc/one.LP/seven.LP strongly positive  P/four.LP/five.LP/zero.LPc/one.LP/seven.LP weakly positive P/four.LP/five.LP/zero.LPc/one.LP/seven.LP weakly positive ** 5 0No.,Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
7/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e31Adult granulosa cell tumors of the ovary,Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
PUBMED  | CROSSREF 8/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e31Adult granulosa cell tumors of the ovary,Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
PUBMED  | CROSSREF 9/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e31Adult granulosa cell tumors of the ovary,Non-OADS,/arxiv_data1/oa_pdf/87/94/jgo-28-e31.PMC5447140.pdf
1/6 https://ejgo.orgABSTRACT Objective:  To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in  patients with prior taxane HSR.,Non-OADS,/arxiv_data1/oa_pdf/21/03/jgo-28-e38.PMC5447141.pdf
"2017 Jul;28(4):e38 https://doi.org/10.3802/jgo.2017.28.e38 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Aug 8, 2016 Revised:  Feb 9, 2017 Accepted:  Feb 15, 2017 Correspondence to Kathryn Maurer Division of Gynecologic Oncology, OB/GYN  and Women's Health Institute, 9500 Euclid  Avenue, Cleveland, OH 44195, USA.",Non-OADS,/arxiv_data1/oa_pdf/21/03/jgo-28-e38.PMC5447141.pdf
ORCID Kathryn Maurer https://orcid.org/0000-0002-5917-0173 Chad Michener https://orcid.org/0000-0001-5170-6626 Haider Mahdi https://orcid.org/0000-0002-6343-5314 Peter G. Rose https://orcid.org/0000-0001-7705-3432 Conflict of Interest No potential conflict of interest relevant to this  article was reported.,Non-OADS,/arxiv_data1/oa_pdf/21/03/jgo-28-e38.PMC5447141.pdf
Six women (16.2%) had a prior  HSR to both paclitaxel and docetaxel while the other 31 (83.8%) women had not received  2/6 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e38No hypersensitivity reactions with nab-paclitaxel,Non-OADS,/arxiv_data1/oa_pdf/21/03/jgo-28-e38.PMC5447141.pdf
"Agents received  in combination were: carboplatin (n=28, 75.7%), intraperitoneal cisplatin (n=1, 2.7%),  3/6 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e38No hypersensitivity reactions with nab-paclitaxel Table 1.",Non-OADS,/arxiv_data1/oa_pdf/21/03/jgo-28-e38.PMC5447141.pdf
4/6 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e38No hypersensitivity reactions with nab-paclitaxel,Non-OADS,/arxiv_data1/oa_pdf/21/03/jgo-28-e38.PMC5447141.pdf
PUBMED  | CROSSREF 5/6 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e38No hypersensitivity reactions with nab-paclitaxel Table 2.,Non-OADS,/arxiv_data1/oa_pdf/21/03/jgo-28-e38.PMC5447141.pdf
PUBMED  | CROSSREF 6/6 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e38No hypersensitivity reactions with nab-paclitaxel,Non-OADS,/arxiv_data1/oa_pdf/21/03/jgo-28-e38.PMC5447141.pdf
1/12 https://ejgo.orgABSTRACT Objective:  To define genetic profiling of homologous recombination (HR) deficiency in  Chinese ovarian cancer patients.,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
"2017 Jul;28(4):e39 https://doi.org/10.3802/jgo.2017.28.e39 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Jan 18, 2017 Revised:  Feb 21, 2017 Accepted:  Mar 3, 2017 Correspondence to Keng Shen Department of Obstetrics and Gynecology,  Peking Union Medical College Hospital, No.",Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
"ORCID Qianying Zhao https://orcid.org/0000-0003-3026-4827 Jiaxin Yang https://orcid.org/0000-0001-9286-0558 Dongyan Cao https://orcid.org/0000-0002-7260-2495 Keng Shen https://orcid.org/0000-0003-3867-7407Qianying Zhao,1,* Jiaxin Yang,1,* Lei Li,1 Dongyan Cao,1 Mei Yu,1 Keng Shen,1   BGI Group2 1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of  Medical Sciences and Peking Union Medical College, Beijing, China 2BGI Group, Shenzhen, ChinaGermline and somatic mutations in  homologous recombination genes  among Chinese ovarian cancer  patients detected using next- generation sequencing",Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
The diagnosis for the case of  2/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
The 1st degree family history referred to hereditary breast and ovarian cancer (HBOC) and  3/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
4/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer Table 1.,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
5/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer A Germline Somatic Negative leucinerich/two.LP/seven.LP /parenleft.cap/five.LP/four.LP/parenright.cap/one.LP/eight.LP /parenleft.cap/three.LP/six.LP/parenright.cap /five.LP /parenleft.cap/one.LP/zero.LP/parenright.cap/eight.LP /parenleft.cap/three.LP/eight.LP./one.LP/zero.LP/parenright.cap/four.LP /parenleft.cap/one.LP/nine.LP./zero.LP/five.LP/parenright.cap/one.LP /parenleft.cap/two.LP/zero.LP/parenright.cap /one.LP /parenleft.cap/two.LP/zero.LP/parenright.cap/one.LP /parenleft.cap/two.LP/zero.LP/parenright.cap /one.LP /parenleft.cap/two.LP/zero.LP/parenright.cap /two.LP /parenleft.cap/four.LP/zero.LP/parenright.cap/three.LP /parenleft.cap/one.LP/four.LP./two.LP/nine.LP/parenright.cap /two.LP /parenleft.cap/nine.LP./five.LP/two.LP/parenright.cap/two.LP /parenleft.cap/nine.LP./five.LP/two.LP/parenright.cap /one.LP /parenleft.cap/four.LP./seven.LP/six.LP/parenright.cap /one.LP /parenleft.cap/four.LP./seven.LP/six.LP/parenright.capB ATR BRCA 1 BRCA2 CHEK2 RAD50 RAD52 RAD54BC BRCA 1 BRCA2 RAD50 RAD54B Fig.,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
Forty-three out of 48  6/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer Table 2.,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
"3A ): patients with mutations in other HR  genes had a median survival of 30.6 m, compared with 63.4 m for patients without any HR  7/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer APlatinum sensitivity rate (%)100 80 60 2040 0 BRCA /one.LP/slash.cap/two.LP Other HR NoneSensitive ResistantBRemission proportion (%)100 80 60 2040 0 BRCA /one.LP/slash.cap/two.LP Other HR NoneRemission Non-remission Fig.",Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
In our  8/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer A B Time (mo)0.6 0.40.2 0 500.81.0 10 20 30 40 50 10 20 30 40 Time (mo)0.60.40.2 00.81.0Progression-free survival Progression-free survivalNoneOther HRBRCA/one.LP/slash.cap/two.LP Residual ≥/one.LP cmResidual /less.cap/one.LP cm Fig.,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
9/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
PUBMED  | CROSSREF 10/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
PUBMED  | CROSSREF 11/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
Available  from: http://www.sign.ac.uk/.,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
PUBMED  | CROSSREF 12/12 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e39Homologous recombination defect in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/65/ee/jgo-28-e39.PMC5447142.pdf
1/10 https://ejgo.orgABSTRACT Objective:  Ovarian needle aspiration and biopsy (ONAB) may be employed for pretreatment  diagnosis of ovarian malignancies or intraoperatively to facilitate removal of ovarian masses.,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
"2017 Jul;28(4):e40 https://doi.org/10.3802/jgo.2017.28.e40 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Nov 4, 2016 Revised:  Feb 16, 2017 Accepted:  Mar 3, 2017 Correspondence to Kimberly Nagamine Department of Obstetrics, Gynecology, and  Women's Health, University of Hawaii, 1319  Punahou Street, Suite 824, Honolulu,   HI 96826, USA.",Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
"ORCID Kimberly Nagamine https://orcid.org/0000-0002-8103-3503 Jordan Kondo https://orcid.org/0000-0002-8661-5174 Ricky Kaneshiro https://orcid.org/0000-0001-9170-3753 Pamela Tauchi-Nishi https://orcid.org/0000-0003-3880-172X Keith Terada https://orcid.org/0000-0002-8216-9955 Conflict of Interest No potential conflict of interest relevant to this  article was reported.Kimberly Nagamine,1 Jordan Kondo,2 Ricky Kaneshiro,2 Pamela Tauchi-Nishi,2,3  Keith Terada1 1Department of Obstetrics, Gynecology, and Women's Health, University of Hawaii, Honolulu, HI, USA 2Department of Pathology, The Queen's Medical Center, Honolulu, HI, USA 3Department of Pathology, University of Hawaii, Honolulu, HI, USAOvarian needle aspiration in the  diagnosis and management of ovarian  masses",Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
ROSE was not performed during any of the ovarian cyst  2/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
"3/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology /one.LP/four.LP/four.LP Masses /nine.LP Solid  /one.LP/three.LP/five.LP Cystic /one.LP Malignant (Histology)  by gynecology /eight.LP Malignant (Histology)  /one.LP Benign (Histology) /one.LP Benign (Cytology)  /eight.LP Malignant (Cytology)  /one.LP Malignant (Cytology)  /one.LP/three.LP/four.LP Benign (Cytology) /three.LP Malignant (Histology) /two.LP by gynecology /one.LP by surgeon /one.LP/three.LP/one.LP Benign (Histology) /one.LP/one.LP/nine.LP by gynecology/three.LP by surgeons/nine.LP by otherRadiologists Gynecology, surgeons, other Fig.",Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
4/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology Table 1.,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
The overall sensitivity and specificity of ovarian needle aspiration and biopsy  5/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology Table 3.,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
6/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology Fig.,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
There are no reports of such adverse complications in the  7/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology Fig.,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
8/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
PUBMED  | CROSSREF 9/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
PUBMED  | CROSSREF 10/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e40Ovarian aspiration cytology,Non-OADS,/arxiv_data1/oa_pdf/61/de/jgo-28-e40.PMC5447143.pdf
1/10 https://ejgo.orgABSTRACT Objective:  To determine the impact of time interval (TI) from radical hysterectomy with pelvic  node dissection (RHND) to adjuvant therapy on oncological outcomes in cervical cancer.,Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
"2017 Jul;28(4):e42 https://doi.org/10.3802/jgo.2017.28.e42 pISSN 2005-0380·eISSN 2005-0399 Original Article Jitti Hanprasertpong,1 Ingporn Jiamset,1 Alan Geater,2 Kittinun Leetanaporn,1  Thanarpan Peerawong3 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Prince  of Songkla University, Songkhla, Thailand 2Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand 3Department of Radiology, Faculty of Medicine, Prince of Songkla University, Songkhla, ThailandImpact of time interval between  radical hysterectomy with pelvic  node dissection and initial adjuvant  therapy on oncological outcomes of  early stage cervical cancer Received:  Jan 24, 2017 Revised:  Mar 5, 2017 Accepted:  Mar 5, 2017 Correspondence to Jitti Hanprasertpong Division of Gynecologic Oncology,  Department of Obstetrics and Gynecology,  Faculty of Medicine, Prince of Songkla  University, 15 Karnjanavanich Road, Hat Yai,  Songkhla 90110, Thailand.",Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
ORCID Jitti Hanprasertpong https://orcid.org/0000-0002-0640-6824 Ingporn Jiamset https://orcid.org/0000-0002-5771-2557 Alan Geater https://orcid.org/0000-0003-1219-9814 Kittinun Leetanaporn https://orcid.org/0000-0002-7621-4510 Thanarpan Peerawong https://orcid.org/0000-0003-1725-6355,Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
"Details on clinicopathologic variables and clinical data from the medical records (age,  tumor size, stage, histology, lymph-vascular space invasion [LVSI], DSI, lymph node status,  2/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer",Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
"DSI, PI, and the interaction between histology and time  3/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer",Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
"The 2 TI groups did not differ in age,  4/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer Table 1.",Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
On  5/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer Table 2.,Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
6/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer Table 3.,Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
A study  7/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
PUBMED  | CROSSREF 8/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
PUBMED 9/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
PUBMED  | CROSSREF 10/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e42Timing of adjuvant therapy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/ab/a3/jgo-28-e42.PMC5447144.pdf
1/14 https://ejgo.orgABSTRACT Objective:  To evaluate the prognostic value of metabolic parameters measured by  preoperative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/ computed tomography (CT) in patients with uterine carcinosarcoma (UCS).,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
"2017 Jul;28(4):e43 https://doi.org/10.3802/jgo.2017.28.e43 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Nov 20, 2016 Revised:  Feb 20, 2017 Accepted:  Mar 6, 2017 Correspondence to Jeong-Yeol Park Department of Obstetrics and Gynecology,  University of Ulsan College of Medicine,  Asan Medical Center, 88 Olympic-ro 43-gil,  Songpa-gu, Seoul 05505, Korea.",Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
ORCID Hyun Ju Lee https://orcid.org/0000-0003-0115-1022 Jeong-Yeol Park https://orcid.org/0000-0003-2475-7123 Conflict of Interest No potential conflict of interest relevant to this  article was reported.,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
2/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
3/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
"Cutoff values of metabolic parameters as predictors of disease progression  and death Using the time-dependent ROC curve for primary tumors, optimal cutoff values for  predicting 3-year disease progression were 8.33 (area under the curve [AUC]=0.541;  sensitivity, 75.4%; specificity, 49.5%), 63.92 mL (AUC=0.755; sensitivity, 66.2%; specificity,  4/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma",Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
5/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma Table 1.,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
"The analysis of metabolic  parameters as continuous variables determined that SUV max (p=0.873), MTV 2.5 (p=0.070),  6/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma Table 2.",Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
"Similarly, the 3-year OS rates in patients with low vs. high  SUV max, MTV 2.5, and TLG 2.5 were 71.4% vs. 45.6% (p=0.147), 71.0% vs. 31.3% (p=0.011), and  7/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma Table 3.",Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
8/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma p=/zero.LP./one.LP/four.LP/one.LP p=/zero.LP./zero.LP/one.LP/three.LPSUV max ≥/eight.LP./three.LP/three.LPA Time (mo)0.6 0.40.2 0 1200.81.0 100 20 40 60 80Progression-free survival F 120 100 20 40 60 80 Time (mo)0.60.40.2 00.81.0Overall survivalSUV max /less.cap/eight.LP./three.LP/three.LP TLG /two.LP./five.LP ≥/three.LP/nine.LP/six.LP./one.LP/six.LPTLG /two.LP./five.LP /less.cap/three.LP/nine.LP/six.LP./one.LP/six.LPp=/zero.LP./zero.LP/zero.LP/two.LPB 120 100 20 40 60 80 Time (mo)0.60.40.2 00.81.0Progression-free survivalMTV /two.LP./five.LP ≥/six.LP/three.LP./nine.LP/two.LPMTV /two.LP./five.LP /less.cap/six.LP/three.LP./nine.LP/two.LPp=/zero.LP./one.LP/four.LP/seven.LPD 120 100 20 40 60 80 Time (mo)0.60.40.2 00.81.0Overall survivalSUV max ≥/eight.LP./three.LP/three.LPSUV max /less.cap/eight.LP./three.LP/three.LP p=/zero.LP./zero.LP/one.LP/one.LPC Time (mo)0.60.40.2 0 1200.81.0 100 20 40 60 80Progression-free survivalTLG /two.LP./five.LP ≥/three.LP/nine.LP/six.LP./one.LP/six.LPTLG /two.LP./five.LP /less.cap/three.LP/nine.LP/six.LP./one.LP/six.LPp=/zero.LP./zero.LP/one.LP/one.LPE Time (mo)0.60.40.2 0 1200.81.0 100 20 40 60 80Overall survivalMTV /two.LP./five.LP ≥/six.LP/three.LP./nine.LP/two.LPMTV /two.LP./five.LP /less.cap/six.LP/three.LP./nine.LP/two.LP Fig.,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
9/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma Table 4.,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
10/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
Click here to view 11/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
PUBMED  | CROSSREF 12/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
PUBMED  | CROSSREF 13/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
PUBMED 14/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e43Metabolic biomarkers of uterine carcinosarcoma,Non-OADS,/arxiv_data1/oa_pdf/6b/dd/jgo-28-e43.PMC5447145.pdf
1/11 https://ejgo.orgABSTRACT Objective:  To evaluate the oncologic safety of ovarian preservation (OP) in premenopausal  women diagnosed with the International Federation of Gynecology and Obstetrics (FIGO)  stage I uterine sarcoma.,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
"2017 Jul;28(4):e46 https://doi.org/10.3802/jgo.2017.28.e46 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Feb 16, 2017 Revised:  Mar 7, 2017 Accepted:  Mar 12, 2017 Correspondence to Dimitrios Nasioudis Department of Obstetrics and Gynecology,  Weill Cornell Medicine, 1300 York Avenue, Box  35, New York, NY 10065, USA.",Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
ORCID Dimitrios Nasioudis https://orcid.org/0000-0001-6260-5353 Eloise Chapman-Davis https://orcid.org/0000-0002-1349-8579 Melissa Frey https://orcid.org/0000-0002-6705-1211 Kevin Holcomb https://orcid.org/0000-0002-6916-5271 Conflict of Interest No potential conflict of interest relevant to this  article was reported.,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
"Moreover, given that the administration of radiation therapy can have a negative  2/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma",Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
"For cases of  AS, 69 (58%) women had stage IA while 42 (35.3%) and 8 (6.7%) had stage IB and IC disease,  3/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma",Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
4/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma Time (mo)0.6 0.40.2 0 50 100 150 200Overall survival 0.81.0 250 300Hysterectomy without oophorectomy Hysterectomy with oophorectomy Hysterectomy without oophorectomy -censored Hysterectomy with oophorectomy -censored Fig.,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
5/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma Time (mo)0.6 0.40.2 0 50 100 150 200Overall survival 0.81.0 250 300Hysterectomy without oophorectomy Hysterectomy with oophorectomy Hysterectomy without oophorectomy -censored Hysterectomy with oophorectomy -censored Fig.,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
6/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma Time (mo)0.6 0.40.2 0 50 100 150 200Overall survival 0.81.0 250 300Hysterectomy without oophorectomy Hysterectomy with oophorectomy Hysterectomy without oophorectomy -censored Hysterectomy with oophorectomy -censored Fig.,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
[ 6] reported a lower recurrence  rate for premenopausal women who underwent BSO (n=34) compared to those who did not  7/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma Table 1.,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
8/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
PUBMED  | CROSSREF 9/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
Available from: https://seer.cancer.gov/resources/.,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
Available from: https://seer.cancer.gov/ data/citation.html.,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
PUBMED  | CROSSREF 10/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
PUBMED  | CROSSREF 11/11 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e46Ovarian preservation for uterine sarcoma,Non-OADS,/arxiv_data1/oa_pdf/cb/1e/jgo-28-e46.PMC5447146.pdf
"1/10 https://ejgo.orgABSTRACT Objective:  To investigate the survival outcomes in patients with bulky stage IIIC and IV  ovarian cancer, treated by primary debulking surgery (PDS) and selective use of neoadjuvant  chemotherapy (NAC) according to institutional criteria.",Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
"2017 Jul;28(4):e48 https://doi.org/10.3802/jgo.2017.28.e48 pISSN 2005-0380·eISSN 2005-0399 Original Article Myong Cheol Lim,1,4,5,6 Heong Jong Yoo,4,7 Yong Jung Song,4,8 Sang-Soo Seo,4  Sokbom Kang,2,4,6 Sun Ho Kim,4 Chong Woo Yoo,4 Sang-Yoon Park3,4 1Cancer Healthcare Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea.",Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
ORCID Myong Cheol Lim https://orcid.org/0000-0001-8964-7158 Yong Jung Song https://orcid.org/0000-0002-6103-2466 Sokbom Kang https://orcid.org/0000-0002-8428-9555 Sang-Yoon Park https://orcid.org/0000-0001-8325-6009 Conflict of Interest No potential conflict of interest relevant to this  article was reported.,Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
"Patients with bulky stage IIIC and IV ovarian, tubal, and primary  2/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer",Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
"Posttreatment surveillance included imaging  studies such as sonography, CT, magnetic resonance imaging (MRI), or positron emission  tomography (PET)/CT and serum CA125 every 3 months for 2–3 years and then every  3/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer Table 1.",Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
"Median age at NCC  seems to be lower than that of MSKCC (60 years) and the EORTC trial (62 and 63 years for the  4/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer Stage III, IV patients (n=/three.LP/one.LP/six.LP) identiﬁed from database of ovarian cancer surgery between December /two.LP/zero.LP/zero.LP/zero.LP and March /two.LP/zero.LP/zero.LP/nine.LP Exclusion of IIIA, IIIB (n=/two.LP/four.LP/parenright.cap Isolated lymph node metastasis IIIC (n=/one.LP/three.LP/parenright.cap Optimal cytoreduction /nine.LP/six.LP% (n=/one.LP/three.LP/seven.LP)  Complete cytoreduction /six.LP/six.LP% (n=/nine.LP/four.LP) Suboptimal cytoreduction /four.LP% (n=/six.LP) Optimal cytoreduction /nine.LP/six.LP% (n=/one.LP/three.LP/one.LP)  Complete cytoreduction /eight.LP/zero.LP% (n=/one.LP/zero.LP/eight.LP) Suboptimal cytoreduction /four.LP% (n=/five.LP) All patients “eligible” for study (n=/two.LP/seven.LP/nine.LP/parenright.cap PDS /five.LP/one.LP% (n=/one.LP/four.LP/three.LP/parenright.cap  NAC /plus.capPDS /four.LP/nine.LP% (n=/one.LP/three.LP/six.LP/parenright.cap Fig.",Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
5/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer Table 2.,Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
6/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer A Time (mo)0.50 0.25 0 24 48 72 84 108 120Progression-free survival0.751.00 0.500.250.751.00 12 36 60 96 24 48 72 84 108 120 12 36 60 96 0B Time (mo)Overall survival p=/zero.LP./two.LP/five.LP/two.LP p=/zero.LP./zero.LP/three.LP/three.LPNAC (n=/one.LP/four.LP/three.LP) PDS (n=/one.LP/three.LP/six.LP)NAC (n=/one.LP/four.LP/three.LP) PDS (n=/one.LP/three.LP/six.LP) Fig.,Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
"Therefore,  7/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer",Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
PUBMED  | CROSSREF 8/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
PUBMED  | CROSSREF 9/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
PUBMED  | CROSSREF 10/10 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e48Neoadjuvant chemotherapy in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/8a/d2/jgo-28-e48.PMC5447147.pdf
"1/13 https://ejgo.orgABSTRACT Objective:  To assess the prognosis of surgically-staged non-invasive uterine clear cell  carcinoma (UCCC), and to determine the role of adjuvant therapy.",Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
"2017 Jul;28(4):e49 https://doi.org/10.3802/jgo.2017.28.e49 pISSN 2005-0380·eISSN 2005-0399 Original Article Mustafa Erkan Sarı,1 Mehmet Mutlu Meydanlı,1 Osman Türkmen,2   Günsü Kimyon Cömert,2 Ahmet Taner Turan,2 Alper Karalök,2 Hanifi Şahin,1   Ali Haberal,3 Eda Kocaman,3 Özgür Akbayır,4 Baki Erdem,4 Ceyhun Numanoğlu,4  Kemal Güngördük,5 Muzaffer Sancı,5 Mehmet Gökçü,5 Nejat Özgül,6   Mehmet Coşkun Salman,6 Gökhan Boyraz,6 Kunter Yüce,6 Tayfun Güngör,1   Salih Taşkın,7 Duygun Altın,7 Uğur Fırat Ortaç,7 Hülya Aydın Ayık,8 Tayup Şimşek,8  Macit Arvas,9 and Ali Ayhan3 1 Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital,  Faculty of Medicine, University of Health Sciences, Ankara, Turkey 2 Department of Gynecologic Oncology, Etlik Zubeyde Hanım Women's Health Teaching and Research  Hospital, Ankara, Turkey 3 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent  University, Ankara, Turkey 4 Department of Gynecologic Oncology, Kanuni Sultan Suleyman Teaching and Research Hospital, Istanbul,  Turkey 5Department of Gynecologic Oncology, Tepecik Education and Research Hospital, Izmir, Turkey 6 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine,  Hacettepe University, Ankara, Turkey 7 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Ankara  University, Ankara, Turkey 8 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Akdeniz  University, Antalya, Turkey 9 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cerrahpasa Faculty of  Medicine, Istanbul University, Istanbul, TurkeyPrognostic factors and treatment  outcomes in surgically-staged non- invasive uterine clear cell carcinoma:  a Turkish Gynecologic Oncology Group  study Received:  Feb 2, 2017 Revised:  Mar 13, 2017 Accepted:  Apr 9, 2017 Correspondence to Mustafa Erkan Sarı Department of Gynecologic Oncology,  Zekai Tahir Burak Women's Health Training  and Research Hospital, Talatpasa Bulvari,  Hamamonu, Altindag/Ankara 06230, Turkey.",Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
ORCID Mustafa Erkan Sarı https://orcid.org/0000-0003-1202-9823 Mehmet Mutlu Meydanlı https://orcid.org/0000-0001-6763-9720 Osman Türkmen https://orcid.org/0000-0002-1470-7731 Günsü Kimyon Cömert https://orcid.org/0000-0003-0178-4196 Ahmet Taner Turan https://orcid.org/0000-0001-8120-1143 Alper Karalök https://orcid.org/0000-0002-0059-8773 Hanifi Şahin https://orcid.org/0000-0001-8522-9119 Ali Haberal https://orcid.org/0000-0002-1486-7209 Eda Kocaman https://orcid.org/0000-0002-1741-7035,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
Özgür Akbayır https://orcid.org/0000-0002-2699-4969 Baki Erdem https://orcid.org/0000-0002-6407-8718 Ceyhun Numanoğlu https://orcid.org/0000-0003-4164-1763 Kemal Güngördük https://orcid.org/0000-0002-2325-1756 Muzaffer Sancı https://orcid.org/0000-0002-8494-4302 Mehmet Gökçü https://orcid.org/0000-0002-3187-2317 Nejat Özgül https://orcid.org/0000-0002-4257-9431 Mehmet Coşkun Salman https://orcid.org/0000-0003-1504-1756 Gökhan Boyraz https://orcid.org/0000-0001-6165-1497 Kunter Yüce https://orcid.org/0000-0001-7768-8278 Tayfun Güngör https://orcid.org/0000-0002-3261-1186 Salih Taşkın https://orcid.org/0000-0002-9651-2224 Duygun Altın https://orcid.org/0000-0002-9072-9393 Uğur Fırat Ortaç https://orcid.org/0000-0001-6735-5760 Hülya Aydın Ayık https://orcid.org/0000-0002-3028-7247 Tayup Şimşek https://orcid.org/0000-0003-1088-3970 Macit Arvas https://orcid.org/0000-0003-2548-1667 Ali Ayhan https://orcid.org/0000-0001-7155-9096 Conflict of Interest No potential conflict of interest relevant to this  article was reported.,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
2/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
In order to evaluate  3/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
"One patient (1.9%) with non-invasive UCCC was defined as “vanishing endometrial cancer”  4/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma Patients with endometrial cancer (n=/seven.LP,/four.LP/nine.LP/five.LP) /two.LP/three.LP/two.LP UCCC (/three.LP./one.LP %) Excluded with synchronous malignancy, incomplete medical records, lack of follow-up, and incomplete staging (n=/one.LP/one.LP) Patients with complete surgical staging (ﬁnal analysis) (n=/five.LP/three.LP) Limited to the endometrium (n=/four.LP/one.LP)  Extra-uterine disease (n=/one.LP/two.LP) Adjuvant treatment (n=/two.LP/eight.LP) No adjuvant treatment (n=/one.LP/three.LP) UCCC with myometrial invasion (n=/one.LP/six.LP/eight.LP)  UCCC without myometrial invasion (n=/six.LP/four.LP) Fig.",Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
"Of those, 1 had stage IIIA, 1 had stage  5/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma Table 1.",Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
She was dead of  6/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma Table 2.,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
7/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma Time (mo)0.6 0.40.2 0 20 40 60 80Overall survival 0.81.0 100 120p=/zero.LP./zero.LP/four.LP/five.LPAdjuvant treatment Present Absent Absent-censoredPresent-censored Fig.,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
8/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma Table 5.,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
The  authors characterized omentectomy as a surgical procedure that may not be necessary and  suggested close inspection of the omentum and all peritoneal surfaces including the bowel  9/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma A Time (mo)0.6 0.4 0.2 0 20 40 60 80 100 120Disease-free survival 0.81.0 0 20 40 60 80 100 120B Time (mo)0.6 0.4 0.2Overall survival0.81.0 p</zero.LP./zero.LP/zero.LP/one.LP p</zero.LP./zero.LP/zero.LP/one.LPExtra-uterine disease Present Absent Absent-censoredPresent-censoredExtra-uterine disease Present Absent Absent-censoredPresent-censored Fig.,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
10/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
11/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
PUBMED 12/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
PUBMED  | CROSSREF 13/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e49Non-invasive uterine clear cell carcinoma,Non-OADS,/arxiv_data1/oa_pdf/4c/f0/jgo-28-e49.PMC5447148.pdf
"1/4 https://ejgo.org► See the article “Germline and somatic mutations in homologous recombination genes among  Chinese ovarian cancer patients detected using next-generation sequencing” in volume 28, e39.",Non-OADS,/arxiv_data1/oa_pdf/1b/02/jgo-28-e51.PMC5447149.pdf
"2017 Jul;28(4):e51 https://doi.org/10.3802/jgo.2017.28.e51pISSN 2005-0380·eISSN 2005-0399 Editorial Received:  May 11, 2017 Accepted: May 15, 2017 Correspondence to Leslie MRandall.",Non-OADS,/arxiv_data1/oa_pdf/1b/02/jgo-28-e51.PMC5447149.pdf
"ORCID Myong Cheol Limhttps://orcid.org/0000-0001-8964-7158Leslie M. Randallhttps://orcid.org/0000-0003-3790-4858 Conflict of Interest No potential conflict of interest relevant to this article was reported.Myong Cheol Lim,1,2 Leslie M. Randall2 1 Cancer Healthcare Research Branch, Center for Uterine Cancer and Center for Clinical Trials, Research  Institute and Hospital, Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea 2 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Irvine Medical Center, University of California, Orange, CA, USARole and clinical application of next-generation sequencing (NGS) for ovarian cancer",OADS,/arxiv_data1/oa_pdf/1b/02/jgo-28-e51.PMC5447149.pdf
2/4 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e51Next-generation sequencing for ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/1b/02/jgo-28-e51.PMC5447149.pdf
PUBMED | CROSSREF 3/4 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e51Next-generation sequencing for ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/1b/02/jgo-28-e51.PMC5447149.pdf
PUBMED | CROSSREF 4/4 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e51Next-generation sequencing for ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/1b/02/jgo-28-e51.PMC5447149.pdf
1/9 https://ejgo.orgABSTRACT Objective:  Recent evidence has supported the concept that epithelial ovarian cancer (EOC)  arises from the cells of the fallopian tube or endometrium.,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
"2017 Jul;28(4):e52 https://doi.org/10.3802/jgo.2017.28.e52 pISSN 2005-0380·eISSN 2005-0399 Original Article Mikio Mikami,1 Satoru Nagase,2 Wataru Yamagami,3 Kimio Ushijma,4   Hironori Tashiro,5 Hidetaka Katabuchi,5   1Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan 2Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan 3Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan 4Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan 5 Department of Obstetrics and Gynecology, Kumamoto University Graduate School of Medicine,  Kumamoto, JapanOpportunistic bilateral salpingectomy  during benign gynecological surgery  for ovarian cancer prevention: a  survey of Gynecologic Oncology  Committee of Japan Society of  Obstetrics and Gynecology Received:  Feb 9, 2017 Revised:  Apr 10, 2017 Accepted:  Apr 14, 2017 Correspondence to Mikio Mikami Department of Obstetrics and Gynecology,  Tokai University School of Medicine, 143  Shimokasuya, Isehara, Kanagawa 259-1193,  Japan.",Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
ORCID Mikio Mikami https://orcid.org/0000-0002-7496-3518 Wataru Yamagami https://orcid.org/0000-0003-3925-6057 Kimio Ushijma https://orcid.org/0000-0002-6087-8873 Hironori Tashiro https://orcid.org/0000-0001-6236-2849 Hidetaka Katabuchi https://orcid.org/0000-0002-2403-6134,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
"In September 2016,  2/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e52Salpingectomy for ovarian cancer prevention in Japan",Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
4) The theory that EOC  arises from the fallopian tube or endometrium and not directly from the ovary was widely  known at almost 100% of institutions accredited by the JSGO or by both the JSGO and  3/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e52Salpingectomy for ovarian cancer prevention in Japan,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
Although  4/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e52Salpingectomy for ovarian cancer prevention in Japan Table 1.,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
5/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e52Salpingectomy for ovarian cancer prevention in Japan 060 408090100 2070 50 30 10 Both JSGO & JSGOETotal% JSGOE only None JSGO only9.6 28.8 17.843.8 20.6 34.9 3.241.3 25.6 15.4 5.153.8 32.8 11.5 4.451.4 25.2 19.1 6.848.9No Others Cohort survey is better Yes Fig.,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
Combined  6/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e52Salpingectomy for ovarian cancer prevention in Japan,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
Available from: http://ganjoho.jp/reg_stat/statistics/dl/index.html.,OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
Available from: http://www.aihw.gov.,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
Available from:  http://fa.kyorin.co.jp/jsog/readPDF.php?file=64/3/064031029.pdf  10.,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
PUBMED  | CROSSREF 7/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e52Salpingectomy for ovarian cancer prevention in Japan,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
PUBMED  | CROSSREF 8/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e52Salpingectomy for ovarian cancer prevention in Japan,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
We would like to ask your institution's head and other responsible persons to consult with each other in detail before answering our questions 9/9 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e52Salpingectomy for ovarian cancer prevention in Japan  1.,Non-OADS,/arxiv_data1/oa_pdf/78/1f/jgo-28-e52.PMC5447150.pdf
"1/3 https://ejgo.org► See the article “Opportunistic bilateral salpingectomy during benign gynecological surgery for ovar - ian cancer prevention: a survey of Gynecologic Oncology Committee of Japan Society of Obstetrics  and Gynecology” in volume 28, e52.",Non-OADS,/arxiv_data1/oa_pdf/d4/10/jgo-28-e53.PMC5447151.pdf
"2017 Jul;28(4):e53 https://doi.org/10.3802/jgo.2017.28.e53 pISSN 2005-0380·eISSN 2005-0399 Editorial Received:  May 7, 2017 Accepted:  May 7, 2017 Correspondence to Karl Tamussino Department of Obstetrics and Gynecology,  Medical University of Graz, Auenbruggerplatz  14, A-8036, Graz, Austria.",Non-OADS,/arxiv_data1/oa_pdf/d4/10/jgo-28-e53.PMC5447151.pdf
"ORCID Karl Tamussino https://orcid.org/0000-0001-5016-4669 Conflict of Interest No potential conflict of interest relevant to this  article was reported.Karl Tamussino Department of Obstetrics and Gynecology, Medical University of Graz, Graz, AustriaShould national societies recommend  opportunistic salpingectomy?",Non-OADS,/arxiv_data1/oa_pdf/d4/10/jgo-28-e53.PMC5447151.pdf
PUBMED  | CROSSREF 2/3 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e53Opportunistic salpingectomy for ovarian cancer prevention,Non-OADS,/arxiv_data1/oa_pdf/d4/10/jgo-28-e53.PMC5447151.pdf
PUBMED  | CROSSREF 3/3 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e53Opportunistic salpingectomy for ovarian cancer prevention,Non-OADS,/arxiv_data1/oa_pdf/d4/10/jgo-28-e53.PMC5447151.pdf
"1/14 https://ejgo.orgABSTRACT There has been significant progress in the understanding of the pathology and molecular biology  of rare ovarian cancers, which has helped both diagnosis and treatment.",Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
"2017 Jul;28(4):e54 https://doi.org/10.3802/jgo.2017.28.e54 pISSN 2005-0380·eISSN 2005-0399 Review Article Ji Yon Agnes Jang,1 Nozomu Yanaihara,1 Eric Pujade-Lauraine,2 Yoshiki Mikami,3  Katsutoshi Oda,4 Michael Bookman,5 Jonathan Ledermann,6 Muneaki Shimada,7  Takako Kiyokawa,8 Byoung-Gie Kim,9 Noriomi Matsumura,10 Tsunehisa Kaku,11  Takafumi Kuroda,1 Yoko Nagayoshi,1 Ayako Kawabata,1 Yasushi Iida,1   Jae-Weon Kim,12 Michael Quinn,13 Aikou Okamoto1  1Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan  2 Unité Cancer de la Femme et Recherche Clinique, Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu,  Université Paris Descartes, Paris, France  3 Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan  4Department of Obstetrics and Gynecology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan  5US Oncology Research and Arizona Oncology, Tucson, AZ, USA  6UCL Cancer Institute, University College London, London, UK  7Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan  8Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan  9 Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center,  Sungkyunkwan University School of Medicine, Seoul, Korea 10 Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Japan 11Department of Health Sciences, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan 12Department of Obstetrics and Gynecology, Seoul National University, Seoul, Korea 13Women's Cancer Research Center, Royal Women's Hospital, Melbourne, AustraliaUpdate on rare epithelial ovarian  cancers: based on the Rare Ovarian  Tumors Young Investigator Conference Received:  Mar 2, 2017 Revised:  Apr 17, 2017 Accepted:  Apr 18, 2017 Correspondence to Nozomu Yanaihara Department of Obstetrics and Gynecology,  The Jikei University School of Medicine, 3-25-8  Nishi-Shinbashi, Minato-ku, Tokyo 105-8461,  Japan.",Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
ORCID Nozomu Yanaihara https://orcid.org/0000-0003-0160-7085 Byoung-Gie Kim https://orcid.org/0000-0002-0572-8450 Takafumi Kuroda https://orcid.org/0000-0002-2659-1449 Ayako Kawabata https://orcid.org/0000-0001-5220-4409 Jae-Weon Kim https://orcid.org/0000-0003-1835-9436 Aikou Okamoto https://orcid.org/0000-0002-5079-0464 Conflict of Interest No potential conflict of interest relevant to this  article was reported.,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
2/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update Table 1.,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
"Treatment with vemurafenib, a  3/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update Table 2.",Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
"Distinction between primary OMCs and metastatic tumors may be pathologically challenging,  although careful gross examination and thorough sampling of the tumor with assistance of  immunohistochemistry in certain situation could lead to a correct diagnosis in many of the  4/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update",Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
5/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update Table 3.,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
6/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update Table 5.,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
HNF-1 β plays multiple roles in tumorigenesis and  7/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update Table 6.,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
International  8/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
PUBMED  | CROSSREF 9/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
PUBMED  | CROSSREF 10/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
Avaliable from: https://clinicaltrials.gov/ct2/show/NCT02101788.,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
Avaliable from: https://clinicaltrials.gov/ct2/show/NCT01849874.,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
PUBMED  | CROSSREF 11/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
PUBMED  | CROSSREF 12/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
PUBMED  | CROSSREF 13/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
PUBMED  | CROSSREF 14/14 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e54Rare epithelial ovarian cancers update,Non-OADS,/arxiv_data1/oa_pdf/3a/3e/jgo-28-e54.PMC5447152.pdf
"1/3 https://ejgo.org► See the article “Prognostic factors and treatment outcomes in surgically-staged non-invasive uter - ine clear cell carcinoma: a Turkish Gynecologic Oncology Group study” in volume 28, e49.",Non-OADS,/arxiv_data1/oa_pdf/90/c5/jgo-28-e55.PMC5447153.pdf
"2017 Jul;28(4):e55 https://doi.org/10.3802/jgo.2017.28.e55pISSN 2005-0380·eISSN 2005-0399 Editorial Received:  May 9, 2017 Accepted: May 10, 2017 Correspondence to Toru SugiyamaDepartment of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan.E-mail: sugiyama@iwate-med.ac.jp Copyright © 2017.",Non-OADS,/arxiv_data1/oa_pdf/90/c5/jgo-28-e55.PMC5447153.pdf
"ORCID Toru Sugiyamahttps://orcid.org/0000-0002-2385-9040Satoshi Takeuchihttps://orcid.org/0000-0001-8868-6462Hiroaki Itamochihttps://orcid.org/0000-0002-7417-8595 Conflict of Interest No potential conflict of interest relevant to this article was reported.Toru Sugiyama, Satoshi Takeuchi, Hiroaki Itamochi Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, JapanSurgical management of non-invasive  uterine clear cell carcinoma",Non-OADS,/arxiv_data1/oa_pdf/90/c5/jgo-28-e55.PMC5447153.pdf
"Thus, total hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, and peritoneal  2/3 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e55Surgery for uterine clear cell carcinoma",Non-OADS,/arxiv_data1/oa_pdf/90/c5/jgo-28-e55.PMC5447153.pdf
PUBMED | CROSSREF 3/3 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e55Surgery for uterine clear cell carcinoma,Non-OADS,/arxiv_data1/oa_pdf/90/c5/jgo-28-e55.PMC5447153.pdf
1/13 https://ejgo.orgABSTRACT Objective:  Hypermethylation of human papillomavirus (HPV) and host genes has been  reported in cervical cancer.,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
"2017 Jul;28(4):e56 https://doi.org/10.3802/jgo.2017.28.e56 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Jan 26, 2017 Revised:  Apr 22, 2017 Accepted:  Apr 23, 2017 Correspondence to Hung-Cheng Lai Department of Obstetrics and Gynecology,  Translational Epigenetic Center, Shuang Ho  Hospital, Taipei Medical University, No.",Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
"ORCID Yaw-Wen Hsu https://orcid.org/0000-0002-7414-6358 Rui-Lan Huang https://orcid.org/0000-0001-6458-4672 Po-Hsuan Su https://orcid.org/0000-0003-1114-6382Yaw-Wen Hsu,1 Rui-Lan Huang,2,3 Po-Hsuan Su,2,3 Yu-Chih Chen,4 Hui-Chen Wang,5  Chi-Chun Liao,2,5 Hung-Cheng Lai1,2,3,5,6,7 1Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan 2 Department of Obstetrics and Gynecology, Shuang Ho Hospital, Taipei Medical University, New Taipei,  Taiwan 3Translational Epigenetic Center, Shuang Ho Hospital, Taipei Medical University, New Taipei, Taiwan 4 Division of Research and Analysis, Food and Drug Administration, Ministry of Health and Welfare, Taipei,  Taiwan 5 Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical  University, Taipei, Taiwan 6Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China 7 Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics,  Changsha, ChinaGenotype-specific methylation of HPV  in cervical intraepithelial neoplasia",Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
"Yu-Chih Chen https://orcid.org/0000-0002-5721-2317 Hui-Chen Wang https://orcid.org/0000-0002-7514-0126 Chi-Chun Liao https://orcid.org/0000-0003-4185-6254 Hung-Cheng Lai https://orcid.org/0000-0001-8048-3943 Funding This work was supported in part by grants  from Ministry of Science and Technology  (NSC 102-2628-B-038-010-MY3 and MOST  105-2628-B-038-011-MY3), Taipei Medical  University (105TMU-SHH-09), and the  Teh-Tzer Study Group for Human Medical  Research Foundation.",Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
2/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
Informed consent  3/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
"All analyses and graphs were generated using the statistical package in R (version  3.1.2; R Foundation, Vienna, Austria; https://www.R-project.org ).",OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
"In HPV18, the methylation level of 3 CpG sites in region 2, 7110m, 7116m,  4/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN",Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
5/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN /six.LP/three.LP/six.LP/eight.LP /six.LP/four.LP/zero.LP/five.LP /six.LP/four.LP/four.LP/three.LPHPV/five.LP/two.LP L/one.LP CpG siteC p-value site Meth.,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
"Correlation of HPV and candidate host gene methylation Although the HPV genome may be methylated by the host cellular defense mechanisms,  HPV may also influence the host cellular methylation mechanism to alter host genome  6/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN Table 1.",Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
One  appealing idea is to combine analysis of host and viral gene methylation to improve the  7/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN /six.LP/three.LP/six.LP/three.LP /six.LP/three.LP/six.LP/six.LP /seven.LP/zero.LP/nine.LP/zero.LP /seven.LP/one.LP/one.LP/zero.LP /seven.LP/one.LP/one.LP/six.LP /seven.LP/one.LP/two.LP/two.LPHPV/one.LP/eight.LP Region /one.LP Region /one.LPRegion /two.LP Region /two.LP/six.LP/three.LP/six.LP/six.LP/six.LP/three.LP/six.LP/three.LP /seven.LP/zero.LP/nine.LP/zero.LP /seven.LP/one.LP/one.LP/six.LP /seven.LP/one.LP/two.LP/two.LP/seven.LP/one.LP/one.LP/zero.LPB /six.LP/three.LP/six.LP/eight.LP /six.LP/four.LP/zero.LP/five.LP /six.LP/four.LP/four.LP/three.LPHPV/five.LP/two.LP /six.LP/three.LP/six.LP/eight.LP /six.LP/four.LP/zero.LP/five.LP /six.LP/four.LP/four.LP/three.LPC/six.LP/three.LP/six.LP/five.LP /six.LP/six.LP/five.LP/zero.LP/six.LP/three.LP/eight.LP/seven.LP/six.LP/three.LP/six.LP/five.LPHPV/one.LP/six.LP /six.LP/three.LP/eight.LP/seven.LP /six.LP/six.LP/five.LP/zero.LPA /six.LP/three.LP/nine.LP/six.LP /six.LP/four.LP/four.LP/six.LP /six.LP/four.LP/five.LP/seven.LP /six.LP/four.LP/eight.LP/two.LPHPV/five.LP/eight.LP /six.LP/three.LP/nine.LP/six.LP /six.LP/four.LP/four.LP/six.LP /six.LP/four.LP/five.LP/seven.LP /six.LP/four.LP/eight.LP/two.LPD /minus.cap/one.LP./zero.LP /minus.cap/zero.LP./eight.LP /minus.cap/zero.LP./six.LP /minus.cap/zero.LP./four.LP /minus.cap/zero.LP./two.LP /zero.LP./two.LP /zero.LP./four.LP /zero.LP./six.LP /zero.LP./eight.LP /one.LP./zero.LP /zero.LPColor key of correlation coeﬃcient (r) Fig.,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
8/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN CHPV/one.LP/six.LP BHPV/one.LP/eight.LP HPV/five.LP/two.LPA /minus.cap/one.LP./zero.LP /minus.cap/zero.LP./eight.LP /minus.cap/zero.LP./six.LP /minus.cap/zero.LP./four.LP /minus.cap/zero.LP./two.LP /zero.LP./two.LP /zero.LP./four.LP /zero.LP./six.LP /zero.LP./eight.LP /one.LP./zero.LP /zero.LPColor key of correlation coeﬃcient (r)r>/zero.LP./seven.LP n= n= n= n= n=n= HS/three.LPST/two.LP PTPRR POU/four.LPF/three.LP/six.LP/three.LP/six.LP/five.LP /six.LP/three.LP/eight.LP/seven.LP /six.LP/six.LP/five.LP/zero.LP /one.LP/nine.LP /one.LP/nine.LP/two.LP/six.LP/zero.LP./seven.LP≥r≥/zero.LP./four.LP PAX/one.LP AJAP/one.LP ZNF/five.LP/eight.LP/two.LP WT/one.LP NKX/six.LP/hyphen.cap/one.LP SOX/one.LP/six.LP/three.LP/six.LP/five.LP /six.LP/three.LP/eight.LP/seven.LP /six.LP/six.LP/five.LP/zero.LP /three.LP/three.LP /one.LP/nine.LP /two.LP/six.LP /two.LP/six.LP/two.LP/six.LP /three.LP/three.LPr</zero.LP./four.LP DBC/six.LP/three.LP/six.LP/five.LP /six.LP/three.LP/eight.LP/seven.LP /six.LP/six.LP/five.LP/zero.LP /two.LP/six.LP r</zero.LP./four.LP PAX/one.LP SOX/one.LP/six.LP/three.LP/six.LP/three.LP /six.LP/three.LP/six.LP/six.LP /seven.LP/zero.LP/nine.LP/zero.LP /seven.LP/one.LP/one.LP/zero.LP /seven.LP/one.LP/one.LP/six.LP /seven.LP/one.LP/two.LP/two.LP /one.LP/seven.LP /one.LP/seven.LP r>−/zero.LP./four.LP PAX/one.LP SOX/one.LP/six.LP/three.LP/six.LP/eight.LP /six.LP/four.LP/zero.LP/five.LP /six.LP/four.LP/four.LP/five.LP /one.LP/nine.LP /one.LP/nine.LPHPV/five.LP/eight.LPD r</zero.LP./four.LP or r>−/zero.LP./four.LP PAX/one.LP SOX/one.LP/six.LP/three.LP/nine.LP/six.LP /six.LP/four.LP/four.LP/six.LP /six.LP/four.LP/five.LP/seven.LP /six.LP/four.LP/eight.LP/two.LP /six.LP/five.LP/five.LP/three.LP /one.LP/four.LP/one.LP/four.LP Fig.,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
Insertion of viral DNA sequences into the host genome often triggers host defense  9/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN B A Methylation of PAX /one.LP Methylation of PAX /one.LP and HPV/one.LP/six.LP Diagnosis6 5 4 3 2 10 Diagnosis54 3 2 1 0 Adding diagnostic color key Normal CIN/one.LP ≥CIN/two.LP Fig.,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
10/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
PUBMED  | CROSSREF 11/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
PUBMED  | CROSSREF 12/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
PUBMED  | CROSSREF 13/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e56Genotype-specific methylation of HPV in CIN,Non-OADS,/arxiv_data1/oa_pdf/43/81/jgo-28-e56.PMC5447154.pdf
"1/5 https://ejgo.orgTo the Editor, In Japan, the incidence of cervical cancer among young women has been steadily increasing, and  44% of women with cervical cancer are younger than 50 years of age and present with stage I–II  disease [ 1-3].",Non-OADS,/arxiv_data1/oa_pdf/c3/ca/jgo-28-e60.PMC5447155.pdf
"2017 Jul;28(4):e60 https://doi.org/10.3802/jgo.2017.28.e60 pISSN 2005-0380·eISSN 2005-0399 Correspondence Received:  Apr 23, 2017 Revised:  May 4, 2017 Accepted:  May 4, 2017 Correspondence to Muneaki Shimada Department of Obstetrics and Gynecology,  Tottori University School of Medicine, 36‑1  Nishi‑cho, Yonago 683‑8504, Japan.",Non-OADS,/arxiv_data1/oa_pdf/c3/ca/jgo-28-e60.PMC5447155.pdf
"ORCID Koji Matsuo https://orcid.org/0000‑0002 ‑6232 ‑8701 Muneaki Shimada https://orcid.org/0000‑0003‑ 1826‑6723 Mikio Mikami https://orcid.org/0000‑0002 ‑7496‑ 3518 Conflict of Interest No potential conflict of interest relevant to this  article was reported.Koji Matsuo,1,2,* Muneaki Shimada,3,*, † Mikio Mikami4 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern  California, Los Angeles, CA, USA 2Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA 3Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan 4Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, JapanOvarian conservation for young  women with clinical stage IB–IIB  cervical cancer in Japan",Non-OADS,/arxiv_data1/oa_pdf/c3/ca/jgo-28-e60.PMC5447155.pdf
Early-stage disease was associated with a higher rate of ovarian  2/5 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e60Ovary saving in cervical cancer Table 1.,Non-OADS,/arxiv_data1/oa_pdf/c3/ca/jgo-28-e60.PMC5447155.pdf
3/5 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e60Ovary saving in cervical cancer Table 2.,Non-OADS,/arxiv_data1/oa_pdf/c3/ca/jgo-28-e60.PMC5447155.pdf
4/5 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e60Ovary saving in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/c3/ca/jgo-28-e60.PMC5447155.pdf
PUBMED  | CROSSREF 5/5 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e60Ovary saving in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/c3/ca/jgo-28-e60.PMC5447155.pdf
Available at http://www.who.int/csr/don/archive/ disease/coronavirus_infections/en/.,Non-OADS,/arxiv_data1/oa_pdf/6f/e5/SaudiMedJ-38-339.PMC5447184.pdf
Available at http://www.cdc.gov/oralhealth/ infectioncontrol/guidelines/ .,Non-OADS,/arxiv_data1/oa_pdf/6f/e5/SaudiMedJ-38-339.PMC5447184.pdf
Sample references are available from:   http://www.nlm.nih.gov/bsd/uniform_requirements.html,Non-OADS,/arxiv_data1/oa_pdf/98/de/SaudiMedJ-38-344.PMC5447185.pdf
Avaliable from: http://www.moh.gov.sa/en/PCV/Pages/ Vaccination.aspx .,Non-OADS,/arxiv_data1/oa_pdf/32/30/SaudiMedJ-38-350.PMC5447186.pdf
E-mail: gelhiti@ksu.edu.sa ORCID: http://orcid.org/0000-0001-6675-3126 OPEN ACCESS  359  www.smj.org.sa    Saudi Med J 2017; Vol.,Non-OADS,/arxiv_data1/oa_pdf/0a/64/SaudiMedJ-38-359.PMC5447187.pdf
Available form:  http://www.irsa.org/radation_therapy.html .,Non-OADS,/arxiv_data1/oa_pdf/0a/64/SaudiMedJ-38-359.PMC5447187.pdf
Available from: https://dailymed.nlm.,Non-OADS,/arxiv_data1/oa_pdf/0a/64/SaudiMedJ-38-359.PMC5447187.pdf
"Assay Guidance Manual: Cell  Viability Assays, In: Bethesda (MD): Eli Lilly & Company  and the National Center for Advancing T ranslational Sciences,  2013. editors Available from: https://www.ncbi.nlm.nih.gov/ books/NBK53196/ 30.",Non-OADS,/arxiv_data1/oa_pdf/0a/64/SaudiMedJ-38-359.PMC5447187.pdf
E-mail: aagha@kau.edu.sa  ORCID: http://orcid.org/0000-0002-7168-6447 OPEN ACCESS  366 Saudi Med J 2017; Vol.,Non-OADS,/arxiv_data1/oa_pdf/56/ab/SaudiMedJ-38-366.PMC5447188.pdf
E-mail: dr.abulmeaty@gmail.com / mabulmeaty@ksu.edu.sa ORCID: http://orcid.org/0000-0002-1779-0091 OPEN ACCESS  372 Saudi Med J 2017; Vol.,Non-OADS,/arxiv_data1/oa_pdf/df/93/SaudiMedJ-38-372.PMC5447189.pdf
E-mail: xhm001@126.com ORCID: http://orcid.org/0000-0001-8896-571X OPEN ACCESS Disclosure .,Non-OADS,/arxiv_data1/oa_pdf/b4/f7/SaudiMedJ-38-391.PMC5447191.pdf
E-mail: stmedt2008@163.com ORCID: http://orcid.org/0000-0002-8961-6826 OPEN ACCESS Deep vein thrombosis (DVT) is a major health  concern worldwide and results in significant  morbidity and mortality in patients.,Non-OADS,/arxiv_data1/oa_pdf/51/df/SaudiMedJ-38-396.PMC5447192.pdf
E-mail: Abadia792@gmail.com ORCID: http://orcid.org/0000-0002-5885-6069 OPEN ACCESS  400 Saudi Med J 2017; Vol.,Non-OADS,/arxiv_data1/oa_pdf/1b/61/SaudiMedJ-38-400.PMC5447193.pdf
E-mail:  amidris53@gmail.com  ORCID: http://orcid.org/0000-0002-0701-0899 OPEN ACCESS  405  www.smj.org.sa    Saudi Med J 2017; Vol.,Non-OADS,/arxiv_data1/oa_pdf/c3/d6/SaudiMedJ-38-405.PMC5447194.pdf
E-mail: snazhan@ksu.edu.sa / saadnazhan@gmail.com  ORCID: http://orcid.org/0000-0002-5997-0330 OPEN ACCESS  413  www.smj.org.sa    Saudi Med J 2017; Vol.,Non-OADS,/arxiv_data1/oa_pdf/86/d0/SaudiMedJ-38-413.PMC5447195.pdf
Avaliable  from: http://www.idf.org/membership/mena/saudi-arabia.,Non-OADS,/arxiv_data1/oa_pdf/86/d0/SaudiMedJ-38-413.PMC5447195.pdf
"akramjahdali@gmail.com  ORCID: http://orcid.org/0000-0003-0436-9537Case Reports reduction using a variety of prosthetic materials, with or  without amnion preservation, leading to delayed closure  in the neonatal period.1,2 We report our experience  with 2 cases of GO treated with a modification of the  described amnion preservation techniques.",Non-OADS,/arxiv_data1/oa_pdf/38/68/SaudiMedJ-38-422.PMC5447196.pdf
E-mail: aakbr@kau.edu.sa  ORCID: http://orcid.org/0000-0002-6132-862XCase Reports Treating a unilateral posterior cross bite in adults  is challenging.,Non-OADS,/arxiv_data1/oa_pdf/bd/35/SaudiMedJ-38-425.PMC5447197.pdf
E-mail: pt.turki@hotmail.com  ORCID: http://orcid.org/0000-0001-5284-3956 References   1.,Non-OADS,/arxiv_data1/oa_pdf/03/65/SaudiMedJ-38-435.PMC5447199.pdf
E-mail: anaskhalifeh@yahoo.comORCID ID: http://orcid.org/0000-0002-5649-5124 www.smj.org.sa     Saudi Med J 2017; Vol.,Non-OADS,/arxiv_data1/oa_pdf/b7/a8/SaudiMedJ-38-457.PMC5447205.pdf
Available from: http://www.who.int/ mental_health/management/depression/en/   5.,Non-OADS,/arxiv_data1/oa_pdf/b7/a8/SaudiMedJ-38-457.PMC5447205.pdf
Available from: http://apa.org/topics/ depress/index.aspx 12.,Non-OADS,/arxiv_data1/oa_pdf/b7/a8/SaudiMedJ-38-457.PMC5447205.pdf
Available from: http://www.nhs.uk/Livewell/ complementary-alternative-medicine/Pages/complementary-alternative-medicines.aspx 17.,Non-OADS,/arxiv_data1/oa_pdf/b7/a8/SaudiMedJ-38-457.PMC5447205.pdf
Available from: http://nccam.nih.gov/health/whatiscam 20.,Non-OADS,/arxiv_data1/oa_pdf/b7/a8/SaudiMedJ-38-457.PMC5447205.pdf
Available from http://www.ephpp.ca/tools.html   19.,Non-OADS,/arxiv_data1/oa_pdf/12/b4/SaudiMedJ-38-465.PMC5447206.pdf
Available from http://www.spine-health.com/ wellness/sleep/chronic-pain-and-insomnia-breaking-cycle   82.,Non-OADS,/arxiv_data1/oa_pdf/12/b4/SaudiMedJ-38-465.PMC5447206.pdf
Available from: http://www.randomizer.org/ 11.,Non-OADS,/arxiv_data1/oa_pdf/69/e3/SaudiMedJ-38-482.PMC5447208.pdf
E-mail:  faa13@case.edu ORCID ID: http://orcid.org/0000-0002-6954-0844  www.smj.org.sa     Saudi Med J 2017; Vol.,Non-OADS,/arxiv_data1/oa_pdf/56/59/SaudiMedJ-38-491.PMC5447209.pdf
Available from URL: http://emedicine.medscape.com/ article/257007-overview  2.,Non-OADS,/arxiv_data1/oa_pdf/bc/9c/SaudiMedJ-38-497.PMC5447210.pdf
Available from URL: http://reference.medscape.com/refarticle- srch/961497-overview   2.,Non-OADS,/arxiv_data1/oa_pdf/11/dc/SaudiMedJ-38-517.PMC5447213.pdf
Available from URL: http://reference.medscape.,OADS,/arxiv_data1/oa_pdf/11/dc/SaudiMedJ-38-517.PMC5447213.pdf
Available from URL: https://www.uptodate.com/contents/impact-of-universal- infant-immunization-with-pneumococcal-streptococcus- pneumoniae-conjugate-vaccines-in-the-united-states   7.,Non-OADS,/arxiv_data1/oa_pdf/11/dc/SaudiMedJ-38-517.PMC5447213.pdf
Available from URL:  http://emedicine.medscape.com/article/961497- treatment,Non-OADS,/arxiv_data1/oa_pdf/11/dc/SaudiMedJ-38-517.PMC5447213.pdf
Available  from URL: http://www.eucast.org/fileadmin/src/media/PDFs/ EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf.,OADS,/arxiv_data1/oa_pdf/ad/64/SaudiMedJ-38-521.PMC5447214.pdf
Available  from URL: http://www.chs.gov.sa/En/HealthRecords/ CancerRegistry/Pages/CancerRegistry.aspx    2.,Non-OADS,/arxiv_data1/oa_pdf/a6/24/SaudiMedJ-38-528.PMC5447215.pdf
Cancer Incidence Report [Updated 1996;  Accessed  2016 August 15] Available  from URL: http://www.chs.gov.sa/En/HealthRecords/ CancerRegistry/Pages/CancerRegistry.aspx 19.,OADS,/arxiv_data1/oa_pdf/a6/24/SaudiMedJ-38-528.PMC5447215.pdf
Available from URL: https://www.autismspeaks.,Non-OADS,/arxiv_data1/oa_pdf/37/86/SaudiMedJ-38-533.PMC5447216.pdf
Available from:  http://www.who.int/mediacentre/news/releases/2017/medication-related-errors/en/WHO News Release,Non-OADS,/arxiv_data1/oa_pdf/af/12/SaudiMedJ-38-566.PMC5447226.pdf
Availability and Implementation: https://github.com/bfosso/MetaShot Contact: graziano.pesole@uniba.it Supplementary information: Supplementary data are available at Bioinformatics online.,OADS,/arxiv_data1/oa_pdf/0e/2b/btx036.PMC5447231.pdf
"1730 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0e/2b/btx036.PMC5447231.pdf
A software package implementing the MetaShot pipeline isfreely available at https://github.com/bfosso/MetaShot and includesa utility tool for extracting all reads assigned to a specific NCBItaxonomic ID or all those left unassigned.,OADS,/arxiv_data1/oa_pdf/0e/2b/btx036.PMC5447231.pdf
"1647 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0d/82/btx041.PMC5447233.pdf
Availability and documentation: https://github.com/HudsonAlpha/a RNAPipe; DOI: 10.5281/zenodo.202950 Contact: rmyers@hudsonalpha.org Supplementary information: Supplementary data are available at Bioinformatics online.,OADS,/arxiv_data1/oa_pdf/20/04/btx023.PMC5447234.pdf
"1727 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/20/04/btx023.PMC5447234.pdf
"The reports generated for four example data-sets can be accessed online (http://arnapipe.bitbucket.org):(i) Strand-specific paired-end RNA-seq data from nine human sam-ples of different tissues (GSE69241), (ii) unstranded single-enddata from two paired normal and colorectal tumor tissues(GSE29580), (iii) unstranded paired-end data from 11 melanomasamples (GSE20156) and 1 prostate cancer cell line (NCIH660),and (iv) in-house unstranded paired-end data from 20 zebrafishlibraries.",OADS,/arxiv_data1/oa_pdf/20/04/btx023.PMC5447234.pdf
Availability and Implementation: GitHub: https://github.com/mailund/admixture_graph and CRAN: https://cran.r-project.org/web/packages/admixturegraph.Contact: mailund@birc.au.dk.,OADS,/arxiv_data1/oa_pdf/70/76/btx048.PMC5447235.pdf
"1738 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/70/76/btx048.PMC5447235.pdf
", 2016 , https://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/70/76/btx048.PMC5447235.pdf
Availability and Implementation: The described clustering algorithm and visualizations are imple- mented in the hierarchicalSets R package available from CRAN (https://cran.r-project.org/web/pack ages/hierarchicalSets) Contact: thomasp85@gmail.com Supplementary information: Supplementary data are available at Bioinformatics online.,OADS,/arxiv_data1/oa_pdf/89/7d/btx034.PMC5447240.pdf
"1604 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/89/7d/btx034.PMC5447240.pdf
"6 Implementation and availability The described clustering algorithm as well as the different visual-izations are implemented in the hierarchicalSets R package and available for free (GPLv2 license) on all major platforms throughCRAN ( R Core Team, 2016 ) as well as on https://github.com/tho masp85/hierarchicalSets.",OADS,/arxiv_data1/oa_pdf/89/7d/btx034.PMC5447240.pdf
"FindMyFriends: Microbial Comparative Genomics in R. R package version 1.0.2, http://bioconductor.org/packages/FindMy Friends/.",Non-OADS,/arxiv_data1/oa_pdf/89/7d/btx034.PMC5447240.pdf
This ﬁnding suggests that choosing realistic model as-sumptions might not always yield optimal predictions in general and that choosing unrealistically high substitution probabilities close to one might actually improve the classiﬁcation performance of phylogenetic footprinting.Availability and Implementation: The proposed PF is implemented in JAVA and can be down- loaded from https://github.com/mgledi/PhyFoo Contact : martin.nettling@informatik.uni-halle.de Supplementary information: Supplementary data are available at Bioinformatics online.,Non-OADS,/arxiv_data1/oa_pdf/d7/05/btx033.PMC5447242.pdf
"1639 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d7/05/btx033.PMC5447242.pdf
"The implementation of the proposed PFM is avail- able at https://github.com/mgledi/PhyFoo/.3 Results In this section, we investigate the classification performance of the PFM specified in section 2.1 as function of the substitution prob- ability for a synthetic dataset and five real datasets.",OADS,/arxiv_data1/oa_pdf/d7/05/btx033.PMC5447242.pdf
Avail-able from:  https://mimic.physionet.org.,Non-OADS,/arxiv_data1/oa_pdf/ec/cc/JBPE-7-181.PMC5447255.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/30/4a/evx050.PMC5447328.pdf
"TE Discovery We used our custom TE identiﬁcation program, TEFLoN (https://github.com/jradrion/TEFLoN ), to discover the position and superfamily identity of all TEs present in the eight sublines.",OADS,/arxiv_data1/oa_pdf/30/4a/evx050.PMC5447328.pdf
(2011 ;http://modencode.org ).,OADS,/arxiv_data1/oa_pdf/30/4a/evx050.PMC5447328.pdf
2014 DEC 01]; Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/nda/2009/022334s000_ClinPharmR.pdf .,Non-OADS,/arxiv_data1/oa_pdf/37/16/11523_2017_Article_482.PMC5447332.pdf
Available from: http://www.omim.org/entry/129400.,Non-OADS,/arxiv_data1/oa_pdf/cb/b0/IDOJ-8-215.PMC5447346.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/26/f3/main.PMC5447370.pdf
http://dx.doi.org/10.1016/j.jdcr.2017.02.022 253,OADS,/arxiv_data1/oa_pdf/26/f3/main.PMC5447370.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/73/main.PMC5447372.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/73/main.PMC5447372.pdf
http://dx.doi.org/10.1016/j.eucr.2017.04.011Urology Case Reports 13 (2017) 158 e159,Non-OADS,/arxiv_data1/oa_pdf/7b/73/main.PMC5447372.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ed/27/main.PMC5447373.pdf
This is because ARB infections often result in increased mortality rates and cause http://dx.doi.org/10.1016/j.jare.2017.05.007 2090-1232/ /C2112017 Production and hosting by Elsevier B.V. on behalf of Cairo University.,Non-OADS,/arxiv_data1/oa_pdf/ed/27/main.PMC5447373.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Peer review under responsibility of Cairo University.,Non-OADS,/arxiv_data1/oa_pdf/ed/27/main.PMC5447373.pdf
This is an open a ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0f/23/main.PMC5447374.pdf
http://dx.doi.org/10.1016/j.pmedr.2017.05.005 2211-3355/Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/0f/23/main.PMC5447374.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0f/23/main.PMC5447374.pdf
Contents lists available at ScienceDirect Preventive Medicine Reports journal homepage: http://ees.elsevier.com/pmedr,Non-OADS,/arxiv_data1/oa_pdf/0f/23/main.PMC5447374.pdf
http://dx.doi.org/ 10.1249/MSS.0b013e31821ece12 .,Non-OADS,/arxiv_data1/oa_pdf/0f/23/main.PMC5447374.pdf
This  is  an  open access article under the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8c/b3/main.PMC5447375.pdf
Immuno- http://dx.doi.org/10.1016/j.ijscr.2017.04.029 2210-2612/© 2017  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/8c/b3/main.PMC5447375.pdf
"105  (March  (4))  (2012)  415–419,  http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/8c/b3/main.PMC5447375.pdf
"32 (May  (5))  (2008)  682–690,  http://dx.doi.org/10.1097/PAS.0b013e3181590ba4 .",Non-OADS,/arxiv_data1/oa_pdf/8c/b3/main.PMC5447375.pdf
This  is  an  open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5d/d8/main.PMC5447376.pdf
We  performed  a  postoperatively  ultrasound  showing  a  reduction http://dx.doi.org/10.1016/j.ijscr.2017.04.022 2210-2612/© 2017  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/5d/d8/main.PMC5447376.pdf
This  is  an  open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6e/20/main.PMC5447378.pdf
http://dx.doi.org/10.1016/j.ijscr.2017.05.004 2210-2612/© 2017  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/6e/20/main.PMC5447378.pdf
This  is  an  open access article under the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b4/03/main.PMC5447379.pdf
"However,  in  addition  to  poor  pulmonary status  of  the  patient,  adhesions  in  the  intrathoracic  cavity  were  sus- http://dx.doi.org/10.1016/j.ijscr.2017.05.013 2210-2612/© 2017  The  Author(s).",Non-OADS,/arxiv_data1/oa_pdf/b4/03/main.PMC5447379.pdf
This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/b0/e6/main.PMC5447382.pdf
http://dx.doi.org/10.1016/j.jdcr.2017.02.020 256,OADS,/arxiv_data1/oa_pdf/b0/e6/main.PMC5447382.pdf
"2016. http://dx.doi.org/10.1111/ajd.12464 , published online March 1, 2016.",OADS,/arxiv_data1/oa_pdf/b0/e6/main.PMC5447382.pdf
33 RESULTS Cell Injection Ex Vivo versus In Vivo We tested whether there were differences in the radiolabel detection when the cells were injected ex vivo on a muscle fragment (where we could ensure that all cells were inside the muscle sample before Received 4 May 2017; accepted 8 May 2017; http://dx.doi.org/10.1016/j.omtm.2017.05.002 .,OADS,/arxiv_data1/oa_pdf/f4/19/main.PMC5447384.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f4/19/main.PMC5447384.pdf
Recent reports of other soluble molecular mediators of in ﬂammation in NAFLD http://dx.doi.org/10.1016/j.redox.2017.05.005 Received 12 April 2017; Received in revised form 1 May 2017; Accepted 5 May 2017⁎Corresponding author.,OADS,/arxiv_data1/oa_pdf/ed/b2/main.PMC5447385.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/ed/b2/main.PMC5447385.pdf
Supplementary material Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.redox.2017.05.005 .,OADS,/arxiv_data1/oa_pdf/ed/b2/main.PMC5447385.pdf
1936-5233/17http://dx.doi.org/10.1016/j.tranon.2017.03.004,OADS,/arxiv_data1/oa_pdf/14/81/main.PMC5447386.pdf
"All statistical analyses were conducted with RevMan, version 5, from the CochraneCollaboration ( http://www.cochrane.org /) or Stata Version 12.0 software (Stata Corp, College Station, TX).",OADS,/arxiv_data1/oa_pdf/14/81/main.PMC5447386.pdf
1936-5233/17http://dx.doi.org/10.1016/j.tranon.2017.04.002,OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1016/B978-0-12-380888-2.00003-0 .,OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1073/ pnas.0806671106 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"Sci Rep 6, 21519. http://dx.doi.org/10.1038/srep21519 .",Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1126/ scisignal.aac9704 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.4161/cc.4.1.1299 .Translational Oncology Vol.,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1124/mi.11.2.11 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1038/ sj.onc.1204942 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"J Natl Cancer Inst 88, 956 –965 [ http://dx.doi.org/jnci.",Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"Clin Cancer Res 2, 791 –797 [ http://dx.doi.org/clincancerres.",Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1177/0091270005274549 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1016/j.bmcl.2010.10.113 .,OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1016/j.bmcl.2010.10.114 .,OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1158/1535-7163.MCT-10-0928 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"JC l i nO n c o l 33, 1060– 1066. http://dx.doi.org/10.1200/JCO.2014.57.5027 .",Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1002/ijc.22198 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.4161/cc.27055 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1158/1535-7163.MCT-13-0404 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1158/1535-7163.MCT-10-0809 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/ 10.18362/oncotarget.12311 .,OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1158/1541-7786.MCR-11-0491 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1016/j.exphem.2003.07.005.,OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"Cell Stem Cell 5, 515 –526.http://dx.doi.org/10.1016/j.stem.2009.08.017 .",OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1007/s00018-013-1307-3 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1038/cdd.2008.47 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1007/s13277-010-0042-8 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"Front Oncol 2, 116. http://dx.doi.org/10.3389/fonc.2012.00116 .",Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.4161/cc.6.3.3834 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1016/j.ijrobp.2012.08.006 .,OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"Cancer Res 70, 4972– 4981. http://dx.doi.org/10.1158/ 0008-5472.CAN-09-3573 .",Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1158/1078-0432.CCR-12-3748 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"Oncogene 32, 2963– 2972. http://dx.doi.org/10.1038/ onc.2012.310.",OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"EMBO Rep 8, 603– 609. http://dx.doi.org/10.1038/ sj.embor.7400962 .",OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1038/onc.2008.17 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/10.1016/j.celrep.2015.09.040 .,OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
"Nat Cell Biol 6, 884– 891.http://dx.doi.org/10.1038/ncb1165.",OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
http://dx.doi.org/ 10.1073/pnas.0604987103 .,Non-OADS,/arxiv_data1/oa_pdf/66/00/main.PMC5447387.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e1/cb/main.PMC5447389.pdf
The  nipple  showed  50% distortion  due  to  the  previous  shave  biopsy  but  no  retraction  or http://dx.doi.org/10.1016/j.ijscr.2017.05.020 2210-2612/© 2017  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/e1/cb/main.PMC5447389.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c3/9d/main.PMC5447390.pdf
"Case  report 101  year  old  female  with  past  medical  history  of  dyslipidemia and  hypertension and taking aspirin 81  mg  for  primary  prevention, presented to  a  regional  emergency  department  complaining  of  sud- http://dx.doi.org/10.1016/j.ijscr.2017.05.009 2210-2612/© 2017  The  Author(s).",Non-OADS,/arxiv_data1/oa_pdf/c3/9d/main.PMC5447390.pdf
"[10] Sahar Parvizi,  A  rare  cause  of  upper  airway  obstruction:  spontaneous synchronous sublingual  and  laryngeal  haematomas,  BMJ  Case  Reports  (2011), http://dx.doi.org/10.1136/bcr.03.2011.3930 .",Non-OADS,/arxiv_data1/oa_pdf/c3/9d/main.PMC5447390.pdf
"This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: DementiaMild cognitive impairmentExercise, adherenceCompliance Motivator Adherence supportBehavior change Contents 1 .",Non-OADS,/arxiv_data1/oa_pdf/e2/bc/main.PMC5447393.pdf
http://dx.doi.org/10.1016/j.pmedr.2017.05.007 2211-3355/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/e2/bc/main.PMC5447393.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e2/bc/main.PMC5447393.pdf
Contents lists available at ScienceDirect Preventive Medicine Reports journal homepage: http://ees.elsevier.com/pmedr,Non-OADS,/arxiv_data1/oa_pdf/e2/bc/main.PMC5447393.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Cardiorespiratory ﬁtness Cardiovascular diseaseChronic diseaseExercise capacityFramingham risk scoreMen Risk 1.,Non-OADS,/arxiv_data1/oa_pdf/69/e8/main.PMC5447395.pdf
http://dx.doi.org/10.1016/j.pmedr.2017.05.008 2211-3355/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/69/e8/main.PMC5447395.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/69/e8/main.PMC5447395.pdf
Contents lists available at ScienceDirect Preventive Medicine Reports journal homepage: http://ees.elsevier.com/pmedr,Non-OADS,/arxiv_data1/oa_pdf/69/e8/main.PMC5447395.pdf
"By inﬂ uen- cing glutamate excitotoxicity, oxidative stress and acidosis, which areprimary mediators of neuronal death during ischemia and reperfusion [10], IP astrocytes could e ﬀectively protect neurons from ischemia and http://dx.doi.org/10.1016/j.redox.2017.05.010 Received 12 April 2017; Received in revised form 16 May 2017; Accepted 19 May 2017⁎Corresponding authors.",OADS,/arxiv_data1/oa_pdf/22/6d/main.PMC5447396.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/22/6d/main.PMC5447396.pdf
online version at http://dx.doi.org/10.1016/j.redox.2017.05.010 .,OADS,/arxiv_data1/oa_pdf/22/6d/main.PMC5447396.pdf
"To determine the optimal TCRmodi ﬁcation, we have made modi ﬁcations to our previously described TCR isolated from an HLA-A2-restricted hepatitis C virus(HCV) NS3:1406-1415-reactive CD8 +T cell clone.21,22Due to its high Received 20 April 2017; accepted 13 May 2017; http://dx.doi.org/10.1016/j.omto.2017.05.004 .",Non-OADS,/arxiv_data1/oa_pdf/8e/7e/main.PMC5447397.pdf
105 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8e/7e/main.PMC5447397.pdf
SUPPLEMENTAL INFORMATION Supplemental Information includes three tables and can be foundwith this article online at http://dx.doi.org/10.1016/j.omto.2017.,OADS,/arxiv_data1/oa_pdf/8e/7e/main.PMC5447397.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/05/21/main.PMC5447402.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/05/21/main.PMC5447402.pdf
http://dx.doi.org/10.1016/j.shaw.2016.09.001Safety and Health at Work 8 (2017) 156 e161,Non-OADS,/arxiv_data1/oa_pdf/05/21/main.PMC5447402.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/7f/main.PMC5447403.pdf
http://dx.doi.org/10.1016/j.jsps.2017.04.007 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.,Non-OADS,/arxiv_data1/oa_pdf/06/7f/main.PMC5447403.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author at: Research Center on Life Sciences and Environmental Sciences, Harbin University of Commerce, Harbin 150076, China.",Non-OADS,/arxiv_data1/oa_pdf/06/7f/main.PMC5447403.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6d/31/main.PMC5447404.pdf
"Chen et C. Ling, Curcuma longa L, http://dx.doi.org/10.1016/j.jsps.2017.04.015 1319-0164/ /C2112017 The Authors.",OADS,/arxiv_data1/oa_pdf/6d/31/main.PMC5447404.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/6d/31/main.PMC5447404.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/15/7d/main.PMC5447405.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/15/7d/main.PMC5447405.pdf
http://dx.doi.org/10.1016/j.shaw.2016.11.003Safety and Health at Work 8 (2017) 169 e174,Non-OADS,/arxiv_data1/oa_pdf/15/7d/main.PMC5447405.pdf
Available from: http://www.julkari.,Non-OADS,/arxiv_data1/oa_pdf/15/7d/main.PMC5447405.pdf
Available from: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/15/7d/main.PMC5447405.pdf
Available from: http://www.julkari.,Non-OADS,/arxiv_data1/oa_pdf/15/7d/main.PMC5447405.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/61/ad/main.PMC5447406.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/61/ad/main.PMC5447406.pdf
http://dx.doi.org/10.1016/j.shaw.2016.06.002Safety and Health at Work 8 (2017) 151 e155,Non-OADS,/arxiv_data1/oa_pdf/61/ad/main.PMC5447406.pdf
Available from: http://www.sdt.com.au/ safedrive-directory-STOPPINGDISTANCE.htm .,OADS,/arxiv_data1/oa_pdf/61/ad/main.PMC5447406.pdf
IEEE 2016. http://dx.doi.org/10.1109/ IVS.2012.6232154 .,OADS,/arxiv_data1/oa_pdf/61/ad/main.PMC5447406.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/ab/main.PMC5447407.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/eb/ab/main.PMC5447407.pdf
http://dx.doi.org/10.1016/j.shaw.2016.10.003Safety and Health at Work 8 (2017) 162 e168,Non-OADS,/arxiv_data1/oa_pdf/eb/ab/main.PMC5447407.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1f/3c/main.PMC5447408.pdf
"The CD44 gene can generate many functionally distinct iso- forms such as the CD44 standard isoform (CD44S) and CD44 vari- ant isoforms (CD44V) by complex alternative splicing ( Xu et al., http://dx.doi.org/10.1016/j.jsps.2017.04.011 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.",Non-OADS,/arxiv_data1/oa_pdf/1f/3c/main.PMC5447408.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding authors.,Non-OADS,/arxiv_data1/oa_pdf/1f/3c/main.PMC5447408.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/be/48/main.PMC5447409.pdf
A meta-analysis found that the addition of dexamethasone into local anesthetics prolongs brachial http://dx.doi.org/10.1016/j.jsps.2017.04.012 1319-0164/ /C2112017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/be/48/main.PMC5447409.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/be/48/main.PMC5447409.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/1a/main.PMC5447410.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c5/1a/main.PMC5447410.pdf
http://dx.doi.org/10.1016/j.shaw.2017.02.001Safety and Health at Work 8 (2017) 130 e142,Non-OADS,/arxiv_data1/oa_pdf/c5/1a/main.PMC5447410.pdf
"Third, to test which type of exposure dose-response model, linear or quadratic, ﬁtted the data best, we also used the meta-regression model as implemented in a web-based R-version written by Crippa and Orsini ( https://cran.r-project.org/web/packages/ dosresmeta/index.html )[15,42] .",Non-OADS,/arxiv_data1/oa_pdf/c5/1a/main.PMC5447410.pdf
J Stat Softw 2016;72. http://dx.doi.org/10.18637/jss.v072.c01 .,OADS,/arxiv_data1/oa_pdf/c5/1a/main.PMC5447410.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2d/40/main.PMC5447411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2d/40/main.PMC5447411.pdf
http://dx.doi.org/10.1016/j.shaw.2016.09.004Safety and Health at Work 8 (2017) 220 e225,Non-OADS,/arxiv_data1/oa_pdf/2d/40/main.PMC5447411.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/72/1e/main.PMC5447412.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/72/1e/main.PMC5447412.pdf
http://dx.doi.org/10.1016/j.shaw.2016.10.001Safety and Health at Work 8 (2017) 206 e211,Non-OADS,/arxiv_data1/oa_pdf/72/1e/main.PMC5447412.pdf
Available from: http://www.bls.,Non-OADS,/arxiv_data1/oa_pdf/72/1e/main.PMC5447412.pdf
Available from: https://www.nhlbi.nih.gov/health/educational/lose_ wt/BMI/bmi_dis.htm .,Non-OADS,/arxiv_data1/oa_pdf/72/1e/main.PMC5447412.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/63/06/main.PMC5447413.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/63/06/main.PMC5447413.pdf
http://dx.doi.org/10.1016/j.shaw.2017.04.003Safety and Health at Work 8 (2017) 143 e150,Non-OADS,/arxiv_data1/oa_pdf/63/06/main.PMC5447413.pdf
"Literature searches were performed using the following sites: PubMed ( http://www.ncbi.nlm.nih.gov/pubmed ), Google Scholar (http://scholar.google.com ), and ScienceDirect ( http://www.",OADS,/arxiv_data1/oa_pdf/63/06/main.PMC5447413.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ed/2c/main.PMC5447414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ed/2c/main.PMC5447414.pdf
http://dx.doi.org/10.1016/j.shaw.2016.10.002Safety and Health at Work 8 (2017) 175 e182,Non-OADS,/arxiv_data1/oa_pdf/ed/2c/main.PMC5447414.pdf
Available from: http://www.ilo.org/public/english/protection/safework/papers/index.htm .,Non-OADS,/arxiv_data1/oa_pdf/ed/2c/main.PMC5447414.pdf
Available from: http://www.legislation.gov.uk/ukpga/1974/37/pdfs/ukpga_ 19740037_en.pdf .,Non-OADS,/arxiv_data1/oa_pdf/ed/2c/main.PMC5447414.pdf
Available from: https://www.academia.,Non-OADS,/arxiv_data1/oa_pdf/ed/2c/main.PMC5447414.pdf
Available from: http://www.hse.gov.uk/pUbns/priced/hsg144.pdf .,Non-OADS,/arxiv_data1/oa_pdf/ed/2c/main.PMC5447414.pdf
Available from: http://www.hse.gov.uk/ pubns/indg199.pdf .,Non-OADS,/arxiv_data1/oa_pdf/ed/2c/main.PMC5447414.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1b/ba/main.PMC5447415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1b/ba/main.PMC5447415.pdf
http://dx.doi.org/10.1016/j.shaw.2016.11.004Safety and Health at Work 8 (2017) 117 e129,Non-OADS,/arxiv_data1/oa_pdf/1b/ba/main.PMC5447415.pdf
Available from: http://www.bls.gov/news.,Non-OADS,/arxiv_data1/oa_pdf/1b/ba/main.PMC5447415.pdf
Available from: http://www.cdc.gov/nationalhealthyworksite/docs/ ﬁghting_obesity_in_ the_workplace_ ﬁnal_2_8_13.pdf .,Non-OADS,/arxiv_data1/oa_pdf/1b/ba/main.PMC5447415.pdf
Available from: http://www.rand.,Non-OADS,/arxiv_data1/oa_pdf/1b/ba/main.PMC5447415.pdf
Available from: https://www.towerswatson.com/en-US/Insights/Saf Health Work 2017;8:117 e129 128,Non-OADS,/arxiv_data1/oa_pdf/1b/ba/main.PMC5447415.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/af/76/main.PMC5447416.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/af/76/main.PMC5447416.pdf
http://dx.doi.org/10.1016/j.shaw.2016.10.005Safety and Health at Work 8 (2017) 212 e219,Non-OADS,/arxiv_data1/oa_pdf/af/76/main.PMC5447416.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/29/3b/main.PMC5447417.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/29/3b/main.PMC5447417.pdf
http://dx.doi.org/10.1016/j.shaw.2016.11.001Safety and Health at Work 8 (2017) 183 e188,Non-OADS,/arxiv_data1/oa_pdf/29/3b/main.PMC5447417.pdf
2016. p. 1e14.http://www.nfpa.org/news-and-research/ ﬁre-statistics-and-reports/ ﬁre-statistics/the- ﬁre-service/fatalities-and-injuries/an-analysis-of-volunteer- ﬁreﬁghter-injuries-2009-to-2011 .,Non-OADS,/arxiv_data1/oa_pdf/29/3b/main.PMC5447417.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/27/f2/main.PMC5447418.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/27/f2/main.PMC5447418.pdf
http://dx.doi.org/10.1016/j.shaw.2016.11.002Safety and Health at Work 8 (2017) 189 e197,Non-OADS,/arxiv_data1/oa_pdf/27/f2/main.PMC5447418.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b4/e3/main.PMC5447419.pdf
"Polytron Technologies Inc; the GSP kit is produced by Nanjing Institute of Biological Engineering; Insulin test kit of R&D company; IAA test kit of R&D company; TC Reagent box was produced by Beijing North Kang clinical Reagent Co. Ltd; TG reagent, Beijing North Kang clinical reagent co.; HDL reagent kit, Beijing North Chemical Reagent Co., Ltd, LDL kit, Beijing North Chemical Reagent Co., Ltd. http://dx.doi.org/10.1016/j.jsps.2017.04.014 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.",Non-OADS,/arxiv_data1/oa_pdf/b4/e3/main.PMC5447419.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/b4/e3/main.PMC5447419.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e1/4b/main.PMC5447420.pdf
Financial losses due to IBD per year were approximately http://dx.doi.org/10.1016/j.jsps.2017.04.005 1319-0164/ /C2112017 The Authors.,OADS,/arxiv_data1/oa_pdf/e1/4b/main.PMC5447420.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author at: Nuclear Institute for Agriculture and Biology, Faisal- abad, Pakistan.",Non-OADS,/arxiv_data1/oa_pdf/e1/4b/main.PMC5447420.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f4/e6/main.PMC5447421.pdf
Collection and preparation of extract Black pepper and ajwa date were purchased from market and was identiﬁed and authenticated by taxonomist at Department of http://dx.doi.org/10.1016/j.jsps.2017.04.004 1319-0164/ /C2112017 The Authors.,OADS,/arxiv_data1/oa_pdf/f4/e6/main.PMC5447421.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/f4/e6/main.PMC5447421.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4a/b8/main.PMC5447422.pdf
"CTFG, also known as CCN2 ( Jun and Lau, 2011; Hall-Glenn and Lyons, 2011 ), is a matricellular protein of the CCN family of http://dx.doi.org/10.1016/j.jsps.2017.04.013 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.",Non-OADS,/arxiv_data1/oa_pdf/4a/b8/main.PMC5447422.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/4a/b8/main.PMC5447422.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/ae/main.PMC5447423.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/ae/main.PMC5447423.pdf
http://dx.doi.org/10.1016/j.shaw.2016.10.004Safety and Health at Work 8 (2017) 198 e205,Non-OADS,/arxiv_data1/oa_pdf/a3/ae/main.PMC5447423.pdf
2008 http://www.crcnetbase.com/ doi/pdfplusdirect/10.1201/9781584889830.fmatt .,Non-OADS,/arxiv_data1/oa_pdf/a3/ae/main.PMC5447423.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/47/cf/main.PMC5447424.pdf
"It helps improve the disorders of glucose levels and fat metabolism of mice models, and relieve the http://dx.doi.org/10.1016/j.jsps.2017.04.009 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.",Non-OADS,/arxiv_data1/oa_pdf/47/cf/main.PMC5447424.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/47/cf/main.PMC5447424.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/40/f3/main.PMC5447425.pdf
http://dx.doi.org/10.1016/j.jsps.2017.04.017 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.,Non-OADS,/arxiv_data1/oa_pdf/40/f3/main.PMC5447425.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/40/f3/main.PMC5447425.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/fb/main.PMC5447426.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/fb/main.PMC5447426.pdf
http://dx.doi.org/10.1016/j.shaw.2016.09.006Safety and Health at Work 8 (2017) 226 e230,Non-OADS,/arxiv_data1/oa_pdf/46/fb/main.PMC5447426.pdf
Available from: http://www.cdc.gov/ niosh/topics/buyquiet .,OADS,/arxiv_data1/oa_pdf/46/fb/main.PMC5447426.pdf
Available from: https://www.cdc.gov/niosh/ docs/2016-101/ .Saf Health Work 2017;8:226 e230 230,Non-OADS,/arxiv_data1/oa_pdf/46/fb/main.PMC5447426.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7f/e6/main.PMC5447427.pdf
The rabbits http://dx.doi.org/10.1016/j.jsps.2017.04.016 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.,Non-OADS,/arxiv_data1/oa_pdf/7f/e6/main.PMC5447427.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/7f/e6/main.PMC5447427.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/de/df/main.PMC5447428.pdf
"Graphene oxidized (GO) is a special derivative of graphene, its sur- face is rich in functional groups containing oxygen, such as epoxy group-CH(O)CH- ,hydroxy-OH, and carboxy-COOH, which can change van der Waals force among sheet layers of GO and have http://dx.doi.org/10.1016/j.jsps.2017.04.008 1319-0164/ /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/de/df/main.PMC5447428.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author at: College of Basic Medical Sciences, Shenyang Medical College, Shenyang 110034, China.",Non-OADS,/arxiv_data1/oa_pdf/de/df/main.PMC5447428.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/bf/cc/main.PMC5447429.pdf
"In the present study, the immunomodulatory activities of S. imbricatus were determined in CTX-induced immunosuppressed http://dx.doi.org/10.1016/j.jsps.2017.04.006 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.",Non-OADS,/arxiv_data1/oa_pdf/bf/cc/main.PMC5447429.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding authors at: Zhuhai College, Jilin University, Zhuhai 519041, China.",Non-OADS,/arxiv_data1/oa_pdf/bf/cc/main.PMC5447429.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/79/48/main.PMC5447430.pdf
"When the umbilical arterial atresia was observed, linear array of high fre- quency probe frequency was used, and the ﬂoating umbilical cord which was near to the pregnant woman abdominal wall was http://dx.doi.org/10.1016/j.jsps.2017.04.010 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.",OADS,/arxiv_data1/oa_pdf/79/48/main.PMC5447430.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Peer review under responsibility of King Saud University.,Non-OADS,/arxiv_data1/oa_pdf/79/48/main.PMC5447430.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d8/c9/main.PMC5447431.pdf
Cellular models of hypoxia-reoxygenation (HR) have provided use- ful tools for the study of reactive species mediated mechanisms of http://dx.doi.org/10.1016/j.jsps.2017.04.033 1319-0164/ /C2112017 The Authors.,OADS,/arxiv_data1/oa_pdf/d8/c9/main.PMC5447431.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/c9/main.PMC5447431.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0d/44/main.PMC5447432.pdf
http://dx.doi.org/10.1016/j.jsps.2017.04.042 1319-0164/ /C2112017 The Authors.,OADS,/arxiv_data1/oa_pdf/0d/44/main.PMC5447432.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/0d/44/main.PMC5447432.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/04/main.PMC5447433.pdf
"APC anti-mouse CD4 (L3T4) (Clo- neGK1.8), FITC anti-mouse CD3e (p425-2e11), PE anti-mouse CD8a (Ly-2), and a 1 /C2RBC lysis buffer were purchased from eBio- science Ltd. http://dx.doi.org/10.1016/j.jsps.2017.04.038 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.",Non-OADS,/arxiv_data1/oa_pdf/f3/04/main.PMC5447433.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/f3/04/main.PMC5447433.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5c/c5/main.PMC5447434.pdf
http://dx.doi.org/10.1016/j.jsps.2017.04.025 1319-0164/ /C2112017 Production and hosting by Elsevier B.V. on behalf of King Saud University.,Non-OADS,/arxiv_data1/oa_pdf/5c/c5/main.PMC5447434.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/5c/c5/main.PMC5447434.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/0f/main.PMC5447435.pdf
"Subsequently, the protective effects of TSA and the underly- ing mechanisms related to the modulation of mitochondria and http://dx.doi.org/10.1016/j.jsps.2017.04.029 1319-0164/ /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/06/0f/main.PMC5447435.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/06/0f/main.PMC5447435.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9f/3b/main.PMC5447436.pdf
(2016) also showed that bone marrow mesenchymal stem cells can differentiate into osteoblasts under the action of magnetic nanoparticles and the http://dx.doi.org/10.1016/j.jsps.2017.04.026 1319-0164/ /C2112017 The Authors.,OADS,/arxiv_data1/oa_pdf/9f/3b/main.PMC5447436.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author at: Shenzhen National Key Department of Orthopedics, Shenzhen Second People’s Hospital, Shenzhen 518035, China.",Non-OADS,/arxiv_data1/oa_pdf/9f/3b/main.PMC5447436.pdf
http://dx.doi.org/10.1016/j.actbio.2016.09.020 .,OADS,/arxiv_data1/oa_pdf/9f/3b/main.PMC5447436.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/77/8a/main.PMC5447437.pdf
"In addition, baclofen increases the http://dx.doi.org/10.1016/j.jsps.2017.04.041 1319-0164/ /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/77/8a/main.PMC5447437.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/77/8a/main.PMC5447437.pdf
Published by Elsevier B.V. on behalf of King Saud University This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0e/f8/main.PMC5447438.pdf
"Instruments DL-CJ-1N type super clean workbench, Beijing donglianha’er Instruments Manufacturing Co., LTD; Adventurer electronic bal- ance, OHAUS Company; CO-150 type carbon dioxide cell incubator, http://dx.doi.org/10.1016/j.jsps.2017.04.036 1319-0164/ /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/0e/f8/main.PMC5447438.pdf
"Published by Elsevier B.V. on behalf of King Saud University This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding author at: Research Center on Life Sciences and Environmental Sciences, Harbin University of Commerce, Harbin 150076, China.",Non-OADS,/arxiv_data1/oa_pdf/0e/f8/main.PMC5447438.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/85/main.PMC5447439.pdf
http://dx.doi.org/10.1016/j.jsps.2017.04.034 1319-0164/ /C2112017 The Authors.,OADS,/arxiv_data1/oa_pdf/2a/85/main.PMC5447439.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).⇑Corresponding authors.,Non-OADS,/arxiv_data1/oa_pdf/2a/85/main.PMC5447439.pdf
